
<html lang="en"     class="pb-page"  data-request-id="3d11d1b1-cb48-4e31-8a92-bbe545d96c47"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00249;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application" /></meta><meta name="dc.Creator" content="Xinrui  Yuan" /></meta><meta name="dc.Creator" content="Hong  Bu" /></meta><meta name="dc.Creator" content="Jinpei  Zhou" /></meta><meta name="dc.Creator" content="Chao-Yie  Yang" /></meta><meta name="dc.Creator" content="Huibin  Zhang" /></meta><meta name="dc.Description" content="SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an importan..." /></meta><meta name="Description" content="SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an importan..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 27, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00249" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00249" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00249" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00249" /></link>
        
    
    

<title>Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00249" /></meta><meta property="og:title" content="Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0029.jpeg" /></meta><meta property="og:description" content="SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways. Mutations and/or overexpression of SHP2 has been associated with genetic developmental diseases and cancers. Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clinical development. Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site. To date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid tumors. This review will provide a summary of the physiological and biological functions of SHP2 and discuss the development of nonallosteric/allosteric SHP2 inhibitors in recent years." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00249"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00249">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00249&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00249&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00249&amp;href=/doi/10.1021/acs.jmedchem.0c00249" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 11368-11396</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00176" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00524" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xinrui Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinrui Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</div><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinrui++Yuan">Xinrui Yuan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Bu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Bu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Bu">Hong Bu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinpei Zhou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinpei Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.Z.: email, <a href="/cdn-cgi/l/email-protection#620812180a0d1754545a225354514c010d0f"><span class="__cf_email__" data-cfemail="9ff5efe5f7f0eaa9a9a7dfaea9acb1fcf0f2">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinpei++Zhou">Jinpei Zhou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5904-6164" title="Orcid link">http://orcid.org/0000-0002-5904-6164</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao-Yie Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao-Yie Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><span class="conrtib-corresp"><strong>*</strong>C.-Y.Y.: email, <a href="/cdn-cgi/l/email-protection#72110b131c1540443207061a01115c171607"><span class="__cf_email__" data-cfemail="3d5e445c535a0f0b7d4849554e5e13585948">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao-Yie++Yang">Chao-Yie Yang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5445-0109" title="Orcid link">http://orcid.org/0000-0002-5445-0109</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Huibin Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huibin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>H.Z.: email, <a href="/cdn-cgi/l/email-protection#661c0e0708010e045e562605161348030213480508"><span class="__cf_email__" data-cfemail="fe84969f9099969cc6cebe9d8e8bd09b9a8bd09d90">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huibin++Zhang">Huibin Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00249&amp;href=/doi/10.1021%2Facs.jmedchem.0c00249" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 11368–11396</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 27, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 February 2020</li><li><span class="item_label"><b>Published</b> online</span>27 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00249" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00249</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11368%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXinrui%2BYuan%252C%2BHong%2BBu%252C%2BJinpei%2BZhou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D20%26contentID%3Dacs.jmedchem.0c00249%26title%3DRecent%2BAdvances%2Bof%2BSHP2%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BCurrent%2BDevelopment%2Band%2BClinical%2BApplication%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11396%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00249"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7141</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00249" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xinrui&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Bu&quot;},{&quot;first_name&quot;:&quot;Jinpei&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Chao-Yie&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Huibin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;11368-11396&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00249&quot;},&quot;abstract&quot;:&quot;SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways. Mutations and/or overexpression of SHP2 has been associated with genetic developmental diseases and cancers. Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clinical development. Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site. To date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid tumors. This review will provide a summary of the physiological and biological functions of SHP2 and discuss the development of nonallosteric/allosteric&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00249&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00249" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00249&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00249" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00249&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00249" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00249&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00249&amp;href=/doi/10.1021/acs.jmedchem.0c00249" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00249" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00249" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00249%26sid%3Dliteratum%253Aachs%26pmid%3D32460492%26genre%3Darticle%26aulast%3DYuan%26date%3D2020%26atitle%3DRecent%2BAdvances%2Bof%2BSHP2%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BCurrent%2BDevelopment%2Band%2BClinical%2BApplication%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D20%26spage%3D11368%26epage%3D11396%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/jmcmar.2020.63.issue-20/20201022/jmcmar.2020.63.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways. Mutations and/or overexpression of SHP2 has been associated with genetic developmental diseases and cancers. Because of the role of SHP2 plays in many diseases, the development of inhibitors targeting the catalytic site in SHP2 has been pursued for more than a decade, but none has advanced to clinical development. Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site. To date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid tumors. This review will provide a summary of the physiological and biological functions of SHP2 and discuss the development of nonallosteric/allosteric SHP2 inhibitors in recent years.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Protein Tyrosine Phosphatases and SHP2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The initiation, propagation, and termination of signaling cascades controlling many normal cellular processes are determined by the phosphorylation status of tyrosine in signaling proteins and regulated by protein tyrosine kinases (PTKs, phosphorylation) and protein tyrosine phosphatases (PTPs, dephosphorylation).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Because of the important roles in transducing signals, aberrant regulation by these enzymes frequently contributes to the pathogenesis of various human diseases including diabetes, cancers, and autoimmune disorders.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> From a therapeutic intervention viewpoint, proteins participating in tyrosine phosphorylation within the signaling transduction pathways could be promising targets for drug development because these proteins relay multiple growth factor signals in tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Indeed, inhibitors of PTK, such as Bcr-Abl, c-Kit, ErbB, and EGFR,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> have been successfully used to treat cancers. In contrast, the therapeutic potential of several recently identified PTP targets remains underexplored because of the unacceptable potency/selectivity of the known inhibitors, the incomplete understanding of the biological functions of the targets, and the poor pharmacokinetic properties of the existing inhibitors.</div><div class="NLM_p">Nonetheless, increased tyrosine phosphorylation activity is a hallmark of many cancers and is usually caused by excessive activation and/or overexpression of receptor PTKs (e.g., EGFR) and non-receptor PTKs (e.g., Abl and Src).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> By performing dephosphorylation of phosphotyrosine (pTyr) residues, PTPs are generally considered as negative regulators of signaling pathways and products of tumor suppressor genes. Indeed, PTPRT (protein tyrosine phosphatase receptor type T) is the most frequently mutated PTPs in 17% of gastric and lung cancers and 26% of colorectal cancers, and <i>PTPRT</i><sup>–/–</sup> mice are highly prone to develop colon tumors.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> The lipid phosphatase PTEN (phosphatase and tensin homolog) is another frequently mutated tumor suppressor that can downregulate PI3K pathway activation.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><div class="NLM_p">Despite the tumor suppressive roles of many PTPs, genetic analysis of human cancers revealed that several PTPs have oncogenic activities in diverse cancers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> For instance, overexpression of PRL3 (phosphatase regenerating liver 3) is closely related to many human cancers and contributes to the activation of Rho GTPase and ERK signaling pathways.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Gain-of-function (GOF) mutation of SHP2 was initially observed in JMML (juvenile myelomonocytic leukemia), MDS (myelodysplastic syndromes), and AML (acute myeloid leukemia) and identified as an oncoprotein.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Aberrant activation or mutation of SHP2 was subsequently found in multiple leukemias and solid tumors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Protein Tyrosine Phosphatases Reported To Possess the Tumor Suppressor or Oncogenic Function in Diverse Human Cancers</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">function</th><th class="colsep0 rowsep0" align="center">PTPs</th><th class="colsep0 rowsep0" align="center">affected signaling pathway</th><th class="colsep0 rowsep0" align="center">cancers</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tumor suppressor</td><td class="colsep0 rowsep0" align="left">PTPRT</td><td class="colsep0 rowsep0" align="left">EGFR, paxillin, and STAT3 signaling</td><td class="colsep0 rowsep0" align="left">Colorectal, gastric, and lung</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PTEN</td><td class="colsep0 rowsep0" align="left">PI3K signaling</td><td class="colsep0 rowsep0" align="left">Glioblastoma and bladder</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PTPRD</td><td class="colsep0 rowsep0" align="left">STAT3 signaling</td><td class="colsep0 rowsep0" align="left">Melanoma, glioblastoma, colorectal, liver, lung, head and neck</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Oncoprotein</td><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">RAS/Raf, Jak-STAT, and PI3K signaling</td><td class="colsep0 rowsep0" align="left">Juvenile myelomonocytic leukemia and B-cell acute lymphoblastic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PRL3</td><td class="colsep0 rowsep0" align="left">Rho GTPase activation and ERK signaling</td><td class="colsep0 rowsep0" align="left">Prostate, colorectal, and ovarian</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PRL1</td><td class="colsep0 rowsep0" align="left">Rho GTPase activation and AKT signaling</td><td class="colsep0 rowsep0" align="left">Pancreatic and colorectal</td></tr></tbody></table></div></div><div class="NLM_p">SHP (Src homology-2 domain-containing protein tyrosine phosphatase) is a small subfamily of non-receptor-type protein tyrosine phosphatases comprising SHP1 (encoded by <i>PTPN6</i>) and SHP2 (encoded by <i>PTPN11</i>). SHP1 and SHP2 share a 75% amino acid sequence similarity and a 61% sequence identity in the PTP domain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). SHP1 and SHP2 have a similar domain arrangement including two tandem SH2 domains (N-SH2 and C-SH2), a PTP catalytic domain, and a C-terminal tail with two tyrosine phosphorylation sites (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The surface electrostatic potential of the catalytic site in human SHP2 is more basic than that in human SHP1.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Although amino acid residues of the catalytic sites in SHP1 and SHP2 are highly identical, four proximal regions around the catalytic site contain different residues between SHP1 and SHP2 (discussed below).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Sequence alignment of SHP1 and SHP2 PTP catalytic domains. Identical and similar residues are red and pink. (B) Overview of the native human SHP2 domains. SHP2 contains two SH2 domains (N-SH2 and C-SH2), a PTP catalytic domain, and a C-terminal tail containing two tyrosine phosphorylation sites (Tyr542 and Tyr580).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Located in cytoplasm, SHP2 can be recruited by various receptor tyrosine kinases to induce cell signaling and is involved in multiple intracellular oncogenic signaling cascades, such as Jak/STAT,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> PI3K/AKT,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> RAS/Raf/MAPK,<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> PD-1/PD-L1,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> and mTOR pathways.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Because of its catalytic action, SHP2 plays an important role in multiple cellular functions including cell cycle maintenance, proliferation, differentiation, and migration.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Unlike the ubiquitous expression of SHP2, SHP1 is expressed in hematopoietic cells and certain epithelial cells. In some leukemias and lymphomas, SHP1 is silenced genetically or epigenetically.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> SHP1 plays negative roles in intracellular signaling processes, but SHP2 shows a positive function in signaling transduction of growth factors, cytokines, and extracellular matrix proteins.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  SHP2: Biology and Its Implication in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SHP2 is a well-validated PTP oncoprotein in humans and is emerging as an important target for cancer treatment (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). GOF mutations of <i>PTPN11</i> have been identified in about 50% of the developmental disorder Noonan Syndrome (NS) cases and in >30% of the most common pediatric leukemia, juvenile myelomonocytic leukemia (JMML) - a progressive myelodysplastic/myeloproliferative disorder with overproduction of tissue-infiltrating myeloid cells.<a onclick="showRef(event, 'ref15 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref15 ref33 ref34 ref35">(15,33−35)</a> Germline <i>PTPN11</i> mutations are reported in up to 90% of patients with LEOPARD syndrome (LS) characterized by multiple lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary stenosis, abnormalities of the genitalia, growth retardation, and sensorineural deafness.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Mutations of <i>PTPN11</i> also have been found in individuals with myelodysplastic syndrome (10%), juvenile acute myeloid leukemia (AML) (5%), and B-cell acute lymphoblastic leukemia (7%). Besides these, mutations also occur in sporadic solid tumors including lung cancer, colon cancer, neuroblastoma, and melanoma (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> On the basis of the data curated in the Catalogue of Somatic Mutations in Cancer (COSMIC),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> 75.5% of tumor samples harbor <i>PTPN11</i> missense mutations and occur more frequently in the N-SH2 and PTP domains (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Schematic illustration of SHP2 mutations in various cancers (e.g., AML, JMML, and ALL) and NS. (B) Frequency of missense mutations in SHP2 in 1182 of 1677 tumor samples (∼75.5%) curated in COSMIC v91 (<a href="https://cancer.sanger.ac.uk/cosmic" class="extLink">https://cancer.sanger.ac.uk/cosmic</a>). Purple and orange bars correspond to the amino acid mutations in cancer and NS listed in (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">NS is a genetic disorder with facial dysmorphia, short height, congenital heart defects, bleeding problems, and skeletal malformations. Thirty-nine <i>PTPN11</i> mutations have been identified in NS patients, and the most common mutation, SHP2<sup>N308D</sup> mutant, accounted for 25% cases.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Further, GOF mutations of <i>KRAS</i> (1–2%), <i>SOS1</i> (10%), or <i>RAF</i> (5%) were identified in NS patients without <i>PTPN11</i> mutations. These findings indicate that the RAS/Raf/MAPK signaling pathway plays an important role in NS development.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> If untreated, some NS cases with specific <i>PTPN11</i> mutations can gradually transform into JMML. Somatic <i>PTPN11</i> mutations (e.g., D61Y and E76K) are the major cause of sporadic JMML. Similar to NS, JMML patients without <i>PTPN11</i> mutations have either hyperactivated <i>RAS</i> mutation or homozygous deficiency of <i>neurofibromatosis 1</i> (<i>NF1</i>). The <i>NF1</i> gene, encoding neurofibromin (a GTPase-activating protein), could downregulate the RAS/Raf/MAPK pathway. Collectively, mutations of <i>PTPN11</i>, <i>RAS</i>, and <i>NF1</i> accounted for about 85% of JMML cases.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">LS is a rare autosomal dominant disorder for the major features of skin, facial, and heart abnormalities. Two recurrent mutations of <i>PTPN11</i>, Y279C and T468M, are found in about 65% of LS patients.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The LS patients have the increased risk of neuroblastoma and AML.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><i>PTPN11</i> mutations have a low prevalence in children and adolescent AML (5%) and are rare in adult leukemias. However, overexpression of SHP2 is the main association factor in adult AML, CML (chronic myeloid leukemia), and ALL (acute lymphoblastic leukemia). The level of SHP2 mRNA is significantly increased in many primary leukemia specimens. The expression of SHP2 and SHP2 mRNA in the leukemia patients with hyperplastic bone marrow is significantly higher than those with hypoplastic bone marrow, indicating that overexpression/excessive activation of SHP2 is closely related to the hyperproliferative leukemias.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></div><div class="NLM_p">SHP2 mutations are rarely found in solid tumors.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In various solid tumors, excessive activation of SHP2 was reported to play a vital pathogenic role. For example, SHP2 expression is upregulated by up to 70% in ductal invasive breast cancer and SHP2 binding protein GAB2 is also overexpressed in 10–15% of human breast cancers.<a onclick="showRef(event, 'ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48">(46−48)</a> Knockdown of SHP2 markedly suppresses the proliferation of breast tumor-initiating cells and blocks maintenance and progression of breast cancer.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The level of SHP2 is also frequently elevated in melanoma, and the high expression level is closely associated with poorer prognosis and a more metastatic phenotype.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Moreover, SHP2 inhibition can suppress the growth of RTK-driven cancer cells, such as EGFR<sup>L858R</sup>-driven lung adenocarcinoma, <i>BRAF</i>-mutated colon cancers, and <i>KRAS</i>-mutated breast carcinoma.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> In <i>KRAS</i>-mutated non-small-cell lung cancer (NSCLC) blocking SHP2 is sufficient to induce tumor senescence, which triggers cancer cell clearance by the immune system. MEK inhibition can enhance the antitumor activity of SHP2 inhibitor in <i>KRAS</i>-mutated NSCLC.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Tumor specimen analysis of advanced EGFR-mutated positive NSCLC patients shows that patients with increased expression of SHP2 and ILK (Integrin-linked kinase) benefit less from EGFR TKI therapy compared with those with lower levels of SHP2 and ILK.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p last">The close association between SHP2 abnormality and human disease makes SHP2 an attractive target for developing mechanism-based therapy. Identification of highly bioactive and selective SHP2 inhibitors will be important not only for drug development but also for a better understanding of SHP2 function.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  SHP2 Mediated Downstream Signaling Pathways</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In multiple growth factor, cytokine, and extracellular-matrix receptor-induced signaling pathways, SHP2 is positioned at the common node downstream of RTKs and required for the full activation of RAS/Raf/ERK signaling pathway. In the RAS/Raf/ERK pathway, RAS is the key GTPase, which cycles between the GDP-bound inactive state and the GTP-bound active state to transduce signal from extracellular cues to the nucleus. These two states are regulated by GTPase-activating proteins (GAPs) (such as NF1, RASA/p120) and guanine nucleotide exchange factors (GEFs) (including SOS1). While GAP stimulates the GTP hydrolysis activity of RAS-GTP to produce RAS-GDP, GEF assists in the release of GDP in RAS-GDP and the switch to the active RAS-GTP state.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> SHP2 dephosphorylates SPRY/Sprouty, a negative regulator of RAS, and releases the inhibition of SPRY to GRB2/SOS1 dependent RAS activation.<a onclick="showRef(event, 'ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58">(56−58)</a> SHP2 also binds to the GAB1-GRB2-SOS1 complex recruited to the RTKs at the plasma membrane and facilitates the exchange of RAS-GDP to RAS-GTP.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Recently, GRB2 was reported to bind to the N-SH2 and PTP domains of SHP2 without RTK activities and released SHP2 from the autoinhibited conformation.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This introduces another layer of complexity, i.e., that cancer cells lacking specific RTKs may possess activated SHP2 to regulate downstream signaling in the MAPK pathway. Dephosphorylation of Tyr32 on RAS by SHP2 was also observed, which relieved the inhibitory binding of RAS with Raf required for downstream RAS/ERK/MAPK signaling.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Besides RAS, dephosphorylation of RASA/p120 was found to promote the switch from the inactive RAS-GDP state to the active RAS-GTP state in EGFR signaling.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Collectively, a primary oncogenic role of SHP2 in the RAS/Raf pathway is to dephosphorylate Tyr in adaptor/scaffolding proteins that results in increased conversion to RAS-GTP from RAS-GDP. This role also makes SHP2 an important facilitator for the RAS signaling reactivation when acquired resistance occurs to bypass pharmacological inhibition. For example, inhibition of MEK induces negative feedback to increase the RTK activity that leads to the reactivation of RAS/Raf/ERK pathway or increases the activities of other cascades, such as PI3K/AKT pathway. To sustain the MEK inhibition in the ERK/MAPK signaling, higher dosage and repeated administration are required.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In this context, inhibition of SHP2 can abrogate the RAS/Raf/ERK pathway reactivation and represents a potential therapeutic strategy to prevent the adaptive resistance of MEK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Schematic illustration of SHP2-associated growth factor dependent signaling pathways, RAS/Raf/ERK and PI3K/AKT. (B) Schematic illustration of SHP2-associated immune dependent signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Regulation of the PI3K/AKT signaling pathway by SHP2 is receptor-specific, cell-specific, or both.<a onclick="showRef(event, 'ref52 ref61'); return false;" href="javascript:void(0);" class="ref ref52 ref61">(52,61)</a> In some RTK pathways, SHP2 is required for PI3K/AKT activation induced by growth factors. But SHP2 can dephosphorylate PI3K binding sites on GAB1 and downregulate GAB1-mediated PI3K/AKT activation in the EGFR signaling pathway.<a onclick="showRef(event, 'ref32 ref64'); return false;" href="javascript:void(0);" class="ref ref32 ref64">(32,64)</a> SHP2 also directly binds to p85 and forms a ternary complex of GAB2-SHP2-p85 to block the PI3K pathway (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> SHP2 not only is necessary to maintain high expression levels of key transcription factors (ZEB1 and c-Myc), which are implicated in self-renewal and stem-like characters,<a onclick="showRef(event, 'ref47 ref66'); return false;" href="javascript:void(0);" class="ref ref47 ref66">(47,66)</a> but also is involved in increasing the transcriptional activity of oncoprotein YAP and in stimulating the transcription of the TEAD target genes.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">Recent discovery of SHP2 involvement in the immune signaling pathways offers new opportunities for the immunotherapeutic approaches. SHP2 regulates the IFN-induced Jak/STAT1 pathway by dephosphorylating STAT1 in fibroblasts. Overexpression of SHP2 can induce the dephosphorylation of STAT5 in response to IL-3 stimulation in primary bone marrow hematopoietic progenitor cells. SHP2 also negatively regulates STAT3, which is an important protein in the response of hematopoietic cells to cytokines.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> However, SHP2 has a positive function in the Jak2/STAT5 pathway to indirectly activate STAT5 phosphorylation and upregulate STAT5-related gene expression in mammary epithelial cells.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Collectively, regulation of the Jak/STAT signaling pathway by SHP2 is receptor-specific and/or cell-specific.</div><div class="NLM_p last">Although SHP2 is expressed in T cells ubiquitously, a significantly higher level of SHP2 is found in tumor-infiltrating lymphocytes than in peripheral blood lymphocytes from head and neck squamous cell carcinoma (HNSCC) patients. In patients with HNSCC, the expression level of SHP2 positively correlates with that of PD-1 in tumor-infiltrating T cells.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> After PD-L1/PD-L2 bound to PD-1, two tyrosine-containing motifs of PD-1 (ITIM and ITSM) are phosphorylated by Src kinase. Tyr-phosphorylated ITSM in PD-1 then binds to the C-SH2 domain of SHP2 with high affinity to recruit SHP2 followed by the interaction of Tyr-phosphorylated ITIM in PD-1 with the N-SH2 domain to relieve the autoinhibition of PTP domain in SHP2.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Ultimately, recruitment of SHP2 by PD-1 via the ITIM/ITSM domains can block T cell activation signal through TCR and co-stimulating CD28, which modulates the downstream pathways including PI3K/AKT, RAS/Raf, and phospholipase Cγ (PLCγ). The inhibitory effects by SHP2 cause the suppression of the T cell-dependent immune response through decreasing the cytokine expression and T cell activation/proliferation/survival (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref26 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref26 ref71 ref72">(26,71,72)</a> Therefore, blocking PD-1/SHP2 binding may rescue T cell activation in the tumor microenvironment. PD-1/SHP2 interaction also leads to the inhibitory effect of PD-1 on Th1 cells (T helper type 1 cells) in the tumor microenvironment and SHP2 inhibition is sufficient to restore robust Th1 immunity and Th1 cell activation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Despite the reported data associating SHP2 with T cell suppression, the modulation of T cell exhaustion by SHP2 has been questioned in SHP2-deficient mice subjected to chronic infection.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Because of the success of anti-PD-1/PD-L1 therapeutics, identifying the utility of SHP2 inhibitors in combination with immune checkpoint inhibitors in cancer immunotherapy may lead to improved treatment for cancer patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">4.  SHP2: Structure and Mutations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SHP2 comprises two tandem Src homology 2 (SH2) domains (N-SH2 and C-SH2), a single catalytic domain (PTP), and a C-terminal tail containing two tyrosine phosphorylation sites (Tyr542 and Tyr580). The structure of the autoinhibited SHP2 has been determined by X-ray crystallography at 2.0 Å resolution.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> On the basis of the structure, the PTP domain contains nine α helices and 14 stranded β sheets; the N-SH2 and C-SH2 domains both consist of a central four-stranded β sheet flanked at either surface by an α helix. Both the N-SH2 and C-SH2 domains can interact with short amino acid motifs (pTyr peptide) in diverse receptors and promote SHP2 association with these receptors (see examples in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">The catalytic site of SHP2 is surrounded by five loops including the WPD, β5-β6, P, Q, and pTyr loops (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Alignment of the ligand-bound or ligand-free SHP2 crystal structures at the catalytic site shows that the WPD loop can adopt either an in- or an out-conformation, likely contributing to substrate recognition (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The β5−β6 loop of SHP2 in the catalytic site also exhibited high flexibility (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). When comparing the catalytic sites between SHP2 and SHP1, similar mobility of the WPD and the β5-β6 loops was found in the crystal structures (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Because SHP1 and SHP2 have high sequence identities in the PTP domains (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), only six amino acids peripheral to the catalytic sites between SHP1 and SHP2 are different (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C) and may be responsible for substrate selectivity. On the basis of the sequence and structural alignment (discussed below), Cys215 of PTP1B is located at the same position as Cys459 of SHP2 (Cys453 in SHP1). Either S-nitrosylation or oxidation of Cys215 in PTP1B was reported to inactivate the catalytic activity of PTP1B.<a onclick="showRef(event, 'ref75 ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77 ref78">(75−78)</a> Whether chemical modification of the cysteine residue regulates the catalytic activity of SHP1/2 is not known.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Alignment of the PTP domain in SHP2 based on reported crystal structures (<i>n</i> = 50) of wild-type, mutant SHP2 with or without ligands at the binding sites. Some of the N-SH2 domain in SHP2 are not shown for clarity. (B) Same with (A) but the catalytic PTP domain of SHP1 (<i>n</i> = 9) is shown. (C) Comparison of the PTP domains between SHP1 (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PS5">3PS5</a><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) and SHP2 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP">2SHP</a><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a>). Residue differences between SHP1 and SHP2 are depicted in the stick model and labeled (top, SHP1; bottom, SHP2). A phosphate ion (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GRZ">4GRZ</a><a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a>) is shown to refer to the location of the phosphate group in the pTyr peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The selectivity of inhibitors against the PTP domains in SHP1, SHP2, and PTP1B has been determined in some studies discussed later. To aid the discussion, we compared the structures of the PTP domains between SHP1, SHP2, and PTP1B. In-depth reviews of PTP1B can be found elsewhere.<a onclick="showRef(event, 'ref80 ref81 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82 ref83 ref84">(80−84)</a> In contrast to SHP1 and SHP2, PTP1B contains only the PTP domain that adopts a fold similar to those in SHP1 and SHP2 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). In PTP1B, the switch of the WPD loop between two conformations (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) regulates the substrate binding and participates in the catalysis.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> The amino acids in the catalytic sites of PTP1B are less conserved when compared with those of SHP1 or SHP2 (cf. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). Specifically, 17 residues in the proximity of the catalytic site in PTP1B are different from those in SHP1 or SHP2 and likely contribute to the selectivity of SHP2 inhibitors against PTP1B.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Alignment of 117 PTP1B structures with or without ligands and different temperatures reported by Fraser’s group.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> A PTP1B inhibitor (5b) is shown to indicate the binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T19">5T19</a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (B) Comparison of the PTP domain binding sites between SHP1 (orange), SHP2 (green), and PTP1B (cyan). The backbone structure of SHP1 is not shown for clarity. Residues differing between SHP1, SHP2, and PTP1B are depicted as the stick model and labeled. A PTP1B inhibitor (LZP-25, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EB1">3EB1</a>) is displayed for comparison.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the basal state, the PTP domain in SHP2 is autoinhibited by N-SH2. On the basis of the crystal structure, D′ sheet, E sheet, and D′E loop of the N-SH2 domain dock into the catalytic pocket of the PTP domain to interact with several key residues, including Tyr279 in the pTyr loop and the catalytic Cys459 in the P loop. Specifically, Tyr62 and Asp61 in D′E loop mimic the pTyr substrate to form hydrogen bonds with Tyr279 and Cys459, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). An extensive hydrogen bond network involving Asn58, Gly60, Ala72, Gln503, Gln506, and Gln510 between D′E loop and the catalytic pocket further stabilizes their interaction (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Outside the catalytic pocket, additional polar interactions between the N-SH2 (αB helix and βA/βD′/βE/βF sheets) and the PTP (αB/αC helixes and DB/αHI loops) domains are also found (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Autoinhibitory conformation of SHP2. D′E loop of N-SH2 domain extends into the catalytic pocket of the PTP domain; D′E loop is cyan; pTyr loop is orange; P loop is magenta; WPD loop is blue; Q loop is green. (B) Hydrogen bond interactions between the residues in the PTP and N-SH2 domains. Hydrogen bonds are depicted in yellow dashed lines. (C) Inactive state of N-SH2 domain and the active state of N-SH2 domain. In the inactive state, the closure of the EF loop (66–68) and BG loop (89–92) blocks the binding site of the pTyr peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the autoinhibited SHP2 conformation, the pTyr binding sites of two SH2 domains are oriented away from the interface of N-SH2, C-SH2, and PTP domains (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The pTyr binding site of the N-SH2 domain has two conformations representing the activated peptide-bound state and the inactive PTP-bound state (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). In the inactive state, the N-SH2 domain binds to the PTP domain exclusively so that the interaction between the EF and the BG loops blocks the binding site of the pTyr peptide. When the stimulatory pTyr peptide binds to the N-SH2 domain, the conformation of N-SH2 is transformed from the inactive state to the activated state (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) and the autoinhibitory interaction between N-SH2 and PTP is disrupted to make the catalytic pocket accessible for binding to substrates containing pTyr residues (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). After the pTyr residue in the substrate binds to the catalytic pocket, the WPD loop then closes in to establish a catalytic conformation for substrate dephosphorylation.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Organization of the N-SH2 (blue), the C-SH2 (red), and the PTP domain (green) in the autoinhibited (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMV">6BMV</a>) and activated (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O">3B7O</a>) state of SHP2. The structure of N-SH2 and the Gab1 peptide (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4QSY">4QSY</a>) is aligned with N-SH2, C-SH2 to show the binding sites of the pY motif. Activation via the signaling at the cell membrane is illustrated as an example. SHP2 can also be activated by cytosolic molecules or in the mitochondria. Y denotes a tyrosine residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The C-SH2 domain forms very few interactions with the N-SH2/PTP domains and has no inhibitory effect on the PTP domain. When only the N-SH2 domain binds to the pTyr peptide, the activated SHP2 can maintain a basal activity. However, when both the N-SH2 and C-SH2 domains bind to the pTyr peptides, SHP2 exhibited a 10-fold higher dephosphorylation activity, indicating that C-SH2 can also modulate the catalytic activity of the PTP domain.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Moreover, tandem SH2 domains can bind more selectively to substrates than a single N-SH2 domain. In summary, C-SH2 contributes to the substrate-binding specificity and the catalytic activity of SHP2.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Although the crystal structure of ligand-free SHP1 showed a similar autoinhibitory conformation regulated by the N-SH2 domain, yet the C-SH2 domain of SHP1 is more flexible than that of SHP2 and has a different orientation.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p">Although substrates recognized by the SH2 domains have been investigated previously, studies have shown that sequence similarities of the SH2 domains generally do not correlate well with binding specificity to the pTyr peptide motifs.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> By use of a tyrosine phosphopeptide chip technology and 6202 phosphopeptides (13 amino acids in length), motifs recognized by the SH2 domains in SHP2 were classified into a group that included eight other SH2 containing proteins (SOCS7, FGR, SRMS, YES, SRC, LYN, TNS3, and SH2D3C).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Studies by Pei’s group further confirmed the motif specificity of N-SH2 and C-SH2 in SHP2 using 6-mer pTyr peptides as probes.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> While a peptide with a sequence of TIpYATI has been found to bind to N-SH2 and C-SH2 of SHP2 at 3.9 and 0.60 μM, VIpYFVP binds to N-SH2 and C-SH2 of SHP2 at 0.044 and 11 μM exhibiting 250 fold of selectivity. Studies also identified binding interaction between 26 proteins and the SH2 domains of either SHP1 or SHP2. Additional 51 proteins were predicted to bind with the SH2 domains of SHP1/SHP2 based on the peptide sequences used in the probes.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> This finding further highlights the complex regulatory role of SHP1 and SHP2 by interacting with various partner proteins.</div><div class="NLM_p">GOF mutations of <i>PTPN11</i> typically cause hyperactive catalytic activity of PTP because the autoinhibitory conformation of SHP2 is compromised. To date, mutations at 506 positions have been reported. Most of the mutated residues are located at the interface between the N-SH2 and PTP domains (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> These mutations can disrupt the intramolecular interaction of SHP2 that results in a partially open conformation and increases accessibility of the catalytic site to substrates.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mapped locations of reported amino acid mutations in hematological (yellow) and solid (purple) tumors in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A using the autoinhibited SHP2 structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Functional and structural analysis of SHP2 mutants further showed that the location of the amino acid mutation correlates with phosphatase activity and the biological function of SHP2. For example, SHP2<sup>N308D</sup> is the most common mutant, resulting in nearly 25% of NS cases, and Asn308 represents a mutation hotspot for NS (see also <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The E76K mutation at the N-SH2 domain of SHP2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), the most widespread leukemia-associated mutant, increases basal phosphatase activity by about 20-fold leading to abnormal proliferation of multiple hematopoietic cell lines and driving leukemogenesis in murine models.<a onclick="showRef(event, 'ref34 ref96'); return false;" href="javascript:void(0);" class="ref ref34 ref96">(34,96)</a> As a dominant loss-of-function mutation, the SHP2<sup>Q510E</sup> mutant prevents the formation of hydrogen bond between the residues Gly60 and Gln510, thereby weakening the stability of the autoinhibited SHP2 conformation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) and leading to cell migration and hypertrophic cardiomyopathy by upregulating the AKT/mTOR signaling pathway.<a onclick="showRef(event, 'ref29 ref97'); return false;" href="javascript:void(0);" class="ref ref29 ref97">(29,97)</a> For SHP2<sup>E76Q</sup> and SHP2<sup>S502P</sup>, X-ray structures reveal that the critical Glu76-Ser502 interdomain hydrogen bond interaction between N-SH2 and PTP domains is lost (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Furthermore, SHP2<sup>F285S</sup> can destabilize the hydrophobic B′C loop of the PTP domain and leads to a 2 Å opening in the closed conformation.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> NS-causative (A72S, I282V, and N308D) and recurrent leukemia-associated (D61G) SHP2 mutants can also weaken the interaction between N-SH2 and PTP domains and increase basal PTP catalytic activity.<a onclick="showRef(event, 'ref15 ref99'); return false;" href="javascript:void(0);" class="ref ref15 ref99">(15,99)</a> Because SHP2 is inactivated at the basal level due to its autoinhibition, inhibiting SHP2 by small-molecule inhibitors is not expected to affect the basal state. This makes SHP2 a promising target for drug development. In the following section, we summarize SHP2 inhibitors reported in the literature.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">5.  SHP2 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SHP2 contains two SH2 domains and one PTP domain. Currently, two types of small molecules inhibiting SHP2 activity have been reported. To aid our discussion, we have classified them into type I and type II inhibitors. Type I SHP2 inhibitors interact specifically with the PTP catalytic pocket; type II SHP2 inhibitors (or allosteric inhibitors) bind to a region outside of the PTP catalytic pocket and exhibit higher selectivity against other members in the phosphatase family. These inhibitors are at different stages of investigation ranging from preclinical biological evaluation to clinical trials. Currently, four SHP2 inhibitors (<b>JAB-3068</b>, <b>TNO155</b>, <b>RMC-4630</b>, and <b>RLY-1971</b>) in clinical trials are type II inhibitors.</div><div class="NLM_p">Before our discussion, we note that the reported IC<sub>50</sub> values of the inhibitors may depend on the assay conditions used by different laboratories.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> Comparing the potency of different compounds between laboratories may be problematic unless the same control inhibitor and assay conditions were used between studies. Although we are inclusive to include reported inhibitors, yet compounds exhibiting high micromolar inhibition activity may produce off-target effects, and follow-up studies of the compounds will be needed to confirm their on-target activities.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">5.1.  Type I SHP2 Inhibitors</h3><div class="NLM_p">Several SHP2 inhibitors have been reported in early development. By use of a biology-oriented synthesized library, furofurans derivative <b>1</b> (<b>NAT6-297775</b>) was discovered to inhibit SHP2 with an IC<sub>50</sub> value of 2.47 μM (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> By screening of a combinatory library<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> and use of a structure-based approach,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> the SHP2 inhibitors <b>2</b> (SHP2 IC<sub>50</sub> = 10 μM) and <b>3</b> (SHP2 IC<sub>50</sub> = 1.8 μM) were identified (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Both were found to also inhibit the phosphatase activity of PTP1B and SHP1. Other cinnamic acid derivatives <b>4</b> and <b>5</b> were initially discovered to bind to retinoid acid receptor γ (RARγ) to induce apoptosis in several cancer cell lines including AML.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Follow-up study indicated that <b>4</b> (SHP2 IC<sub>50</sub> = 2.1 μM) and <b>5</b> (SHP2 IC<sub>50</sub> = 0.45 μM) have inhibitory activity against SHP2, but the selectivity was not evaluated (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a><b>5</b> contains a 3-chlorocinnamic acid group in which the β carbon in the cinnamic acid may function as a Michael acceptor to react with cysteine in protein.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The mode of SHP2 inhibition by <b>5</b> remains to be determined.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and IC<sub>50</sub> values of compounds <b>1</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2006, Chen et al. reported that compound <b>6</b> (<b>NSC-87877</b>) had a dual SHP1 and SHP2 inhibitory activity (SHP1 IC<sub>50</sub> = 0.36 μM; SHP2 IC<sub>50</sub> = 0.32 μM) based on a high-throughput screening campaign using the NCI Diversity Set chemical library (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). By use of HEK293 and MDA-MB-468 cell lines, <b>6</b> not only inhibited the catalytic activity of the PTP domain in SHP2 but also blocked SHP2-dependent ERK1/2 activation effectively.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a><b>6</b> displayed IC<sub>50</sub> values in the micromolar range against several leukemic cell lines, but this compound showed no differential sensitivity between <i>PTPN11</i>-mutated cells and wild-type cells in four tissue samples collected from AML patients.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a><b>6</b> was the first compound identified as an SHP2 PTP inhibitor that suppressed SHP2-dependent ERK1/2 activation in cells.</div><div class="NLM_p">By screening a library of 10 000 natural products targeting the peripheral site of the PTP catalytic cleft, Qu and co-workers identified cryptotanshinone <b>7</b> as a dual inhibitor against SHP1 and SHP2 (SHP1 IC<sub>50</sub> = 39.5 μM; SHP2 IC<sub>50</sub> = 22.5 μM). Further optimization led to the discovery of derivatives <b>8</b>–<b>10</b> with approximate 6- to 9-fold improvement in the potency of SHP1 and SHP2, respectively (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Cryptotanshinone is the major active ingredient in the root of <i>Salivia miltiorrhiza</i> Bunge used in traditional Chinese medicine.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Previous studies showed that <b>7</b> can act as an oxygen radical generator<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> and inhibited Tyr705 phosphorylation in STAT3.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Whether <b>7</b> is promiscuous against SHP1 and SHP2 remains to be determined.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and IC<sub>50</sub> values of compounds <b>7</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the structural comparison discussed in <a class="ref internalNav" href="#sec4" aria-label="section 4">section 4</a>, SHP2 and SHP1 have high sequence similarity and are more divergent from PTP1B in the PTP domain. Highly selective type I inhibitor between SHP1 and SHP2 can be challenging to discover and develop. However, Hellmuth’s and Lawrence’s groups described compounds that exhibited more than 10-fold selectivity between SHP1 and SHP2 (more potent toward SHP2). In 2008, Klaus Hellmuth and co-workers identified phenylhydrazonopyrazolone sulfonate <b>11</b> (<b>PHPS1</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) as a selective SHP2 inhibitor against SHP1 and PTP1B using a high-throughput screening approach (SHP1 IC<sub>50</sub> = 30 μM; SHP2 IC<sub>50</sub> = 2.1 μM; PTP1B IC<sub>50</sub> = 19 μM). On the basis of their docking analysis of <b>11</b> with SHP2 (the docking mode of <b>11</b> with SHP2 was not shown), the sulfonic acid group was suggested to function as a pTyr mimetic and extended to the substrate-binding pocket. Titration studies showed that inhibition of SHP2 by <b>11</b> followed the Michaelis–Menten equation, indicating that this inhibitor functioned as a substrate competitive inhibitor. Addition of the carboxylic ethyl ester group to <b>11</b> resulted in a 3-fold improvement in potency (<b>12</b>, SHP1 IC<sub>50</sub> = 1.8 μM; SHP2 IC<sub>50</sub> = 0.63 μM; PTP1B IC<sub>50</sub> = 2.1 μM, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). However, <b>11</b> gave better selectivity for SHP2 against other PTPs and inhibited SHP2-dependent activation of the RAS/MAPK pathway specifically in the SHP2<sup>E76K</sup> HEK293 cells. Further, <b>11</b> could block the increased phosphorylation of ERK1/2, the upregulation of the ErbB2 receptor, and the function of GAB2 adaptor in the SHP2<sup>E76K</sup> HEK293 cells.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Progressive development of compounds <b>11</b>–<b>17</b> and the binding model of <b>17</b> with SHP2. The binding model of <b>17</b> (green) with SHP2 (gray) is reproduced in reference to the work published by Grosskopf et al. using the crystal structure of SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3">3ZM3</a>) and the Glide program.<a onclick="showRef(event, 'ref115 ref116 ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117 ref118">(115−118)</a> Alignment of the crystal structure of malate (orange) with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O">3B7O</a>)<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3">3ZM3</a>) highlights the location of the potential phosphate group in pTyr. Hydrogen bonds are depicted by cyan dashed lines. The view of the model is oriented similarly to that reported in Grosskopf et al.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further modification and optimization strategies implemented by Rademann and co-workers furnished novel <b>PHPS1</b> derivatives giving <b>13</b>–<b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Introduction of various substituents to this phenyl ring may potentially form additional interactions with the surface of SHP2. 4-Trifluoromethyl and 4-chloro derivatives of <b>11</b> (<b>15</b> and <b>16)</b> were equally tolerated. Substitution of 4-methyl and 4-methoxy to <b>11</b> (<b>13</b> and <b>14</b>) led to 4-fold increase in potency. An optimized inhibitor, <b>17</b> (<b>GS-493</b>, SHP1 IC<sub>50</sub> = 2.08 μM; SHP2 IC<sub>50</sub> = 71 nM; PTP1B IC<sub>50</sub> = 3.17 μM) containing a 4-nitro group, was obtained (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). On the basis of their reported binding mode of <b>17</b>, the benzenesulfonic group mimics the pTyr to interact with Cys459 and the two nitrobenzene groups extended into two regions in the binding site (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). All the compounds exhibited preferred inhibitory activity against SHP2. <b>17</b> was the most potent type I SHP2 inhibitor reported in their works and exhibited better specificity than <b>11</b> against SHP2. However, no cocrystal structures were available from the study. On the basis of the model of <b>17</b> with SHP2 proposed in the study<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), Arg362 in SHP2 may interact with <b>17</b> and the corresponding residue is Lys356 in SHP1 (cf. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). Although Arg362 interacts more strongly than Lys356 with the nitrobenzene group via a cation−π interaction, the underlying selectivity of <b>17</b> between SHP1 and SHP2 remains to be determined. In the scatter assay with HPAF II pancreatic cancer cells, <b>17</b> reversed the HGF/SF-induced endothelial mesenchymal transition completely. Additionally, <b>17</b> was found to inhibit the anchorage-independent colony formation of NSCLC cell line LXFA 526L. In the LXFA 526L tumor xenograft model, <b>17</b> was administrated through intraperitoneal (ip) injection once daily and induced 42.6% tumor regression at a dose of 46 mg/kg, while the median relative tumor volume remained constant.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values of Compounds <b>13</b>–<b>17</b> against SHP1, SHP2, and PTP1B</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">SHP1</th><th class="colsep0 rowsep0" align="center" char=".">SHP2</th><th class="colsep0 rowsep0" align="center" char=".">PTP1B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">9.83</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">6.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">2.14</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">6.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">14.4</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="char" char=".">1.16</td><td class="colsep0 rowsep0" align="char" char=".">8.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b> (<b>GS-493</b>)</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td><td class="colsep0 rowsep0" align="char" char=".">3.17</td></tr></tbody></table></div></div><div class="NLM_p">Lawrence et al.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> reported another type I inhibitor exhibiting selectivity between SHP2 and SHP1. This group initially identified an oxindole derivative <b>18</b> (<b>NSC-117199</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) as a potential SHP2 inhibitor (SHP1 IC<sub>50</sub> = 68 μM, SHP2 IC<sub>50</sub> = 46.8 μM, PTP1B <i>K</i><sub>i</sub> = 96.7 μM). The binding model of <b>18</b> and SHP2 suggested that extension of the hydrazone aromatic ring to the PTP active site allowed the nitro group to mimic the phosphate substrate, whereas the sulfonic acid group formed additional hydrogen bonds with Arg362 and Lys366. On the basis of their model, the oxindole of <b>18</b> pointed well into the catalytic site, indicating that hydrazine and sulfonic acid could be replaced by other polar groups. The potency of bis-carboxylic derivative <b>19</b> (SHP1 IC<sub>50</sub> = 15.4 μM; SHP2 IC<sub>50</sub> = 0.8 μM; PTP1B IC<sub>50</sub> = 1.5 μM) was improved by 58-fold compared with <b>18</b>. 3-Carboxylic derivative <b>20</b> showed weak activity (SHP1 IC<sub>50</sub> = 72.5 μM, SHP2 IC<sub>50</sub> = 15.8 μM, PTP1B IC<sub>50</sub> = 38.2 μM), further demonstrating the importance of the carboxylic group position at the hydrazine aromatic ring. More efforts to enhance the inhibitory activity and selectivity by the group led to the identification of <b>21</b> (SHP1 IC<sub>50</sub> = 18.3 μM; SHP2 IC<sub>50</sub> = 1 μM; PTP1B IC<sub>50</sub> = 14.5 μM) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Interestingly, the carboxyl group positioned at the 3-position of the hydrazine aromatic ring in the sulfonamide derivatives produced better activity and selectivity. Introducing a sulfonamide group also greatly improved the solubility of <b>21</b>. The selectivity of compounds in this series was attributed to a more positively charged environment in SHP2 than SHP1 and the potential interaction of the compounds with different residues between SHP2 and SHP1 based on their models including SHP2 (Arg362) versus SHP1 (Lys356) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). No cocrystal structures of SHP2 with the compounds were available to provide structural insights.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures and IC<sub>50</sub> values of <b>18</b>–<b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although sulfonic acid, carboxyl, or nitro groups can be a pTyr mimic, these derivatives are not drug-like and have poor membrane permeability and bioavailability. Further, pTyr in the substrate is not sufficient to achieve high affinity, and many residues flanking pTyr are found essential for the substrate binding.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Thus, designing novel SHP2 inhibitors to simultaneously bind to the catalytic site and a nearby less-conserved subpocket may produce higher activity, selectivity, and druggability. On the basis of this design idea, Zhang et al. identified a series of hydroxyindole carboxyl derivatives as SHP2 inhibitors (<b>23</b>, SHP1 IC<sub>50</sub> = 15.7 μM; SHP2 IC<sub>50</sub> = 5.5 μM; PTP1B IC<sub>50</sub> = 14.3 μM, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Because the indole motif was considered as one of the ideal scaffolds for drug development, an indole-based salicylic acid derivative <b>22</b> was selected to mimic pTyr. The biphenyl group in <b>23</b> was expected to extend to the subpocket, giving <b>23</b> a highly specific mode of interaction with SHP2 in contrast to other PTPs (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and IC<sub>50</sub> values of compounds <b>22</b>–<b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As demonstrated in the X-ray structure of <b>23</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a>), the salicylic acid moiety of <b>23</b> (mimicking pTyr) docked into the binding pocket and established extensive interactions with residues in the PTP signature motif including the pTyr, P, and WPD loops (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The phenolic hydroxyl group of <b>23</b> formed a hydrogen bond with Arg465 of the P loop, whereas the carboxyl group formed two polar interactions with Arg465 and Gln510 and two hydrogen bonds with Arg465 and Trp423, respectively (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). The salicylic acid scaffold also formed water-mediated interaction with Pro424, Asp425, and Gly427 of the WPD loop and Ser460 of the P loop. Further study of the <b>23</b> and SHP2 complex revealed that the biphenyl group stacked between the side chains of Arg362 and Lys364 in the β<sub>5</sub>–β<sub>6</sub> loop was likely responsible for the potency and selectivity of <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Removing the biphenyl group (<b>22</b>) and replacing it with a phenyl group (<b>26</b>) resulted in 38.5- and 15.6-fold reduction, respectively, suggesting the importance of interaction between the biphenyl group and peripheral less-conserved residues (SHP2<sup>R362</sup>/SHP1<sup>K364</sup>). Either a decrease or an increase of the linker length (<b>24</b> and <b>25</b>) led to about 2-fold reduction in potency, further demonstrating the importance of the biphenyl group. The structure also indicated that binding of <b>23</b> disrupted the close conformation of the WPD loop, suggesting that <b>23</b> may be distinctive from SHP2 inhibitors requiring the closed WPD loop for high affinity.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) X-ray crystallography structure of <b>23</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a>). (B) Alignment of SHP2/23 with SHP1/JAK1<sub>AL</sub> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GS0">4GS0</a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> JAK1<sub>AL</sub> is a JAK1 activation loop peptide containing a difluorophosphonomethyl phenylalanine group mimicking phosphotyrosine. (C) X-ray crystallography structure of <b>11c-9</b> (an analog of <b>27</b>) with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PVG">4PVG</a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> (D) Alignment of SHP2/<b>11c-9</b> with SHP1/JAK1<sub>AL</sub>. The P, WPD, Q, pY loops, and the β5−β6 loop are colored in pink, blue, green, orange, light green, respectively. Amino acids interact with the ligands are shown in the stick models and labeled. Water molecules are depicted as red spheres. Hydrogen bonds are shown as cyan dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the mutant SHP2 assay, <b>23</b> showed weaker potency against SHP2 mutants, including SHP2<sup>K364R</sup> (IC<sub>50</sub> = 9 μM) and SHP2<sup>K364S</sup> (IC<sub>50</sub> = 10.8 μM), suggesting the importance of Lys364 in potency and selectivity (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). In the HEK293 and NIH3T3 cell lines, <b>23</b> strongly inhibited ERK1/2 activation in a dose-dependent manner. <b>23</b> also inhibited SHP2 mutant (SHP2<sup>E76K</sup> and SHP2<sup>D61Y</sup>)-induced hematopoietic progenitor hyperproliferation in response to GM-CSF.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In the FLT3-ITD-bearing cell line, recruitment of SHP2 to FLT3-ITD contributes to STAT5 activation and STAT5 phosphorylation (p-STAT5).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> STAT5 is likely phosphorylated by Src family kinases (SFK) after SFK is dephosphorylated by SHP2. SHP2 was also found colocalized with p-STAT5 in the nucleus to promote the expression of proleukemogenic genes including <i>BCL2L1</i> encoding Bcl-xL in the same cell line. Administration of <b>23</b> showed suppressed FLT3 ligand-stimulated phosphorylation of STAT5 and inhibited proliferation of the N51-FLT3-expressing cell likely attributed to inhibition of the dual roles of SHP2 on STAT5 activation in the FLT3-ITD-expressing cells.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p">Though the salicylic acid scaffold was proved to serve as a pTyr mimetic and exhibited excellent cellular activity, the activity and selectivity of <b>23</b> were still unsatisfactory and insufficient for further development. In 2014, a novel series of SHP2 inhibitors containing salicylic acid scaffold were discovered by the same research group.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> In this study, a fragment-based library screening strategy was employed to convert <b>23</b> into more potent and selective SHP2 inhibitors <b>27</b>-<b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). On the basis of their analysis, no significant contact between the triazol linker of <b>23</b> and SHP2 was noted, and this linker was first removed. In addition, little interaction between the 2-phenyl group and SHP2 was observed. Their molecular modeling analysis suggested that functionalized modification at the meta-position of the 2-phenyl group could increase the affinity between the inhibitor and the SHP2 active site. In their SAR exploration of the 2-phenyl group, several compounds (<b>27</b>–<b>30)</b> gave submicromolar IC<sub>50</sub> values. Among them, <b>27</b> exhibited the best inhibitory activity against SHP2.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and IC<sub>50</sub> values of compounds <b>27</b>–<b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Their study also showed that replacement of the thiophene ring with a phenyl group decreased potency by about 3-fold (<b>28</b> versus <b>27</b>) while a cyano substitution at the 4-position of the phenyl group (<b>29</b>) improved potency. The 3-position substitution of a thiophenyl group led to a 3-fold reduction in potency (<b>30</b> versus <b>27</b>), and replacing the oxalic linker with a succinic linker to extend the length also reduced the potency by 10-fold (<b>31</b> versus <b>27</b>). Overall, introducing either an oxalic linker or a biaryl group is preferred for the potency. In the PTP selectivity profiling, they showed that <b>27</b> exhibited 7-fold and 11-fold preference for SHP2 over SHP1 and PTP1B (SHP1 IC<sub>50</sub> = 1.44 μM; SHP2 IC<sub>50</sub> = 0.2 μM; PTP1B IC<sub>50</sub> = 2.29 μM). (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><div class="NLM_p">The study by Zeng et al.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> suggested that the binding model of <b>27</b> and SHP2 was similar to the crystal structure of <b>23</b> and SHP2. In a crystal structure of <b>11c-9</b> (SHP2 IC<sub>50</sub> = 14 μM and an analog of <b>27</b>) with SHP2 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>C,D), the hydroxyindole carboxyl group of <b>11c-9</b> also docked into the PTP catalytic site, but the hydroxyindole carboxyl moiety of <b>11c-9</b> was oriented 180° from that in <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a><b>)</b>. For <b>11c-9</b>, the carboxyl group formed hydrogen bonds with Arg465, Ser450, Ala461, and the phenolic hydroxyl group interacted with the backbone amide group of Arg465 in the P loop. Overall, the hydroxyindole carboxyl group of <b>11c-9</b> mimics the pTyr motif at the catalytic site and the indole moiety of <b>11c-9</b> in the catalytic site formed van der Waals contacts with several residues in the P loop (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>D). The crystal structure also showed that the distal benzo[<i>d</i>][1,3]dioxole tail interacted with the side chains of Arg362 and Lys364 at the β<sub>5</sub>–β<sub>6</sub> loop. Similarly, a more rigid phenylthiophene group in <b>27</b> was expected to exert more optimal interaction with the β<sub>5</sub>–β<sub>6</sub> loop based on their molecular modeling. On the basis of the modeling data, the more favorable interactions between <b>27</b> and SHP2 were suggested to contribute to the improved potency and selectivity of <b>27</b>.</div><div class="NLM_p">In their mutant SHP2 assay, the potency of <b>27</b> for SHP2<sup>R362A</sup> and SHP2<sup>K364S</sup> was reduced by 2.2-fold and 1.5-fold compared with that of the wild-type SHP2, supporting the importance of interaction between phenylthiophene group and Arg362/Lys364 of the β<sub>5</sub>–β<sub>6</sub> loop. Additionally, <b>27</b> inhibited EGF-induced ERK1/2 phosphorylation in a dose-dependent manner and increased the phosphorylation level of Tyr118 in paxillin (a substrate of SHP2) in the patient-derived NSCLC cell line H1975. As expected, <b>27</b> showed potent antiproliferative activity against the H1975 lung cell, the ErbB2-positive SKBR3 breast cancer cell, and the oncogenic KIT<sup>D814V</sup>-bearing 32D myeloid cell. However, <b>27</b> did not exhibit any significant suppression of the growth of the wild-type KIT-bearing cells at 1 or 5 μM.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a><b>27</b> also effectively blocked ERK1/2 and AKT activation in the MeWO and B16F10 metastatic melanoma cell lines. In the melanoma xenograft models, daily administration of <b>27</b> once through the ip route significantly suppressed tumor growth by 52% at a dosage of 15 mg/kg.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">Most of the PTP inhibitors containing a pTyr mimic are known to possess poor bioavailability. To overcome this problems, Zhang and co-workers<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> screened the Johns Hopkins Drug Library and identified cefsulodin <b>32</b> (a β-lactam antibiotic, SHP2 IC<sub>50</sub> = 16.8 μM, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) as an SHP2 inhibitor. <b>32</b> displayed over 10-fold selectivity against other PTPs except SHP1. When solving the crystal structure of <b>32</b> with SHP2, they found that a hydrolyzed product of <b>32</b>, namely, <b>33</b>, instead bound to the SHP2 catalytic site. This finding was verified using kinetic and mass spectrometry analyses. Their investigation showed that binding of cefsulodin <b>32</b> to SHP2 led to the hydrolysis of the β-lactam ring and the formation of the hydrolyzed intermediate (<b>33</b>). Besides the binding of <b>33</b> to the PTP domain in SHP2, they also found that <b>33</b> could form a covalent adduct with Cys318 from the surface of SHP2 in an asymmetric unit. In the X-ray structure of <b>33</b> with SHP2 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B), the sulfonic acid formed multiple hydrogen bonds with Ser460, Ala461, Ile463, Gly464, and Arg465 in the P loop, and the phenyl group extended to a hydrophobic pocket formed by Tyr279, Ile282, Ala461, and Ile463. Further, the carboxyl group made multiple water-mediated polar interaction with Thr507 and Gln510 in the Q loop as well as Trp423 and Gly427 in the WPD loop (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). On the basis of the structure of <b>33</b> and hits identified from the fragment-based focused library screening, <b>34</b> was developed, conferring an enhanced activity and selectivity (SHP1 IC<sub>50</sub> = 7.3 μM; SHP2 IC<sub>50</sub> = 1.5 μM; PTP1B IC<sub>50</sub> = 9.3 μM). <b>34</b> could inhibit the proliferation of the H1975 cell, the MDA-MB-231 cell, and the ErbB2-positive SKBR3 breast cancer cell in a dose-dependent manner and also increase the phosphorylation level of Tyr118 in paxillin.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Structures and IC<sub>50</sub> values of <b>32</b>–<b>34</b>. (B) X-ray crystallography structure of <b>33</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RDD">4RDD</a><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a>). Water molecules are shown in red spheres, and hydrogen bonds are depicted as cyan dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2013, Qu et al. identified a relatively less potent SHP2 inhibitor <b>35</b> (SHP1 IC<sub>50</sub> = 37.7 μM; SHP2 IC<sub>50</sub> = 13.9 μM), which could downregulate RAS/ERK, PI3K/AKT, and Jak2/STAT5 pathways. Compared with the wild-type SHP2 cell, the SHP2<sup>E76K</sup> mutant cell line was more sensitive to compound <b>35</b>. <b>35</b> blocked the GM-CSF-induced colony formation of myeloid blast cells from the SHP2<sup>E76K</sup> mutant JMML patients (IC<sub>50</sub> = 7.24 μM) and inhibited the proliferation of JMML cells in the presence of GM-CSF (IC<sub>50</sub> = 3.09 μM).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In 2015, Chen et al. identified fumosorinone <b>36</b> as a selective SHP2 inhibitor (SHP2 IC<sub>50</sub> = 6.3 μM). <b>36</b> inhibited EGF-induced ERK1/2 and RAS activation in the HeLa and the HEK293T cell lines.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> In 2017, Zhou et al.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> reported another series of 1<i>H</i>-2,3-dihydroperimidine derivatives as SHP2 inhibitors, and the representative compound <b>37</b> also had weak inhibitory activity and selectivity against SHP2 in the biochemical assay (SHP1 IC<sub>50</sub> = 4.28 μM; SHP2 IC<sub>50</sub> = 2.11 μM; PTP1B IC<sub>50</sub> = 50.2 μM) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). <b>37</b> is relatively small in size (molecular weight = 175) and contains a thiol-reactive chemotype that exhibits promiscuous activity.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Further evaluation of the on-target activity of <b>37</b> will be needed.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures and IC<sub>50</sub> values of compounds <b>35</b>–<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">5.2.  Type II SHP2 Inhibitors</h3><div class="NLM_p">Highly conserved sequences in the catalytic site among PTPs present a considerable challenge in obtaining the PTP domain targeted inhibitors achieving high selectivity. Additionally, the positively charged environment in the PTP catalytic site requires type I SHP2 inhibitors to have multiple negative ionizable functional groups (e.g., sulfonic acid, carboxyl, and nitro groups) for a strong interaction. These functional groups generally give poor cell permeability and oral bioavailability in drug development.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Because of these underlying issues, type I SHP2 inhibitors typically lacked acceptable selectivity against other PTPs (SHP1 and PTP1B especially) and favorable drug-like properties<a onclick="showRef(event, 'ref84 ref129'); return false;" href="javascript:void(0);" class="ref ref84 ref129">(84,129)</a> for interrogating the role of SHP2 in oncogenic signaling pathways in preclinical studies.</div><div class="NLM_p">“The best way to tackle the phosphatase class of target is with allostery”, said Geraldine Harriman, CSO and cofounder of a company devoted to discovering PTP allosteric candidates.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Recent discovery of compounds binding to the allosteric pockets in phosphatases thus incites enthusiasm in the pharmaceutical industries seeking alternative development strategies. Currently, at least nine phosphatase inhibitors are in clinical trials, and five of them are allosteric inhibitors, including four SHP2 inhibitors, <b>JAB-3068</b>, <b>TNO155</b>, <b>RMC-4630</b>, and <b>RLY-1971</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Advancement of SHP2 inhibitors to clinical trials has further renewed a broader interest by the therapeutic development community to develop allosteric inhibitors targeting other proteins in the PTP family.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Select List of Phosphatase Inhibitors in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">NCT identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>IFB-088</b></td><td class="colsep0 rowsep0" align="left">InFlectis BioScience</td><td class="colsep0 rowsep0" align="left">PPP1R15A</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Charcot–Marie–Tooth disease</td><td class="colsep0 rowsep0" align="left">NCT03610334</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>LB-100</b></td><td class="colsep0 rowsep0" align="left">Lixte Biotechnology</td><td class="colsep0 rowsep0" align="left">PP2A</td><td class="colsep0 rowsep0" align="left">Catalytic inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">NCT01837667</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">Recurrent glioblastoma</td><td class="colsep0 rowsep0" align="left">NCT03027388</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AKB-9778</b></td><td class="colsep0 rowsep0" align="left">Aerpio Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">VE-PTP</td><td class="colsep0 rowsep0" align="left">Catalytic inhibitor</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">Retinal vein occlusion</td><td class="colsep0 rowsep0" align="left">NCT02387788</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Nonproliferative diabetic retinopathy</td><td class="colsep0 rowsep0" align="left">NCT03197870</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Diabetic macular edema</td><td class="colsep0 rowsep0" align="left">NCT01702441</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02050828</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>PRL3-zumab</b></td><td class="colsep0 rowsep0" align="left">A*STAR</td><td class="colsep0 rowsep0" align="left">PRL3</td><td class="colsep0 rowsep0" align="left">Monoclonal antibody</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Advanced solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03191682</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>MSI-1436</b></td><td class="colsep0 rowsep0" align="left">Genaera Corporation</td><td class="colsep0 rowsep0" align="left">PTP1B</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Diabetes mellitus</td><td class="colsep0 rowsep0" align="left">NCT00806338</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JAB-3068</b></td><td class="colsep0 rowsep0" align="left">Jacobio</td><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Advanced solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03518554</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>TNO155</b></td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Advanced solid tumor</td><td class="colsep0 rowsep0" align="left">NCT03114319</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>RMC-4630</b></td><td class="colsep0 rowsep0" align="left">Revolution Medicines/Sanofi</td><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Relapsed/refractory solid tumor</td><td class="colsep0 rowsep0" align="left">NCT03634982</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>RLY-1971</b></td><td class="colsep0 rowsep0" align="left">Relay Therapeutics</td><td class="colsep0 rowsep0" align="left">SHP2</td><td class="colsep0 rowsep0" align="left">Allosteric inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Advanced or metastatic solid tumors</td><td class="colsep0 rowsep0" align="left">NCT04252339</td></tr></tbody></table></div></div><div class="NLM_p">In this pursuit, Novartis was the first to identify the allosteric SHP2 inhibitors. In 2015, Novartis reported a new series of allosteric SHP2 inhibitors based on a pyrazinyl core.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> By employment of a high-throughput screening approach, <b>38</b> (<b>SHP836</b>) was identified as a weak allosteric SHP2 inhibitor giving an IC<sub>50</sub> > 100 μM against the PTP catalytic domain of SHP2 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). The X-ray structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>) revealed and confirmed that <b>38</b> did not bind to the PTP catalytic pocket but to a tunnel-like pocket surrounded by the C-SH2, N-SH2, and PTP domains (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>A). In the structure, the aminopyrimidine group of <b>38</b> formed a hydrogen bond with Glu250, and the dichlorophenyl group extended to a hydrophobic pocket formed by Arg111, Thr253, Leu254, Gln257, and Gln495. The dichlorophenyl group also partially formed a cation−π interaction with Arg111; note that two alternative Arg111 conformations were resolved. Binding of this tunnel-like allosteric pocket with <b>38</b> stabilized the autoinhibited conformation of SHP2 in which the catalytic site was inaccessible to the substrate. The structure also showed that the methyl groups of <b>38</b> formed van der Waals interaction with His114 and Glu249 of SHP2 and the solvent-exposed piperazine ring system can be subject to further modifications (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>B).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures and IC<sub>50</sub> values of compounds <b>38</b>–<b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. (A) X-ray crystallography structure of <b>38</b> with SHP2 in the close conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a><a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>). (B) Binding mode of <b>38</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>). (C) Binding mode of <b>46</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In their SAR study, replacement of dimethylpiperazine with 4-amino-4-methylpiperdine or pyrimidine with pyrazine indeed improved inhibition activity (<b>46</b>, <b>SHP099</b>, SHP2 IC<sub>50</sub> = 0.07 μM). For the dichlorophenyl moiety, removing or repositioning the halogen group resulted in a considerable reduction in potency (<b>38</b> versus <b>39</b>–<b>41</b>). Further, replacing piperazine with 4-aminopiperidine resulted in a 10-fold improvement in biochemical activity (<b>42</b> versus <b>38</b>). Although replacing the amino group with the dimethylamino group reduced the inhibitory activity by 5-fold (<b>43</b> versus <b>42</b>), yet adding a methyl group to the piperidine ring further improved potency by 5-fold likely through conformationally fixing of the amino conformation (<b>44</b> versus <b>42</b>). Further modification at the central pyrimidine ring showed replacement of pyrimidine with 1,2,4-triazine was tolerated (<b>44</b> versus <b>45</b>), and the aminopyrazine core (<b>46</b>, <b>SHP099</b>) produced the greatest inhibition activity in the biochemical assay. In contrast, deletion of amino or introduction of methylamino to the pyrazine ring reduced the potency significantly (<b>47</b> and <b>48</b>) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Comparison of the X-ray structures of <b>46</b>/SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a>) and <b>38</b>/SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>) further elucidated that three more hydrogen bonds were formed between 4-amino-4-methylpiperdine in <b>46</b> and Glu110, Thr108, and Phe113 from the N-SH2 and C-SH2 domains (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>C). The multiple hydrogen bond interactions between <b>46</b> and SHP2 appeared to play an important role in the activity improvement of <b>46</b>. Further, the pyrazine group of <b>46</b> not only maintained the same hydrogen bond with Glu250 as <b>38</b> but also made a partial new hydrogen bond with Arg111 (two conformations were resolved, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>C). The new hydrogen bond between <b>46</b> and Arg111 may further stabilize the cation−π stacking interaction between the dichlorophenyl group and Arg111. The structure also showed that the dichlorophenyl group of <b>46</b> extended to the hydrophobic pocket surrounded by Leu254, Gln257, Pro491, and Gln495 in the PTP domain (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>C) and contributed to the potency of <b>46</b>. A recent study showed that binding of <b>46</b> with the mutant SHP2<sup>E76K</sup> is weaker (<i>K</i><sub>D</sub> = 1.5 versus 0.073 μM for SHP2<sup>WT</sup>) but can also stabilize the autoinhibited SHP2<sup>E76K</sup> conformation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><div class="NLM_p">In the selectivity evaluation, <b>46</b> exhibited no inhibitory activity in 21 phosphatases and 66 kinases, indicating that <b>46</b> was highly selective for SHP2. In the SHP2-dependent cancer cell lines, MDA-MB-468 and KYSE520, <b>46</b> inhibited the phosphorylation level of ERK with an IC<sub>50</sub> value of 0.25 μM. In the antiproliferation studies, the oncogenic RTK-mutated hematopoietic cancer cell lines (e.g., MV-4-11 and EOL-1) were sensitive to <b>46</b>, whereas the colorectal cancer cell lines (e.g., NCI-H508 and HT115) sensitive to the HER1/2 and EGFR inhibitors also responded to <b>46</b>. In contrast, the RAS or <i>BRAF</i>-mutated cancer cell lines (e.g., HCT116) were resistant to <b>46</b>.<a onclick="showRef(event, 'ref131 ref133'); return false;" href="javascript:void(0);" class="ref ref131 ref133">(131,133)</a> In the esophageal squamous carcinoma KYSE-520 xenograft model, <b>46</b> demonstrated antitumor activity in a dose-dependent manner and achieved tumor stasis at a dose of 100 mg/kg.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Among the four common oncogenic SHP2 mutants (SHP2<sup>D61Y</sup>, SHP2<sup>E69K</sup>, SHP2<sup>A72V</sup>, and SHP2<sup>E76K</sup>), only SHP2<sup>E69K</sup> was sensitive to <b>46</b>. <b>46</b> not only reduced the expression of p-ERK1/2 and Bcl-XL in the SHP2<sup>E69K</sup>-expressing erythroleukemic TF-1 cell line but also inhibited the proliferation of the TF-1 cell line with an IC<sub>50</sub> value of 0.42 μM.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Further, <b>46</b> increased the expression of IFN-γ/granzyme B and the number of CD8<sup>+</sup>IFN-γ<sup>+</sup> and CD8<sup>+</sup>GZMB<sup>+</sup> cells in tumor tissues. In the colon cancer MC-38 and colorectal carcinoma CT-26 xenograft models, a combination of <b>46</b> and anti-PD-1 increased the level of cytokines/granules expressed by cytotoxic T cells and exhibited a significant synergistic antitumor effect.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p"><b>46</b> (<b>SHP099</b>) was the first potent, highly selective, and bioavailable allosteric SHP2 inhibitor that stabilized the autoinhibited SHP2 conformation. Further optimization was explored and patented by Novartis in the following few years.<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137−139)</a> For example, <b>49</b> and <b>50</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) had identical bioactivity as <b>46</b>. On the basis of <b>46</b>, incorporation of a thioether linker and a spiro-heterocycle into the aminopyrazine ring resulted in <b>51</b> giving 7-fold higher activity. Furthermore, introducing tetrahydro-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidine (<b>52</b>, SHP2 IC<sub>50</sub> = 1 nM) gave 10-fold improvement in potency compared with <b>51</b>. In 2019, Novartis reported aminopyrimidinone derivatives of <b>SHP099</b> (<b>53</b>–<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Replacement of aminopyrazine with aminopyrimidinone led to <b>53</b> (SHP2 IC<sub>50</sub> = 12 nM) giving acceptable cellular potency (p-ERK IC<sub>50</sub> = 49 nM), suggesting the aminopyrimidinone scaffold could be further optimized. This hypothesis led to cyclization of the spirocyclic ether in <b>54</b> producing a 2-fold improvement in potency (SHP2 IC<sub>50</sub> = 5 nM, p-ERK IC<sub>50</sub> = 5 nM). Though high potency, drug exposure, and bioavailability were found, <b>54</b> had undesirable hERG inhibition (hERG IC<sub>50</sub> = 4 μM). Redesign of the dichlorophenyl group resulted in <b>55</b> with trifluoromethylpyridine (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). <b>55</b> not only exhibited acceptable hERG selectivity and pharmacokinetic properties (hERG IC<sub>50</sub> > 30 μM) but also produced a dose-dependent reduction of tumor growth in the Detroit-562 xenograft model.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures, IC<sub>50</sub> values, and development paths of compounds <b>49</b>–<b>55</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another series of pyrazolopyrimidinone derivatives of <b>SHP099</b> were also described by Novartis (<b>56</b>, <b>58</b>, and <b>59</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a><b>56</b> exhibited high potency (SHP2 IC<sub>50</sub> = 67 nM) against SHP2 that was comparable to <b>46</b>. Further optimization of <b>56</b> by introducing spirocyclic amine resulted in 62-fold improvement compared to <b>58</b> in the p-ERK modulation but no benefit in hERG inhibition. Of note, the pyrazolopyrazine derivative, <b>57</b>, was a remarkably potent SHP2 inhibitor (SHP2 IC<sub>50</sub> = 6 nM), but the development of <b>57</b> was unfortunately terminated because of its hERG inhibition (hERG IC<sub>50</sub> = 4 nM). Finally, replacing the dichlorophenyl group with cyclopropyl aminopyridine led to <b>59</b> with similar potency and acceptable hERG inhibition (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>A). In the X-ray structure of <b>59</b> and SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDC">6MDC</a>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>B), the pyrazolopyrimidinone carbonyl and N–H groups formed hydrogen bonds with Arg111 and Glu250, respectively, while the spirocyclic amino group formed one hydrogen bond with Phe113. In addition, spirocyclic amine formed hydrogen bonds with Thr108, Glu110, and Phe113.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. (A) Structures, IC<sub>50</sub> values, and development paths of compounds <b>56</b>–<b>59</b>. (B) X-ray crystallography structure of <b>59</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDC">6MDC</a><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of <b>SHP099</b>, another series of compounds were described by Revolution Medicines.<a onclick="showRef(event, 'ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145">(143−145)</a> The representative compounds <b>60</b> (<b>RMC-4550</b>), <b>61</b>, and <b>62</b> showed high SHP2 inhibitory activity giving IC<sub>50</sub> values of 1.5 nM, 37 nM, and 34 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Among them, <b>60</b> was a highly potent and selective SHP2 allosteric inhibitor with IC<sub>50</sub> values of >10 μM against 14 other phosphatases including SHP1 and PTP1B. <b>60</b> induced a dose-dependent reduction in p-ERK level with an IC<sub>50</sub> value of 31 nM in the PC9 cell line, and <b>60</b> is effective against the cancer model bearing the class 3 BRAF mutation (RAS mutations or NF1 deletion).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In the NCI-H1838, NCI-H358, and MIA PaCa-2 xenograft models, <b>60</b> suppressed tumor growth and <i>in vivo</i> p-ERK level in a concentration-dependent manner. Dose-dependent tumor growth inhibition was also observed in patient-derived xenograft models (<i>BRAF</i>-mutated NSCLC, LUN023, and LUN037).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures and IC<sub>50</sub> values of <b>60</b>–<b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oral daily administration of <b>60</b> at 30 mg/kg could suppress the tumor growth significantly in CT26 tumor model. However, <b>60</b> did not suppress the viability and the level of p-ERK in CT26 cell line <i>in vitro</i>. Besides, no inhibitory effect of <b>60</b> on tumor growth was observed in CT26 tumor models established in RAG-2 deficient mice lacking T and B lymphocytes and in immunocompetent mice depleted of CD4<sup>+</sup> and CD8<sup>+</sup> T cells. These findings indicated that the immune effector cells in the tumor microenvironment are essential for the observed <i>in vivo</i> efficacy of SHP2 inhibitors.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> More importantly, <b>60</b> enhanced antitumor immunity in PD-1 sensitive tumors by improving CD8<sup>+</sup> T cell infiltration in the tumor, increasing proinflammatory M1-like macrophages, and inhibiting the CSF-1 signaling pathway in human monocytes.<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a></div><div class="NLM_p">In addition to development by Novartis and Revolution Medicines, Jacobio Pharmaceuticals,<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> Relay Therapeutics,<a onclick="showRef(event, 'ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152">(150−152)</a> Synblia,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> University of Texas,<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Otsuka Pharmaceutical,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Aray Biopharma,<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> and Hansoh Pharmaceutical<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> also published patents containing novel <b>SHP099</b> derivatives (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). For example, compound <b>63</b> showed high inhibition activity against SHP2 with an IC<sub>50</sub> value of 8 nM. On the basis of <b>63</b>, a heteroaromatic group was introduced to the spirocyclic ring to give a series of A ring and B ring derivatives. Among the A ring derivatives, <b>64</b> displayed a similar inhibitory potency to <b>63</b>. However, replacing the phenyl ring with the pyridine ring to <b>65</b> resulted in a complete loss of potency. Compared with the A ring compounds, the B ring compounds achieved higher potency (<b>66</b> versus <b>64</b>). Similar to the SAR in the A ring compounds, replacement of the phenyl ring with the pyridine ring in the B ring compounds reduced their potency (<b>67</b>–<b>69</b> versus <b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Among the B ring modifications, a thiazole group in <b>70</b> produced the highest inhibition activity (SHP2, IC<sub>50</sub> = 3 nM) (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Relay Therapeutics and Otsuka Pharmaceutical both reported a new series of <b>SHP099</b> analogs with a pyrazolopyrazine scaffold (e.g., <b>71</b> and <b>72</b>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Meanwhile, Synblia Therapeutics and the University of Texas developed pyrazinone and pyrimidone derivatives (e.g., <b>73</b> and <b>74</b>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) in patents published in 2019 and 2020. Over the years, Aray Biopharma and Hansoh Pharmaceutical both made efforts to develop effective SHP2 inhibitors based on bicyclic core scaffold (e.g., <b>75</b>, <b>76</b>, and <b>77</b>) (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures and IC<sub>50</sub> values of compounds <b>63</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and IC<sub>50</sub> values of <b>71</b>–<b>77</b>. Novelty of the compounds is highlighted by the red color.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Discovery of the allosteric SHP2 inhibitors by Novartis also inspired new development in several academic laboratories. In 2017, Zhu et al. reported a series of thiazole derivatives as novel allosteric SHP2 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> On the basis of the SHP2<sup>E76A</sup> biochemical screening assay, <b>78</b> showed inhibitory activity against SHP2<sup>E76A</sup> with an IC<sub>50</sub> value of 19.1 μM and had no inhibition activity against SHP2<sup>PTP</sup>. <b>78</b> was subsequently used as a lead compound for structure-based computational analysis and inhibitor optimization. From their study, replacement of the phenyl ring with naphthalene was found to improve potency by 7.5-fold (<b>79</b>, SHP2 IC<sub>50</sub> = 2.55 μM). Introducing substituted piperidine, pyrrolidine, or piperazine was also tolerated (<b>80</b>–<b>84</b>), but the methyl substituent on piperazine (<b>85</b>) produced weaker activity. Although <b>80</b> displayed the highest activity, this compound was unstable in the DMSO solution at −20 °C. Overall, <b>84</b> showed acceptable bioactivity and chemical stability and was selected for further optimization. In one example, the same 4-aminopiperidine group in <b>46</b> (<b>SHP099</b>) was adopted in <b>84</b>, indicating that this amino functional group in <b>84</b> may form hydrogen bonds with surrounding residues in SHP2 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>B).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> On the basis of the SAR, substituents on naphthalene, such as Cl, F, methoxy, Br, and methoxycarbonyl (<b>86</b>–<b>90</b>) were well-tolerated, suggesting that both electron-withdrawing and electron-donating groups to the phenyl group were compatible with the hydrophobic pocket. However, the carboxyl and hydroxymethyl derivatives (<b>91</b> and <b>92</b>) had almost no inhibitory activity. On the basis of their efforts, <b>89</b> (SHP2 IC<sub>50</sub> = 0.71 μM) exhibited over 30-fold selectivity against other PTPs, including SHP1 and PTP1B. When evaluated in SHP2<sup>N58S</sup> mutant NCI-H661 cancer cells and EGFR<sup>T790M</sup> mutant H1975 cancer cells, <b>89</b> inhibited the phosphorylation level of ERK and AKT. <b>89</b> also increased the phosphorylation of YAP and blocked the expression of YAP genes. In the MV-4-11 xenograft model, a daily oral administration of 10 or 30 mg/kg of <b>89</b> suppressed tumor growth by 44.6% and 56.0%, respectively.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures and IC<sub>50</sub> values of <b>78</b>–<b>92</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, LaMarche and co-workers<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> reported the discovery of two new allosteric binding sites in SHP2 that were located at the interface between the N-SH2 and the PTP domain interface and named latch-like and groove-like sites (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>A). By screening of a library of about 1.5 million compounds against SHP2, <b>93</b> (<b>SHP244</b>) was identified and showed weak inhibitory activity against SHP2 (SHP2<sup>1-525</sup> IC<sub>50</sub> = 60 μM) (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>B).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The X-ray structure of <b>93</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMR">6BMR</a>) showed that <b>93</b> bound to the latch-like binding pocket. On the basis of structural alignment, the conformation of <b>93</b>/SHP2 was similar to <b>46</b> (<b>SHP099</b>)/SHP2 protein structure (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>A). The structure also indicated that the phenol group of <b>93</b> formed a hydrogen bond with Leu262 and Arg265, and the triazole group interacted with Arg265 and Gln269. Additionally, the chlorophenyl and quinazolinone phenyl ring interacted with Gln269 and Gln79, respectively, via the cation−π interaction (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>C).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Allosteric binding sites in the autoinhibitory conformation of SHP2. (B) Structures and IC<sub>50</sub> values of <b>93</b>–<b>96</b>. (C) X-ray crystallography structure of <b>93</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMR">6BMR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the crystal structure, the chlorophenyl ring of <b>93</b> did not completely fill the hydrophobic groove. Substituted groups on the chlorophenyl ring in <b>93</b> may interact with the hydrophilic residues Lys280 and Lys274 (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>C). On the basis of this observation, <b>94</b> (<b>SHP844</b>, SHP2<sup>1-525</sup> IC<sub>50</sub> = 18.9 μM) was designed to extend to the hydrophobic channel to allow proline acid to form a hydrogen bond with Lys280. The IC<sub>50</sub> value of <b>94</b> was improved by 3-fold compared with <b>93</b>. Although deletion of the methoxy group in <b>94</b> led to a complete loss of activity in <b>95</b> (<b>SHP357</b>), yet adding the carboxy group to the 4-position of the phenol ring in <b>95</b> restored the activity (<b>96</b>, <b>SHP504</b>, SHP2<sup>1-525</sup> IC<sub>50</sub> = 21 μM) (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>B), potentially by forming a hydrogen bond with Lys266. When evaluated in the KYSE-520 cell line, <b>93</b>, <b>94</b>, and <b>96</b> produced a dose-dependent downregulation of the <i>DUSP6</i> level (a downstream marker of MAPK pathway) by 65%, 43%, and 55%, respectively. But in the <i>BRAF</i><sup><i>V600E</i></sup> mutant A375 cell, these compounds did not downregulate the transcription level of <i>DUSP6</i>. However, <b>96</b> enhanced the inhibitory activity of <b>SHP099</b> against SHP2 and combined treatment of <b>96</b> and <b>SHP099</b> induced greater downregulation of <i>DUSP6</i> compared with a single treatment, indicating that the simultaneous binding of inhibitors to the tunnel and latch allosteric pockets of SHP2 produced a synergistic effect of stabilizing the autoinhibited SHP2 conformation.</div><div class="NLM_p">Recently, Wu et al. reported the discovery of an allosteric inhibitor <b>98</b> (<b>LY6</b>, SHP2 IC<sub>50</sub> = 9.8 μM, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) using CADD (computer-aided drug design)-based <i>in silico</i> screening for discovery followed by inhibitor optimization.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> First, they analyzed potential allosteric sites for <i>in silico</i> screening using the SiteMap program.<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> Their analysis identified a much larger inner space (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>A) connected to the tunnel-like allosteric site where <b>46</b> binds (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>A). An <i>in silico</i> screening against this site was performed, which identified <b>97</b> (<b>NSC681129</b>) as the most promising lead. After conducting the lead optimization and docking calculations, <b>98</b>, <b>99</b>, and <b>100</b> were three of the top ten derivatives giving the high docking scores yet exhibiting weak inhibition activity. While <b>99</b> and <b>100</b> were excluded because of acute cytotoxicity, <b>98</b> showed 7.4-fold selectivity over SHP1 and was selected for subsequent evaluation (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>B).</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A) Larger potential allosteric binding site (cyan spheres) in SHP2 identified using the Sitemap program. This is reproduced by using the SHP2 structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a>) and the Sitemap program from the Schrodinger program suite in reference to Wu et al.’s work.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> (B) Identification of compounds <b>97</b>–<b>100</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">When evaluated in the Ba/F3 cell line, <b>98</b> blocked IL3-induced RAS/ERK, PI3K/AKT, and Jak2/STAT5 signaling pathways and inhibited IL-3 stimulated cell proliferation. Further, leukemia cells bearing SHP2<sup>E76K</sup> activating mutations from <i>PTPN11</i><sup><i>E76K/+</i></sup> mice and human JMML patients were more sensitive to the inhibitory activity of <b>98</b> compared with SHP2<sup>WT</sup> control cells. The sensitivity of <i>PTPN11</i>-mutated leukemia cells to their SHP2 inhibitors confirmed that SHP2 was a promising target for the treatment of <i>PTPN11</i>-mutated cancers.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">6.  Allosteric Inhibitors of Other PTPs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Besides the development of targeting SHP2, various allosteric inhibitors of other phosphatases have been reported including Wip1 (<b>101</b>, <b>GSK2830371</b>), PPP1R15A (<b>102</b>, <b>Sephin-1</b>), and PTP1B (<b>103</b> and <b>104</b>) allosteric inhibitors (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref163 ref164 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165 ref166">(163−166)</a> All these compounds do not bind to the catalytic pocket and induce the phosphatases to maintain catalytically unfavorable conformations.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and IC<sub>50</sub> values of compounds <b>101</b>–<b>104</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For example, the PTP1B allosteric inhibitor <b>103</b> (<b>MSI-1436</b>) binds to two allosteric pockets to lock the protein in an inactive state. The first molecule of <b>103</b> bound to the interface between α7 helix and C-terminal α9′ helix that could bring α7 helix close to α3−α6 and induce the formation of the second pocket for another molecule to bind.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> In contrast to the action of <b>103</b>, the PTP1B allosteric inhibitor <b>104</b> disrupts the interaction between α7 helix and α3−α6 and blocks the closure of the WPD loop to participate in the catalysis by maintaining the autoinhibited PTP1B conformation.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Although these inhibitors provide better potency and selectivity, developing allosteric inhibitors requires biochemical assays utilizing full-length proteins that are more likely to aggregate and possess unexpected protein behavior in vitro. This has presented a technical challenge to novel discovery. Further, smaller molecules or fragments in the library are frequently adopted in the screening campaign; these molecules have weak binding affinity and may be promiscuous, rendering the selection of candidate compounds difficult and time-consuming. Follow-up confirmation of allosteric inhibition also demands multiple experimental designs and cross-validation to eliminate compounds bound to the active sites that have been evolutionally optimized for substrates. In summary, many technical barriers need to be overcome before the discovery of allosteric inhibitors can be adapted routinely into medicinal chemistry development programs.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">7.  SHP2 Inhibitors under Clinical Trials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Currently, four SHP2 allosteric inhibitors (<b>JAB-3068</b>, <b>TNO155</b>, <b>RMC-4630</b>, and <b>RLY-1971</b>) based on the <b>SHP099</b> structure developed by Jacobio, Novartis, Revolution Medicines/Sanofi, and Relay Therapeutics are in clinical trials. These are all type II SHP2 inhibitors, and their structures have not been fully described. Among the four compounds, <b>JAB-3068</b> (Jacobio) was first granted orphan drug designation by the FDA for the treatment of esophageal cancer in February 2019 and later advanced to phase IIa clinical trials in May 2019. The clinical trials of <b>JAB-3068</b> (NCT03518554; NCT03565003; NCT04121286; NCT04045496) are ongoing and currently are focusing on efficacy evaluation. Novartis’ <b>TNO155</b> is in phase I trials as a single agent for advanced solid tumors (NCT03114319). In March 2020, a multinational phase Ib clinical trial of <b>TNO155</b> was initiated in China, but as of this writing, no efficacy data for <b>TNO155</b> have been reported.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In February 2020, another multicenter, open-label, dose escalation phase I clinical trial of <b>RLY-1971</b> (Relay Therapeutics) was initiated to evaluate its safety, tolerability, PK, and preliminary efficacy in patients with advanced or metastatic solid tumors (NCT04252339).</div><div class="NLM_p"><b>RMC-4630</b> (Revolution Medicines/Sanofi) is another orally bioavailable and potent SHP2 allosteric inhibitor. Preclinical studies have shown dose-dependent tumor growth inhibition with a repeated daily administration of <b>RMC-4630</b> in patient-derived xenograft models (<i>KRAS</i><sup>G12C</sup> LUN092 and class 3 <i>BRAF</i>-mutated LUN023 NSCLC).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In January 2020, Revolution Medicines announced preliminary data for <b>RMC4630</b> in a phase I clinical trial for NSCLC patients with <i>KRAS</i> mutant at the sixth AACR-IASLC international joint conference.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> 63 patients (35 male, 28 female, median age 64 years, range 34–84) were recruited; 49 patients were treated daily and the rest were treated intermittently. Intermittent administration resulted in fewer adverse events, indicating that the intermittent schedule was better tolerated than the daily schedule. More importantly, preliminary clinical efficacy was observed in patients with oncogenic <i>KRAS</i>-mutated NSCLC, especially <i>KRAS</i><sup>G12C</sup> mutation. <b>RMC-4630</b> is still in early clinical development as a single agent for patients with relapsed/refractory solid tumors (NCT03634982).</div><div class="NLM_p last">Because of the important role of SHP2 in regulating the reactivation of the RAS/Raf/ERK/MAPK pathway in cancers, the combination of allosteric SHP2 inhibitors with other targeted therapy on this pathway has been investigated.<a onclick="showRef(event, 'ref53 ref59 ref171 ref172 ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref53 ref59 ref171 ref172 ref173 ref174">(53,59,171−174)</a> In the preclinical studies, combination therapies were shown to be more effective than a single agent and could overcome resistance to a single agent. Examples included the combination of <b>SHP099</b> with MEK inhibitors,<a onclick="showRef(event, 'ref53 ref59 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref53 ref59 ref171 ref172">(53,59,171,172)</a> ALK inhibitors,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> and ERK inhibitors.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Combination of MEK inhibitors and <b>46</b> (<b>SHP099</b>) was shown to be especially effective in <i>KRAS</i> mutant tumors that acquired <i>KRAS</i> signaling caused by losing negative feedback inhibition due to SHP2 activation.<a onclick="showRef(event, 'ref63 ref172'); return false;" href="javascript:void(0);" class="ref ref63 ref172">(63,172)</a> Further, a low-dose combination of <b>RMC4630</b> (10 mg/kg) with the MEK inhibitor cobimetinib (2.5 mg/kg) showed synergistic efficacy in the <i>KRAS</i><sup><i>G12C</i></sup> NCI-H358 xenograft model and prevented tumor growth.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Encouraged by these data, the clinical trial combining <b>RMC4630</b> and cobimetinib (NCT03989115) is currently recruiting patients. More clinical results of <b>RMC4630</b> remain to be disclosed in the future. In addition, <b>TNO155</b> was combined with spartalizumab (a PD-1 antibody) or ribociclib (a CDK inhibitor) for advanced solid tumors (NCT04000529), with MRTX849 (a KRAS<sup>G12C</sup> inhibitor) for <i>KRAS</i><sup><i>G12C</i></sup> solid tumor (NCT04330664), and with select drugs (Dabrafenib/BRAF, LTT462/ERK, trametinib/MEK, LXH254/RAF, spartalizumab/PD-1) for advanced/metastatic <i>BRAF</i> V600 colorectal cancer (NCT04294160) in clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">8.  Future Directions To Target SHP2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Efficacy of inhibitors relies on high binding-site occupancy and usually demands high binding affinities of the inhibitors to sustain long resident time on targets.<a onclick="showRef(event, 'ref175 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177">(175−177)</a> An alternative approach to achieve efficacy is to eliminate the targeted proteins using the established genetic method such as RNA interference technology.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Genetic knockdown or deletion of SHP2 is also an important tool to identify SHP2 as a target and validate the pharmacological effects of SHP2 inhibitor in the studies of NS/LEOPARD,<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> oral cancer,<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> breast cancer cells,<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> and multiple cancer cell lines.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> For example, SHP2 knockout by CRISPR-Cas9 induces senescence in serum-limited <i>KRAS</i> mutant NSCLC cell lines <i>in vitro</i> and impairs tumor growth in xenograft models of <i>KRAS</i> mutant tumors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Knockout of the <i>PTPN11</i> gene encoding SHP2 in <i>KRAS</i> mutant human ductal adenocarcinoma (PDAC) cells also reduced tumor cell proliferation.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In both studies, <i>PTPN11</i>-knockout <i>KRAS</i> mutant cancer cells were highly responsive to MEK inhibitors. Similarly, a study using shRNA library screening identified <i>PTPN11</i> knockdown enhanced the treatment of ceritinib (an ALK inhibitor) in ALK-rearranged NSCLC by blocking the RAS and ERK1/2 reactivation.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Although <b>46</b> (SHP099) was used to demonstrate the proof-of-concept in these studies, these findings suggested that depletion of SHP2 protein could be a novel approach to enhance other targeted therapies for human cancers.</div><div class="NLM_p">Besides genetic methods, an emerging paradigm in developing small-molecule compounds to target disease-associated proteins is to chemically induce targeted protein degradation using proteolysis-targeting chimeras (PROTACs) technology.<a onclick="showRef(event, 'ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref182 ref183">(182,183)</a> Protein targets susceptible to endogenous degradation enabled by PROTACs have been increasingly reported. To date, no PROTAC-based compound that degrades SHP2 is known. However, antibodies (aNSa1 and aCS3) recognizing the N-SH2 or C-SH2 domains of SHP2 have been fused to Von Hippel–Lindau (VHL, an E3 ligase) and transfected into cells. Both the aNSa1-VHL and aCS3-VHL chimera were found to recruit endogenous SHP2 to the EloB/C/CUL2/RBX1 E3 ligase machinery and were capable of inducing SHP2 degradation.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> The finding indicated that endogenous E3 ligases can be hijacked to degrade SHP2 in cells. In the foreseeable future, the uses of the PROTAC-based SHP2 degrading molecules in cancer models remain to be fully investigated.</div><div class="NLM_p last">SHP2 also contains two SH2 domains that bind to pTyr motifs in partnering proteins. No small-molecule inhibitor targeting the SH2 domains of SHP2 was reported. Direct targeting the pTyr motif binding site in the SH2 domain may face the same challenge as those in type I inhibitors. However, allosteric molecules binding to the groove at the interface between PTP and N-SH2 (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>A) or targeting unidentified allosteric sites in either of the SH2 domains in SHP2 remain to be discovered. Combination of the PROTAC technology and these yet identified compounds to chemically induce SHP2 degradation can also be explored.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">9.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">GOF mutation or aberrant overexpression of SHP2 in various hematologic and solid tumors strongly indicates that small-molecule SHP2 inhibitors may have important therapeutic applications. Progress in the development of PTP inhibitors has lagged behind that of PTK inhibitors. A great challenge in developing highly selective PTP inhibitors to target the catalytic site is attributed to the high sequence homology in PTP catalytic pockets between different PTPs. In addition, the positive-charged environment of the PTP catalytic pocket requires multiple negatively charged groups in the type I inhibitors, rendering these inhibitors to have reduced cell permeability and bioavailability.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></div><div class="NLM_p">In the case of SHP2, significant efforts have been invested in the development of type I inhibitors. Limited success was achieved until the discovery of the first type II SHP2 inhibitor (allosteric inhibitors) in 2015. The first small-molecule candidate (<b>46</b>, <b>SHP099</b>) developed by Novartis is an SHP2 allosteric inhibitor that locks SHP2 into an autoinhibited conformation. In the following 5 years, additional allosteric binding pockets/allosteric inhibitors were identified and four <b>SHP099</b>-related compounds (<b>JAB-3068</b> (Jacobio), <b>TNO155</b> (Novartis), <b>RMC-4630</b> (Revolution Medicines/Sanofi), and <b>RLY-1971</b> (Relay Therapeutics)) have entered clinical trials to treat various solid tumors. In preclinical studies, <b>SHP099</b> shows strong synergy with MEK inhibitors against wild-type amplified <i>KRAS</i> gastroesophageal cancer<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> and <i>KRAS</i> mutant NSCLC and pancreatic ductal adenocarcinoma<a onclick="showRef(event, 'ref53 ref172'); return false;" href="javascript:void(0);" class="ref ref53 ref172">(53,172)</a> by blocking both direct and feedback RAS signaling. Translation of such combination therapy to treat cancer remains to be fully evaluated in clinics.</div><div class="NLM_p">The PD-1/SHP2 binding interaction mediates the immune invasion of tumors via the PD-1/PD-L1 signaling pathway. SHP2 participates in the PD-1/PD-L1 signaling pathway through the phosphatase function to mitigate cytotoxic T cell activity. On the basis of this finding, SHP2 inhibitors have potential applications in T cell-boosting tumor immunotherapy. Because of overlapping signaling pathways between many kinases and SHP2, SHP2 inhibitors may also be combined with kinase inhibitors to downregulate interconnected signaling pathways synergistically. The rational combination therapy for SHP2 inhibitors with agents (e.g., MEK, KRAS, RTK, and PD-1/PD-L1 inhibitors) may produce less drug resistance in patients compared with a single agent.<a onclick="showRef(event, 'ref135 ref174'); return false;" href="javascript:void(0);" class="ref ref135 ref174">(135,174)</a> Though the importance of SHP2 in RAS/Raf and PD-1/PD-L1 signaling pathway is observed, many more studies are needed to elucidate the precise role of SHP2 in the signal transduction.</div><div class="NLM_p last">In view of the important role of SHP2 as a potential antitumor target, development of SHP2 inhibitors, especially allosteric inhibitors, has attracted a broad interest in the scientific community. Although important progress has been made in recent years, reported potent and selective SHP2 inhibitors are still in early clinical studies. However, additional biological functions of SHP2 revealed through the use of these compounds in different settings will allow the expansion of their clinical applications to other diseases.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00249" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinpei Zhou</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, 24 Tongjiaxiang, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5904-6164" title="Orcid link">http://orcid.org/0000-0002-5904-6164</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2a405a5042455f1c1c126a1b1c1904494547"><span class="__cf_email__" data-cfemail="96fce6ecfef9e3a0a0aed6a7a0a5b8f5f9fb">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao-Yie Yang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5445-0109" title="Orcid link">http://orcid.org/0000-0002-5445-0109</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#96f5eff7f8f1a4a0d6e3e2fee5f5b8f3f2e3"><span class="__cf_email__" data-cfemail="1e7d677f70792c285e6b6a766d7d307b7a6b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huibin Zhang</span> - <span class="hlFld-Affiliation affiliation">Center
of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#94eefcf5faf3fcf6aca4d4f7e4e1baf1f0e1baf7fa"><span class="__cf_email__" data-cfemail="9fe5f7fef1f8f7fda7afdffcefeab1fafbeab1fcf1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinrui Yuan</span> - <span class="hlFld-Affiliation affiliation">Center
of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Bu</span> - <span class="hlFld-Affiliation affiliation">Center
of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Xinrui Yuan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=BIO-d7e4039-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xinrui Yuan</b> received his Ph.D. in Medicinal Chemistry in 2019 under the supervision of Prof. Huibin Zhang at Chinese Pharmaceutical University. Currently, Dr. Yuan is a postdoctoral fellow in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center. He focuses on design and discovery of novel small-molecule agents toward immune-related targets.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Hong Bu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=BIO-d7e4044-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong Bu</b> is a Master student in Medicinal Chemistry under the supervision of Prof. Huibin Zhang at Chinese Pharmaceutical University. Her research interest is mainly focused on the discovery and development of small-molecule inhibitors toward key targets relevant to cancers.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Jinpei Zhou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=BIO-d7e4049-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jinpei Zhou</b> obtained his Ph.D. in Medicinal Chemistry from Chinese Pharmaceutical University in 1999. He did his research in medicinal chemistry as a visiting scholar in Gifu Pharmaceutical University, JP, between 2005 and 2006. Currently, he is a Professor in the Department of Medicinal Chemistry, China Pharmaceutical University. His main research interest is the design and development of small-molecule inhibitors targeting cancer-related proteins.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Chao-Yie Yang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=BIO-d7e4054-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chao-Yie Yang</b> obtained his Ph.D. in Theoretical Chemistry from Case Western Reserve University in 1996. He conducted structure-based drug design research to develop anticancer drugs at University of Michigan between 2001 and 2019. Currently, he is an Associate Professor in the Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center. His main research interest is the design and development of small-molecule inhibitors targeting proteins associated with cancers and immune-mediated diseases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Huibin Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=BIO-d7e4059-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Huibin Zhang</b> obtained her Bachelor’s degree in 1989 and her Ph.D. in Medicinal Chemistry in 2004 from Chinese Pharmaceutical University. Currently, she is a Research Professor in Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University. Her research interests mainly focus on small-molecule modulators for immuno-oncology.</p></figure></div><div class="ack" id="ACK-d7e4064-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study is supported in part by funding from the Natural Science Foundation of Jiangsu Province (Grant BK20141349, H.Z.) and the China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs (Grant 2013ZX09301303-002, H.Z.). We thank a reviewer for directing us to a recent publication<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> when this manuscript was under initial review. We also thank Mingliang Wang for helpful suggestions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B (PKB)</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CADD</td><td class="NLM_def"><p class="first last">computer-aided drug design</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">GAB2</td><td class="NLM_def"><p class="first last">GRB2 associated binding protein 2</p></td></tr><tr><td class="NLM_term">GAP</td><td class="NLM_def"><p class="first last">GTPase-activating protein</p></td></tr><tr><td class="NLM_term">GEF</td><td class="NLM_def"><p class="first last">guanine nucleotide exchange factor</p></td></tr><tr><td class="NLM_term">GOF</td><td class="NLM_def"><p class="first last">gain-of-function</p></td></tr><tr><td class="NLM_term">HNSCC</td><td class="NLM_def"><p class="first last">head and neck squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">ILK</td><td class="NLM_def"><p class="first last">integrin-linked kinase</p></td></tr><tr><td class="NLM_term">ITIM</td><td class="NLM_def"><p class="first last">immunoreceptor tyrosine-based inhibition motif</p></td></tr><tr><td class="NLM_term">ITSM</td><td class="NLM_def"><p class="first last">immunoreceptor tyrosine-based switch motif</p></td></tr><tr><td class="NLM_term">Jak</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JMML</td><td class="NLM_def"><p class="first last">juvenile myelomonocytic leukemia</p></td></tr><tr><td class="NLM_term">LS</td><td class="NLM_def"><p class="first last">LEOPARD syndrome</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MDS</td><td class="NLM_def"><p class="first last">myelodysplastic syndromes</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NS</td><td class="NLM_def"><p class="first last">Noonan syndrome</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PLCγ</td><td class="NLM_def"><p class="first last">phospholipase Cγ</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera</p></td></tr><tr><td class="NLM_term">PTK</td><td class="NLM_def"><p class="first last">protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">PTP</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">PTPRT</td><td class="NLM_def"><p class="first last">phosphatase and tensin homolog</p></td></tr><tr><td class="NLM_term">PTP1B</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase 1B</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase non-receptor type</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PRL3</td><td class="NLM_def"><p class="first last">phosphatase regenerating liver 3</p></td></tr><tr><td class="NLM_term">PTPRD</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase receptor type D</p></td></tr><tr><td class="NLM_term">PD-1/PD-L1</td><td class="NLM_def"><p class="first last">programmed death-1/programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">pTyr</td><td class="NLM_def"><p class="first last">phosphotyrosine</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TEAD</td><td class="NLM_def"><p class="first last">TEA domain family</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T cell receptor</p></td></tr><tr><td class="NLM_term">YAP</td><td class="NLM_def"><p class="first last">yes-associated protein</p></td></tr><tr><td class="NLM_term">ZEB1</td><td class="NLM_def"><p class="first last">zinc finger E-box-binding homeobox 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 185 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Tyrosine-phosphorylation: thirty years and counting</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2009.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ceb.2009.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19269802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=140-146&author=T.+Hunter&title=Tyrosine-phosphorylation%3A+thirty+years+and+counting&doi=10.1016%2Fj.ceb.2009.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphorylation: thirty years and counting</span></div><div class="casAuthors">Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-146</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the 30 years since its discovery, tyrosine phosphorylation has emerged as a fundamentally important mechanism of signal transduction and regulation in all eukaryotic cells, governing many processes, including cell proliferation, cell cycle progression, metabolic homeostasis, transcriptional activation, neural transmission, differentiation and development, and aging.  Perturbations in tyrosine phosphorylation underlie many human diseases, and in particular cancer, and this has prompted the development of inhibitors of tyrosine kinases implicated in disease, a no. of which were approved for clin. use.  The following is a brief personal reflection on some of the salient findings over the past 30 years that led to the development of tyrosine kinase inhibitors for disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozf_yslNwApbVg90H21EOLACvtfcHk0lhjOhjFofWVuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClurs%253D&md5=ef5dbec53a41f9691317cc5b1b47b3cb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DTyrosine-phosphorylation%253A%2520thirty%2520years%2520and%2520counting%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D140%26epage%3D146%26doi%3D10.1016%2Fj.ceb.2009.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: from genes, to function, to disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/nrm2039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrm2039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17057753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSms77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=833-846&author=N.+K.+Tonks&title=Protein+tyrosine+phosphatases%3A+from+genes%2C+to+function%2C+to+disease&doi=10.1038%2Fnrm2039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: from genes, to function, to disease</span></div><div class="casAuthors">Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">833-846</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The protein tyrosine phosphatase (PTP) superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signalling pathways that underlie a broad spectrum of fundamental physiol. processes.  In this review, I describe recent breakthroughs in our understanding of the role of the PTPs in the regulation of signal transduction and the etiol. of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5NdnwoKCC1bVg90H21EOLACvtfcHk0lhjOhjFofWVuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSms77I&md5=20a078267093bb8415d9035a13b8ad17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm2039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2039%26sid%3Dliteratum%253Aachs%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520from%2520genes%252C%2520to%2520function%252C%2520to%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D833%26epage%3D846%26doi%3D10.1038%2Fnrm2039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: prospects for therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(00)00223-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS1367-5931%2800%2900223-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11470605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=416-423&author=Z.+Y.+Zhang&title=Protein+tyrosine+phosphatases%3A+prospects+for+therapeutics&doi=10.1016%2FS1367-5931%2800%2900223-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: prospects for therapeutics</span></div><div class="casAuthors">Zhang, Z.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Protein tyrosine phosphatases (PTPs) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  PTPs are also implicated in a wide variety of other disorders, including cancer.  Significant progress has been made in identifying small mols. that simultaneously bind both the active site and a unique adjacent site that enables specific inhibition of individual PTP isoenzymes.  As a consequence, there are compelling reasons to believe that PTP inhibitors may ultimately serve as powerful therapeutic weapons in the authors' arsenal for battling human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgujWWYVWfjbVg90H21EOLACvtfcHk0ljRB3nyXPLkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D&md5=eee42d18a57b314321cffca4e3892ac1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900223-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900223-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520prospects%2520for%2520therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D416%26epage%3D423%26doi%3D10.1016%2FS1367-5931%2800%2900223-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Julien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dube, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. L.</span></span> <span> </span><span class="NLM_article-title">Inside the human cancer tyrosine phosphatome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1038/nrc2980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrc2980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=21179176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WisrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=35-49&author=S.+G.+Julienauthor=N.+Dubeauthor=S.+Hardyauthor=M.+L.+Tremblay&title=Inside+the+human+cancer+tyrosine+phosphatome&doi=10.1038%2Fnrc2980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inside the human cancer tyrosine phosphatome</span></div><div class="casAuthors">Julien, Sofi G.; Dube, Nadia; Hardy, Serge; Tremblay, Michel L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-49</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the protein tyrosine phosphatase (Ptp) family dephosphorylate target proteins and counter the activities of protein tyrosine kinases that are involved in cellular phosphorylation and signalling.  As such, certain PTPs might be tumor suppressors.  Indeed, PTPs play an important part in the inhibition or control of growth, but accumulating evidence indicates that some PTPs may exert oncogenic functions.  Recent large-scale genetic analyses of various human tumors have highlighted the relevance of PTPs either as putative tumor suppressors or as candidate oncoproteins.  Progress in understanding the regulation and function of PTPs has provided insights into which PTPs might be potential therapeutic targets in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomjWFudpQjhLVg90H21EOLACvtfcHk0ljRB3nyXPLkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WisrbM&md5=ffd5f76f3d0b2d0ef220e5d398794f2e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2980%26sid%3Dliteratum%253Aachs%26aulast%3DJulien%26aufirst%3DS.%2BG.%26aulast%3DDube%26aufirst%3DN.%26aulast%3DHardy%26aufirst%3DS.%26aulast%3DTremblay%26aufirst%3DM.%2BL.%26atitle%3DInside%2520the%2520human%2520cancer%2520tyrosine%2520phosphatome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D35%26epage%3D49%26doi%3D10.1038%2Fnrc2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Munter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, M.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities in the development of protein phosphatase-directed therapeutics</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/cb300597g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300597g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSjurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=36-45&author=S.+De%0AMunterauthor=M.+Kohnauthor=M.+Bollen&title=Challenges+and+opportunities+in+the+development+of+protein+phosphatase-directed+therapeutics&doi=10.1021%2Fcb300597g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Opportunities in the Development of Protein Phosphatase-Directed Therapeutics</span></div><div class="casAuthors">De Munter, Sofie; Kohn, Maja; Bollen, Mathieu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-45</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein phosphatases have both protective and promoting roles in the etiol. of diseases.  A prominent example is the existence of oncogenic as well as tumor-suppressing protein phosphatases.  A few protein phosphatase activity modulators are already applied in therapies.  These were however not developed in target-directed approaches, and the recent discovery of phosphatase involvement followed their application in therapy.  Nevertheless, these examples demonstrate that small mols. can be generated that modulate the activity of protein phosphatases and are beneficial for the treatment of protein phosphorylation diseases.  We describe here strategies for the development of activators and inhibitors of protein phosphatases and clarify some long-standing misconceptions concerning the drug ability of these enzymes.  Recent developments suggest that it is feasible to design potent and selective protein phosphatase modulators with a therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTwo-BD9sHS7Vg90H21EOLACvtfcHk0ljRB3nyXPLkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSjurrF&md5=a6bccc84309271ecdec328d6b1b84294</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcb300597g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300597g%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMunter%26aufirst%3DS.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DBollen%26aufirst%3DM.%26atitle%3DChallenges%2520and%2520opportunities%2520in%2520the%2520development%2520of%2520protein%2520phosphatase-directed%2520therapeutics%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D36%26epage%3D45%26doi%3D10.1021%2Fcb300597g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebreda, Á. R.</span></span> <span> </span><span class="NLM_article-title">Protein kinases and phosphatases as therapeutic targets in cancer</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1007/s12094-006-0005-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1007%2Fs12094-006-0005-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16648114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=153-160&author=J.+J.+Venturaauthor=%C3%81.+R.+Nebreda&title=Protein+kinases+and+phosphatases+as+therapeutic+targets+in+cancer&doi=10.1007%2Fs12094-006-0005-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases and phosphatases as therapeutic targets in cancer</span></div><div class="casAuthors">Ventura, Juan-Jose; Nebreda, Angel R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Translational Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-160</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Instituto de Investigaciones Biomedicas CSIC/UAM</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation plays key roles in many physiol. processes and is often deregulated in pathol. conditions.  Our current understanding of how protein kinases and phosphatases orchestrate the phosphorylation changes that control cellular functions has made these enzymes potential drug targets for the treatment of many diseases.  The success of the tyrosine kinase inhibitor Gleevec in the treatment of some cancers has further invigorated the development of kinase inhibitors as anti-cancer drugs.  A large no. of these compds. are currently undergoing clin. trials and there is much expectation on the therapeutic potential of these mols., as more specific and less toxic drugs than currently used generic chemotherapeutic agents.  In this manuscript, we review the current status of more than 30 protein kinase inhibitors with proven or potential therapeutic value for cancer treatment.  These include inhibitors of receptor and cytosolic tyrosine kinases as well as compds. that target different families of serine/threonine kinases involved in signalling and cell cycle regulation.  We also briefly touch on the prospects of phosphatase inhibitors.  The combination of kinase inhibitors to target different components of signalling pathways that are found deregulated in tumors is also emerging as an interesting approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdO6Up4gp6n7Vg90H21EOLACvtfcHk0lgubap_-RPU2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFentb0%253D&md5=57a09f7b6916b45b1154b608cd1f17af</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12094-006-0005-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-006-0005-0%26sid%3Dliteratum%253Aachs%26aulast%3DVentura%26aufirst%3DJ.%2BJ.%26aulast%3DNebreda%26aufirst%3D%25C3%2581.%2BR.%26atitle%3DProtein%2520kinases%2520and%2520phosphatases%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2006%26volume%3D8%26spage%3D153%26epage%3D160%26doi%3D10.1007%2Fs12094-006-0005-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span> <span> </span><span class="NLM_article-title">Chemical inhibitors of protein kinases</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">2541</span>– <span class="NLM_lpage">2571</span>, <span class="refDoi"> DOI: 10.1021/cr000250y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr000250y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2001&pages=2541-2571&author=A.+J.+Bridges&title=Chemical+inhibitors+of+protein+kinases&doi=10.1021%2Fcr000250y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical inhibitors of protein kinases</span></div><div class="casAuthors">Bridges, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2541-2571</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 258 refs. on development protein kinase inhibitors as potential antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWn7KO1AXzrVg90H21EOLACvtfcHk0lgubap_-RPU2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWnt7k%253D&md5=05ee78880cc9dcf485684e05327108db</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr000250y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr000250y%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DChemical%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DChem.%2520Rev.%26date%3D2001%26volume%3D101%26spage%3D2541%26epage%3D2571%26doi%3D10.1021%2Fcr000250y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery - What’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery+-+What%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0lgubap_-RPU2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%2520-%2520What%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinases as targets for cancer therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1056/NEJMra044389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+kinases+as+targets+for+cancer+therapy&doi=10.1056%2FNEJMra044389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0lgC_9HpDDdaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187%26doi%3D10.1056%2FNEJMra044389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">Mutational analysis of the tyrosine phosphatome in colorectal cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1126/science.1096096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.1096096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15155950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1164-1166&author=Z.+H.+Wangauthor=D.+Shenauthor=D.+W.+Parsonsauthor=A.+Bardelliauthor=J.+Sagerauthor=S.+Szaboauthor=J.+Ptakauthor=N.+Sillimanauthor=B.+A.+Petersauthor=M.+S.+van+der+Heijdenauthor=G.+Parmigianiauthor=H.+Yanauthor=T.+L.+Wangauthor=G.+Rigginsauthor=S.+M.+Powellauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=Mutational+analysis+of+the+tyrosine+phosphatome+in+colorectal+cancers&doi=10.1126%2Fscience.1096096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers</span></div><div class="casAuthors">Wang, Zhenghe; Shen, Dong; Parsons, D. Williams; Bardelli, Alberto; Sager, Jason; Szabo, Steve; Ptak, Janine; Silliman, Natalie; Peters, Brock A.; van der Heijden, Michiel S.; Parmigiani, Giovanni; Yan, Hai; Wang, Tian-Li; Riggins, Greg; Powell, Steven M.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5674</span>),
    <span class="NLM_cas:pages">1164-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis.  A mutational anal. of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a smaller fraction of lung, breast, and gastric cancers.  Fifteen mutations were nonsense, frameshift, or splice-site alterations predicted to result in truncated proteins lacking phosphatase activity.  Five missense mutations in the most commonly altered PTP (PTPRT) were biochem. examd. and found to reduce phosphatase activity.  Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth.  These observations suggest that the mutated tyrosine phosphatases are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9NQWiEUTTMbVg90H21EOLACvtfcHk0lgC_9HpDDdaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVyit7c%253D&md5=3466921b63561835ad9bf1f2f4f5d81e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096096%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DParsons%26aufirst%3DD.%2BW.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSager%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DM.%2BS.%26aulast%3DParmigiani%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%2BL.%26aulast%3DRiggins%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DMutational%2520analysis%2520of%2520the%2520tyrosine%2520phosphatome%2520in%2520colorectal%2520cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1164%26epage%3D1166%26doi%3D10.1126%2Fscience.1096096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2592</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1073/pnas.0914884107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0914884107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=20133777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1aksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=2592-2597&author=Y.+Q.+Zhaoauthor=X.+D.+Zhangauthor=K.+Gudaauthor=E.+Lawrenceauthor=Q.+Sunauthor=T.+Watanabeauthor=Y.+Iwakuraauthor=M.+Asanoauthor=L.+L.+Weiauthor=Z.+R.+Yangauthor=W.+P.+Zhengauthor=D.+Dawsonauthor=J.+Willisauthor=S.+D.+Markowitzauthor=M.+Satakeauthor=Z.+H.+Wang&title=Identification+and+functional+characterization+of+paxillin+as+a+target+of+protein+tyrosine+phosphatase+receptor+T&doi=10.1073%2Fpnas.0914884107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T</span></div><div class="casAuthors">Zhao, Yiqing; Zhang, Xiaodong; Guda, Kishore; Lawrence, Earl; Sun, Qun; Watanabe, Toshio; Iwakura, Yoichiro; Asano, Masahide; Wei, Lanlan; Yang, Zhirong; Zheng, Weiping; Dawson, Dawn; Willis, Joseph; Markowitz, Sanford D.; Satake, Masanobu; Wang, Zhenghe</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2592-2597, S2592/1-S2592/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase receptor-type T (PTPRT) is the most frequently mutated tyrosine phosphatase in human cancers.  However, the cell signaling pathways regulated by PTPRT largely remain to be elucidated.  Here, the authors show that paxillin is a direct substrate of PTPRT and that-PTPRT specifically regulates paxillin phosphorylation at tyrosine residue 88 (Y88) in colorectal cancer (CRC) cells.  The authors engineered CRC cells homozygous for a paxillin Y88F knock-in mutant and found that these cells exhibit significantly reduced cell migration and impaired anchorage-independent growth, fail to form xenograft tumors in nude mice, and have decreased phosphorylation of p130CAS, SHP2, and AKT.  PTPRT knockout mice that the authors generated exhibit increased levels of colonic paxillin phosphorylation at residue Y88 and are highly susceptible to carcinogen azoxymethane-induced colon tumor, providing crit. in vivo evidence that PTPRT normally functions as a tumor suppressor.  Moreover, similarly increased paxillin pY88 is also found as a common feature of human colon cancers.  These studies reveal an important signaling pathway that plays a crit. role in colorectal tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpXrtavoElLVg90H21EOLACvtfcHk0lgC_9HpDDdaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1aksLY%253D&md5=98e1034f41e18f0b21c0acc926dbdb8d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0914884107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0914884107%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DX.%2BD.%26aulast%3DGuda%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%2BR.%26aulast%3DZheng%26aufirst%3DW.%2BP.%26aulast%3DDawson%26aufirst%3DD.%26aulast%3DWillis%26aufirst%3DJ.%26aulast%3DMarkowitz%26aufirst%3DS.%2BD.%26aulast%3DSatake%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520paxillin%2520as%2520a%2520target%2520of%2520protein%2520tyrosine%2520phosphatase%2520receptor%2520T%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D2592%26epage%3D2597%26doi%3D10.1073%2Fpnas.0914884107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podsypanina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miliaresis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCombie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovanella, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tycko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibshoosh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span> <span> </span><span class="NLM_article-title">PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1126/science.275.5308.1943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.275.5308.1943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9072974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK2sXit1Wgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1943-1947&author=J.+Liauthor=C.+Yenauthor=D.+Liawauthor=K.+Podsypaninaauthor=S.+Boseauthor=S.+I.+Wangauthor=J.+Pucauthor=C.+Miliaresisauthor=L.+Rodgersauthor=R.+McCombieauthor=S.+H.+Bignerauthor=B.+C.+Giovanellaauthor=M.+Ittmannauthor=B.+Tyckoauthor=H.+Hibshooshauthor=M.+H.+Wiglerauthor=R.+Parsons&title=PTEN%2C+a+putative+protein+tyrosine+phosphatase+gene+mutated+in+human+brain%2C+breast%2C+and+prostate+cancer&doi=10.1126%2Fscience.275.5308.1943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</span></div><div class="casAuthors">Li, Jing; Yen, Clifford; Liaw, Danny; Podsypanina, Katrina; Bose, Shikha; Wang, Steven I.; Puc, Janusz; Miliaresis, Christa; Rodgers, Linda; McCombie, Richard; Bigner, Sandra H.; Giovanella, Beppino C.; Ittmann, Michael; Tycko, Ben; Hibshoosh, Hanina; Wigler, Michael H.; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5308</span>),
    <span class="NLM_cas:pages">1943-1947</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers.  In preliminary screens, mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of prostate cancer cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas.  The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homol. to tensin, a protein that interacts with actin filaments at focal adhesions.  These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPNCE1bqsPNLVg90H21EOLACvtfcHk0lhPnlcmGix7kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1Wgtbk%253D&md5=9b3810f68cbd7cbb882ff75e98a2f1bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5308.1943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5308.1943%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DC.%26aulast%3DLiaw%26aufirst%3DD.%26aulast%3DPodsypanina%26aufirst%3DK.%26aulast%3DBose%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BI.%26aulast%3DPuc%26aufirst%3DJ.%26aulast%3DMiliaresis%26aufirst%3DC.%26aulast%3DRodgers%26aufirst%3DL.%26aulast%3DMcCombie%26aufirst%3DR.%26aulast%3DBigner%26aufirst%3DS.%2BH.%26aulast%3DGiovanella%26aufirst%3DB.%2BC.%26aulast%3DIttmann%26aufirst%3DM.%26aulast%3DTycko%26aufirst%3DB.%26aulast%3DHibshoosh%26aufirst%3DH.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DPTEN%252C%2520a%2520putative%2520protein%2520tyrosine%2520phosphatase%2520gene%2520mutated%2520in%2520human%2520brain%252C%2520breast%252C%2520and%2520prostate%2520cancer%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1943%26epage%3D1947%26doi%3D10.1126%2Fscience.275.5308.1943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zbuk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, C.</span></span> <span> </span><span class="NLM_article-title">Cancer phenomics: RET and PTEN as illustrative models</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1038/nrc2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrc2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17167516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCht7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=35-45&author=K.+M.+Zbukauthor=C.+Eng&title=Cancer+phenomics%3A+RET+and+PTEN+as+illustrative+models&doi=10.1038%2Fnrc2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer phenomics: RET and PTEN as illustrative models</span></div><div class="casAuthors">Zbuk, Kevin M.; Eng, Charis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer phenomics, the systematic acquisition and objective documentation of host and/or somatic cancer phenotypic data at many levels, is a young field compared with other mol.-based 'omics'.  Two relatively advanced phenomic paradigms are assocd. with phosphatase and tensin homolog (PTEN) and rearranged during transfection (RET), genes that are assocd. with cancer predisposition syndromes in addn. to developmental disorders.  The phenomic characterization of PTEN and RET underscores the importance of incorporating robust phenomics into the host 'omic' profile, and shows that the evolution of phenomics will be crucial to the advancement of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOxv_KNE-ybVg90H21EOLACvtfcHk0lhPnlcmGix7kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCht7nE&md5=60d58273a64e401da8eb23a23fe17e1f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2037%26sid%3Dliteratum%253Aachs%26aulast%3DZbuk%26aufirst%3DK.%2BM.%26aulast%3DEng%26aufirst%3DC.%26atitle%3DCancer%2520phenomics%253A%2520RET%2520and%2520PTEN%2520as%2520illustrative%2520models%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D35%26epage%3D45%26doi%3D10.1038%2Fnrc2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romans, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span> <span> </span><span class="NLM_article-title">PRL-3 expression in metastatic cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5607</span>– <span class="NLM_lpage">5615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14654542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVejtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5607-5615&author=A.+Bardelliauthor=S.+Sahaauthor=J.+A.+Sagerauthor=K.+E.+Romansauthor=B.+Z.+Xinauthor=S.+D.+Markowitzauthor=C.+Lengauerauthor=V.+E.+Velculescuauthor=K.+W.+Kinzlerauthor=B.+Vogelstein&title=PRL-3+expression+in+metastatic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3 expression in metastatic cancers</span></div><div class="casAuthors">Bardelli, Alberto; Saha, Saurabh; Sager, Jason A.; Romans, Kathy E.; Xin, Baozhong; Markowitz, Sanford D.; Lengauer, Christoph; Velculescu, Victor E.; Kinzler, Kenneth W.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5607-5615</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of the PRL-3 tyrosine phosphatase is elevated in liver metastases derived from colorectal cancer (CRC).  The authors sought to det. the cellular basis of this elevation and assess the expression of PRL-3 in metastatic lesions derived from cancers of the colon and other tissues.  The authors developed modifications of in situ hybridization methods that facilitated the study of paraffin-embedded sections.  They also evaluated PRL-3 gene copy nos. using fluorescence in situ hybridization and developed antibodies to assess PRL-3 subcellular localization.  PRL-3 mRNA expression was elevated in nearly all metastatic lesions derived from CRCs, regardless of the site of metastasis (liver, lung, brain, or ovary).  Expression was found in neoplastic cells, although tumor endothelium also expressed the gene.  In contrast, little or no PRL-3 expression was obsd. in normal colon, nonmetastatic primary cancers, or metastatic lesions derived from cancers other than those of the colon (pancreas, stomach, or esophagus).  Interphase fluorescence in situ hybridization confirmed that gene amplification was not the major cause of PRL-3 overexpression.  Immunohistochem. anal. with anti-PRL-3 antibodies showed a cell membrane localization, consistent with the predicted isoprenylation of the protein.  These studies establish an unexpected and unprecedented specificity in metastatic gene expression profiles: PRL-3 is apparently expressed in CRC metastases to any organ but is not expressed in metastases of other cancers to the same organs or in nonmetastatic CRCs.  PRL-3 is also expressed in tumor vasculature, regardless of the tumor source.  These data raise intriguing questions about the role of protein phosphorylation in angiogenesis and cell-type-specific metastatic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn3vWdorK4YrVg90H21EOLACvtfcHk0ljs52vmbrvurQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVejtbY%253D&md5=da10edae1f3cbdb06792fc2f1a1fa72d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DSager%26aufirst%3DJ.%2BA.%26aulast%3DRomans%26aufirst%3DK.%2BE.%26aulast%3DXin%26aufirst%3DB.%2BZ.%26aulast%3DMarkowitz%26aufirst%3DS.%2BD.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DPRL-3%2520expression%2520in%2520metastatic%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5607%26epage%3D5615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemeyer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buechner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahlen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/ng1156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fng1156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12717436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=148-150&author=M.+Tartagliaauthor=C.+M.+Niemeyerauthor=A.+Fragaleauthor=X.+L.+Songauthor=J.+Buechnerauthor=A.+Jungauthor=K.+Hahlenauthor=H.+Hasleauthor=J.+D.+Lichtauthor=B.+D.+Gelb&title=Somatic+mutations+in+PTPN11+in+juvenile+myelomonocytic+leukemia%2C+myelodysplastic+syndromes+and+acute+myeloid+leukemia&doi=10.1038%2Fng1156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span></div><div class="casAuthors">Tartaglia, Marco; Niemeyer, Charlotte M.; Fragale, Alessandra; Song, Xiaoling; Buechner, Jochen; Jung, Andreas; Haehlen, Karel; Hasle, Henrik; Licht, Jonathan D.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-150</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML.  Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML).  Functional analyses documented that the two most common mutations in PTPN11 assocd. with JMML caused a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwFhlUQDJQLVg90H21EOLACvtfcHk0ljs52vmbrvurQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D&md5=67d6900b46520ee461330bed95cbc890</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fng1156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1156%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DX.%2BL.%26aulast%3DBuechner%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DHahlen%26aufirst%3DK.%26aulast%3DHasle%26aufirst%3DH.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DSomatic%2520mutations%2520in%2520PTPN11%2520in%2520juvenile%2520myelomonocytic%2520leukemia%252C%2520myelodysplastic%2520syndromes%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2003%26volume%3D34%26spage%3D148%26epage%3D150%26doi%3D10.1038%2Fng1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellamy, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1002/jcb.23125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fjcb.23125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=21465528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslamtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2011&pages=2062-2071&author=W.+Wangauthor=L.+J.+Liuauthor=X.+Songauthor=Y.+Moauthor=C.+Kommaauthor=H.+D.+Bellamyauthor=Z.+J.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+human+protein+tyrosine+phosphatase+SHP-1+in+the+open+conformation&doi=10.1002%2Fjcb.23125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation</span></div><div class="casAuthors">Wang, Wei; Liu, Lijun; Song, Xi; Mo, Yi; Komma, Chandrasekhar; Bellamy, Henry D.; Zhao, Zhizhuang Joe; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2062-2071</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">SHP-1 belongs to the family of non-receptor protein tyrosine phosphatases (PTPs) and generally acts as a neg. regulator in a variety of cellular signaling pathways.  Previously, the crystal structures of tail-truncated SHP-1 and SHP-2 revealed an autoinhibitory conformation.  To understand the regulatory mechanism of SHP-1, the authors detd. the crystal structure of full-length SHP-1 at 3.1 Å.  Although the tail was disordered in the current structure, the huge conformational rearrangement of the N-SH2 domain and the incorporation of sulfate ions into the ligand-binding site of each domain indicated that SHP-1 was in the open conformation.  The N-SH2 domain in the current structure was shifted away from the active site of the PTP domain to the other side of the C-SH2 domain, resulting in exposure of the active site.  Meanwhile, the C-SH2 domain was twisted anti-clockwise by ∼110°.  In addn., a set of new interactions between 2 SH2 domains and between the N-SH2 and the catalytic domains was identified, which could be responsible for the stabilization of SHP-1 in the open conformation.  Based on the structural comparison, a model for the activation of SHP-1 was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbClbkZ-6vn7Vg90H21EOLACvtfcHk0ljs52vmbrvurQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslamtLs%253D&md5=7da59a40ae5a36fb3842922de1135744</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fjcb.23125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.23125%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DKomma%26aufirst%3DC.%26aulast%3DBellamy%26aufirst%3DH.%2BD.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520human%2520protein%2520tyrosine%2520phosphatase%2520SHP-1%2520in%2520the%2520open%2520conformation%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2011%26volume%3D112%26spage%3D2062%26epage%3D2071%26doi%3D10.1002%2Fjcb.23125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">28199</span>– <span class="NLM_lpage">28207</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.43.28199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.273.43.28199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9774441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXntVClsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=28199-28207&author=J.+Yangauthor=X.+S.+Liangauthor=T.+Q.+Niuauthor=W.+Y.+Mengauthor=Z.+Z.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+the+catalytic+domain+of+protein-tyrosine+phosphatase+SHP-1&doi=10.1074%2Fjbc.273.43.28199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1</span></div><div class="casAuthors">Yang, Jian; Liang, Xiaoshan; Niu, Tianqi; Meng, Wuyi; Zhao, Zhizhuang; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">28199-28207</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structures of the phosphoprotein-tyrosine phosphatase (PTPase) SHP-1 catalytic domain and the complex formed with the substrate analog, tungstate, were detd. and refined to crystallog. R values of 0.209 at 2.5 Å resoln. and 0.207 at 2.8 Å resoln., resp.  Despite low sequence similarity, the catalytic domain of SHP-1 showed high similarity in secondary and tertiary structures with other PTPases.  In contrast to the conformational changes obsd. in the crystal structures of PTPase 1B and Yersinia PTPase, the WPD loop (Trp-419-Pro-428) in the catalytic domain of SHP-1 moved away from the substrate binding pocket after binding tungstate.  Sequence alignment and structural anal. suggested that the residues in the WPD loop, esp. the amino acid following Asp-421, are crit. for the movement of WPD loop on binding substrates and the specific activity of PTPases.  The authors' mutagenesis and kinetic measurements supported this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT1ZhDJzM3m7Vg90H21EOLACvtfcHk0lgguO2LIx0NTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntVClsr8%253D&md5=363373fd7941078c2a3fb0b4f57c667e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.43.28199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.43.28199%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%2BS.%26aulast%3DNiu%26aufirst%3DT.%2BQ.%26aulast%3DMeng%26aufirst%3DW.%2BY.%26aulast%3DZhao%26aufirst%3DZ.%2BZ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520the%2520catalytic%2520domain%2520of%2520protein-tyrosine%2520phosphatase%2520SHP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D28199%26epage%3D28207%26doi%3D10.1074%2Fjbc.273.43.28199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/jm8002526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4948-4956&author=H.+R.+Lawrenceauthor=R.+Piredduauthor=L.+W.+Chenauthor=Y.+T.+Luoauthor=S.+S.+Sungauthor=A.+M.+Szymanskiauthor=M.+L.+R.+Yipauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=J.+Wuauthor=N.+J.+Lawrence&title=Inhibitors+of+Src+homology-2+domain+containing+protein+tyrosine+phosphatase-2+%28Shp2%29+based+on+oxindole+scaffolds&doi=10.1021%2Fjm8002526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span></div><div class="casAuthors">Lawrence, Harshani R.; Pireddu, Roberta; Chen, Liwei; Luo, Yunting; Sung, Shen-Shu; Szymanski, Ann Marie; Yip, M. L. Richard; Guida, Wayne C.; Sebti, Said M.; Wu, Jie; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4948-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of the NCI diversity set of compds. has led to the identification of NSC-117199, which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 μM.  A focused library incorporating an isatin scaffold was designed and evaluated for inhibition of Shp2 and Shp1 PTP activities.  Several compds. were identified that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar activity.  A model for the binding of the active compds. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqLAauyGNBbVg90H21EOLACvtfcHk0lgguO2LIx0NTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D&md5=572227c5a8cfffb108388616bd36fdfe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm8002526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002526%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DLuo%26aufirst%3DY.%2BT.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DSzymanski%26aufirst%3DA.%2BM.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Src%2520homology-2%2520domain%2520containing%2520protein%2520tyrosine%2520phosphatase-2%2520%2528Shp2%2529%2520based%2520on%2520oxindole%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4948%26epage%3D4956%26doi%3D10.1021%2Fjm8002526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1128/MCB.19.3.2416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.19.3.2416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10022928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFCjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2416-2424&author=M.+Youauthor=D.+H.+Yuauthor=G.+S.+Feng&title=Shp-2+tyrosine+phosphatase+functions+as+a+negative+regulator+of+the+interferon-stimulated+Jak%2FSTAT+pathway&doi=10.1128%2FMCB.19.3.2416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway</span></div><div class="casAuthors">You, Min; Yu, De-Hua; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2416-2424</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Shp-2 is an SH2 domain-contg. protein tyrosine phosphatase.  Although the mechanism remains to be defined, substantial exptl. data suggest that Shp-2 is primarily a pos. regulator in cell growth and development.  The authors present evidence here that Shp-2, while acting to promote mitogenic signals, also functions as a neg. effector in interferon (IFN)-induced growth-inhibitory and apoptotic pathways.  Treatment of mouse fibroblast cells lacking a functional Shp-2 with IFN-α or IFN-γ resulted in an augmented suppression of cell viability compared to that of wild-type cells.  To dissect the mol. mechanism, the authors examd. IFN-induced activation of signal transducers and activators of transcription (STATs) by electrophoretic mobility shift assay, using a specific DNA probe (hSIE).  The amts. of STAT proteins bound to hSIE upon IFN-α or IFN-γ stimulation were increased in Shp-2-/- cells.  Consistently, tyrosine phosphorylation levels of Stat1 upon IFN-γ treatment and, to a lesser extent, upon IFN-α stimulation were markedly elevated in mutant cells.  Furthermore, IFN-γ induced a higher level of caspase 1 expression in Shp-2-/- cells than in wild-type cells.  Reintroduction of wild-type Shp-2 protein reversed the hypersensitivity of Shp-2-/- fibroblasts to the cytotoxic effect of IFN-α and IFN-γ.  Excessive activation of STATs by IFNs was also diminished in mutant cells in which Shp-2 had been reintroduced.  Thus, Shp-2 functions as a neg. regulator of the Jak/STAT pathway.  The authors propose that Shp-2 acts to promote cell growth and survival via 2 mechanisms, i.e., the stimulation of growth factor-initiated mitogenic pathways and the suppression of cytotoxic effect elicited by cytokines, such as IFNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiGe5yc6ZR-rVg90H21EOLACvtfcHk0lgguO2LIx0NTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFCjs7Y%253D&md5=ec6e07bdca1d8126e40cedda80358b7c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.2416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.2416%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DShp-2%2520tyrosine%2520phosphatase%2520functions%2520as%2520a%2520negative%2520regulator%2520of%2520the%2520interferon-stimulated%2520Jak%252FSTAT%2520pathway%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2416%26epage%3D2424%26doi%3D10.1128%2FMCB.19.3.2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapeau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">16064</span>– <span class="NLM_lpage">16069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0405041101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0405041101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15520383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGis7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=16064-16069&author=E.+E.+Zhangauthor=E.+Chapeauauthor=K.+Hagiharaauthor=G.+S.+Feng&title=Neuronal+Shp2+tyrosine+phosphatase+controls+energy+balance+and+metabolism&doi=10.1073%2Fpnas.0405041101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism</span></div><div class="casAuthors">Zhang, Eric E.; Chapeau, Emilie; Hagihara, Kazuki; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">16064-16069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Shp2, a Src homol. 2-contg. tyrosine phosphatase, has been implicated in a variety of growth factor or cytokine signaling pathways.  However, it is conceivable that this enzyme acts predominantly in one pathway vs. the others in a cell, depending on the cellular context.  To det. the putative functions of Shp2 in the adult brain, we selectively deleted Shp2 in postmitotic forebrain neurons by crossing CaMKIIα-Cre transgenic mice with a conditional Shp2 mutant (Shp2flox) strain.  Surprisingly, a prominent phenotype of the mutant (CaMKIIα-Cre:Shp2flox/flox or CaSKO) mice was the development of early-onset obesity, with increased serum levels of leptin, insulin, glucose, and triglycerides.  The mutant mice were not hyperphagic but developed enlarged and steatotic liver.  Consistent with previous in vitro data, we found that Shp2 down-regulates Jak2/Stat3 (signal transducer and activator of transcription 3) activation by leptin in the hypothalamus.  However, Jak2/Stat3 down-regulation is offset by a dominant Shp2 promotion of the leptin-stimulated Erk pathway, leading to induction rather than suppression of leptin resistance upon Shp2 deletion in the brain.  Collectively, these results suggest that a primary function of Shp2 in postmitotic forebrain neurons is to control energy balance and metab., and that this phosphatase is a crit. signaling component of leptin receptor ObRb in the hypothalamus.  Shp2 shows potential as a neuronal target for pharmaceutical sensitization of obese patients to leptin action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHDhmkfITz8bVg90H21EOLACvtfcHk0liM5EaEOyp3DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGis7zF&md5=bf9d1224a7e2703040ab2c8b73d19276</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405041101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405041101%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DE.%2BE.%26aulast%3DChapeau%26aufirst%3DE.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DNeuronal%2520Shp2%2520tyrosine%2520phosphatase%2520controls%2520energy%2520balance%2520and%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D16064%26epage%3D16069%26doi%3D10.1073%2Fpnas.0405041101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6018</span>– <span class="NLM_lpage">6025</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsj.onc.1204699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11593409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVCjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=6018-6025&author=C.+J.+Wuauthor=D.+M.+O%E2%80%99Rourkeauthor=G.+S.+Fengauthor=G.+R.+Johnsonauthor=Q.+Wangauthor=M.+I.+Greene&title=The+tyrosine+phosphatase+SHP-2+is+required+for+mediating+phosphatidylinositol+3-kinase%2FAkt+activation+by+growth+factors&doi=10.1038%2Fsj.onc.1204699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors</span></div><div class="casAuthors">Wu, Chuan-Jin; O'Rourke, Donald M.; Feng, Gen-Sheng; Johnson, Gibbes R.; Wang, Qiang; Greene, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6018-6025</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SHP-2 is a ubiquitously expressed non-transmembrane tyrosine phosphatase with two SH2 domains.  Multiple reverse-genetic studies have indicated that SHP-2 is a required component for organ and animal development.  SHP-2 wild-type and homozygous mutant mouse fibroblast cells in which the N-terminal SH2 domain was target-deleted were used to examine the function of SHP-2 in regulating phosphatidylinositol 3-kinase (PI3K) activation by growth factors.  In addn., SHP-2 and various mutants were introduced into human glioblastoma cells as well as SHP-2-/- mouse fibroblasts.  We found that EGF stimulation and EGFR oncoprotein (ΔEGFR) expression independently induced the co-immunopptn. of the p85 subunit of PI3K with SHP-2.  Targeted deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation.  Ectopic expression of SHP-2 in U87MG glioblastoma cells elevated EGF-induced Akt phosphorylation, and the effect was abolished by mutation of its N-terminal SH2 domain.  Likewise, the reconstitution of SHP-2 expression in the SHP-2-/- cells enhanced Akt phosphorylation induced by EGF while rescuing that induced by PDGF and IGF.  Further lipid kinase activity assays confirmed that SHP-2 modulation of Akt phosphorylation correlated with its regulation of PI3K activation.  Based on these results, we conclude that SHP-2 is required for mediating PI3K/Akt activation, and the N-terminal SH2 domain is critically important for a "pos." role of SHP-2 in regulating PI3K pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCyPto0sgBL7Vg90H21EOLACvtfcHk0liM5EaEOyp3DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVCjsLs%253D&md5=d700f46c6127c929099ecc7c94b4d180</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204699%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DD.%2BM.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520SHP-2%2520is%2520required%2520for%2520mediating%2520phosphatidylinositol%25203-kinase%252FAkt%2520activation%2520by%2520growth%2520factors%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D6018%26epage%3D6025%26doi%3D10.1038%2Fsj.onc.1204699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsiaras, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4062</span>– <span class="NLM_lpage">4072</span>, <span class="refDoi"> DOI: 10.1128/MCB.22.12.4062-4072.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.22.12.4062-4072.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12024020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=4062-4072&author=S.+Q.+Zhangauthor=W.+G.+Tsiarasauthor=T.+Arakiauthor=G.+Y.+Wenauthor=L.+Minichielloauthor=R.+Kleinauthor=B.+G.+Neel&title=Receptor-specific+regulation+of+phosphatidylinositol+3%E2%80%B2-kinase+activation+by+the+protein+tyrosine+phosphatase+Shp2&doi=10.1128%2FMCB.22.12.4062-4072.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2</span></div><div class="casAuthors">Zhang, Si Qing; Tsiaras, William G.; Araki, Toshiyuki; Wen, Gengyun; Minichiello, Liliana; Klein, Ruediger; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4062-4072</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases (RTKs) play distinct roles in multiple biol. systems.  Many RTKs transmit similar signals, raising questions about how specificity is achieved.  One potential mechanism for RTK specificity is control of the magnitude and kinetics of activation of downstream pathways.  We have found that the protein tyrosine phosphatase Shp2 regulates the strength and duration of phosphatidylinositol 3'-kinase (PI3K) activation in the epidermal growth factor (EGF) receptor signaling pathway.  Shp2 mutant fibroblasts exhibit increased assocn. of the p85 subunit of PI3K with the scaffolding adapter Gab1 compared to that for wild-type (WT) fibroblasts or Shp2 mutant cells reconstituted with WT Shp2.  Far-Western anal. suggests increased phosphorylation of p85 binding sites on Gab1.  Gab1-assocd. PI3K activity is increased and PI3K-dependent downstream signals are enhanced in Shp2 mutant cells following EGF stimulation.  Analogous results are obtained in fibroblasts inducibly expressing dominant-neg. Shp2.  Our results suggest that, in addn. to its role as a pos. component of the Ras-Erk pathway, Shp2 neg. regulates EGF-dependent PI3K activation by dephosphorylating Gab1 p85 binding sites, thereby terminating a previously proposed Gab1-PI3K pos. feedback loop.  Activation of PI3K-dependent pathways following stimulation by other growth factors is unaffected or decreased in Shp2 mutant cells.  Thus, Shp2 regulates the kinetics and magnitude of RTK signaling in a receptor-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdw-2VHpyGFrVg90H21EOLACvtfcHk0liM5EaEOyp3DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSmur8%253D&md5=abd02620597dc8ca097ba0b0d4d7ed8e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.12.4062-4072.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.12.4062-4072.2002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26aulast%3DTsiaras%26aufirst%3DW.%2BG.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DG.%2BY.%26aulast%3DMinichiello%26aufirst%3DL.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DReceptor-specific%2520regulation%2520of%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%2520activation%2520by%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D4062%26epage%3D4072%26doi%3D10.1128%2FMCB.22.12.4062-4072.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunnick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desponts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of the mitogen-activated protein kinase signaling pathway by SHP2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">9498</span>– <span class="NLM_lpage">9504</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110547200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M110547200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11779868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=9498-9504&author=J.+M.+Cunnickauthor=S.+S.+Mengauthor=Y.+Renauthor=C.+Despontsauthor=H.+G.+Wangauthor=J.+Y.+Djeuauthor=J.+Wu&title=Regulation+of+the+mitogen-activated+protein+kinase+signaling+pathway+by+SHP2&doi=10.1074%2Fjbc.M110547200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the mitogen-activated protein kinase signaling pathway by SHP2</span></div><div class="casAuthors">Cunnick, Jess M.; Meng, Songshu; Ren, Yuan; Desponts, Caroline; Wang, Hong-Gang; Djeu, Julie Y.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9498-9504</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Gab1-SHP2 assocn. is required for Erk mitogen-activated protein kinase activation by several growth factors.  Gab1-SHP2 interaction activates SHP2.  However, an activated SHP2 still needs to assoc. with Gab1 to mediate Erk activation.  It was unclear whether SHP2 is required to dephosphorylate a neg. phosphorylation site on Gab1 or whether SHP2 needs the Gab1 pleckstrin homol. (PH) domain to target it to the plasma membrane.  The authors found that expression of a fusion protein consisting of the Gab1 PH domain and an active SHP2 (Gab1PH-SHP2ΔN) induced constitutive Mek1 and Erk2 activation.  Linking the active SHP2ΔN to the PDK1 PH domain or the FRS2β myristoylation sequence also induced Mek1 activation.  Mek1 activation by Gab1PH-SHP2ΔN was inhibited by an Src inhibitor and by Csk.  Significantly, Gab1PH-SHP2ΔN induced Src activation.  Gab1PH-SHP2ΔN expression activated Ras, and the Gab1PH-SHP2ΔN-induced Mek1 activation was blocked by RasN17.  These findings suggest that Gab1PH-SHP2ΔN activated a signaling step upstream of Src and Ras.  The SHP2 tyrosine phosphatase activity is essential for the function of the fusion protein.  Together, these data show that the Gab1 sequence, besides the PH domain and SHP2 binding sites, is dispensable for Erk activation, suggesting that the primary role of Gab1 assocn. with an activated SHP2 is to target is to the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhARBgZq1OALVg90H21EOLACvtfcHk0lhcrWs3ITn85A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2kt7Y%253D&md5=9ee335040759d61b1bf0f706123cf24e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110547200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110547200%26sid%3Dliteratum%253Aachs%26aulast%3DCunnick%26aufirst%3DJ.%2BM.%26aulast%3DMeng%26aufirst%3DS.%2BS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DDesponts%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DDjeu%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520the%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520by%2520SHP2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D9498%26epage%3D9504%26doi%3D10.1074%2Fjbc.M110547200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naujokas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado-Madruga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8513</span>– <span class="NLM_lpage">8525</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.22.8513-8525.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.20.22.8513-8525.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11046147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFWrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=8513-8525&author=C.+R.+Marounauthor=M.+A.+Naujokasauthor=M.+Holgado-Madrugaauthor=A.+J.+Wongauthor=M.+Park&title=The+tyrosine+phosphatase+SHP-2+is+required+for+sustained+activation+of+extracellular+signal-regulated+kinase+and+epithelial+morphogenesis+downstream+from+the+Met+receptor+tyrosine+kinase&doi=10.1128%2FMCB.20.22.8513-8525.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase</span></div><div class="casAuthors">Maroun, Christiane R.; Naujokas, Monica A.; Holgado-Madruga, Marina; Wong, Albert J.; Park, Morag</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8513-8525</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Epithelial morphogenesis is crit. during development and wound healing, and alterations in this program contribute to neoplasia.  Met, the hepatocyte growth factor (HGF) receptor, promotes a morphogenic program in epithelial cell lines in matrix cultures.  Previous studies have identified Gab1, the major phosphorylated protein following Met activation, as important for the morphogenic response.  Gab1 is a docking protein that couples the Met receptor with multiple signaling proteins, including phosphatidylinositol-3 kinase, phospholipase Cγ, the adapter protein Crk, and the tyrosine specific phosphatase SHP-2.  HGF induces sustained phosphorylation of Gab1 and sustained activation of extracellular signal-regulated kinase (Erk) in epithelial Madin-Darby canine kidney cells.  In contrast, epidermal growth factor fails to promote a morphogenic program and induces transient Gab1 phosphorylation and Erk activation.  To elucidate the Gab1-dependent signals required for epithelial morphogenesis, the authors undertook a structure-function approach and demonstrate that assocn. of Gab1 with the tyrosine phosphatase SHP-2 is required for sustained Erk activation and for epithelial morphogenesis downstream from the Met receptor.  Epithelial cells expressing a Gab1 mutant protein unable to recruit SHP-2 elicit a transient activation of Erk in response to HGF.  Moreover, SHP-2 catalytic activity is required, since the expression of a catalytically inactive SHP-2 mutant, C/S, abrogates sustained activation of Erk and epithelial morphogenesis by the Met receptor.  These data identify SHP-2 as a pos. modulator of Erk activity and epithelial morphogenesis downstream from the Met receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Fb7TTQh5h7Vg90H21EOLACvtfcHk0lhcrWs3ITn85A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFWrtLk%253D&md5=11ac09ad73d32eb988e51100514bad38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.22.8513-8525.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.22.8513-8525.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26aulast%3DNaujokas%26aufirst%3DM.%2BA.%26aulast%3DHolgado-Madruga%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%2BJ.%26aulast%3DPark%26aufirst%3DM.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520SHP-2%2520is%2520required%2520for%2520sustained%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinase%2520and%2520epithelial%2520morphogenesis%2520downstream%2520from%2520the%2520Met%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D8513%26epage%3D8525%26doi%3D10.1128%2FMCB.20.22.8513-8525.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.5.1526-1536.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.20.5.1526-1536.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10669730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtF2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=1526-1536&author=Z.+Q.+Shiauthor=D.+H.+Yuauthor=M.+Parkauthor=M.+Marshallauthor=G.+S.+Feng&title=Molecular+mechanism+for+the+Shp-2+tyrosine+phosphatase+function+in+promoting+growth+factor+stimulation+of+Erk+activity&doi=10.1128%2FMCB.20.5.1526-1536.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity</span></div><div class="casAuthors">Shi, Zhong-Qing; Yu, De-Hua; Park, Morag; Marshall, Mark; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1526-1536</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We have previously shown that activation of extracellular signal-regulated kinase (Erk) by epidermal growth factor (EGF) treatment was significantly decreased in mouse fibroblast cells expressing a mutant Shp-2 mol. lacking 65 amino acids in the SH2-N domain, Shp-2Δ46-110.  To address the mol. mechanism for the pos. role of Shp-2 in mediating Erk induction, we evaluated the activation of signaling components upstream of Erk in Shp-2 mutant cells.  EGF-stimulated Ras, Raf, and Mek activation was significantly attenuated in Shp-2 mutant cells, suggesting that Shp-2 acts to promote Ras activation or to suppress the down-regulation of activated Ras.  Biochem. analyses indicate that upon EGF stimulation, Shp-2 is recruited into a multiprotein complex assembled on the Gab1 docking mol. and that Shp-2 seems to exert its biol. function by specifically dephosphorylating an unidentified mol. of 90 kDa in the complex.  The mutant Shp-2Δ46-110 mol. failed to participate in the Gab1-organized complex for dephosphorylation of p90, correlating with a defective activation of the Ras-Raf-Mek-Erk cascade in EGF-treated Shp-2 mutant cells.  Evidence is also presented that Shp-2 does not appear to modulate the signal relay from EGF receptor to Ras through the Shc, Grb2, and Sos proteins.  These results begin to elucidate the mechanism of Shp-2 function downstream of a receptor tyrosine kinase to promote the activation of the Ras-Erk pathway, with potential therapeutic applications in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs6Oeb8PVXK7Vg90H21EOLACvtfcHk0lhcrWs3ITn85A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtF2ntr4%253D&md5=6ce724c8a2cdbecd29fdfe1f30f00446</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.5.1526-1536.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.5.1526-1536.2000%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%2BQ.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DMolecular%2520mechanism%2520for%2520the%2520Shp-2%2520tyrosine%2520phosphatase%2520function%2520in%2520promoting%2520growth%2520factor%2520stimulation%2520of%2520Erk%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D1526%26epage%3D1536%26doi%3D10.1128%2FMCB.20.5.1526-1536.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildener-Leapman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span> <span> </span><span class="NLM_article-title">PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-14-1215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25480946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=508-518&author=J.+Liauthor=H.+B.+Jieauthor=Y.+Leiauthor=N.+Gildener-Leapmanauthor=S.+Trivediauthor=T.+Greenauthor=L.+P.+Kaneauthor=R.+L.+Ferris&title=PD-1%2FSHP-2+inhibits+Tc1%2FTh1+phenotypic+responses+and+the+activation+of+T+cells+in+the+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-14-1215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Li, Jing; Jie, Hyun-Bae; Lei, Yu; Gildener-Leapman, Neil; Trivedi, Sumita; Green, Tony; Kane, Lawrence P.; Ferris, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study addresses the mechanisms through which PD-1 antibody therapy restores the ability of the immune system to recognize and attack tumors by skewing intratumoral T cells toward a more potent activation phenotype that is assocd. with enhanced signaling and a reversal of their immunosuppressed phenotype.  Immune rejection of tumors is mediated by IFNγ prodn. and T-cell cytolytic activity.  These processes are impeded by PD-1, a coinhibitory mol. expressed on T cells that is elevated in tumor-infiltrating lymphocytes (TIL).  PD-1 elevation may reflect T-cell exhaustion marked by decreased proliferation, prodn. of type I cytokines, and poor cytolytic activity.  Although anti-PD-1 antibodies enhance IFNγ secretion after stimulation of the T-cell receptor (TCR), the mechanistic link between PD-1 and its effects on T-cell help (Tc1/Th1 skewing) remains unclear.  In prospectively collected cancer tissues, we found that TIL exhibited dampened Tc1/Th1 skewing and activation compared with peripheral blood lymphocytes (PBL).  When PD-1 bound its ligand PD-L1, we obsd. a marked suppression of crit. TCR target genes and Th1 cytokines.  Conversely, PD-1 blockade reversed these suppressive effects of PD-1:PD-L1 ligation.  We also found that the TCR-regulated phosphatase SHP-2 was expressed higher in TIL than in PBL, tightly correlating with PD-1 expression and neg. regulation of TCR target genes.  Overall, these results defined a PD-1/SHP-2/STAT1/T-bet signaling axis mediating the suppressive effects of PD-1 on Th1 immunity at tumor sites.  Our findings argue that PD-1 or SHP-2 blockade will be sufficient to restore robust Th1 immunity and T-cell activation and thereby reverse immunosuppression in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6jAWHNatvLVg90H21EOLACvtfcHk0lgd2Wuf7FvVOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D&md5=695007f0715b5eee2b7e47deaf87ae23</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1215%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DH.%2BB.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DGildener-Leapman%26aufirst%3DN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DKane%26aufirst%3DL.%2BP.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26atitle%3DPD-1%252FSHP-2%2520inhibits%2520Tc1%252FTh1%2520phenotypic%2520responses%2520and%2520the%2520activation%2520of%2520T%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D508%26epage%3D518%26doi%3D10.1158%2F0008-5472.CAN-14-1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, R. D.</span></span> <span> </span><span class="NLM_article-title">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.aaf1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.aaf1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28280247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1428-1433&author=E.+F.+Huiauthor=J.+Cheungauthor=J.+Zhuauthor=X.+L.+Suauthor=M.+J.+Taylorauthor=H.+A.+Wallweberauthor=D.+K.+Sasmalauthor=J.+Huangauthor=J.+M.+Kimauthor=I.+Mellmanauthor=R.+D.+Vale&title=T+cell+costimulatory+receptor+CD28+is+a+primary+target+for+PD-1-mediated+inhibition&doi=10.1126%2Fscience.aaf1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span></div><div class="casAuthors">Hui, Enfu; Cheung, Jeanne; Zhu, Jing; Su, Xiaolei; Taylor, Marcus J.; Wallweber, Heidi A.; Sasmal, Dibyendu K.; Huang, Jun; Kim, Jeong M.; Mellman, Ira; Vale, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6332</span>),
    <span class="NLM_cas:pages">1428-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">PD-1-targeted therapies have been a breakthrough for treating certain tumors and can rejuvenate T cells to unleash the anticancer immune response (see the Perspective by Clouthier and Ohashi).  It is widely believed that PD-1 suppresses signaling through the T cell receptor (TCR).  However, Hui et al. find instead that the TCR costimulatory receptor, CD28, is the primary target of PD-1 signaling.  Independently, Kamphorst et al. show that CD28 is required for PD-1 therapies to kill cancer cells efficiently and eliminate chronic viral infections in mice.  Lung cancer patients that responded to PD-1 therapy had more CD28+ T cells, which suggests that CD28 may predict treatment response.  Science, ibid p. 1428, p. 1423; see also p. 1373.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_s4cf1lkxrVg90H21EOLACvtfcHk0lgd2Wuf7FvVOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D&md5=69750b99b68316ee035a0b7eeddfb9fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf1292%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DE.%2BF.%26aulast%3DCheung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%2BL.%26aulast%3DTaylor%26aufirst%3DM.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BA.%26aulast%3DSasmal%26aufirst%3DD.%2BK.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DVale%26aufirst%3DR.%2BD.%26atitle%3DT%2520cell%2520costimulatory%2520receptor%2520CD28%2520is%2520a%2520primary%2520target%2520for%2520PD-1-mediated%2520inhibition%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1428%26epage%3D1433%26doi%3D10.1126%2Fscience.aaf1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Germ-line and somatic PTPN11 mutations in human disease. <i>Eur</i></span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejmg.2005.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ejmg.2005.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpsFKrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=81-96&author=M.+Tartagliaauthor=B.+D.+Gelb&title=Germ-line+and+somatic+PTPN11+mutations+in+human+disease.+Eur&doi=10.1016%2Fj.ejmg.2005.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Germ-line and somatic PTPN11 mutations in human disease</span></div><div class="casAuthors">Tartaglia Marco; Gelb Bruce D</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medical genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-96</span>
        ISSN:<span class="NLM_cas:issn">1769-7212</span>.
    </div><div class="casAbstract">Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream intracellular transducers is a major regulatory mechanism used to modulate cellular responses to extracellular stimuli, and its deregulation frequently drives aberrant cell proliferation, survival and/or differentiation.  SHP-2 is a cytoplasmic Src-homology 2 domain-containing protein tyrosine phosphatase that plays an important role in intracellular signaling and is required during development and hematopoiesis.  Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders.  More recently, a distinct class of missense mutations in the same gene has been identified to occur as a somatic event contributing to myeloid and lymphoid malignancies.  This review focuses on the role of SHP-2 in signal transduction, development and hematopoiesis, as well as on the consequences of SHP-2 gain-of-function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6C367GYPEDOxsqfvU0ziafW6udTcc2eb8NZzvOe9Y3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpsFKrtQ%253D%253D&md5=b1972274ecf5d806bc83f435600d826b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmg.2005.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmg.2005.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DGerm-line%2520and%2520somatic%2520PTPN11%2520mutations%2520in%2520human%2520disease.%2520Eur%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2005%26volume%3D48%26spage%3D81%26epage%3D96%26doi%3D10.1016%2Fj.ejmg.2005.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R. F.</span></span> <span> </span><span class="NLM_article-title">Functions of Shp2 in cancer</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fjcmm.12618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26088100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=2075-2083&author=J.+Zhangauthor=F.+Zhangauthor=R.+F.+Niu&title=Functions+of+Shp2+in+cancer&doi=10.1111%2Fjcmm.12618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of Shp2 in cancer</span></div><div class="casAuthors">Zhang, Jie; Zhang, Fei; Niu, Ruifang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diagnostics and therapies have shown evident advances.  Tumor surgery, chemotherapy and radiotherapy are the main techniques in treat cancers.  Targeted therapy and drug resistance are the main focus in cancer research, but many mol. intracellular mechanisms remain unknown.  Src homol. region 2-contg. protein tyrosine phosphatase 2 (Shp2) is assocd. with breast cancer, leukemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.  Signalling pathways involving Shp2 have also been discovered.  Shp2 is related to many diseases.  Mutations in the ptpn11 gene cause Noonan syndrome, LEOPARD syndrome and childhood leukemia.  Shp2 is also involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance.  Based on the structure and function of Shp2, scientists have investigated specific mechanisms involved in cancer.  Shp2 may be a potential therapeutic target because this phosphatase is implicated in many aspects.  Furthermore, Shp2 inhibitors have been used in expts. to develop treatment strategies.  However, conflicting results related to Shp2 functions have been presented in the literature, and such results should be resolved in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozU4uZ0Uifx7Vg90H21EOLACvtfcHk0lhB78LrIIeubw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtb%252FF&md5=fced523e7a96135ecd28883240ad7026</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12618%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DR.%2BF.%26atitle%3DFunctions%2520of%2520Shp2%2520in%2520cancer%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2015%26volume%3D19%26spage%3D2075%26epage%3D2083%26doi%3D10.1111%2Fjcmm.12618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiyama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akagi, T.</span></span> <span> </span><span class="NLM_article-title">Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6390</span>– <span class="NLM_lpage">6394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12438221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFOlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6390-6394&author=T.+Okaauthor=M.+Ouchidaauthor=M.+Koyamaauthor=Y.+Ogamaauthor=S.+Takadaauthor=Y.+Nakataniauthor=T.+Tanakaauthor=T.+Yoshinoauthor=K.+Hayashiauthor=N.+Oharaauthor=E.+Kondoauthor=K.+Takahashiauthor=J.+Tsuchiyamaauthor=M.+Tanimotoauthor=K.+Shimizuauthor=T.+Akagi&title=Gene+silencing+of+the+tyrosine+phosphatase+SHP1+gene+by+aberrant+methylation+in+leukemias%2Flymphomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas</span></div><div class="casAuthors">Oka, Takashi; Ouchida, Mamoru; Koyama, Maho; Ogama, Yoichiro; Takada, Shinichi; Nakatani, Yoko; Tanaka, Takehiro; Yoshino, Tadashi; Hayashi, Kazuhiko; Ohara, Nobuya; Kondo, Eisaku; Takahashi, Kiyoshi; Tsuchiyama, Junjiro; Tanimoto, Mitsune; Shimizu, Kenji; Akagi, Tadaatsu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6390-6394</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High-frequent silencing of hematopoietic cell-specific protein-tyrosine phosphatase SHP1 gene by promoter methylation was detected in various kinds of leukemias and lymphomas, as well as in many hematopoietic cell lines, which is supported by the authors' previous observation of strong decrease of SHP1 mRNA and protein.  The promoter methylation of the SHP1 gene was clearly correlated with the clin. stage.  Loss of heterozygosity with microsatellite markers near the SHP1 gene was shown in 79% of informative acute lymphoblastic leukemia cases.  These results suggest that functional loss of SHP1 is assocd. with the pathogenesis of leukemias/lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtl-YJLqbz7bVg90H21EOLACvtfcHk0lhB78LrIIeubw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFOlur4%253D&md5=8f9c6d58f20d8500eeb667b56e0d272c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DT.%26aulast%3DOuchida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DM.%26aulast%3DOgama%26aufirst%3DY.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DNakatani%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DOhara%26aufirst%3DN.%26aulast%3DKondo%26aufirst%3DE.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DTsuchiyama%26aufirst%3DJ.%26aulast%3DTanimoto%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DAkagi%26aufirst%3DT.%26atitle%3DGene%2520silencing%2520of%2520the%2520tyrosine%2520phosphatase%2520SHP1%2520gene%2520by%2520aberrant%2520methylation%2520in%2520leukemias%252Flymphomas%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6390%26epage%3D6394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecular weight inhibitors of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7396</span>– <span class="NLM_lpage">7404</span>, <span class="refDoi"> DOI: 10.1021/jm800229d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800229d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7396-7404&author=W.+M.+Yuauthor=O.+Guvenchauthor=A.+D.+MacKerellauthor=C.+K.+Qu&title=Identification+of+small+molecular+weight+inhibitors+of+Src+Homology+2+Domain-Containing+Tyrosine+Phosphatase+2+%28SHP-2%29+via+in+silico+database+screening+combined+with+experimental+assay&doi=10.1021%2Fjm800229d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small Molecular Weight Inhibitors of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 (SHP-2) via in Silico Database Screening Combined with Experimental Assay</span></div><div class="casAuthors">Yu, Wen-Mei; Guvench, Olgun; MacKerell, Alexander D.; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7396-7404</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Virtual screening methods combined with exptl. assays were used to identify low mol. wt. inhibitors for Src homol. 2 domain-contg. phosphatase 2 (SHP-2) that is mutated and hyperactivated in Noonan syndrome and a significant portion of childhood leukemias.  Virtual screening included multiple conformations of the protein, score normalization procedures, and chem. similarity considerations.  As the catalytic core of SHP-2 shares extremely high homol. to those of the related SHP-1 phosphatase and other tyrosine phosphatases, in order to identify selective inhibitors, we chose to target an adjacent protein surface pocket that is predicted to be important for binding to phosphopeptides and that has structural features unique to SHP-2.  From a database of 1.3 million compds., 9 out of 165 computationally selected compds. were shown to inhibit SHP-2 activity with IC50 values of ≈ 100 μM.  Two of the active compds. were further verified for their ability to inhibit SHP-2-mediated cellular functions.  Fluorescence titrn. expts. confirmed their direct binding to SHP-2.  Because of their simple chem. structures, these small org. compds. have the potential to act as lead compds. for the development of novel anti-SHP-2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Kw_2kNl-RbVg90H21EOLACvtfcHk0lhB78LrIIeubw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrfI&md5=915691bc2e64243286cf305314b3a470</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm800229d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800229d%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%2BM.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DIdentification%2520of%2520small%2520molecular%2520weight%2520inhibitors%2520of%2520Src%2520Homology%25202%2520Domain-Containing%2520Tyrosine%2520Phosphatase%25202%2520%2528SHP-2%2529%2520via%2520in%2520silico%2520database%2520screening%2520combined%2520with%2520experimental%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7396%26epage%3D7404%26doi%3D10.1021%2Fjm800229d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L.</span></span> <span> </span><span class="NLM_article-title">The ’Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0968-0004%2803%2900091-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12826400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=284-293&author=B.+G.+Neelauthor=H.+H.+Guauthor=L.+Pao&title=The+%E2%80%99Shp%E2%80%99ing+news%3A+SH2+domain-containing+tyrosine+phosphatases+in+cell+signaling&doi=10.1016%2FS0968-0004%2803%2900091-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span></div><div class="casAuthors">Neel, Benjamin G.; Gu, Haihua; Pao, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2 (SH2) domain-contg. phosphatases (Shps) are a small, highly conserved subfamily of protein tyrosine phosphatases, members of which are present in both vertebrates and invertebrates.  The mechanism of regulation of Shps by ligand binding is now well understood.  Much is also known about the normal signaling pathways regulated by each Shp and the consequences of Shp deficiency.  Recent studies have identified mutations in human Shp2 as the cause of the inherited disorder, Noonan syndrome.  Shp2 mutations might also contribute to the pathogenesis of some leukemias.  In addn., Shp2 might be a key virulence determinant for the important human pathogen, Helicobacter pylori.  Despite these efforts, however, the key targets of each Shp have remained elusive.  Identifying these substrates remains a major challenge for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zIEChntK0rVg90H21EOLACvtfcHk0lj4YKN7xi8Prw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D&md5=bce9fc3db0a41b29ba605251dc46c64f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%2BH.%26aulast%3DPao%26aufirst%3DL.%26atitle%3DThe%2520%25E2%2580%2599Shp%25E2%2580%2599ing%2520news%253A%2520SH2%2520domain-containing%2520tyrosine%2520phosphatases%2520in%2520cell%2520signaling%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26spage%3D284%26epage%3D293%26doi%3D10.1016%2FS0968-0004%2803%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">10472</span>– <span class="NLM_lpage">10482</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.450023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M113.450023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvV2qsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=10472-10482&author=Z.+H.+Yuauthor=J.+Xuauthor=C.+D.+Wallsauthor=L.+Chenauthor=S.+Zhangauthor=R.+Y.+Zhangauthor=L.+Wuauthor=L.+N.+Wangauthor=S.+J.+Liuauthor=Z.+Y.+Zhang&title=Structural+and+mechanistic+insights+into+LEOPARD+syndrome-associated+SHP2+mutations&doi=10.1074%2Fjbc.M113.450023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations</span></div><div class="casAuthors">Yu, Zhi-Hong; Xu, Jie; Walls, Chad D.; Chen, Lan; Zhang, Sheng; Zhang, Ruoyu; Wu, Li; Wang, Lina; Liu, Sijiu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">10472-10482</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SHP2 is an allosteric phosphatase essential for growth factor-mediated Ras activation.  Germ-line mutations in SHP2 cause clin. similar LEOPARD and Noonan syndromes, two of several autosomal-dominant conditions characterized by gain-of-function mutations in the Ras pathway.  Interestingly, Noonan syndrome SHP2 mutants are constitutively active, whereas LEOPARD syndrome SHP2 mutants exhibit reduced phosphatase activity.  How do catalytically impaired LEOPARD syndrome mutants engender gain-of-function phenotypes.  Our study reveals that LEOPARD syndrome mutations weaken the intramol. interaction between the N-SH2 and phosphatase domains, leading to a change in SHP2 mol. switching mechanism.  Consequently, LEOPARD syndrome SHP2 mutants bind upstream activators preferentially and are hypersensitive to growth factor stimulation.  They also stay longer with scaffolding adapters, thus prolonging substrate turnover, which compensates for the reduced phosphatase activity.  The study provides a solid framework for understanding how individual SHP2 mutations cause diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2FSxB8n8oKLVg90H21EOLACvtfcHk0lj4YKN7xi8Prw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvV2qsrg%253D&md5=eddf5aea52051f5471674ac917651298</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.450023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.450023%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWalls%26aufirst%3DC.%2BD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DStructural%2520and%2520mechanistic%2520insights%2520into%2520LEOPARD%2520syndrome-associated%2520SHP2%2520mutations%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D10472%26epage%3D10482%26doi%3D10.1074%2Fjbc.M113.450023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismat, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1038/nm1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15273746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=849-857&author=T.+Arakiauthor=M.+G.+Mohiauthor=F.+A.+Ismatauthor=R.+T.+Bronsonauthor=I.+R.+Williamsauthor=J.+L.+Kutokauthor=W.+T.+Yangauthor=L.+I.+Paoauthor=D.+G.+Gillilandauthor=J.+A.+Epsteinauthor=B.+G.+Neel&title=Mouse+model+of+Noonan+syndrome+reveals+cell+type-+and+gene+dosage-dependent+effects+of+Ptpn11+mutation&doi=10.1038%2Fnm1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</span></div><div class="casAuthors">Araki, Toshiyuki; Mohi, M. Golam; Ismat, Fraz A.; Bronson, Roderick T.; Williams, Ifor R.; Kutok, Jeffery L.; Yang, Wentian; Pao, Lily I.; Gilliland, D. Gary; Epstein, Jonathan A.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">849-857</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Noonan syndrome is a common human autosomal dominant birth defect, characterized by short stature, facial abnormalities, heart defects and possibly increased risk of leukemia.  Mutations of Ptpn11 (also known as Shp2), which encodes the protein-tyrosine phosphatase Shp2, occur in ∼50% of individuals with Noonan syndrome, but their mol., cellular and developmental effects, and the relationship between Noonan syndrome and leukemia, are unclear.  We generated mice expressing the Noonan syndrome-assocd. mutant D61G.  When homozygous, the D61G mutant is embryonic lethal, whereas heterozygotes have decreased viability.  Surviving Ptpn11D61G/+ embryos (∼50%) have short stature, craniofacial abnormalities similar to those in Noonan syndrome, and myeloproliferative disease.  Severely affected Ptpn11D61G/+ embryos (∼50%) have multiple cardiac defects similar to those in mice lacking the Ras-GAP protein neurofibromin.  Their endocardial cushions have increased Erk activation, but Erk hyperactivation is cell and pathway specific.  Our results clarify the relationship between Noonan syndrome and leukemia and show that a single Ptpn11 gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage-dependent and pathway-selective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsmxo_WGTel7Vg90H21EOLACvtfcHk0lj4YKN7xi8Prw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWrt78%253D&md5=69aae2a9730455356988fa32e7652c00</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnm1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1084%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DIsmat%26aufirst%3DF.%2BA.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DWilliams%26aufirst%3DI.%2BR.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DW.%2BT.%26aulast%3DPao%26aufirst%3DL.%2BI.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DEpstein%26aufirst%3DJ.%2BA.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DMouse%2520model%2520of%2520Noonan%2520syndrome%2520reveals%2520cell%2520type-%2520and%2520gene%2520dosage-dependent%2520effects%2520of%2520Ptpn11%2520mutation%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D849%26epage%3D857%26doi%3D10.1038%2Fnm1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leedy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munugalavadla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhorst, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span> <span> </span><span class="NLM_article-title">Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3737</span>– <span class="NLM_lpage">3742</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-10-4002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15644411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFejtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=3737-3742&author=R.+J.+Chanauthor=M.+B.+Leedyauthor=V.+Munugalavadlaauthor=C.+S.+Voorhorstauthor=Y.+J.+Liauthor=M.+G.+Yuauthor=R.+Kapur&title=Human+somatic+PTPN11+mutations+induce+hematopoietic-cell+hypersensitivity+to+granulocyte-macrophage+colony-stimulating+factor&doi=10.1182%2Fblood-2004-10-4002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor</span></div><div class="casAuthors">Chan, Rebecca J.; Leedy, Melissa B.; Munugalavadla, Veerendra; Voorhorst, Cara S.; Li, Yanjun; Yu, Menggang; Kapur, Reuben</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3737-3742</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Juvenile myelomonocytic leukemia (JMML) is a lethal disease of young children characterized by hypersensitivity of hematopoietic progenitors to granulocyte-macrophage colony-stimulating factor (GM-CSF).  Mutations in PTPN11, which encodes the protein tyrosine phosphatase Shp-2, are common in JMML.  We hypothesized that PTPN11 mutations induce hypersensitivity of hematopoietic progenitors to GM-CSF and confer increased GM-CSF-stimulated phospho-extracellular signal-regulated kinase (Erk) levels.  To test this hypothesis, the wild-type (WT) and 3 mutant Ptpn11 cDNAs (E76K, D61V, and D61Y) were transduced into murine bone marrow cells to examine GM-CSF-stimulated granulocyte-macrophage colony-forming unit (CFU-GM) growth, macrophage progenitor proliferation, and activation of the Ras signaling pathway.  Expression of the Shp-2 mutants induced progenitor cell hypersensitivity to GM-CSF compared with cells transduced with vector alone or WT Shp-2.  Macrophage progenitors expressing the Shp-2 mutants displayed both basal and GM-CSF-stimulated hyperproliferation compared with cells transduced with vector alone or WT Shp-2.  Consistently, macrophage progenitors transduced with the Shp-2 mutants demonstrated constitutively elevated phospho-Erk levels and sustained activation of phospho-Erk following GM-CSF stimulation compared with vector alone or WT Shp-2.  These data support the hypothesis that PTPN11 mutations induce hematopoietic progenitor hypersensitivity to GM-CSF due to hyperactivation of the Ras signaling axis and provide a basis for the GM-CSF signaling pathway as a target for rational drug design in JMML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDzelkPWl227Vg90H21EOLACvtfcHk0ljKBnLFc-2wNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFejtLY%253D&md5=3120af906beb1ae08c2b6717a6030235</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4002%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DLeedy%26aufirst%3DM.%2BB.%26aulast%3DMunugalavadla%26aufirst%3DV.%26aulast%3DVoorhorst%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DM.%2BG.%26aulast%3DKapur%26aufirst%3DR.%26atitle%3DHuman%2520somatic%2520PTPN11%2520mutations%2520induce%2520hematopoietic-cell%2520hypersensitivity%2520to%2520granulocyte-macrophage%2520colony-stimulating%2520factor%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D3737%26epage%3D3742%26doi%3D10.1182%2Fblood-2004-10-4002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z. R.</span></span> <span> </span><span class="NLM_article-title">Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2639</span>– <span class="NLM_lpage">2643</span>, <span class="refDoi"> DOI: 10.3892/mmr.2016.5547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.3892%2Fmmr.2016.5547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27484170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSjtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2639-2643&author=J.+Zhangauthor=J.+W.+Shenauthor=R.+H.+Chengauthor=C.+Niauthor=J.+Y.+Liangauthor=M.+Liauthor=Z.+R.+Yao&title=Identification+of+a+PTPN11+hot+spot+mutation+in+a+child+with+atypical+LEOPARD+syndrome&doi=10.3892%2Fmmr.2016.5547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome</span></div><div class="casAuthors">Zhang, Jia; Shen, Jinwen; Cheng, Ruhong; Ni, Cheng; Liang, Jianying; Li, Ming; Yao, Zhirong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2639-2643</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">LEOPARD syndrome (LS) is an autosomal dominant inherited disorder primarily caused by mutations in the PTPN11, RAF1 and BRAF genes.  Characteristic features include lentigines, craniofacial dysmorphism, myocardium or valve abnormalities, eletrocardiog. conduction defects and deafness.  LS, neurofibromatosis type 1, Noonan syndrome and Legius syndrome are a group of highly overlapped disorders termed 'RASopathies'.  Therefore, clin. discrimination between these syndromes represents a huge challenge.  The present study reports a young child diagnosed with LS via identification of a common p.Thr468Met mutation in PTPN11.  Taking into account two Taiwanese LS cases with an identical mutation, Thr468Met is likely to be the most prevalent mutation in the Chinese population.  Furthermore, this study suggests that a clin. diagnosis of LS should be considered for individuals with congenital cardiac defects and atypical lentigines (i.e., light brown freckles) scattered particularly on the face.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWyNq3-2cy7Vg90H21EOLACvtfcHk0ljKBnLFc-2wNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSjtbvL&md5=dc00abe698beda2030812b6c49e9983a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5547%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%2BW.%26aulast%3DCheng%26aufirst%3DR.%2BH.%26aulast%3DNi%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DZ.%2BR.%26atitle%3DIdentification%2520of%2520a%2520PTPN11%2520hot%2520spot%2520mutation%2520in%2520a%2520child%2520with%2520atypical%2520LEOPARD%2520syndrome%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D2639%26epage%3D2643%26doi%3D10.3892%2Fmmr.2016.5547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarbaker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">8816</span>– <span class="NLM_lpage">8820</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-04-1923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15604238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOms7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=8816-8820&author=M.+Bentires-Aljauthor=J.+G.+Paezauthor=F.+S.+Davidauthor=H.+Keilhackauthor=B.+Halmosauthor=K.+Naokiauthor=J.+M.+Marisauthor=A.+Richardsonauthor=A.+Bardelliauthor=D.+J.+Sugarbakerauthor=W.+G.+Richardsauthor=J.+Y.+Duauthor=L.+Girardauthor=J.+D.+Minnaauthor=M.+L.+Lohauthor=D.+E.+Fisherauthor=V.+E.+Velculescuauthor=B.+Vogelsteinauthor=M.+Meyersonauthor=W.+R.+Sellersauthor=B.+G.+Neel&title=Activating+mutations+of+the+Noonan+syndrome-associated+SHP2%2FPTPN11+gene+in+human+solid+tumors+and+adult+acute+myelogenous+leukemia&doi=10.1158%2F0008-5472.CAN-04-1923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia</span></div><div class="casAuthors">Bentires-Alj, Mohamed; Paez, J. Guillermo; David, Frank S.; Keilhack, Heike; Halmos, Balazs; Naoki, Katsuhiko; Maris, John M.; Richardson, Andrea; Bardelli, Alberto; Sugarbaker, David J.; Richards, William G.; Du, Jinyan; Girard, Luc; Minna, John D.; Loh, Mignon L.; Fisher, David E.; Velculescu, Victor E.; Vogelstein, Bert; Meyerson, Matthew; Sellers, William R.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8816-8820</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The SH2 domain-contg. protein-tyrosine phosphatase PTPN11 (Shp2) is required for normal development and is an essential component of signaling pathways initiated by growth factors, cytokines, and extracellular matrix.  In many of these pathways, Shp2 acts upstream of Ras.  About 50% of patients with Noonan syndrome have germ-line PTPN11 gain of function mutations.  Assocns. between Noonan syndrome and an increased risk of some malignancies, notably leukemia and neuroblastoma, have been reported, and recent data indicate that somatic PTPN11 mutations occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia (AML).  Juvenile myelomonocytic leukemia patients without PTPN11 mutations have either homozygotic NF-1 deletion or activating RAS mutations.  Given the role of Shp2 in Ras activation and the frequent mutation of RAS in human tumors, these data raise the possibility that PTPN11 mutations play a broader role in cancer.  The authors asked whether PTPN11 mutations occur in other malignancies in which activating RAS mutations occur at low but significant frequency.  Sequencing of PTPN11 from 13 different human neoplasms including breast, lung, gastric, and neuroblastoma tumors and adult AML and acute lymphoblastic leukemia revealed 11 missense mutations.  Five are known mutations predicted to result in an activated form of Shp2, whereas six are new mutations.  Biochem. anal. confirmed that several of the new mutations result in increased Shp2 activity.  The data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, esp. neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3taKvDtHXBLVg90H21EOLACvtfcHk0ljKBnLFc-2wNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOms7fK&md5=f6f9fb8c6e9d5260901a03081db259c7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1923%26sid%3Dliteratum%253Aachs%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DDavid%26aufirst%3DF.%2BS.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DActivating%2520mutations%2520of%2520the%2520Noonan%2520syndrome-associated%2520SHP2%252FPTPN11%2520gene%2520in%2520human%2520solid%2520tumors%2520and%2520adult%2520acute%2520myelogenous%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D8816%26epage%3D8820%26doi%3D10.1158%2F0008-5472.CAN-04-1923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic acid based small molecule inhibitor for the oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+T.+Heauthor=S.+J.+Liuauthor=Z.+H.+Yuauthor=Z.+X.+Jiangauthor=Z.+Y.+Yangauthor=Y.+S.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+N.+Wangauthor=R.+J.+Chanauthor=Z.+Y.+Zhang&title=Salicylic+acid+based+small+molecule+inhibitor+for+the+oncogenic+Src+Homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0lhN5NNtnGzTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DDong%26aufirst%3DY.%2BS.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSalicylic%2520acid%2520based%2520small%2520molecule%2520inhibitor%2520for%2520the%2520oncogenic%2520Src%2520Homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+tyrosine+phosphatase+Shp2+%28PTPN11%29+in+cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lhN5NNtnGzTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520Shp2%2520%2528PTPN11%2529%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tate, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutselakis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jupe, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponting, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramshaw, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rye, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speedy, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefancsik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, S. A.</span></span> <span> </span><span class="NLM_article-title">COSMIC: the catalogue of somatic mutations in cancer</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D941</span>– <span class="NLM_lpage">D947</span>, <span class="refDoi"> DOI: 10.1093/nar/gky1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1093%2Fnar%2Fgky1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30371878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cgt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D941-D947&author=J.+G.+Tateauthor=S.+Bamfordauthor=H.+C.+Jubbauthor=Z.+Sondkaauthor=D.+M.+Beareauthor=N.+Bindalauthor=H.+Boutselakisauthor=C.+G.+Coleauthor=C.+Creatoreauthor=E.+Dawsonauthor=P.+Fishauthor=B.+Harshaauthor=C.+Hathawayauthor=S.+C.+Jupeauthor=C.+Y.+Kokauthor=K.+Nobleauthor=L.+Pontingauthor=C.+C.+Ramshawauthor=C.+E.+Ryeauthor=H.+E.+Speedyauthor=R.+Stefancsikauthor=S.+L.+Thompsonauthor=S.+C.+Wangauthor=S.+Wardauthor=P.+J.+Campbellauthor=S.+A.+Forbes&title=COSMIC%3A+the+catalogue+of+somatic+mutations+in+cancer&doi=10.1093%2Fnar%2Fgky1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">COSMIC: the Catalogue Of Somatic Mutations In Cancer</span></div><div class="casAuthors">Tate, John G.; Bamford, Sally; Jubb, Harry C.; Sondka, Zbyslaw; Beare, David M.; Bindal, Nidhi; Boutselakis, Harry; Cole, Charlotte G.; Creatore, Celestino; Dawson, Elisabeth; Fish, Peter; Harsha, Bhavana; Hathaway, Charlie; Jupe, Steve C.; Kok, Chai Yin; Noble, Kate; Ponting, Laura; Ramshaw, Christopher C.; Rye, Claire E.; Speedy, Helen E.; Stefancsik, Ray; Thompson, Sam L.; Wang, Shicai; Ward, Sari; Campbell, Peter J.; Forbes, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D941-D947</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">COSMIC, the Catalog Of Somatic Mutations In Cancer (https://cancer.sanger.ac.uk) is the most detailed and comprehensive resource for exploring the effect of somatic mutations in human cancer.  The latest release, COSMIC v86 (August 2018), includes almost 6 million coding mutations across 1.4 million tumor samples, curated from over 26,000 publications.  In addn. to coding mutations, COSMIC covers all the genetic mechanisms by which somatic mutations promote cancer, including non-coding mutations, gene fusions, copy-no. variants and drug resistance mutations.  COSMIC is primarily handcurated, ensuring quality, accuracy and descriptive data capture.  Building on our manual curation processes, we are introducing new initiatives that allow us to prioritize key genes and diseases, and to react more quickly and comprehensively to new findings in the literature.  Alongside improvements to the public website and data-download systems, new functionality in COSMIC-3D allows exploration of mutations within three-dimensional protein structures, their protein structural and functional impacts, and implications for druggability.  In parallel with COSMIC's deep and broad variant coverage, the Cancer Gene Census (CGC) describes a curated catalog of genes driving every form of human cancer.  Currently describing 719 genes, the CGC has recently introduced functional descriptions of how each gene drives disease, summarized into the 10 cancer Hallmarks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyWHUT512HAbVg90H21EOLACvtfcHk0lhN5NNtnGzTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cgt7bM&md5=56574cedbe9adc54c097a5af5fe41eb8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1015%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DJ.%2BG.%26aulast%3DBamford%26aufirst%3DS.%26aulast%3DJubb%26aufirst%3DH.%2BC.%26aulast%3DSondka%26aufirst%3DZ.%26aulast%3DBeare%26aufirst%3DD.%2BM.%26aulast%3DBindal%26aufirst%3DN.%26aulast%3DBoutselakis%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DC.%2BG.%26aulast%3DCreatore%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DE.%26aulast%3DFish%26aufirst%3DP.%26aulast%3DHarsha%26aufirst%3DB.%26aulast%3DHathaway%26aufirst%3DC.%26aulast%3DJupe%26aufirst%3DS.%2BC.%26aulast%3DKok%26aufirst%3DC.%2BY.%26aulast%3DNoble%26aufirst%3DK.%26aulast%3DPonting%26aufirst%3DL.%26aulast%3DRamshaw%26aufirst%3DC.%2BC.%26aulast%3DRye%26aufirst%3DC.%2BE.%26aulast%3DSpeedy%26aufirst%3DH.%2BE.%26aulast%3DStefancsik%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DWard%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DForbes%26aufirst%3DS.%2BA.%26atitle%3DCOSMIC%253A%2520the%2520catalogue%2520of%2520somatic%2520mutations%2520in%2520cancer%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD941%26epage%3DD947%26doi%3D10.1093%2Fnar%2Fgky1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span>; <span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Noonan syndrome and related disorders: Genetics and pathogenesis</span>. In  <i>Annual Review of Genomics and Human Genetics</i>; <span class="NLM_publisher-name">Annual Reviews</span>: <span class="NLM_publisher-loc">Palo Alto, CA</span>, <span class="NLM_year">2005</span>; Vol.  <span class="NLM_volume">6</span>, pp  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">68</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1146%2Fannurev.genom.6.080604.162305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=45-68&author=M.+Tartaglia&author=B.+D.+Gelb&title=Annual+Review+of+Genomics+and+Human+Genetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1146%2Fannurev.genom.6.080604.162305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1146%252Fannurev.genom.6.080604.162305%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26atitle%3DNoonan%2520syndrome%2520and%2520related%2520disorders%253A%2520Genetics%2520and%2520pathogenesis%26btitle%3DAnnual%2520Review%2520of%2520Genomics%2520and%2520Human%2520Genetics%26pub%3DAnnual%2520Reviews%26date%3D2005%26volume%3D6%26spage%3D45%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The role of Shp2 (PTPN11) in cancer</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2006.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.gde.2006.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17227708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=23-30&author=M.+G.+Mohiauthor=B.+G.+Neel&title=The+role+of+Shp2+%28PTPN11%29+in+cancer&doi=10.1016%2Fj.gde.2006.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Mohi, M. Golam; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes.  Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer.  Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene.  We now know that at least one other PTP, the SH2 domain-contg. phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors.  Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0V_cNPfFwLVg90H21EOLACvtfcHk0lgHLlDz3-nlog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D&md5=a571192d3fffdff69ddfc264bb9108ce</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520role%2520of%2520Shp2%2520%2528PTPN11%2529%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.gde.2006.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span> <span> </span><span class="NLM_article-title">Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-14-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1186%2F1472-6807-14-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24628801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCmsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=10&author=W.+Qiuauthor=X.+N.+Wangauthor=V.+Romanovauthor=A.+Hutchinsonauthor=A.+Linauthor=M.+Ruzanovauthor=K.+P.+Battaileauthor=E.+F.+Paiauthor=B.+G.+Neelauthor=N.+Y.+Chirgadze&title=Structural+insights+into+Noonan%2FLEOPARD+syndrome-related+mutants+of+protein-tyrosine+phosphatase+SHP2+%28PTPN11%29&doi=10.1186%2F1472-6807-14-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)</span></div><div class="casAuthors">Qiu, Wei; Wang, Xiaonan; Romanov, Vladimir; Hutchinson, Ashley; Lin, Andres; Ruzanov, Maxim; Battaile, Kevin P.; Pai, Emil F.; Neel, Benjamin G.; Chirgadze, Nickolay Y.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Structural Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">BSBMBB</span>;
        ISSN:<span class="NLM_cas:issn">1472-6807</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The ubiquitous non-receptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) plays a key role in RAS/ERK signaling downstream of most, if not all growth factors, cytokines and integrins, although its major substrates remain controversial.  Mutations in PTPN11 lead to several distinct human diseases.  Germ-line PTPN11 mutations cause about 50% of Noonan Syndrome (NS), which is among the most common autosomal dominant disorders.  LEOPARD Syndrome (LS) is an acronym for its major syndromic manifestations: multiple Lentigines, Electrocardiog. abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormalities of genitalia, Retardation of growth, and sensorineural Deafness.  Frequently, LS patients have hypertrophic cardiomyopathy, and they might also have an increased risk of neuroblastoma (NS) and acute myeloid leukemia (AML).  Consistent with the distinct pathogenesis of NS and LS, different types of PTPN11 mutations cause these disorders.  Although multiple studies have reported the biochem. and biol. consequences of NS- and LS-assocd. PTPN11 mutations, their structural consequences have not been analyzed fully.  Here we report the crystal structures of WT SHP2 and five NS/LS-assocd. SHP2 mutants.  These findings enable direct structural comparisons of the local conformational changes caused by each mutation.  Our structural anal. agrees with, and provides addnl. mechanistic insight into, the previously reported catalytic properties of these mutants.  The results of our research provide new information regarding the structure-function relationship of this medically important target, and should serve as a solid foundation for structure-based drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbrX4o8Z0i8rVg90H21EOLACvtfcHk0lgHLlDz3-nlog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCmsrbP&md5=d6830509c6a36e299806f872570c51a6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-14-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-14-10%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%2BN.%26aulast%3DRomanov%26aufirst%3DV.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26atitle%3DStructural%2520insights%2520into%2520Noonan%252FLEOPARD%2520syndrome-related%2520mutants%2520of%2520protein-tyrosine%2520phosphatase%2520SHP2%2520%2528PTPN11%2529%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2014%26volume%3D14%26spage%3D10%26doi%3D10.1186%2F1472-6807-14-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-10-4057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16030196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3142-3149&author=R.+Z.+Xuauthor=Y.+Yuauthor=S.+Zhengauthor=X.+Y.+Zhaoauthor=Q.+H.+Dongauthor=Z.+W.+Heauthor=Y.+Liangauthor=Q.+H.+Luauthor=Y.+M.+Fangauthor=X.+X.+Ganauthor=X.+H.+Xuauthor=S.+Z.+Zhangauthor=Q.+Dongauthor=X.+H.+Zhangauthor=G.+S.+Feng&title=Overexpression+of+Shp2+tyrosine+phosphatase+is+implicated+in+leukemogenesis+in+adult+human+leukemia&doi=10.1182%2Fblood-2004-10-4057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia</span></div><div class="casAuthors">Xu, Rongzhen; Yu, Yingzi; Zheng, Shu; Zhao, Xiaoying; Dong, Qinghua; He, Zhiwen; Liang, Yun; Lu, Qinghua; Fang, Yongmin; Gan, Xiaoxian; Xu, Xiaohua; Zhang, Suzhan; Dong, Qi; Zhang, Xiaohong; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3142-3149</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Shp2 tyrosine phosphatase plays a crit. role in hematopoiesis, and dominant active mutations were detected in the human gene PTPN11, encoding Shp2, in child leukemia patients.  The authors report here that although no such mutations were detected in 44 adult leukemia patients screened, Shp2 expression levels were significantly elevated in primary leukemia cells and leukemia cell lines, as compared with normal hematopoietic progenitor cells.  The Shp2 protein amts. correlated well with the hyperproliferative capacity but were inversely assocd. with the differentiation degree of leukemia cells.  Suppression of Shp2 expression induced apoptosis and inhibition of leukemic cell clonogenic growth.  Notably, the majority of Shp2 was preferentially localized to the plasma membrane and was constitutively phosphorylated on tyrosine in leukemia cells, and also in normal hematopoietic cells following mitogenic stimulation.  Based on these results, the authors propose that aberrantly increased expression of Shp2 may contribute, collaboratively with other factors, to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBjdoCIKiqrVg90H21EOLACvtfcHk0lgY4rwh0XIXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr3I&md5=22c0a22421a9fa0b7faca326b61f0c27</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4057%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%2BY.%26aulast%3DDong%26aufirst%3DQ.%2BH.%26aulast%3DHe%26aufirst%3DZ.%2BW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DQ.%2BH.%26aulast%3DFang%26aufirst%3DY.%2BM.%26aulast%3DGan%26aufirst%3DX.%2BX.%26aulast%3DXu%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DS.%2BZ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DOverexpression%2520of%2520Shp2%2520tyrosine%2520phosphatase%2520is%2520implicated%2520in%2520leukemogenesis%2520in%2520adult%2520human%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3142%26epage%3D3149%26doi%3D10.1182%2Fblood-2004-10-4057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzaniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giarin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrangeli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorcini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span> <span> </span><span class="NLM_article-title">Somatic PTPN11 mutations in childhood acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2005.05457.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1365-2141.2005.05457.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15842656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlWntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=333-339&author=M.+Tartagliaauthor=S.+Martinelliauthor=I.+Iavaroneauthor=G.+Cazzanigaauthor=M.+Spinelliauthor=E.+Giarinauthor=V.+Petrangeliauthor=C.+Cartaauthor=R.+Masettiauthor=M.+Aricoauthor=F.+Locatelliauthor=G.+Bassoauthor=M.+Sorciniauthor=A.+Pessionauthor=A.+Biondi&title=Somatic+PTPN11+mutations+in+childhood+acute+myeloid+leukaemia&doi=10.1111%2Fj.1365-2141.2005.05457.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic PTPN11 mutations in childhood acute myeloid leukaemia</span></div><div class="casAuthors">Tartaglia, Marco; Martinelli, Simone; Iavarone, Ivano; Cazzaniga, Giovanni; Spinelli, Monica; Giarin, Emanuela; Petrangeli, Valentina; Carta, Claudio; Masetti, Riccardo; Arico, Maurizio; Locatelli, Franco; Basso, Giuseppe; Sorcini, Mariella; Pession, Andrea; Biondi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-339</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukemogenesis.  In a recent study of 69 children and adolescents with de novo acute myeloid leukemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes.  Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases).  Here, we report on the results of a mol. screening performed on 181 addnl. unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clin. relevance.  We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4·4%), although they recur in a considerable percentage of patients with FAB-M5 (18%).  PTPN11 lesions rarely occur in other subtypes.  Within the FAB-M5 group no clear assocn. of PTPN11 mutations with any clin. variable was evident.  Nearly two third of the patients with this subtype were found to harbor an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUZ4vnyzIembVg90H21EOLACvtfcHk0ljrx4_fOub_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlWntL8%253D&md5=d43133a39091c175b1f0e7355ec0c96f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2005.05457.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2005.05457.x%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DS.%26aulast%3DIavarone%26aufirst%3DI.%26aulast%3DCazzaniga%26aufirst%3DG.%26aulast%3DSpinelli%26aufirst%3DM.%26aulast%3DGiarin%26aufirst%3DE.%26aulast%3DPetrangeli%26aufirst%3DV.%26aulast%3DCarta%26aufirst%3DC.%26aulast%3DMasetti%26aufirst%3DR.%26aulast%3DArico%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DSorcini%26aufirst%3DM.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26atitle%3DSomatic%2520PTPN11%2520mutations%2520in%2520childhood%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2005%26volume%3D129%26spage%3D333%26epage%3D339%26doi%3D10.1111%2Fj.1365-2141.2005.05457.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span> <span> </span><span class="NLM_article-title">A role for the scaffolding adapter GAB2 in breast cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nm1341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm1341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16369543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=114-121&author=M.+Bentires-Aljauthor=S.+G.+Gilauthor=R.+Chanauthor=Z.+G.+C.+Wangauthor=Y.+P.+Wangauthor=N.+Imanakaauthor=L.+N.+Harrisauthor=A.+Richardsonauthor=B.+G.+Neelauthor=H.+H.+Gu&title=A+role+for+the+scaffolding+adapter+GAB2+in+breast+cancer&doi=10.1038%2Fnm1341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A role for the scaffolding adapter GAB2 in breast cancer</span></div><div class="casAuthors">Bentires-Alj, Mohamed; Gil, Susana G.; Chan, Richard; Wang, Zhigang C.; Wang, Yongping; Imanaka, Naoko; Harris, Lyndsay N.; Richardson, Andrea; Neel, Benjamin G.; Gu, Haihua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-121</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The scaffolding adapter GAB2 maps to a region (11q13-14) commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and primary tumors, but its functional role in mammary carcinogenesis has remained unexplored.  We found that overexpression of GAB2 (Grb2-assocd. binding protein 2) increases proliferation of MCF10A mammary cells in three-dimensional culture.  Coexpression of GAB2 with antiapoptotic oncogenes causes lumenal filling, whereas coexpression with Neu (also known as ErbB2 and HER2) results in an invasive phenotype.  These effects of GAB2 are mediated by hyperactivation of the Shp2-Erk pathway.  Furthermore, overexpression of Gab2 potentiates, whereas deficiency of Gab2 ameliorates, Neu-evoked breast carcinogenesis in mice.  Finally, GAB2 is amplified in some GAB2-overexpressing human breast tumors.  Our data suggest that GAB2 may be a key gene within an 11q13 amplicon in human breast cancer and propose a role for overexpression of GAB2 in mammary carcinogenesis.  Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTgOzDFXnf37Vg90H21EOLACvtfcHk0ljrx4_fOub_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KmsA%253D%253D&md5=d1cad81db61467b25fecd674ed6cdc8c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnm1341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1341%26sid%3Dliteratum%253Aachs%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DS.%2BG.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DZ.%2BG.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DImanaka%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%2BH.%26atitle%3DA%2520role%2520for%2520the%2520scaffolding%2520adapter%2520GAB2%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D114%26epage%3D121%26doi%3D10.1038%2Fnm1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bocanegra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajput, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langerod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntsman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borresen-Dale, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span> <span> </span><span class="NLM_article-title">Focal amplification and oncogene dependency of GAB2 in breast cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fonc.2009.364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19881546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=774-779&author=M.+Bocanegraauthor=A.+Bergamaschiauthor=Y.+H.+Kimauthor=M.+A.+Millerauthor=A.+B.+Rajputauthor=J.+Kaoauthor=A.+Langerodauthor=W.+Hanauthor=D.+Y.+Nohauthor=S.+S.+Jeffreyauthor=D.+G.+Huntsmanauthor=A.+L.+Borresen-Daleauthor=J.+R.+Pollack&title=Focal+amplification+and+oncogene+dependency+of+GAB2+in+breast+cancer&doi=10.1038%2Fonc.2009.364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Focal amplification and oncogene dependency of GAB2 in breast cancer</span></div><div class="casAuthors">Bocanegra, M.; Bergamaschi, A.; Kim, Y. H.; Miller, M. A.; Rajput, A. B.; Kao, J.; Langerod, A.; Han, W.; Noh, D.-Y.; Jeffrey, S. S.; Huntsman, D. G.; Borresen-Dale, A.-L.; Pollack, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addn. to cyclin D1 (CCND1).  One such candidate, the scaffolding adapter protein, GRB2-assocd. binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer.  However, the amplification status and function of GAB2 in the context of amplification remain undefined.  In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we obsd. focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role.  Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling.  GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2.  Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKkR4hV7pYArVg90H21EOLACvtfcHk0liaiVpIUs3nUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7nE&md5=2151d9c9c72ea83e0888d658d6ae63e5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.364%26sid%3Dliteratum%253Aachs%26aulast%3DBocanegra%26aufirst%3DM.%26aulast%3DBergamaschi%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DRajput%26aufirst%3DA.%2BB.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DLangerod%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DNoh%26aufirst%3DD.%2BY.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DHuntsman%26aufirst%3DD.%2BG.%26aulast%3DBorresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26atitle%3DFocal%2520amplification%2520and%2520oncogene%2520dependency%2520of%2520GAB2%2520in%2520breast%2520cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D774%26epage%3D779%26doi%3D10.1038%2Fonc.2009.364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducatman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agazie, Y. M.</span></span> <span> </span><span class="NLM_article-title">SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis</span>. <i>Histopathology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2559.2008.03103.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1365-2559.2008.03103.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18643929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2008&pages=389-402&author=X.+Zhouauthor=J.+Coadauthor=B.+Ducatmanauthor=Y.+M.+Agazie&title=SHP2+is+up-regulated+in+breast+cancer+cells+and+in+infiltrating+ductal+carcinoma+of+the+breast%2C+implying+its+involvement+in+breast+oncogenesis&doi=10.1111%2Fj.1365-2559.2008.03103.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis</span></div><div class="casAuthors">Zhou X; Coad J; Ducatman B; Agazie Y M</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-402</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  To determine whether Src homology phosphotyrosyl phosphatase 2 (SHP2) is up-regulated in breast cancer and, if so, to determine whether its up-regulation has any relationship with clinical variables of breast cancer.  METHODS AND RESULTS:  Immunoblotting, immunohistochemistry and immunofluorescence microscopy were used to assess the state of SHP2 expression in breast cancer cells and in infiltrating ductal carcinoma (IDC) of breast.  The possible role of SHP2 in breast cancer cell transformation was determined by dominant-negative expression and anchorage-independent growth assays.  All of the breast cancer cell lines tested and 72% of IDC breast tumours analysed had increased amounts of the SHP2 protein.  In support of its positive role, dominant-negative SHP2 blocked anchorage-independent growth of breast cancer cells.  Furthermore, overexpression of SHP2 seemed to have a positive relationship to HER2 overexpression, nuclear accumulation of hormone receptors, higher tumour grade and lymph node metastasis, but not to age of breast cancer patients.  CONCLUSION:  SHP2 is a widely overexpressed signalling protein in IDC breast tumours.  Given SHP2's positive role in cell growth, transformation and stem cell survival, the positive relationship of its overexpression to lymph node metastasis, nuclear accumulation of hormone receptors and higher tumour grade suggests that SHP2 promotes breast oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIF5GvxYY_9-cVm4E2RlLfW6udTcc2eaO0Po0fqDaFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhsFyksA%253D%253D&md5=83c19a6cc4a7b70d8accd75f9b83a169</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2008.03103.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2008.03103.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DCoad%26aufirst%3DJ.%26aulast%3DDucatman%26aufirst%3DB.%26aulast%3DAgazie%26aufirst%3DY.%2BM.%26atitle%3DSHP2%2520is%2520up-regulated%2520in%2520breast%2520cancer%2520cells%2520and%2520in%2520infiltrating%2520ductal%2520carcinoma%2520of%2520the%2520breast%252C%2520implying%2520its%2520involvement%2520in%2520breast%2520oncogenesis%26jtitle%3DHistopathology%26date%3D2008%26volume%3D53%26spage%3D389%26epage%3D402%26doi%3D10.1111%2Fj.1365-2559.2008.03103.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausgruber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkhaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidatzis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzarol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confalonieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balwierz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachkov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nimwegen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span> <span> </span><span class="NLM_article-title">Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1038/nm.2645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm.2645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22388088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1yisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=529-537&author=N.+Acetoauthor=N.+Sausgruberauthor=H.+Brinkhausauthor=D.+Gaidatzisauthor=G.+Martiny-Baronauthor=G.+Mazzarolauthor=S.+Confalonieriauthor=M.+Quartoauthor=G.+Huauthor=P.+J.+Balwierzauthor=M.+Pachkovauthor=S.+J.+Elledgeauthor=E.+van+Nimwegenauthor=M.+B.+Stadlerauthor=M.+Bentires-Alj&title=Tyrosine+phosphatase+SHP2+promotes+breast+cancer+progression+and+maintains+tumor-initiating+cells+via+activation+of+key+transcription+factors+and+a+positive+feedback+signaling+loop&doi=10.1038%2Fnm.2645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop</span></div><div class="casAuthors">Aceto, Nicola; Sausgruber, Nina; Brinkhaus, Heike; Gaidatzis, Dimos; Martiny-Baron, Georg; Mazzarol, Giovanni; Confalonieri, Stefano; Quarto, Micaela; Hu, Guang; Balwierz, Piotr J.; Pachkov, Mikhail; Elledge, Stephen J.; van Nimwegen, Erik; Stadler, Michael B.; Bentires-Alj, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New cancer therapies are likely to arise from an in-depth understanding of the signaling networks influencing tumor initiation, progression and metastasis.  We show a fundamental role for Src-homol. 2 domain-contg. phosphatase 2 (SHP2) in these processes in human epidermal growth factor receptor 2 (HER2)-pos. and triple-neg. breast cancers.  Knockdown of SHP2 eradicated breast tumor-initiating cells in xenograft models, and SHP2 depletion also prevented invasion in three-dimensional cultures and in a transductal invasion assay in vivo.  Notably, SHP2 knockdown in established breast tumors blocked their growth and reduced metastasis.  Mechanistically, SHP2 activated stemness-assocd. transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.  We found these genes to be simultaneously activated in a large subset of human primary breast tumors that are assocd. with invasive behavior and poor prognosis.  These results provide new insights into the signaling cascades influencing tumor-initiating cells as well as a rationale for targeting SHP2 in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBsjLtiOIWbVg90H21EOLACvtfcHk0linhrgMiuDhOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1yisrg%253D&md5=ea1d756b2f9d21771ca5f25d2dfda798</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm.2645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2645%26sid%3Dliteratum%253Aachs%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DSausgruber%26aufirst%3DN.%26aulast%3DBrinkhaus%26aufirst%3DH.%26aulast%3DGaidatzis%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMazzarol%26aufirst%3DG.%26aulast%3DConfalonieri%26aufirst%3DS.%26aulast%3DQuarto%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DBalwierz%26aufirst%3DP.%2BJ.%26aulast%3DPachkov%26aufirst%3DM.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3Dvan%2BNimwegen%26aufirst%3DE.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DBentires-Alj%26aufirst%3DM.%26atitle%3DTyrosine%2520phosphatase%2520SHP2%2520promotes%2520breast%2520cancer%2520progression%2520and%2520maintains%2520tumor-initiating%2520cells%2520via%2520activation%2520of%2520key%2520transcription%2520factors%2520and%2520a%2520positive%2520feedback%2520signaling%2520loop%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D529%26epage%3D537%26doi%3D10.1038%2Fnm.2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 phosphatase as a novel therapeutic target for melanoma treatment</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73817</span>– <span class="NLM_lpage">73829</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.18632%2Foncotarget.12074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27650545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2svisVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73817-73829&author=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=L.+F.+Zengauthor=S.+Zhangauthor=Y.+P.+Baiauthor=J.+M.+Miaoauthor=L.+Chenauthor=J.+W.+Xieauthor=Z.+Y.+Zhang&title=SHP2+phosphatase+as+a+novel+therapeutic+target+for+melanoma+treatment&doi=10.18632%2Foncotarget.12074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 phosphatase as a novel therapeutic target for melanoma treatment</span></div><div class="casAuthors">Zhang Ruo-Yu; Yu Zhi-Hong; Zhang Sheng; Bai Yunpeng; Miao Jinmin; Chen Lan; Zhang Zhong-Yin; Zeng Lifan; Xie Jingwu; Zhang Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">73817-73829</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Melanoma ranks among the most aggressive and deadly human cancers.  Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses.  Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment.  Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis.  We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways.  We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation.  Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis.  Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5ZzG02x4ZGROk4JA3soTqfW6udTcc2eZCV6aUSsvPrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svisVGqsQ%253D%253D&md5=374e0635fe58c11dcda57c24ef17b43a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12074%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%2BP.%26aulast%3DMiao%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSHP2%2520phosphatase%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520melanoma%2520treatment%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D73817%26epage%3D73829%26doi%3D10.18632%2Foncotarget.12074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+is+a+central+node+in+intrinsic+and+acquired+resistance+to+targeted+cancer+drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0linhrgMiuDhOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520is%2520a%2520central%2520node%2520in%2520intrinsic%2520and%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneeberger, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luetteke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6191</span>– <span class="NLM_lpage">6202</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.18632%2Foncotarget.3356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25730908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2MrpvFOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6191-6202&author=V.+E.+Schneebergerauthor=Y.+Renauthor=N.+Luettekeauthor=Q.+L.+Huangauthor=L.+W.+Chenauthor=H.+R.+Lawrenceauthor=N.+J.+Lawrenceauthor=E.+B.+Hauraauthor=J.+M.+Koomenauthor=D.+Coppolaauthor=J.+Wu&title=Inhibition+of+Shp2+suppresses+mutant+EGFR-induced+lung+tumors+in+transgenic+mouse+model+of+lung+adenocarcinoma&doi=10.18632%2Foncotarget.3356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma</span></div><div class="casAuthors">Schneeberger Valentina E; Ren Yuan; Huang Qingling; Chen Liwei; Koomen John M; Wu Jie; Schneeberger Valentina E; Koomen John M; Wu Jie; Luetteke Noreen; Lawrence Harshani R; Lawrence Nicholas J; Lawrence Nicholas J; Haura Eric B; Koomen John M; Coppola Domenico; Wu Jie; Haura Eric B; Coppola Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6191-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy.  However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active.  Thus, it is important to uncover mediators of EGFR mutant-driven lung tumors to develop new treatment strategies.  The protein tyrosine phosphatase (PTP) Shp2 mediates EGF signaling.  Nevertheless, it is unclear if Shp2 is activated by oncogenic EGFR mutants in lung carcinoma or if inhibiting the Shp2 PTP activity can suppress EGFR mutant-induced lung adenocarcinoma.  Here, we generated transgenic mice containing a doxycycline (Dox)-inducible PTP-defective Shp2 mutant (tetO-Shp2CSDA).  Using the rat Clara cell secretory protein (CCSP)-rtTA-directed transgene expression in the type II lung pneumocytes of transgenic mice, we found that the Gab1-Shp2 pathway was activated by EGFRL858R in the lungs of transgenic mice.  Consistently, the Gab1-Shp2 pathway was activated in human lung adenocarcinoma cells containing mutant EGFR.  Importantly, Shp2CSDA inhibited EGFRL858R-induced lung adenocarcinoma in transgenic animals.  Analysis of lung tissues showed that Shp2CSDA suppressed Gab1 tyrosine phosphorylation and Gab1-Shp2 association, suggesting that Shp2 modulates a positive feedback loop to regulate its own activity.  These results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJtlG99S4uDhpyrDyM_m9cfW6udTcc2eYujKAEmZzS_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrpvFOntg%253D%253D&md5=925fbaa74576c95ccd76a3ce0afd959c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3356%26sid%3Dliteratum%253Aachs%26aulast%3DSchneeberger%26aufirst%3DV.%2BE.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DLuetteke%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DQ.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DCoppola%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Shp2%2520suppresses%2520mutant%2520EGFR-induced%2520lung%2520tumors%2520in%2520transgenic%2520mouse%2520model%2520of%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D6191%26epage%3D6202%26doi%3D10.18632%2Foncotarget.3356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-Sanchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Goncalves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+required+for+growth+of+KRAS-mutant+non-small-cell+lung+cancer+in+vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0lhT8ga-nFE7xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-Sanchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGoncalves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520required%2520for%2520growth%2520of%2520KRAS-mutant%2520non-small-cell%2520lung%2520cancer%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracht, J. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldeguer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bruno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ebiom.2018.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30473379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3crksV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=207-214&author=N.+Karachaliouauthor=A.+F.+Cardonaauthor=J.+W.+P.+Brachtauthor=E.+Aldeguerauthor=A.+Drozdowskyjauthor=M.+Fernandez-Brunoauthor=I.+Chaibauthor=J.+Berenguerauthor=M.+Santarpiaauthor=M.+Itoauthor=J.+Codony-Servatauthor=R.+Rosell&title=Integrin-linked+kinase+%28ILK%29+and+src+homology+2+domain-containing+phosphatase+2+%28SHP2%29%3A+Novel+targets+in+EGFR-mutation+positive+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1016%2Fj.ebiom.2018.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Karachaliou Niki; Cardona Andres Felipe; Bracht Jillian Wilhelmina Paulina; Aldeguer Erika; Berenguer Jordi; Ito Masaoki; Codony-Servat Jordi; Drozdowskyj Ana; Fernandez-Bruno Manuel; Chaib Imane; Santarpia Mariacarmela; Rosell Rafael</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The activation of multiple signaling pathways jeopardizes the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutation positive non-small cell lung cancer (NSCLC).  Integrin-linked kinase (ILK) regulates the interactions between tumor cells and extracellular environment to activate signaling pathways and promote cell proliferation, migration, and epithelial-mesenchymal transition.  Src homology 2 domain-containing phosphatase 2 (SHP2) is essential for receptor tyrosine kinase signaling and mitogen-activated protein kinase (MAPK) pathway activation.  METHODS:  We analyzed tumor ILK, β-receptor subunit glycoprotein 130 (gp130), SHP2, and stromal hepatocyte growth factor (HGF) and interleukin-6 (IL-6) mRNA expression in baseline tumor specimens of advanced EGFR-mutation positive NSCLC patients treated with EGFR TKIs.  RESULTS:  ILK, when highly expressed, was an independent poor prognostic factor for the progression-free survival of the patients, both in the univariate (hazard ratio [HR for disease progression, 2.49; 95% CI, 1.37-4.52; P = .0020]) and in the multivariate (HR 3.74; 95% CI, 1.33-10.56; P = .0126) Cox regression model.  Patients with high SHP2 expression had an almost 13-month shorter progression-free survival (P = .0094) and an 18-month shorter overall survival (P = .0182) in comparison to those with low SHP2 mRNA expression.  INTERPRETATION:  The levels of ILK and SHP2 could be predictive for upfront combinatory therapy of EGFR TKIs plus SHP2 or ILK inhibitors.  FUND: A grant from La Caixa Foundation, an Instituto de Salud Carlos III grant (RESPONSE, PIE16/00011), an Instituto de Salud Carlos III grant (PI14/01678), a Marie Sklodowska-Curie Innovative Training Networks European Grant (ELBA No 765492) and a Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDk6kgt3Zd7BItaL1WaVAfW6udTcc2eauRy9GpGB9l7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksV2mtA%253D%253D&md5=02e23573d10225a1d365e777ca55bcfa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DCardona%26aufirst%3DA.%2BF.%26aulast%3DBracht%26aufirst%3DJ.%2BW.%2BP.%26aulast%3DAldeguer%26aufirst%3DE.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DFernandez-Bruno%26aufirst%3DM.%26aulast%3DChaib%26aufirst%3DI.%26aulast%3DBerenguer%26aufirst%3DJ.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DIntegrin-linked%2520kinase%2520%2528ILK%2529%2520and%2520src%2520homology%25202%2520domain-containing%2520phosphatase%25202%2520%2528SHP2%2529%253A%2520Novel%2520targets%2520in%2520EGFR-mutation%2520positive%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D39%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.ebiom.2018.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simanshu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissley, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">RAS proteins and their regulators in human disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2017.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28666118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=17-33&author=D.+K.+Simanshuauthor=D.+V.+Nissleyauthor=F.+McCormick&title=RAS+proteins+and+their+regulators+in+human+disease&doi=10.1016%2Fj.cell.2017.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">RAS Proteins and their regulators in human disease</span></div><div class="casAuthors">Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-33</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  RAS proteins are binary switches, cycling between ON and OFF states during signal transduction.  These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active.  The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear.  All RAS biol. occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoH9cHufj4FLVg90H21EOLACvtfcHk0lgm947mIGd7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP&md5=638a0c0efac88f2873c352715e332a92</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DSimanshu%26aufirst%3DD.%2BK.%26aulast%3DNissley%26aufirst%3DD.%2BV.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DRAS%2520proteins%2520and%2520their%2520regulators%2520in%2520human%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D17%26epage%3D33%26doi%3D10.1016%2Fj.cell.2017.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanafusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span> <span> </span><span class="NLM_article-title">Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">22992</span>– <span class="NLM_lpage">22995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M312498200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M312498200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15031289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=22992-22995&author=H.+Hanafusaauthor=S.+Toriiauthor=T.+Yasunagaauthor=K.+Matsumotoauthor=E.+Nishida&title=Shp2%2C+an+SH2-containing+protein-tyrosine+phosphatase%2C+positively+regulates+receptor+tyrosine+kinase+signaling+by+dephosphorylating+and+inactivating+the+inhibitor+sprouty&doi=10.1074%2Fjbc.M312498200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty</span></div><div class="casAuthors">Hanafusa, Hiroshi; Torii, Satoru; Yasunaga, Takayuki; Matsumoto, Kunihiro; Nishida, Eisuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">22992-22995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SH2 domain-contg. phosphotyrosine phosphatase Shp2 functions as a pos. effector in receptor tyrosine kinase (RTK) signaling immediately proximal to activated receptors.  However, neither its physiol. substrate(s) nor its mechanism of action in RTK signaling has been defined.  Here, the authors demonstrate that protein Sprouty (Spry), an inhibitor of the Ras-MAP kinase signaling pathway, is a possible target of Shp2.  Spry acts as a conserved inhibitor of RTK signaling, and tyrosine phosphorylation of Spry is indispensable for its inhibitory activity.  Shp2 was able to dephosphorylate fibroblast growth factor (FGF) receptor-induced phosphotyrosines on Spry both in vivo and in vitro.  Shp2-mediated dephosphorylation of Spry resulted in dissocn. of Spry from protein Grb2.  Furthermore, Shp2 could reverse the inhibitory effect of Spry on FGF-induced neurite outgrowth and MAP kinase activation.  These findings suggest that Shp2 acts as a pos. regulator in RTK signaling by dephosphorylating and inactivating Spry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GxPH8eSOr7Vg90H21EOLACvtfcHk0lgFgUG5Z9N0sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gisro%253D&md5=7b08119acef72fe735bf39c972beb70d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M312498200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M312498200%26sid%3Dliteratum%253Aachs%26aulast%3DHanafusa%26aufirst%3DH.%26aulast%3DTorii%26aufirst%3DS.%26aulast%3DYasunaga%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DE.%26atitle%3DShp2%252C%2520an%2520SH2-containing%2520protein-tyrosine%2520phosphatase%252C%2520positively%2520regulates%2520receptor%2520tyrosine%2520kinase%2520signaling%2520by%2520dephosphorylating%2520and%2520inactivating%2520the%2520inhibitor%2520sprouty%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D22992%26epage%3D22995%26doi%3D10.1074%2Fjbc.M312498200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Langhe, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Moral, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellusci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span> <span> </span><span class="NLM_article-title">A novel function for the protein tyrosine phosphatase Shp2 during lung branching morphogenesis</span>. <i>Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.ydbio.2005.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ydbio.2005.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15950607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFSqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2005&pages=422-431&author=D.+Tefftauthor=S.+P.+De+Langheauthor=P.+M.+Del+Moralauthor=F.+Salaauthor=W.+Shiauthor=S.+Bellusciauthor=D.+Warburton&title=A+novel+function+for+the+protein+tyrosine+phosphatase+Shp2+during+lung+branching+morphogenesis&doi=10.1016%2Fj.ydbio.2005.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel function for the protein tyrosine phosphatase Shp2 during lung branching morphogenesis</span></div><div class="casAuthors">Tefft, Denise; De Langhe, Stijn P.; Del Moral, Pierre-Marie; Sala, Frederic; Shi, Wei; Bellusci, Saverio; Warburton, David</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Biology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">422-431</span>CODEN:
                <span class="NLM_cas:coden">DEBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0012-1606</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Branching morphogenesis of many organs, including the embryonic lung, is a dynamic process in which growth factor mediated tyrosine kinase receptor activation is required, but must be tightly regulated to direct ramifications of the terminal branches.  However, the specific regulators that modulate growth factor signaling downstream of the tyrosine kinase receptor remain to be detd.  Herein, we demonstrate for the first time an important function for the intracellular protein tyrosine phosphatase Shp2 in directing embryonic lung epithelial morphogenesis.  We show that Shp2 is specifically expressed in embryonic lung epithelial buds, and that loss of function by the suppression of Shp2 mRNA expression results in a 53% redn. in branching morphogenesis.  Furthermore, by intra-tracheal microinjection of a catalytically inactive adenoviral Shp2 construct, we provide direct evidence that the catalytic activity of Shp2 is required for proper embryonic lung branch formation.  We demonstrate that Shp2 activity is required for FGF10 induced endodermal budding.  Furthermore, a loss of Shp2 catalytic activity in the embryonic lung was assocd. with a redn. in ERK phosphorylation and epithelial cell proliferation.  However, epithelial cell differentiation was not affected.  Our results show that the protein tyrosine phosphatase Shp2 plays an essential role in modulating growth factor mediated tyrosine kinase receptor activation in early embryonic lung branching morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNk_74RxcILVg90H21EOLACvtfcHk0lgFgUG5Z9N0sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFSqs74%253D&md5=144c67aaf99bb63a4c4b5c46b3276463</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ydbio.2005.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ydbio.2005.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DTefft%26aufirst%3DD.%26aulast%3DDe%2BLanghe%26aufirst%3DS.%2BP.%26aulast%3DDel%2BMoral%26aufirst%3DP.%2BM.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DWarburton%26aufirst%3DD.%26atitle%3DA%2520novel%2520function%2520for%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%2520during%2520lung%2520branching%2520morphogenesis%26jtitle%3DDev.%2520Biol.%26date%3D2005%26volume%3D282%26spage%3D422%26epage%3D431%26doi%3D10.1016%2Fj.ydbio.2005.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellusci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span> <span> </span><span class="NLM_article-title">mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins</span>. <i>Am. J. Physiol.-Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">L700</span>– <span class="NLM_lpage">L706</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00372.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1152%2Fajplung.00372.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12225946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2002&pages=L700-L706&author=D.+Tefftauthor=M.+Leeauthor=S.+Smithauthor=D.+L.+Croweauthor=S.+Bellusciauthor=D.+Warburton&title=mSprouty2+inhibits+FGF10-activated+MAP+kinase+by+differentially+binding+to+upstream+target+proteins&doi=10.1152%2Fajplung.00372.2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00372.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00372.2001%26sid%3Dliteratum%253Aachs%26aulast%3DTefft%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DD.%2BL.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DWarburton%26aufirst%3DD.%26atitle%3DmSprouty2%2520inhibits%2520FGF10-activated%2520MAP%2520kinase%2520by%2520differentially%2520binding%2520to%2520upstream%2520target%2520proteins%26jtitle%3DAm.%2520J.%2520Physiol.-Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2002%26volume%3D283%26spage%3DL700%26epage%3DL706%26doi%3D10.1152%2Fajplung.00372.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064-1073&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+P.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+nucleotide+cycling+underlies+the+SHP2+phosphatase+dependence+of+mutant+BRAF-%2C+NF1-and+RAS-driven+cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0lguztxKnjH83A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520nucleotide%2520cycling%2520underlies%2520the%2520SHP2%2520phosphatase%2520dependence%2520of%2520mutant%2520BRAF-%252C%2520NF1-and%2520RAS-driven%2520cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieteska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalverda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladbury, J. E.</span></span> <span> </span><span class="NLM_article-title">Grb2 binding induces phosphorylation-independent activation of Shp2</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1101/859108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1101%2F859108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.-C.+Linauthor=L.+Wieteskaauthor=K.+M.+Suenauthor=A.+Kalverdaauthor=Z.+Ahmedauthor=J.+E.+Ladbury&title=Grb2+binding+induces+phosphorylation-independent+activation+of+Shp2&doi=10.1101%2F859108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1101%2F859108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F859108%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DWieteska%26aufirst%3DL.%26aulast%3DSuen%26aufirst%3DK.%2BM.%26aulast%3DKalverda%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DZ.%26aulast%3DLadbury%26aufirst%3DJ.%2BE.%26atitle%3DGrb2%2520binding%2520induces%2520phosphorylation-independent%2520activation%2520of%2520Shp2%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F859108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8859&author=S.+Bundaauthor=K.+Burrellauthor=P.+Heirauthor=L.+F.+Zengauthor=A.+Alamsahebpourauthor=Y.+Kanoauthor=B.+Raughtauthor=Z.+Y.+Zhangauthor=G.+Zadehauthor=M.+Ohh&title=Inhibition+of+SHP2-mediated+dephosphorylation+of+Ras+suppresses+oncogenesis&doi=10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0lhrrj6bYvZMhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520SHP2-mediated%2520dephosphorylation%2520of%2520Ras%2520suppresses%2520oncogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agazie, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayman, M. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7875</span>– <span class="NLM_lpage">7886</span>, <span class="refDoi"> DOI: 10.1128/MCB.23.21.7875-7886.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.23.21.7875-7886.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14560030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=7875-7886&author=Y.+M.+Agazieauthor=M.+J.+Hayman&title=Molecular+mechanism+for+a+role+of+SHP2+in+epidermal+growth+factor+receptor+signaling&doi=10.1128%2FMCB.23.21.7875-7886.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling</span></div><div class="casAuthors">Agazie, Yehenew M.; Hayman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7875-7886</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Src homol. 2-contg. phosphotyrosine phosphatase (SHP2) is primarily a pos. effector of receptor tyrosine kinase signaling.  However, the mol. mechanism by which SHP2 effects its biol. function is unknown.  The authors provide evidence that defines the mol. mechanism and site of action of SHP2 in the epidermal growth factor-induced mitogenic pathway.  The authors demonstrate that SHP2 acts upstream of Ras and functions by increasing the half-life of activated Ras (GTP-Ras) in the cell by interfering with the process of Ras inactivation catalyzed by Ras GTPase-activating protein (RasGAP).  It does so by inhibition of tyrosine phosphorylation-dependent translocation of RasGAP to the plasma membrane, to its substrate (GTP-Ras) microdomain.  Inhibition is achieved through the dephosphorylation of RasGAP binding sites at the level of the plasma membrane.  The authors have identified Tyr 992 of the epidermal growth factor receptor (EGFR) to be one such site, since its mutation to Phe renders the EGFR refractory to the effect of dominant-neg. SHP2.  To the authors' knowledge, this is the first report to outline the site and mol. mechanism of action of SHP2 in EGFR signaling, which may also serve as a model to describe its role in other receptor tyrosine kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5SXQ45HAFrVg90H21EOLACvtfcHk0lhrrj6bYvZMhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOgtLo%253D&md5=23e83e2e6ea24b006daa799b15a95981</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FMCB.23.21.7875-7886.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.23.21.7875-7886.2003%26sid%3Dliteratum%253Aachs%26aulast%3DAgazie%26aufirst%3DY.%2BM.%26aulast%3DHayman%26aufirst%3DM.%2BJ.%26atitle%3DMolecular%2520mechanism%2520for%2520a%2520role%2520of%2520SHP2%2520in%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D7875%26epage%3D7886%26doi%3D10.1128%2FMCB.23.21.7875-7886.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">A treatment strategy for KRAS-driven tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0111-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0111-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29988139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=902-904&author=T.+T.+Maiauthor=P.+Lito&title=A+treatment+strategy+for+KRAS-driven+tumors&doi=10.1038%2Fs41591-018-0111-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A treatment strategy for KRAS-driven tumors</span></div><div class="casAuthors">Mai, Trang T.; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">902-904</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgaFi5mnw3KrVg90H21EOLACvtfcHk0lhrrj6bYvZMhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK&md5=03c6ec6d34bac76f8826e1f783dac0a7</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0111-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0111-x%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DA%2520treatment%2520strategy%2520for%2520KRAS-driven%2520tumors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D902%26epage%3D904%26doi%3D10.1038%2Fs41591-018-0111-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattoon, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1741-7007-2-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1186%2F1741-7007-2-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15550174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD2M7lsVKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=24&author=D.+R.+Mattoonauthor=B.+Lamotheauthor=I.+Laxauthor=J.+Schlessinger&title=The+docking+protein+Gab1+is+the+primary+mediator+of+EGF-stimulated+activation+of+the+PI-3K%2FAkt+cell+survival+pathway&doi=10.1186%2F1741-7007-2-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway</span></div><div class="casAuthors">Mattoon Dawn R; Lamothe Betty; Lax Irit; Schlessinger Joseph</div><div class="citationInfo"><span class="NLM_cas:title">BMC biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gab1 is a docking protein that recruits phosphatidylinositol-3 kinase (PI-3 kinase) and other effector proteins in response to the activation of many receptor tyrosine kinases (RTKs).  As the autophosphorylation sites on EGF-receptor (EGFR) do not include canonical PI-3 kinase binding sites, it is thought that EGF stimulation of PI-3 kinase and its downstream effector Akt is mediated by an indirect mechanism.  RESULTS:  We used fibroblasts isolated from Gab1-/- mouse embryos to explore the mechanism of EGF stimulation of the PI-3 kinase/Akt anti-apoptotic cell signaling pathway.  We demonstrate that Gab1 is essential for EGF stimulation of PI-3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85, the regulatory subunit of PI-3 kinase, and three canonical tyrosine phosphorylation sites on Gab1.  Furthermore, complex formation between Gab1 and the protein tyrosine phosphatase Shp2 negatively regulates Gab1 mediated PI-3 kinase and Akt activation following EGF-receptor stimulation.  We also demonstrate that tyrosine phosphorylation of ErbB3 may lead to recruitment and activation of PI-3 kinase and Akt in Gab1-/- MEFs.  CONCLUSIONS:  The primary mechanism of EGF-induced stimulation of the PI-3 kinase/Akt anti-apoptotic pathway occurs via the docking protein Gab1.  However, in cells expressing ErbB3, EGF and neuroregulin can stimulate PI-3 kinase and Akt activation in a Gab1-dependent or Gab1-independent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTvj5p-QMRX0Q0lWbKiCflfW6udTcc2eaj6cDz2CH77bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7lsVKisQ%253D%253D&md5=b41b39d518429d4a1f71718588ea6914</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-2-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-2-24%26sid%3Dliteratum%253Aachs%26aulast%3DMattoon%26aufirst%3DD.%2BR.%26aulast%3DLamothe%26aufirst%3DB.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520docking%2520protein%2520Gab1%2520is%2520the%2520primary%2520mediator%2520of%2520EGF-stimulated%2520activation%2520of%2520the%2520PI-3K%252FAkt%2520cell%2520survival%2520pathway%26jtitle%3DBMC%2520Biol.%26date%3D2004%26volume%3D2%26spage%3D24%26doi%3D10.1186%2F1741-7007-2-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitkopf, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontaridis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrimon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span> <span> </span><span class="NLM_article-title">A cross-species study of PI3K protein-protein interactions reveals the direct interaction of p85 and SHP2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20471</span>, <span class="refDoi"> DOI: 10.1038/srep20471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsrep20471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26839216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFant7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=20471&author=S.+B.+Breitkopfauthor=X.+M.+Yangauthor=M.+J.+Begleyauthor=M.+Kulkarniauthor=Y.+H.+Chiuauthor=A.+B.+Turkeauthor=J.+Lauriolauthor=M.+Yuanauthor=J.+Qiauthor=J.+A.+Engelmanauthor=P.+Y.+Hongauthor=M.+I.+Kontaridisauthor=L.+C.+Cantleyauthor=N.+Perrimonauthor=J.+M.+Asara&title=A+cross-species+study+of+PI3K+protein-protein+interactions+reveals+the+direct+interaction+of+p85+and+SHP2&doi=10.1038%2Fsrep20471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2</span></div><div class="casAuthors">Breitkopf, Susanne B.; Yang, Xuemei; Begley, Michael J.; Kulkarni, Meghana; Chiu, Yu-Hsin; Turke, Alexa B.; Lauriol, Jessica; Yuan, Min; Qi, Jie; Engelman, Jeffrey A.; Hong, Pengyu; Kontaridis, Maria I.; Cantley, Lewis C.; Perrimon, Norbert; Asara, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20471</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using a series of immunopptn. (IP) - tandem mass spectrometry (LC-MS/MS) expts. and reciprocal BLAST, we conducted a fly-human cross-species comparison of the phosphoinositide-3-kinase (PI3K) interactome in a drosophila S2R+ cell line and several NSCLC and human multiple myeloma cell lines to identify conserved interacting proteins to PI3K, a crit. signaling regulator of the AKT pathway.  Using H929 human cancer cells and drosophila S2R+ cells, our data revealed an unexpected direct binding of Corkscrew, the drosophila ortholog of the non-receptor protein tyrosine phosphatase type II (SHP2) to the Pi3k21B (p60) regulatory subunit of PI3K (p50/p85 human ortholog) but no assocn. with Pi3k92e, the human ortholog of the p110 catalytic subunit.  The p85-SHP2 assocn. was validated in human cell lines, and formed a ternary regulatory complex with GRB2-assocd.-binding protein 2 (GAB2).  Validation expts. with knockdown of GAB2 and Far-Western blots proved the direct interaction of SHP2 with p85, independent of adaptor proteins and transfected FLAG-p85 provided evidence that SHP2 binding on p85 occurred on the SH2 domains.  A disruption of the SHP2-p85 complex took place after insulin/IGF1 stimulation or imatinib treatment, suggesting that the direct SHP2-p85 interaction was both independent of AKT activation and pos. regulates the ERK signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKh6nokwivmrVg90H21EOLACvtfcHk0lh2ewgn7Db8yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFant7o%253D&md5=93d27c2a1d84db990ddaa959a67d6170</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsrep20471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep20471%26sid%3Dliteratum%253Aachs%26aulast%3DBreitkopf%26aufirst%3DS.%2BB.%26aulast%3DYang%26aufirst%3DX.%2BM.%26aulast%3DBegley%26aufirst%3DM.%2BJ.%26aulast%3DKulkarni%26aufirst%3DM.%26aulast%3DChiu%26aufirst%3DY.%2BH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DLauriol%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHong%26aufirst%3DP.%2BY.%26aulast%3DKontaridis%26aufirst%3DM.%2BI.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPerrimon%26aufirst%3DN.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26atitle%3DA%2520cross-species%2520study%2520of%2520PI3K%2520protein-protein%2520interactions%2520reveals%2520the%2520direct%2520interaction%2520of%2520p85%2520and%2520SHP2%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D20471%26doi%3D10.1038%2Fsrep20471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, M.</span></span> <span> </span><span class="NLM_article-title">SHP2: a new target for pro-senescence cancer therapies</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.15252/embj.201591616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.15252%2Fembj.201591616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25916826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1439-1441&author=M.+Serrano&title=SHP2%3A+a+new+target+for+pro-senescence+cancer+therapies&doi=10.15252%2Fembj.201591616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2: a new target for pro-senescence cancer therapies</span></div><div class="casAuthors">Serrano, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1439-1441</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cellular senescence is a response to stress that disables cell proliferation and orchestrates an inflammatory process that eliminates damaged cells.  The first pro-senescence drugs for cancer treatment are now a clin. reality, but still few targets have been identified whose inactivation results in cancer cell senescence.  Current work published in this issue of The EMBO Journal makes an important contribution to this area by discovering that pharmacol. inhibition of the tyrosine phosphatase SHP2 blocks mouse mammary cancer through the induction of senescence (Lan et al, ).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlsVG2_5YQQLVg90H21EOLACvtfcHk0ljaQZyaM7uQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCnsrk%253D&md5=14b20256721d963f581dfd0d1c7977e4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.15252%2Fembj.201591616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201591616%26sid%3Dliteratum%253Aachs%26aulast%3DSerrano%26aufirst%3DM.%26atitle%3DSHP2%253A%2520a%2520new%2520target%2520for%2520pro-senescence%2520cancer%2520therapies%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D1439%26epage%3D1441%26doi%3D10.15252%2Fembj.201591616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, M.</span></span> <span> </span><span class="NLM_article-title">YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2013.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.devcel.2013.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24035415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=658-665&author=R.+Tsutsumiauthor=M.+Masoudiauthor=A.+Takahashiauthor=Y.+Fujiiauthor=T.+Hayashiauthor=I.+Kikuchiauthor=Y.+Satouauthor=M.+Tairaauthor=M.+Hatakeyama&title=YAP+and+TAZ%2C+Hippo+signaling+targets%2C+act+as+a+rheostat+for+nuclear+SHP2+function&doi=10.1016%2Fj.devcel.2013.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 Function</span></div><div class="casAuthors">Tsutsumi, Ryouhei; Masoudi, Mohammad; Takahashi, Atsushi; Fujii, Yumiko; Hayashi, Takeru; Kikuchi, Ippei; Satou, Yumeko; Taira, Masanori; Hatakeyama, Masanori</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">658-665</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SHP2 is a ubiquitously expressed protein tyrosine phosphatase, deregulation of which is assocd. with malignant neoplasms and developmental disorders.  SHP2 is required for full activation of RAS-Erk signaling in the cytoplasm and is also present in the nucleus, where it promotes Wnt target gene activation through dephosphorylation of parafibromin.  SHP2 is distributed both to the cytoplasm and nucleus at low cell d. but is excluded from the nucleus at high cell d.  Here, we show that SHP2 phys. interacts with transcriptional coactivators YAP and TAZ, targets of the cell-d.-sensing Hippo signal.  Through the interaction, nonphosphorylated YAP/TAZ promote nuclear translocalization of SHP2, which in turn stimulates TCF/LEF- and TEAD-regulated genes via parafibromin dephosphorylation.  Conversely, YAP/TAZ phosphorylated by Hippo signaling sequester SHP2 in the cytoplasm, thereby preventing nuclear accumulation of SHP2.  Hence, YAP/TAZ serve as a rheostat for nuclear SHP2 function, which is switched off by the Hippo signal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqYS_cEzmS8rVg90H21EOLACvtfcHk0ljaQZyaM7uQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCls7bJ&md5=a97dc2ed314db28cb3594244fff2f5ff</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2013.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2013.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsumi%26aufirst%3DR.%26aulast%3DMasoudi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DI.%26aulast%3DSatou%26aufirst%3DY.%26aulast%3DTaira%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DM.%26atitle%3DYAP%2520and%2520TAZ%252C%2520Hippo%2520signaling%2520targets%252C%2520act%2520as%2520a%2520rheostat%2520for%2520nuclear%2520SHP2%2520function%26jtitle%3DDev.%2520Cell%26date%3D2013%26volume%3D26%26spage%3D658%26epage%3D665%26doi%3D10.1016%2Fj.devcel.2013.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases in the JAK/STAT pathway</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4925</span>– <span class="NLM_lpage">4932</span>, <span class="refDoi"> DOI: 10.2741/3051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2741%2F3051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18508557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=4925-4932&author=D.+Xuauthor=C.+K.+Qu&title=Protein+tyrosine+phosphatases+in+the+JAK%2FSTAT+pathway&doi=10.2741%2F3051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases in the JAK/STAT pathway</span></div><div class="casAuthors">Xu, Dan; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4925-4932</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is crucial in controlling cellular activities in response to extracellular cytokines.  Dysfunctions of the JAK/STAT pathway result in various hematopoietic and immune disorders.  The central events in regulating this pathway are tyrosine phosphorylation and dephosphorylation of the signaling components, which are carried out by protein tyrosine kinases and protein tyrosine phosphatases (PTP), resp.  Here, we review recent advances in the regulatory roles of PTPs, in particular, SHP2 phosphatase, in the JAK/STAT signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1iYtqQyD_7Vg90H21EOLACvtfcHk0ljaQZyaM7uQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOjtrs%253D&md5=d3f84b6306220659ef34e4bf43cab87e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2741%2F3051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F3051%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DProtein%2520tyrosine%2520phosphatases%2520in%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D4925%26epage%3D4932%26doi%3D10.2741%2F3051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0ljaQZyaM7uQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyershaeuser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorausch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, T.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of SHP2 activation by PD-1 stimulation</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">eaay4458</span>, <span class="refDoi"> DOI: 10.1126/sciadv.aay4458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fsciadv.aay4458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32064351" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=eaay4458&author=M.+Marascoauthor=A.+Berteottiauthor=J.+Weyershaeuserauthor=N.+Thorauschauthor=J.+Sikorskaauthor=J.+Krauszeauthor=H.+J.+Brandtauthor=J.+Kirkpatrickauthor=P.+Riosauthor=W.+W.+Schamelauthor=M.+Kohnauthor=T.+Carlomagno&title=Molecular+mechanism+of+SHP2+activation+by+PD-1+stimulation&doi=10.1126%2Fsciadv.aay4458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay4458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay4458%26sid%3Dliteratum%253Aachs%26aulast%3DMarasco%26aufirst%3DM.%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DWeyershaeuser%26aufirst%3DJ.%26aulast%3DThorausch%26aufirst%3DN.%26aulast%3DSikorska%26aufirst%3DJ.%26aulast%3DKrausze%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DH.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DJ.%26aulast%3DRios%26aufirst%3DP.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DCarlomagno%26aufirst%3DT.%26atitle%3DMolecular%2520mechanism%2520of%2520SHP2%2520activation%2520by%2520PD-1%2520stimulation%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26spage%3Deaay4458%26doi%3D10.1126%2Fsciadv.aay4458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokosuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi-Imanishi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto-Tane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span> <span> </span><span class="NLM_article-title">Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.1084/jem.20112741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1084%2Fjem.20112741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22641383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslShsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=1201-1217&author=T.+Yokosukaauthor=M.+Takamatsuauthor=W.+Kobayashi-Imanishiauthor=A.+Hashimoto-Taneauthor=M.+Azumaauthor=T.+Saito&title=Programmed+cell+death+1+forms+negative+costimulatory+microclusters+that+directly+inhibit+T+cell+receptor+signaling+by+recruiting+phosphatase+SHP2&doi=10.1084%2Fjem.20112741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2</span></div><div class="casAuthors">Yokosuka, Tadashi; Takamatsu, Masako; Kobayashi-Imanishi, Wakana; Hashimoto-Tane, Akiko; Azuma, Miyuki; Saito, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1201-1217</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death 1 (PD-1) is a neg. costimulatory receptor crit. for the suppression of T cell activation in vitro and in vivo.  Single cell imaging elucidated a mol. mechanism of PD-1-mediated suppression.  PD-1 becomes clustered with T cell receptors (TCRs) upon binding to its ligand PD-L1 and is transiently assocd. with the phosphatase SHP2 (Src homol. 2 domain-contg. tyrosine phosphatase 2).  These neg. costimulatory microclusters induce the dephosphorylation of the proximal TCR signaling mols.  This results in the suppression of T cell activation and blockade of the TCR-induced stop signal.  In addn. to PD-1 clustering, PD-1-TCR colocalization within microclusters is required for efficient PD-1-mediated suppression.  This inhibitory mechanism also functions in PD-1hi T cells generated in vivo and can be overridden by a neutralizing anti-PD-L1 antibody.  Therefore, PD-1 microcluster formation is important for regulation of T cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfykLUUjaIbVg90H21EOLACvtfcHk0lgdZ9k0fQaD4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslShsr4%253D&md5=5c1fad62b4e3e69e177be5718ce92d41</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1084%2Fjem.20112741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20112741%26sid%3Dliteratum%253Aachs%26aulast%3DYokosuka%26aufirst%3DT.%26aulast%3DTakamatsu%26aufirst%3DM.%26aulast%3DKobayashi-Imanishi%26aufirst%3DW.%26aulast%3DHashimoto-Tane%26aufirst%3DA.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DT.%26atitle%3DProgrammed%2520cell%2520death%25201%2520forms%2520negative%2520costimulatory%2520microclusters%2520that%2520directly%2520inhibit%2520T%2520cell%2520receptor%2520signaling%2520by%2520recruiting%2520phosphatase%2520SHP2%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D1201%26epage%3D1217%26doi%3D10.1084%2Fjem.20112741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauken, K. E.</span></span> <span> </span><span class="NLM_article-title">The diverse functions of the PD1 inhibitory pathway</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnri.2017.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28990585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=153-167&author=A.+H.+Sharpeauthor=K.+E.+Pauken&title=The+diverse+functions+of+the+PD1+inhibitory+pathway&doi=10.1038%2Fnri.2017.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse functions of the PD1 inhibitory pathway</span></div><div class="casAuthors">Sharpe, Arlene H.; Pauken, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-167</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">T cell activation is a highly regulated process involving peptide-MHC engagement of the T cell receptor and pos. costimulatory signals.  Upon activation, coinhibitory 'checkpoints', including programmed cell death protein 1 (PD1), become induced to regulate T cells.  PD1 has an essential role in balancing protective immunity and immunopathol., homeostasis and tolerance.  However, during responses to chronic pathogens and tumors, PD1 expression can limit protective immunity.  Recently developed PD1 pathway inhibitors have revolutionized cancer treatment for some patients, but the majority of patients do not show complete responses, and adverse events have been noted.  This Review discusses the diverse roles of the PD1 pathway in regulating immune responses and how this knowledge can improve cancer immunotherapy as well as restore and/or maintain tolerance during autoimmunity and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVq0k2Iq6v-rVg90H21EOLACvtfcHk0ljnKNdWZzDW7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfP&md5=304a93c872e4beaa8f249390d516527e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.108%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DPauken%26aufirst%3DK.%2BE.%26atitle%3DThe%2520diverse%2520functions%2520of%2520the%2520PD1%2520inhibitory%2520pathway%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D153%26epage%3D167%26doi%3D10.1038%2Fnri.2017.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rota, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niogret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonta, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarda, G.</span></span> <span> </span><span class="NLM_article-title">Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29617671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=39-49&author=G.+Rotaauthor=C.+Niogretauthor=A.+T.+Dangauthor=C.+R.+Barrosauthor=N.+P.+Fontaauthor=F.+Alfeiauthor=L.+Morgadoauthor=D.+Zehnauthor=W.+Birchmeierauthor=E.+Vivierauthor=G.+Guarda&title=Shp-2+is+dispensable+for+establishing+T+cell+exhaustion+and+for+PD-1+signaling+in+vivo&doi=10.1016%2Fj.celrep.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo</span></div><div class="casAuthors">Rota, Giorgia; Niogret, Charlene; Dang, Anh Thu; Barros, Cristina Ramon; Fonta, Nicolas Pierre; Alfei, Francesca; Morgado, Leonor; Zehn, Dietmar; Birchmeier, Walter; Vivier, Eric; Guarda, Greta</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In chronic infection and cancer, T cells acquire a dysfunctional state characterized by the expression of inhibitory receptors.  In vitro studies implicated the phosphatase Shp-2 downstream of these receptors, including PD-1.  However, whether Shp-2 is responsible in vivo for such dysfunctional responses remains elusive.  To address this, we generated T cell-specific Shp-2-deficient mice.  These mice did not show differences in controlling chronic viral infections.  In this context, Shp-2-deleted CD8+ T lymphocytes expanded moderately better but were less polyfunctional than control cells.  Mice with Shp-2-deficient T cells also showed no significant improvement in controlling immunogenic tumors and responded similarly to controls to a-PD-1 treatment.  We therefore showed that Shp-2 is dispensable in T cells for globally establishing exhaustion and for PD-1 signaling in vivo.  These results reveal the existence of redundant mechanisms downstream of inhibitory receptors and represent the foundation for defining these relevant mol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PfFYT7Ao57Vg90H21EOLACvtfcHk0ljnKNdWZzDW7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsbo%253D&md5=a11d6aefd737036c5e5533674c83b8c3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DRota%26aufirst%3DG.%26aulast%3DNiogret%26aufirst%3DC.%26aulast%3DDang%26aufirst%3DA.%2BT.%26aulast%3DBarros%26aufirst%3DC.%2BR.%26aulast%3DFonta%26aufirst%3DN.%2BP.%26aulast%3DAlfei%26aufirst%3DF.%26aulast%3DMorgado%26aufirst%3DL.%26aulast%3DZehn%26aufirst%3DD.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DGuarda%26aufirst%3DG.%26atitle%3DShp-2%2520is%2520dispensable%2520for%2520establishing%2520T%2520cell%2520exhaustion%2520and%2520for%2520PD-1%2520signaling%2520in%2520vivo%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D39%26epage%3D49%26doi%3D10.1016%2Fj.celrep.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine phosphatase SHP-2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80938-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0092-8674%2800%2980938-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9491886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=441-450&author=P.+Hofauthor=S.+Pluskeyauthor=S.+Dhe-Paganonauthor=M.+J.+Eckauthor=S.+E.+Shoelson&title=Crystal+structure+of+the+tyrosine+phosphatase+SHP-2&doi=10.1016%2FS0092-8674%2800%2980938-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Hof, Peter; Pluskey, Scott; Dhe-Paganon, Sirano; Eck, Michael J.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The structure of the SHP-2 tyrosine phosphatase, detd. at 2.0 Å resoln., shows how its catalytic activity is regulated by its two SH2 domains.  In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site.  This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft.  Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface.  Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme.  Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcAryHYl6D5bVg90H21EOLACvtfcHk0ljnKNdWZzDW7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D&md5=ea99b7adb90b5db07754c0be75a63c66</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980938-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980938-1%26sid%3Dliteratum%253Aachs%26aulast%3DHof%26aufirst%3DP.%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520phosphatase%2520SHP-2%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D441%26epage%3D450%26doi%3D10.1016%2FS0092-8674%2800%2980938-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1038/nature01680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature01680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12802338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2003&pages=769-773&author=A.+Salmeenauthor=J.+N.+Andersenauthor=M.+P.+Myersauthor=T.+C.+Mengauthor=J.+A.+Hinksauthor=N.+K.+Tonksauthor=D.+Barford&title=Redox+regulation+of+protein+tyrosine+phosphatase+1B+involves+a+sulphenyl-amide+intermediate&doi=10.1038%2Fnature01680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate</span></div><div class="casAuthors">Salmeen, Annette; Andersen, Jannik N.; Myers, Michael P.; Meng, Tzu-Ching; Hinks, John A.; Tonks, Nicholas K.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">6941</span>),
    <span class="NLM_cas:pages">769-773</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The second messenger hydrogen peroxide is required for optimal activation of numerous signal transduction pathways, particularly those mediated by protein tyrosine kinases.  One mechanism by which hydrogen peroxide regulates cellular processes is the transient inhibition of protein tyrosine phosphatases through the reversible oxidization of their catalytic cysteine, which suppresses protein dephosphorylation.  Here the authors describe a structural anal. of the redox-dependent regulation of protein tyrosine phosphatase 1B (PTP1B), which is reversibly inhibited by oxidn. after cells are stimulated with insulin and epidermal growth factor.  The sulfenic acid intermediate produced in response to PTP1B oxidn. is rapidly converted into a previously unknown sulfenyl-amide species, in which the sulfur atom of the catalytic cysteine is covalently linked to the main chain nitrogen of an adjacent residue.  Oxidn. of PTP1B to the sulfenyl-amide form is accompanied by large conformational changes in the catalytic site that inhibit substrate binding.  The authors propose that this unusual protein modification both protects the active-site cysteine residue of PTP1B from irreversible oxidn. to sulfonic acid and permits redox regulation of the enzyme by promoting its reversible redn. by thiols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxAoJy80dnLVg90H21EOLACvtfcHk0liSpaY-XtbWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2itrc%253D&md5=b46983eaf49248015cbb0c87e77129b6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnature01680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01680%26sid%3Dliteratum%253Aachs%26aulast%3DSalmeen%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DJ.%2BN.%26aulast%3DMyers%26aufirst%3DM.%2BP.%26aulast%3DMeng%26aufirst%3DT.%2BC.%26aulast%3DHinks%26aufirst%3DJ.%2BA.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DRedox%2520regulation%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%2520involves%2520a%2520sulphenyl-amide%2520intermediate%26jtitle%3DNature%26date%3D2003%26volume%3D423%26spage%3D769%26epage%3D773%26doi%3D10.1038%2Fnature01680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Montfort, R. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1038/nature01681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature01681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12802339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2003&pages=773-777&author=R.+L.+M.+van%0AMontfortauthor=M.+Congreveauthor=D.+Tisiauthor=R.+Carrauthor=H.+Jhoti&title=Oxidation+state+of+the+active-site+cysteine+in+protein+tyrosine+phosphatase+1B&doi=10.1038%2Fnature01681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B</span></div><div class="casAuthors">van Montfort, Rob L. M.; Congreve, Miles; Tisi, Dominic; Carr, Robin; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">6941</span>),
    <span class="NLM_cas:pages">773-777</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases regulate signal transduction pathways involving tyrosine phosphorylation and have been implicated in the development of cancer, diabetes, rheumatoid arthritis and hypertension.  Increasing evidence suggests that the cellular redox state is involved in regulating tyrosine phosphatase activity through the reversible oxidization of the catalytic cysteine to sulfenic acid (Cys-SOH).  But how further oxidn. to the irreversible sulfinic (Cys-SO2H) and sulfonic (Cys-SO3H) forms is prevented remains unclear.  Here the authors report the crystal structures of the regulatory sulfenic and irreversible sulfinic and sulfonic acids of protein tyrosine phosphatase 1B (PTP1B), an important enzyme in the neg. regulation of the insulin receptor and a therapeutic target in type II diabetes and obesity.  The authors also identify a sulfenyl-amide species that is formed through oxidn. of its catalytic cysteine.  Formation of the sulfenyl-amide causes large changes in the PTP1B active site, which are reversible by redn. with the cellular reducing agent glutathione.  The sulfenyl-amide is a protective intermediate in the oxidative inhibition of PTP1B.  In addn., it may facilitate reactivation of PTP1B by biol. thiols and signal a unique state of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL3MjGivrjqbVg90H21EOLACvtfcHk0liSpaY-XtbWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2it74%253D&md5=90490439b3be879e480badfce2651bc6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature01681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01681%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DOxidation%2520state%2520of%2520the%2520active-site%2520cysteine%2520in%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNature%26date%3D2003%26volume%3D423%26spage%3D773%26epage%3D777%26doi%3D10.1038%2Fnature01681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, K. G.</span></span> <span> </span><span class="NLM_article-title">Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: Evidence for a sulfenic acid intermediate and implications for redox regulation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5633</span>– <span class="NLM_lpage">5642</span>, <span class="refDoi"> DOI: 10.1021/bi973035t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi973035t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXislGht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=5633-5642&author=J.+M.+Denuauthor=K.+G.+Tanner&title=Specific+and+reversible+inactivation+of+protein+tyrosine+phosphatases+by+hydrogen+peroxide%3A+Evidence+for+a+sulfenic+acid+intermediate+and+implications+for+redox+regulation&doi=10.1021%2Fbi973035t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Specific and Reversible Inactivation of Protein Tyrosine Phosphatases by Hydrogen Peroxide: Evidence for a Sulfenic Acid Intermediate and Implications for Redox Regulation</span></div><div class="casAuthors">Denu, John M.; Tanner, Kirk G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5633-5642</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) catalyze the hydrolysis of phosphotyrosine from specific signal-transducing proteins.  Although regulatory mechanisms for protein kinases have been described, no general mechanism for controlling PTPs has been demonstrated.  Numerous reports have shown that cellular redox status plays an important role in tyrosine phosphorylation-dependent signal transduction pathways.  This study explores the proposal that PTPs may be regulated by reversible redn./oxidn. involving cellular oxidants such as hydrogen peroxide (H2O2).  Recent reports indicated that H2O2 is transiently generated during growth factor stimulation and that H2O2 prodn. is concomitant with relevant tyrosine phosphorylation.  By use of recombinant enzymes, the effects of H2O2 on three PTPs (PTP1, LAR, and VHR) and three distinct serine/threonine protein phosphatases (PPs: PP2Cα, calcineurin, and λ phosphatase) were detd.  Hydrogen peroxide had no apparent effect on PP activity.  In contrast, PTPs were rapidly inactivated (kinact = 10-20 M-1 s-1) with low micromolar concns. of H2O2 but not with large alkyl hydroperoxides.  PTP inactivation was fully reversible with glutathione and other thiols.  Because of the slower rate of redn., modification occurred even in the presence of physiol. thiol concns.  By utilization of a variety of biochem. techniques including chem. modification, pH kinetic studies, and mutagenesis, the catalytic cysteine thiolate of PTPs was detd. to be the selective target of oxidn. by H2O2.  By use of the electrophilic reagent 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl), it was shown that a cysteine sulfenic acid intermediate (Cys-SOH) is formed after attack of the catalytic thiolate on H2O2.  A chem. mechanism for reversible inactivation involving a cysteine sulfenic acid intermediate is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpk7IfuQALDbVg90H21EOLACvtfcHk0lhzoOCzz3gJdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislGht7k%253D&md5=0d7c3e14505b4e57c37f38cf76d5f745</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fbi973035t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi973035t%26sid%3Dliteratum%253Aachs%26aulast%3DDenu%26aufirst%3DJ.%2BM.%26aulast%3DTanner%26aufirst%3DK.%2BG.%26atitle%3DSpecific%2520and%2520reversible%2520inactivation%2520of%2520protein%2520tyrosine%2520phosphatases%2520by%2520hydrogen%2520peroxide%253A%2520Evidence%2520for%2520a%2520sulfenic%2520acid%2520intermediate%2520and%2520implications%2520for%2520redox%2520regulation%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D5633%26epage%3D5642%26doi%3D10.1021%2Fbi973035t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T. C.</span></span> <span> </span><span class="NLM_article-title">Cysteine S-nitrosylation protects protein-tyrosine phosphatase 1B against oxidation-induced permanent inactivation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">35265</span>– <span class="NLM_lpage">35272</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805287200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M805287200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18840608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35265-35272&author=Y.+Y.+Chenauthor=H.+M.+Chuauthor=K.+T.+Panauthor=C.+H.+Tengauthor=D.+L.+Wangauthor=A.+H.+J.+Wangauthor=K.+H.+Khooauthor=T.+C.+Meng&title=Cysteine+S-nitrosylation+protects+protein-tyrosine+phosphatase+1B+against+oxidation-induced+permanent+inactivation&doi=10.1074%2Fjbc.M805287200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine S-Nitrosylation Protects Protein-tyrosine Phosphatase 1B against Oxidation-induced Permanent Inactivation</span></div><div class="casAuthors">Chen, Yi-Yun; Chu, Hsing-Mao; Pan, Kuan-Ting; Teng, Chun-Hung; Wang, Danny-Ling; Wang, Andrew H.-J.; Khoo, Kay-Hooi; Meng, Tzu-Ching</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35265-35272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein S-nitrosylation mediated by cellular nitric oxide (NO) plays a primary role in executing biol. functions in cGMP-independent NO signaling.  Although S-nitrosylation appears similar to Cys oxidn. induced by reactive oxygen species, the mol. mechanism and biol. consequence remain unclear.  We investigated the structural process of S-nitrosylation of protein-tyrosine phosphatase 1B (PTP1B).  We treated PTP1B with various NO donors, including S-nitrosothiol reagents and compd.-releasing NO radicals, to produce site-specific Cys S-nitrosylation identified using advanced mass spectrometry (MS) techniques.  Quant. MS showed that the active site Cys-215 was the primary residue susceptible to S-nitrosylation.  The crystal structure of NO donor-reacted PTP1B at 2.6 Å resoln. revealed that the S-NO state at Cys-215 had no discernible irreversibly oxidized forms, whereas other Cys residues remained in their free thiol states.  We further demonstrated that S-nitrosylation of the Cys-215 residue protected PTP1B from subsequent H2O2-induced irreversible oxidn.  Increasing the level of cellular NO by pretreating cells with an NO donor or by activating ectopically expressed NO synthase inhibited reactive oxygen species-induced irreversible oxidn. of endogenous PTP1B.  These findings suggest that S-nitrosylation might prevent PTPs from permanent inactivation caused by oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWEIujim9PN7Vg90H21EOLACvtfcHk0lhzoOCzz3gJdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt73K&md5=287181eba0751b89c7b06e7d2969275a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805287200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805287200%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DChu%26aufirst%3DH.%2BM.%26aulast%3DPan%26aufirst%3DK.%2BT.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DD.%2BL.%26aulast%3DWang%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKhoo%26aufirst%3DK.%2BH.%26aulast%3DMeng%26aufirst%3DT.%2BC.%26atitle%3DCysteine%2520S-nitrosylation%2520protects%2520protein-tyrosine%2520phosphatase%25201B%2520against%2520oxidation-induced%2520permanent%2520inactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D35265%26epage%3D35272%26doi%3D10.1074%2Fjbc.M805287200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alicea-Velazquez, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakoncic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.jsb.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23296072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2013&pages=243-251&author=N.+L.+Alicea-Velazquezauthor=J.+Jakoncicauthor=T.+J.+Boggon&title=Structure-guided+studies+of+the+SHP-1%2FJAK1+interaction+provide+new+insights+into+phosphatase+catalytic+domain+substrate+recognition&doi=10.1016%2Fj.jsb.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Jakoncic, Jean; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-251</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SHP-1 (PTPN6) is a member of the SHP sub-family of protein tyrosine phosphatases and plays a crit. role in the regulation of the JAK/STAT signaling pathway.  Previous studies suggested that SHP-1 contains a PTP1B-like second phosphotyrosine pocket that allows for binding of tandem phosphotyrosine residues, such as those found in the activation loop of JAK kinases.  To discover the structural nature of the interaction between SHP-1 and the JAK family member, JAK1, we detd. the 1.8 Å co-crystal structure of the SHP-1 catalytic domain and a JAK1-derived substrate peptide.  This structure reveals electron d. for only one bound phosphotyrosine residue.  To investigate the role of the predicted second site pocket we detd. the structures of SHP-1 in complex with phosphate and sulfate to 1.37 Å and 1.7 Å, resp., and performed anomalous scattering expts. for a selenate-soaked crystal.  These crystallog. data suggest that SHP-1 does not contain a PTP1B-like second site pocket.  This conclusion is further supported by anal. of the relative dephosphorylation and binding affinities of mono- and tandem-phosphorylated peptide substrates.  The crystal structures instead indicate that SHP-1 contains an extended C-terminal helix α2' incompatible with the predicted second phosphotyrosine binding site.  This study suggests that SHP-1 defines a new category of PTP1B-like protein tyrosine phosphatases with a hindered second phosphotyrosine pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokfZ66Q6-mkrVg90H21EOLACvtfcHk0liPlwxFf1mHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCitb4%253D&md5=c492b2b2b725f30d5f9d336777bf039d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Velazquez%26aufirst%3DN.%2BL.%26aulast%3DJakoncic%26aufirst%3DJ.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DStructure-guided%2520studies%2520of%2520the%2520SHP-1%252FJAK1%2520interaction%2520provide%2520new%2520insights%2520into%2520phosphatase%2520catalytic%2520domain%2520substrate%2520recognition%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D181%26spage%3D243%26epage%3D251%26doi%3D10.1016%2Fj.jsb.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2333</span>– <span class="NLM_lpage">2344</span>, <span class="refDoi"> DOI: 10.1021/jm901090b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901090b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFektLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2333-2344&author=A.+P.+Combs&title=Recent+advances+in+the+discovery+of+competitive+protein+tyrosine+phosphatase+1B+inhibitors+for+the+treatment+of+diabetes%2C+obesity%2C+and+cancer&doi=10.1021%2Fjm901090b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of Diabetes, Obesity, and Cancer</span></div><div class="casAuthors">Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2333-2344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5P49bITC_bVg90H21EOLACvtfcHk0liPlwxFf1mHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFektLzJ&md5=700b2a519c670e1bd9cb41af271d62ae</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm901090b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901090b%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520competitive%2520protein%2520tyrosine%2520phosphatase%25201B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520diabetes%252C%2520obesity%252C%2520and%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2333%26epage%3D2344%26doi%3D10.1021%2Fjm901090b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowarah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V. P.</span></span> <span> </span><span class="NLM_article-title">Anti-diabetic drugs recent approaches and advancements</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115263</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmc.2019.115263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32008883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFCjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115263&author=J.+Dowarahauthor=V.+P.+Singh&title=Anti-diabetic+drugs+recent+approaches+and+advancements&doi=10.1016%2Fj.bmc.2019.115263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-diabetic drugs recent approaches and advancements</span></div><div class="casAuthors">Dowarah, Jayanta; Singh, Ved Prakash</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">115263</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Diabetes is one of the major diseases worldwide and is the third leading cause of death in the United States.  Anti-diabetic drugs are used in the treatment of diabetes mellitus to control glucose levels in the blood.  Most of the drugs are administered orally, except for a few of them, such as insulin, exenatide, and pramlintide.  In this review, we are going to discuss seven major types of anti-diabetic drugs: Peroxisome proliferator-activated receptor (PPAR) agonist, protein tyrosine phosphatase 1B (PTP1B) inhibitors, aldose reductase inhibitors, α-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, G protein-coupled receptor (GPCR) agonists and sodium-glucose co-transporter (SGLT) inhibitors.  Here, we are also discussing some of the recently reported anti-diabetic agents with its multi-target pharmacol. actions.  This review summarises recent approaches and advancement in anti-diabetes treatment concerning characteristics, structure-activity relationships, functional mechanisms, expression regulation, and applications in medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YJxN_zZgZLVg90H21EOLACvtfcHk0liPlwxFf1mHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFCjsr0%253D&md5=6ca9b8ebb4723bea4cb31188811053eb</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115263%26sid%3Dliteratum%253Aachs%26aulast%3DDowarah%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DV.%2BP.%26atitle%3DAnti-diabetic%2520drugs%2520recent%2520approaches%2520and%2520advancements%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115263%26doi%3D10.1016%2Fj.bmc.2019.115263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmouni, S.</span></span> <span> </span><span class="NLM_article-title">Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">2797</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmc.2015.03.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25921264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVamsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2786-2797&author=L.+Tautzauthor=Y.+A.+Senisauthor=C.+Ouryauthor=S.+Rahmouni&title=Perspective%3A+Tyrosine+phosphatases+as+novel+targets+for+antiplatelet+therapy&doi=10.1016%2Fj.bmc.2015.03.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy</span></div><div class="casAuthors">Tautz, Lutz; Senis, Yotis A.; Oury, Cecile; Rahmouni, Souad</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2786-2797</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Arterial thrombosis is the primary cause of most cases of myocardial infarction and stroke, the leading causes of death in the developed world.  Platelets, highly specialized cells of the circulatory system, are key contributors to thrombotic events.  Antiplatelet drugs, which prevent platelets from aggregating, have been very effective in reducing the mortality and morbidity of these conditions.  However, approved antiplatelet therapies have adverse side effects, most notably the increased risk of bleeding.  Moreover, there remains a considerable incidence of arterial thrombosis in a subset of patients receiving currently available drugs.  Thus, there is a pressing medical need for novel antiplatelet agents with a more favorable safety profile and less patient resistance.  The discovery of novel antiplatelet targets is the matter of intense ongoing research.  Recent findings demonstrate the potential of targeting key signaling mols., including kinases and phosphatases, to prevent platelet activation and aggregation.  Here, we offer perspectives to targeting members of the protein tyrosine phosphatase (PTP) superfamily, a major class of enzymes in signal transduction.  We give an overview of previously identified PTPs in platelet signaling, and discuss their potential as antiplatelet drug targets.  We also introduce VHR (DUSP3), a PTP that we recently identified as a major player in platelet biol. and thrombosis.  We review our data on genetic deletion as well as pharmacol. inhibition of VHR, providing proof-of-principle for a novel and potentially safer VHR-based antiplatelet therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9sT_F5AJ_bVg90H21EOLACvtfcHk0lh5JOnzypxwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVamsbg%253D&md5=3ed965e9c4c6b3e0c403abbb1cad941f</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.075%26sid%3Dliteratum%253Aachs%26aulast%3DTautz%26aufirst%3DL.%26aulast%3DSenis%26aufirst%3DY.%2BA.%26aulast%3DOury%26aufirst%3DC.%26aulast%3DRahmouni%26aufirst%3DS.%26atitle%3DPerspective%253A%2520Tyrosine%2520phosphatases%2520as%2520novel%2520targets%2520for%2520antiplatelet%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2786%26epage%3D2797%26doi%3D10.1016%2Fj.bmc.2015.03.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">17075</span>– <span class="NLM_lpage">17084</span>, <span class="refDoi"> DOI: 10.1021/ja8068177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8068177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=17075-17084&author=S.+J.+Liuauthor=L.+F.+Zengauthor=L.+Wuauthor=X.+Yuauthor=T.+Xueauthor=A.+M.+Gunawanauthor=Y.+Q.+Longauthor=Z.+Y.+Zhang&title=Targeting+inactive+enzyme+conformation%3A+aryl+diketoacid+derivatives+as+a+new+class+of+PTP1B+inhibitors&doi=10.1021%2Fja8068177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Inactive Enzyme Conformation: Aryl Diketoacid Derivatives as a New Class of PTP1B Inhibitors</span></div><div class="casAuthors">Liu, Sijiu; Zeng, Li-Fan; Wu, Li; Yu, Xiao; Xue, Ting; Gunawan, Andrea M.; Long, Ya-Qiu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">17075-17084</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There has been considerable interest in protein tyrosine phosphatase 1B (PTP1B) as a therapeutic target for diabetes, obesity, as well as cancer.  Identifying inhibitory compds. with good bioavailability is a major challenge of drug discovery programs targeted toward PTPs.  Most current PTP active site-directed pharmacophores are neg. charged pTyr mimetics which cannot readily enter the cell.  This lack of cell permeability limits the utility of such compds. in signaling studies and further therapeutic development.  Aryl diketoacids were identified as novel pTyr surrogates and neutral amide-linked aryl diketoacid dimers were shown to exhibit excellent PTP inhibitory activity.  Kinetic studies establish that these aryl diketoacid derivs. act as noncompetitive inhibitors of PTP1B.  Crystal structures of ligand-bound PTP1B reveal that both the aryl diketoacid and its dimeric deriv. bind PTP1B at the active site, albeit with distinct modes of interaction, in the catalytically inactive, WPD loop open conformation.  Furthermore, dimeric aryl diketoacids are cell permeable and enhance insulin signaling in hepatoma cells, suggesting that targeting the inactive conformation may provide a unique opportunity for creating active site-directed PTP1B inhibitors with improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojCtLQmIhqo7Vg90H21EOLACvtfcHk0lh5JOnzypxwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb7K&md5=6b6748cc05e8d08ad1a2f5ba317f7baa</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fja8068177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8068177%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTargeting%2520inactive%2520enzyme%2520conformation%253A%2520aryl%2520diketoacid%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520PTP1B%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D17075%26epage%3D17084%26doi%3D10.1021%2Fja8068177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.6b00537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.6b00537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=122-129&author=Z.+Y.+Zhang&title=Drugging+the+undruggable%3A+therapeutic+potential+of+targeting+protein+tyrosine+phosphatases&doi=10.1021%2Facs.accounts.6b00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases</span></div><div class="casAuthors">Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are essential signaling enzymes that, together with protein tyrosine kinases, regulate tyrosine phosphorylation inside the cell.  Proper level of tyrosine phosphorylation is important for a diverse array of cellular processes, such as proliferation, metab., motility, and survival.  Aberrant tyrosine phosphorylation, resulting from alteration of PTP expression, misregulation, and mutation, has been linked to the etiol. of many human ailments including cancer, diabetes/obesity, autoimmune disorders and infectious diseases.  However, despite the fact that PTPs have been garnering attention as compelling drug targets, they remain a largely under-exploited resource for therapeutic intervention.  Indeed, PTPs have been widely dismissed as "undruggable", due to concerns that the highly conserved active site (i.e., pTyr-binding pocket) makes it difficult to achieve inhibitor selectivity among closely related family members, and the pos.-charged active site prefers neg. charged mols., which usually lack cell permeability.  To address the issue of selectivity, the authors advanced a novel paradigm for the acquisition of highly potent and selective PTP inhibitors through generation of bivalent ligands that interact with both PTP active site and adjacent unique peripheral pockets.  To overcome the bioavailability issue, the authors have identified nonhydrolyzable pTyr mimetics that are sufficiently polar to bind the PTP active site, yet still capable of efficiently penetrating cell membranes.  The authors show that these pTyr mimetics interact in the desired inhibitory fashion with the PTP active site and tethering them to appropriate mol. fragments to engage less conserved interactions outside of PTP active site can increase PTP inhibitor potency and selectivity.  The authors demonstrate through three pTyr mimetics fragment-based approaches that it is completely feasible to obtain highly potent and selective PTP inhibitors with robust in vivo efficacy in animal models of oncol., diabetes/obesity, autoimmune disorders, and tuberculosis.  The authors hope that these results will help dispel concerns about the druggability of PTPs and entice further effort in fostering a PTP-based drug discovery enterprise.  Well-characterized, potent, selective and bioactive inhibitors are essential tools for functional interrogation of PTPs in disease biol. and target validation.  They will also play a crit. role in illuminating the druggability of PTPs and provide the groundwork for new therapies for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoBcljiHogLVg90H21EOLACvtfcHk0livoZD1zVwSmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyitbfL&md5=67c8e7a9f57dd733eb97df590d55d583</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.6b00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.6b00537%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DDrugging%2520the%2520undruggable%253A%2520therapeutic%2520potential%2520of%2520targeting%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D122%26epage%3D129%26doi%3D10.1021%2Facs.accounts.6b00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Crystal-structure of human protein-tyrosine phosphatase-1B</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1126/science.8128219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.8128219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=8128219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFyhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1397-1404&author=D.+Barfordauthor=A.+J.+Flintauthor=N.+K.+Tonks&title=Crystal-structure+of+human+protein-tyrosine+phosphatase-1B&doi=10.1126%2Fscience.8128219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Barford, David; Flint, Andrew J.; Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5152</span>),
    <span class="NLM_cas:pages">1397-404</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) constitute a family of receptor-like and cytoplasmic signal transducing enzymes that catalyze the dephosphorylation of phosphotyrosine residues and are characterized by homologous catalytic domains.  The crystal structure of a representative member of this family, the 37-kilodalton form (residues 1 to 321) of PTP1B, has been detd. at 2.8 Å resoln.  The enzyme consists of a single domain with the catalytic site located at the base of a shallow cleft.  The phosphate recognition site is created from a loop that is located at the amino-terminus of an α helix.  This site is formed from an 11-residue sequence motif that is diagnostic of PTPs and the dual specificity phosphatases and that contains the catalytically essential cysteine and arginine residues.  The position of the invariant cysteine residue within the phosphate binding site is consistent with its role as a nucleophile in the catalytic reaction.  The structure of PTP1B should serve as a model for other members of the PTP family and as a framework for understanding the mechanism of tyrosine dephosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcmeGL76vbrVg90H21EOLACvtfcHk0livoZD1zVwSmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFyhsLo%253D&md5=cf529916cc8aabaa7d28402465dd6de4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.8128219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8128219%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DFlint%26aufirst%3DA.%2BJ.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DCrystal-structure%2520of%2520human%2520protein-tyrosine%2520phosphatase-1B%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1397%26epage%3D1404%26doi%3D10.1126%2Fscience.8128219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">17773</span>– <span class="NLM_lpage">17783</span>, <span class="refDoi"> DOI: 10.1021/bi9816958</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9816958" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXnslWqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=17773-17783&author=M.+R.+Grovesauthor=Z.+J.+Yaoauthor=P.+P.+Rollerauthor=T.+R.+Burkeauthor=D.+Barford&title=Structural+basis+for+inhibition+of+the+protein+tyrosine+phosphatase+1B+by+phosphotyrosine+peptide+mimetics&doi=10.1021%2Fbi9816958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics</span></div><div class="casAuthors">Groves, Matthew R.; Yao, Zhu-Jun; Roller, Peter P.; Burke, Terrence R., Jr.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">17773-17783</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases regulate diverse cellular processes and represent important targets for therapeutic intervention in a no. of diseases.  The crystal structures of protein tyrosine phosphatase 1B (PTP1B) in complex with small mol. inhibitors based upon two classes of phosphotyrosine mimetics, the (difluoronaphthylmethyl)phosphonic acids and the fluoromalonyl tyrosines, have been detd. to resolns. greater than 2.3 Å.  The fluoromalonyl tyrosine residue was incorporated within a cyclic hexapeptide modeled on an autophosphorylation site of the epidermal growth factor receptor.  The structure of this inhibitor bound to PTP1B represents the first crystal structure of a non-phosphonate-contg. inhibitor and reveals the mechanism of phosphotyrosine mimicry by the fluoromalonyl tyrosine residue and the nature of its interactions within the catalytic site of PTP1B.  In contrast to complexes of PTP1B with phosphotyrosine-contg. peptides, binding of the fluoromalonyl tyrosine residue to the catalytic site of PTP1B is not accompanied by closure of the catalytic site WPD loop.  Structures of PTP1B in complex with the (difluoronaphthylmethyl)phosphonic acid derivs. reveal that substitutions of the naphthalene ring modulate the mode of inhibitor binding to the catalytic site and provide the potential for enhanced inhibitor affinity and the generation of PTP-specific inhibitors.  These results provide a framework for the rational design of higher affinity and more specific phosphotyrosine mimetic inhibitors of not only protein tyrosine phosphatases but also SH2 and PTB domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9c6iDLueKGbVg90H21EOLACvtfcHk0livoZD1zVwSmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnslWqtL0%253D&md5=8253e0d166692041e3fae452f6d38cd3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fbi9816958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9816958%26sid%3Dliteratum%253Aachs%26aulast%3DGroves%26aufirst%3DM.%2BR.%26aulast%3DYao%26aufirst%3DZ.%2BJ.%26aulast%3DRoller%26aufirst%3DP.%2BP.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DStructural%2520basis%2520for%2520inhibition%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%25201B%2520by%2520phosphotyrosine%2520peptide%2520mimetics%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D17773%26epage%3D17783%26doi%3D10.1021%2Fbi9816958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biel, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmaier, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandao-Neto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span> <span> </span><span class="NLM_article-title">An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e36307</span>, <span class="refDoi"> DOI: 10.7554/eLife.36307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.7554%2FeLife.36307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29877794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e36307&author=D.+A.+Keedyauthor=Z.+B.+Hillauthor=J.+T.+Bielauthor=E.+Kangauthor=T.+J.+Rettenmaierauthor=J.+Brandao-Netoauthor=N.+M.+Pearceauthor=F.+von+Delftauthor=J.+A.+Wellsauthor=J.+S.+Fraser&title=An+expanded+allosteric+network+in+PTP1B+by+multitemperature+crystallography%2C+fragment+screening%2C+and+covalent+tethering&doi=10.7554%2FeLife.36307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.7554%2FeLife.36307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.36307%26sid%3Dliteratum%253Aachs%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DHill%26aufirst%3DZ.%2BB.%26aulast%3DBiel%26aufirst%3DJ.%2BT.%26aulast%3DKang%26aufirst%3DE.%26aulast%3DRettenmaier%26aufirst%3DT.%2BJ.%26aulast%3DBrandao-Neto%26aufirst%3DJ.%26aulast%3DPearce%26aufirst%3DN.%2BM.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520expanded%2520allosteric%2520network%2520in%2520PTP1B%2520by%2520multitemperature%2520crystallography%252C%2520fragment%2520screening%252C%2520and%2520covalent%2520tethering%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26spage%3De36307%26doi%3D10.7554%2FeLife.36307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Punthasee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laciak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddraraju, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, K. S.</span></span> <span> </span><span class="NLM_article-title">Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=2051-2060&author=P.+Punthaseeauthor=A.+R.+Laciakauthor=A.+H.+Cummingsauthor=K.+V.+Ruddrarajuauthor=S.+M.+Lewisauthor=R.+Hillebrandauthor=H.+Singhauthor=J.+J.+Tannerauthor=K.+S.+Gates&title=Covalent+allosteric+inactivation+of+protein+tyrosine+phosphatase+1B+%28PTP1B%29+by+an+inhibitor-electrophile+conjugate&doi=10.1021%2Facs.biochem.7b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate</span></div><div class="casAuthors">Punthasee, Puminan; Laciak, Adrian R.; Cummings, Andrea H.; Ruddraraju, Kasi Viswanatharaju; Lewis, Sarah M.; Hillebrand, Roman; Singh, Harkewal; Tanner, John J.; Gates, Kent S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2051-2060</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase 1B (PTP1B) is a validated drug target, but it has proven difficult to develop medicinally useful, reversible inhibitors of this enzyme.  Here, we explored covalent strategies for the inactivation of PTP1B using a conjugate composed of an active site-directed 5-aryl-1,2,5-thiadiazolidin-3-one 1,1-dioxide inhibitor connected via a short linker to an electrophilic α-bromoacetamide moiety.  The inhibitor-electrophile conjugate caused time-dependent loss of PTP1B activity consistent with a covalent inactivation mechanism.  The inactivation occurred with a 2nd-order rate const. of 1.7 × 102 M-1 min-1.  Mass spectrometric anal. of the inactivated enzyme indicated that the primary site of modification was Cys-121, a residue distant from the active site.  Previous work provided evidence that covalent modification of allosteric residue Cys-121 could cause inactivation of PTP1B.  Overall, the results were consistent with an unusual enzyme inactivation process in which noncovalent binding of the inhibitor-electrophile conjugate to the active site of PTP1B protects the nucleophilic catalytic Cys-215 residue from covalent modification, thus allowing inactivation of the enzyme via selective modification of allosteric residue Cys-121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWbjBooNxw5bVg90H21EOLACvtfcHk0lhRCT9e0WQvdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7c%253D&md5=f6d56427bbc06b14c5316b222c9be164</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00151%26sid%3Dliteratum%253Aachs%26aulast%3DPunthasee%26aufirst%3DP.%26aulast%3DLaciak%26aufirst%3DA.%2BR.%26aulast%3DCummings%26aufirst%3DA.%2BH.%26aulast%3DRuddraraju%26aufirst%3DK.%2BV.%26aulast%3DLewis%26aufirst%3DS.%2BM.%26aulast%3DHillebrand%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DTanner%26aufirst%3DJ.%2BJ.%26aulast%3DGates%26aufirst%3DK.%2BS.%26atitle%3DCovalent%2520allosteric%2520inactivation%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%2520%2528PTP1B%2529%2520by%2520an%2520inhibitor-electrophile%2520conjugate%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D2051%26epage%3D2060%26doi%3D10.1021%2Facs.biochem.7b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+mechanisms+for+SH2+domain+mediated+regulation+of+the+protein+tyrosine+phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0liv8Q7Iw47Ihw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520mechanisms%2520for%2520SH2%2520domain%2520mediated%2520regulation%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human protein-tyrosine phosphatase SHP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6520</span>, <span class="refDoi"> DOI: 10.1074/jbc.M210430200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M210430200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12482860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1ejsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=6516-6520&author=J.+Yangauthor=L.+J.+Liuauthor=D.+D.+Heauthor=X.+Songauthor=X.+S.+Liangauthor=Z.+Z.+J.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+human+protein-tyrosine+phosphatase+SHP-1&doi=10.1074%2Fjbc.M210430200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Human Protein-tyrosine Phosphatase SHP-1</span></div><div class="casAuthors">Yang, Jian; Liu, Lijun; He, Dandan; Song, Xi; Liang, Xiaoshan; Zhao, Zhizhuang Joe; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6516-6520</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SHP-1 is a cytosolic protein tyrosine phosphatase that behaves as a neg. regulator in eukaryotic cellular signaling pathways.  To understand its regulatory mechanism, we have detd. the crystal structure of the C-terminally truncated human SHP-1 in the inactive conformation at 2.8-Å resoln. and refined the structure to a crystallog. R-factor of 24.0%.  The three-dimensional structure shows that the ligand-free SHP-1 has an auto-inhibited conformation.  Its N-SH2 domain blocks the catalytic domain and keeps the enzyme in the inactive conformation, which supports that the phosphatase activity of SHP-1 is primarily regulated by the N-SH2 domain.  In addn., the C-SH2 domain of SHP-1 has a different orientation and is more flexible than that of SHP-2, which enables us to propose an enzymic activation mechanism in which the C-SH2 domains of SHPs could be involved in searching for phosphotyrosine activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxRxIm18VVxrVg90H21EOLACvtfcHk0liv8Q7Iw47Ihw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1ejsLk%253D&md5=944cdc74889eb9dbf3783d5b99d03163</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210430200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210430200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DHe%26aufirst%3DD.%2BD.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DX.%2BS.%26aulast%3DZhao%26aufirst%3DZ.%2BZ.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520human%2520protein-tyrosine%2520phosphatase%2520SHP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D6516%26epage%3D6520%26doi%3D10.1074%2Fjbc.M210430200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiemer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoluzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesareni, G.</span></span> <span> </span><span class="NLM_article-title">The SH2 domain interaction landscape</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2013.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23545499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1293-1305&author=M.+Tintiauthor=L.+Kiemerauthor=S.+Costaauthor=M.+L.+Millerauthor=F.+Saccoauthor=J.+V.+Olsenauthor=M.+Carducciauthor=S.+Paoluziauthor=F.+Langoneauthor=C.+T.+Workmanauthor=N.+Blomauthor=K.+Machidaauthor=C.+M.+Thompsonauthor=M.+Schutkowskiauthor=S.+Brunakauthor=M.+Mannauthor=B.+J.+Mayerauthor=L.+Castagnoliauthor=G.+Cesareni&title=The+SH2+domain+interaction+landscape&doi=10.1016%2Fj.celrep.2013.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The SH2 Domain Interaction Landscape</span></div><div class="casAuthors">Tinti, Michele; Kiemer, Lars; Costa, Stefano; Miller, Martin L.; Sacco, Francesca; Olsen, Jesper V.; Carducci, Martina; Paoluzi, Serena; Langone, Francesca; Workman, Christopher T.; Blom, Nikolaj; Machida, Kazuya; Thompson, Christopher M.; Schutkowski, Mike; Brunak, Soeren; Mann, Matthias; Mayer, Bruce J.; Castagnoli, Luisa; Cesareni, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1305</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Members of the SH2 domain family modulate signal transduction by binding to short peptides contg. phosphorylated tyrosines.  Each domain displays a distinct preference for the sequence context of the phosphorylated residue.  We have developed a high-d. peptide chip technol. that allows for probing of the affinity of most SH2 domains for a large fraction of the entire complement of tyrosine phosphopeptides in the human proteome.  Using this technique, we have exptl. identified thousands of putative SH2-peptide interactions for more than 70 different SH2 domains.  By integrating this rich data set with orthogonal context-specific information, we have assembled an SH2-mediated probabilistic interaction network, which we make available as a community resource in the PepspotDB database.  A predicted dynamic interaction between the SH2 domains of the tyrosine phosphatase SHP2 and the phosphorylated tyrosine in the extracellular signal-regulated kinase activation loop was validated by expts. in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Fe2t6V8ZqLVg90H21EOLACvtfcHk0liv8Q7Iw47Ihw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCru7Y%253D&md5=5b72648ef1cb45c434c226a23cbe715a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTinti%26aufirst%3DM.%26aulast%3DKiemer%26aufirst%3DL.%26aulast%3DCosta%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DSacco%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DPaoluzi%26aufirst%3DS.%26aulast%3DLangone%26aufirst%3DF.%26aulast%3DWorkman%26aufirst%3DC.%2BT.%26aulast%3DBlom%26aufirst%3DN.%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DC.%2BM.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBrunak%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DB.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DL.%26aulast%3DCesareni%26aufirst%3DG.%26atitle%3DThe%2520SH2%2520domain%2520interaction%2520landscape%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1293%26epage%3D1305%26doi%3D10.1016%2Fj.celrep.2013.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablonowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkkainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renkema, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B. J.</span></span> <span> </span><span class="NLM_article-title">High-throughput phosphotyrosine profiling using SH2 domains</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.molcel.2007.05.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17588523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFSqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=899-915&author=K.+Machidaauthor=C.+M.+Thompsonauthor=K.+Dierckauthor=K.+Jablonowskiauthor=S.+Karkkainenauthor=B.+Liuauthor=H.+M.+Zhangauthor=P.+D.+Nashauthor=D.+K.+Newmanauthor=P.+Nollauauthor=T.+Pawsonauthor=G.+H.+Renkemaauthor=K.+Sakselaauthor=M.+R.+Schillerauthor=D.+G.+Shinauthor=B.+J.+Mayer&title=High-throughput+phosphotyrosine+profiling+using+SH2+domains&doi=10.1016%2Fj.molcel.2007.05.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput phosphotyrosine profiling using SH2 domains</span></div><div class="casAuthors">Machida, Kazuya; Thompson, Christopher M.; Dierck, Kevin; Jablonowski, Karl; Karkkainen, Satu; Liu, Bernard; Zhang, Haimin; Nash, Piers D.; Newman, Debra K.; Nollau, Peter; Pawson, Tony; Renkema, G. Herma; Saksela, Kalle; Schiller, Martin R.; Shin, Dong-Guk; Mayer, Bruce J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">899-915</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphorylation controls many aspects of signaling in multicellular organisms.  One of the major consequences of tyrosine phosphorylation is the creation of binding sites for proteins contg. Src homol. 2 (SH2) domains.  To profile the global tyrosine phosphorylation state of the cell, we have developed proteomic binding assays encompassing nearly the full complement of human SH2 domains.  Here we provide a global view of SH2 domain binding to cellular proteins based on large-scale far-western analyses.  We also use reverse-phase protein arrays to generate comprehensive, quant. SH2 binding profiles for phosphopeptides, recombinant proteins, and entire proteomes.  As an example, we profiled the adhesion-dependent SH2 binding interactions in fibroblasts and identified specific focal adhesion complex proteins whose tyrosine phosphorylation and binding to SH2 domains are modulated by adhesion.  These results demonstrate that high-throughput comprehensive SH2 profiling provides valuable mechanistic insights into tyrosine kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRaADjUvBnFLVg90H21EOLACvtfcHk0lj2cH2BMy7pAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFSqsrw%253D&md5=0d2ebb55c613469e13f256a6fda8bbe1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DC.%2BM.%26aulast%3DDierck%26aufirst%3DK.%26aulast%3DJablonowski%26aufirst%3DK.%26aulast%3DKarkkainen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DNash%26aufirst%3DP.%2BD.%26aulast%3DNewman%26aufirst%3DD.%2BK.%26aulast%3DNollau%26aufirst%3DP.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DRenkema%26aufirst%3DG.%2BH.%26aulast%3DSaksela%26aufirst%3DK.%26aulast%3DSchiller%26aufirst%3DM.%2BR.%26aulast%3DShin%26aufirst%3DD.%2BG.%26aulast%3DMayer%26aufirst%3DB.%2BJ.%26atitle%3DHigh-throughput%2520phosphotyrosine%2520profiling%2520using%2520SH2%2520domains%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D26%26spage%3D899%26epage%3D915%26doi%3D10.1016%2Fj.molcel.2007.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wavreille, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Decoding protein-protein interactions through combinatorial chemistry: Sequence specificity of SHP-1, SHP-2, and SHIPSH2 domains</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">14932</span>– <span class="NLM_lpage">14947</span>, <span class="refDoi"> DOI: 10.1021/bi051408h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi051408h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFaltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=14932-14947&author=M.+C.+Sweeneyauthor=A.+S.+Wavreilleauthor=J.+Parkauthor=J.+P.+Butcharauthor=S.+Tridandapaniauthor=D.+Pei&title=Decoding+protein-protein+interactions+through+combinatorial+chemistry%3A+Sequence+specificity+of+SHP-1%2C+SHP-2%2C+and+SHIPSH2+domains&doi=10.1021%2Fbi051408h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding Protein-Protein Interactions through Combinatorial Chemistry: Sequence Specificity of SHP-1, SHP-2, and SHIP SH2 Domains</span></div><div class="casAuthors">Sweeney, Michael C.; Wavreille, Anne-Sophie; Park, Junguk; Butchar, Jonathan P.; Tridandapani, Susheela; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">14932-14947</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general, combinatorial library method for the rapid identification of high-affinity peptide ligands of protein modular domains is reported.  The validity of this method has been demonstrated by detg. the sequence specificity of four Src homol. 2 (SH2) domains derived from protein tyrosine phosphatase SHP-1 and SHP-2 and inositol phosphatase SHIP.  A phosphotyrosyl (pY) peptide library was screened against the SH2 domains, and the beads that carry high-affinity ligands of the SH2 domains were identified and peptides were sequenced by partial Edman degrdn. and mass spectrometry.  The results reveal that the N-terminal SH2 domain of SHP-2 is capable of recognizing four different classes of pY peptides.  Binding competition studies suggest that the four classes of pY peptides all bind to the same site on the SH2 domain surface.  The C-terminal SH2 domains of SHP-1 and SHP-2 and the SHIP SH2 domain each bind to pY peptides of a single consensus sequence.  Database searches using the consensus sequences identified most of the known as well as many potential interacting proteins of SHP-1 and/or SHP-2.  Several proteins are found to bind to the SH2 domains of SHP-1 and SHP-2 through a new, nonclassical ITIM motif, (V/I/L)XpY(M/L/F)XP, which corresponds to the class IV peptides selected from the pY library.  The combinatorial library method should be generally applicable to other protein domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNRV8GxxQyW7Vg90H21EOLACvtfcHk0lj2cH2BMy7pAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFaltbzM&md5=31deef0dc3947db23e64d986a666e8e3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fbi051408h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi051408h%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DM.%2BC.%26aulast%3DWavreille%26aufirst%3DA.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DTridandapani%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DDecoding%2520protein-protein%2520interactions%2520through%2520combinatorial%2520chemistry%253A%2520Sequence%2520specificity%2520of%2520SHP-1%252C%2520SHP-2%252C%2520and%2520SHIPSH2%2520domains%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D14932%26epage%3D14947%26doi%3D10.1021%2Fbi051408h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wavreille, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D. H.</span></span> <span> </span><span class="NLM_article-title">Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains - Critical roles of residues beyond the pY+3 position</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">20271</span>– <span class="NLM_lpage">20282</span>, <span class="refDoi"> DOI: 10.1074/jbc.M601047200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M601047200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16702225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFeqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=20271-20282&author=D.+Imhofauthor=A.+S.+Wavreilleauthor=A.+Mayauthor=M.+Zachariasauthor=S.+Tridandapaniauthor=D.+H.+Pei&title=Sequence+specificity+of+SHP-1+and+SHP-2+Src+homology+2+domains+-+Critical+roles+of+residues+beyond+the+pY%2B3+position&doi=10.1074%2Fjbc.M601047200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence Specificity of SHP-1 and SHP-2 Src Homology 2 Domains. Critical Roles of Residues Beyond the pY+3 Position</span></div><div class="casAuthors">Imhof, Diana; Wavreille, Anne-Sophie; May, Andreas; Zacharias, Martin; Tridandapani, Susheela; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">20271-20282</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A combinatorial phosphotyrosyl (pY) peptide library was screened to det. the amino acid preferences at the pY+4 to pY+6 positions for the four SH2 domains of protein tyrosine phosphatases SHP-1 and SHP-2.  Individual binding sequences selected from the library were resynthesized and their binding affinities and specificities to various SH2 domains were further evaluated by SPR studies, stimulation of SHP-1 and SHP-2 phosphatase activity, and in vitro pulldown assays.  These studies reveal that binding of a pY peptide to the N-SH2 domain of SHP-2 is greatly enhanced by a large hydrophobic residue (Trp, Tyr, Met, or Phe) at the pY+4 and/or pY+5 positions, whereas binding to SHP-1 N-SH2 domain is enhanced by either hydrophobic or pos. charged residues (Arg, Lys, or His) at these positions.  Similar residues at the pY+4 to pY+6 positions are also preferred by SHP-1 and SHP-2 C-SH2 domains, although their influence on the overall binding affinities is much smaller compared with the N-SH2 domains.  A structural model was generated to qual. interpret the contribution of the pY+4 and pY+5 residues to the overall binding affinity.  Examn. of pY motifs from known SHP-1 and SHP-2-binding proteins shows that many of the pY motifs contain a hydrophobic or pos. charged residue(s) at the pY+4 and pY+5 positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottCrfP57BlrVg90H21EOLACvtfcHk0liaGb5MhlujUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFeqt7c%253D&md5=8b12fed8412f591e3309a9a7722d022b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M601047200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M601047200%26sid%3Dliteratum%253Aachs%26aulast%3DImhof%26aufirst%3DD.%26aulast%3DWavreille%26aufirst%3DA.%2BS.%26aulast%3DMay%26aufirst%3DA.%26aulast%3DZacharias%26aufirst%3DM.%26aulast%3DTridandapani%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%2BH.%26atitle%3DSequence%2520specificity%2520of%2520SHP-1%2520and%2520SHP-2%2520Src%2520homology%25202%2520domains%2520-%2520Critical%2520roles%2520of%2520residues%2520beyond%2520the%2520pY%252B3%2520position%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D20271%26epage%3D20282%26doi%3D10.1074%2Fjbc.M601047200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Diverse biochemical properties of Shp2 mutants</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">30984</span>– <span class="NLM_lpage">30993</span>, <span class="refDoi"> DOI: 10.1074/jbc.M504699200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M504699200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15987685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=30984-30993&author=H.+Keilhackauthor=F.+S.+Davidauthor=M.+McGregorauthor=L.+C.+Cantleyauthor=B.+G.+Neel&title=Diverse+biochemical+properties+of+Shp2+mutants&doi=10.1074%2Fjbc.M504699200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse Biochemical Properties of Shp2 Mutants: implications for disease phenotypes</span></div><div class="casAuthors">Keilhack, Heike; David, Frank S.; McGregor, Malcolm; Cantley, Lewis C.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">30984-30993</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mutations in the Src homol. 2 (SH2)-contg. protein-tyrosine phosphatase Shp2 (PTPN11) underlie half of the cases of the autosomal dominant genetic disorder Noonan syndrome, and somatic Shp2 mutations are found in several hematol. and solid malignancies.  Earlier studies of small nos. of mutants suggested that disease-assocd. mutations cause constitutive (SH2 binding-independent) activation and that cancer-assocd. mutants are more active than those assocd. with Noonan syndrome.  We have characterized a larger panel of Shp2 mutants and find that this "activity-centric" model cannot explain the behaviors of all pathogenic Shp2 mutations.  Instead, enzymic, structural, and math. modeling analyses show that these mutants can affect basal activation, SH2 domain-phosphopeptide affinity, and/or substrate specificity to varying degrees.  Furthermore, there is no abs. correlation between the mutants' extents of basal activation and the diseases they induce.  We propose that activated mutants of Shp2 modulate signaling from specific stimuli to a subset of effectors and provide a theor. framework for understanding the complex relationship between Shp2 activation, intracellular signaling, and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJx5YZGoBn6bVg90H21EOLACvtfcHk0liaGb5MhlujUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtL8%253D&md5=649d6897855861aa0e6aaaff4ed57125</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M504699200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M504699200%26sid%3Dliteratum%253Aachs%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DDavid%26aufirst%3DF.%2BS.%26aulast%3DMcGregor%26aufirst%3DM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DDiverse%2520biochemical%2520properties%2520of%2520Shp2%2520mutants%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D30984%26epage%3D30993%26doi%3D10.1074%2Fjbc.M504699200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieuw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. M.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-11-4207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-11-4207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15761018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=311-317&author=S.+Schubbertauthor=K.+Lieuwauthor=S.+L.+Roweauthor=C.+M.+Leeauthor=X.+X.+Liauthor=M.+L.+Lohauthor=D.+W.+Clappauthor=K.+M.+Shannon&title=Functional+analysis+of+leukemia-associated+PTPN11+mutations+in+primary+hematopoietic+cells&doi=10.1182%2Fblood-2004-11-4207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells</span></div><div class="casAuthors">Schubbert, Suzanne; Lieuw, Kenneth; Rowe, Sara L.; Lee, Connie M.; Li, XiaXin; Loh, Mignon L.; Clapp, D. Wade; Shannon, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">PTPN11 encodes the protein tyrosine phosphatase SHP-2, which relays signals from growth factor receptors to Ras and other effectors.  Germline PTPN11 mutations underlie about 50% of Noonan syndrome (NS), a developmental disorder that is assocd. with an elevated risk of juvenile myelomonocytic leukemia (JMML).  Somatic PTPN11 mutations were recently identified in about 35% of patients with JMML; these mutations introduce amino acid substitutions that are largely distinct from those found in NS.  We assessed the functional consequences of leukemia-assocd. PTPN11 mutations in murine hematopoietic cells.  Expressing an E76K SHP-2 protein induced a hypersensitive pattern of granulocyte-macrophage colony-forming unit (CFU-GM) colony growth in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) that was dependent on SHP-2 catalytic activity.  E76K SHP-2 expression also enhanced the growth of immature progenitor cells with high replating potential, perturbed erythroid growth, and impaired normal differentiation in liq. cultures.  In addn., leukemia-assocd. SHP-2 mutations conferred a stronger phenotype than a germline mutation found in patients with NS.  Mutant SHP-2 proteins induce aberrant growth in multiple hematopoietic compartments, which supports a primary role of hyperactive Ras in the pathogenesis of JMML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodGp2TL7I53LVg90H21EOLACvtfcHk0liaGb5MhlujUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrk%253D&md5=bb0309533d245fd69d069a8b69e67a35</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-11-4207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-11-4207%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DLieuw%26aufirst%3DK.%26aulast%3DRowe%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DX.%2BX.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DShannon%26aufirst%3DK.%2BM.%26atitle%3DFunctional%2520analysis%2520of%2520leukemia-associated%2520PTPN11%2520mutations%2520in%2520primary%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D311%26epage%3D317%26doi%3D10.1182%2Fblood-2004-11-4207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. F.</span></span> <span> </span><span class="NLM_article-title">The landscape of protein tyrosine phosphatase (Shp2) and cancer</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3767</span>– <span class="NLM_lpage">3777</span>, <span class="refDoi"> DOI: 10.2174/1381612824666181106100837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2174%2F1381612824666181106100837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=3767-3777&author=A.+U.+Rehmanauthor=M.+U.+Rahmanauthor=M.+T.+Khanauthor=S.+Saudauthor=H.+Liuauthor=D.+Songauthor=P.+Sultanaauthor=A.+Wadoodauthor=H.+F.+Chen&title=The+landscape+of+protein+tyrosine+phosphatase+%28Shp2%29+and+cancer&doi=10.2174%2F1381612824666181106100837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2174%2F1381612824666181106100837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612824666181106100837%26sid%3Dliteratum%253Aachs%26aulast%3DRehman%26aufirst%3DA.%2BU.%26aulast%3DRahman%26aufirst%3DM.%2BU.%26aulast%3DKhan%26aufirst%3DM.%2BT.%26aulast%3DSaud%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DSultana%26aufirst%3DP.%26aulast%3DWadood%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%2BF.%26atitle%3DThe%2520landscape%2520of%2520protein%2520tyrosine%2520phosphatase%2520%2528Shp2%2529%2520and%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2019%26volume%3D24%26spage%3D3767%26epage%3D3777%26doi%3D10.2174%2F1381612824666181106100837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durzynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2277</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2269-2277&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=X.+Xuauthor=I.+Durzynskaauthor=L.+Fanauthor=T.+Stamsauthor=H.+M.+Chanauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=P.+Wangauthor=P.+D.+Fortinauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+and+functional+consequences+of+three+cancer-associated+mutations+of+the+oncogenic+phosphatase+SHP2&doi=10.1021%2Facs.biochem.5b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span></div><div class="casAuthors">LaRochelle, Jonathan R.; Fodor, Michelle; Xu, Xiang; Durzynska, Izabela; Fan, Lixin; Stams, Travis; Chan, Ho Man; LaMarche, Matthew J.; Chopra, Rajiv; Wang, Ping; Fortin, Pascal D.; Acker, Michael G.; Blacklow, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2269-2277</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proto-oncogene PTPN11 encodes a cytoplasmic protein tyrosine phosphatase, SHP2, which is required for normal development and sustained activation of the Ras-MAPK signaling pathway.  Germline mutations in SHP2 cause developmental disorders, and somatic mutations have been identified in childhood and adult cancers and drive leukemia in mice.  Despite our knowledge of the PTPN11 variations assocd. with pathol., the structural and functional consequences of many disease-assocd. mutants remain poorly understood.  Here, we combine X-ray crystallog., small-angle X-ray scattering, and biochem. to elucidate structural and mechanistic features of three cancer-assocd. SHP2 variants harboring single point mutations within the N-SH2:PTP interdomain autoinhibitory interface.  Our findings directly compare the impact of each mutation on autoinhibition of the phosphatase and advance the development of structure-guided and mutation-specific SHP2 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIaFVGm5lArVg90H21EOLACvtfcHk0ljb64o97n5qJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D&md5=720b3dd9b18edde2c443d488cfb90dfc</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDurzynska%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520functional%2520consequences%2520of%2520three%2520cancer-associated%2520mutations%2520of%2520the%2520oncogenic%2520phosphatase%2520SHP2%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2269%26epage%3D2277%26doi%3D10.1021%2Facs.biochem.5b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1002/humu.20005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fhumu.20005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14974085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFegur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=267-277&author=A.+Fragaleauthor=M.+Tartagliaauthor=J.+Wuauthor=B.+D.+Gelb&title=Noonan+syndrome-associated+SHP2%2FPTPN11+mutants+cause+EGF-dependent+prolonged+GAB1+binding+and+sustained+ERK2%2FMAPK1+activation&doi=10.1002%2Fhumu.20005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation</span></div><div class="casAuthors">Fragale, Alessandra; Tartaglia, Marco; Wu, Jie; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-277</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations.  PTPN11 encodes Src homol. 2 domain-contg. tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors.  We compared the functional effects of 3 Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction.  All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation.  Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent.  Binding of SHP2 mutants to Grb2-assocd. binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged.  Coexpression of Grb2-assocd. binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic redn. of extracellular signal-regulated kinase 2 activation.  Taken together, these results document that Noonan syndrome-assocd. PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homol. 2 and protein tyrosine phosphatase domains are altered.  The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-assocd. binder-1 (GAB1), leading to increased cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SbZpUF3L77Vg90H21EOLACvtfcHk0liUcdo6O9WsMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFegur4%253D&md5=696e3e6507da38f135546e2ad4f6d8e4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20005%26sid%3Dliteratum%253Aachs%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DNoonan%2520syndrome-associated%2520SHP2%252FPTPN11%2520mutants%2520cause%2520EGF-dependent%2520prolonged%2520GAB1%2520binding%2520and%2520sustained%2520ERK2%252FMAPK1%2520activation%26jtitle%3DHum.%2520Mutat.%26date%3D2004%26volume%3D23%26spage%3D267%26epage%3D277%26doi%3D10.1002%2Fhumu.20005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span> <span> </span><span class="NLM_article-title">Comparability of mixed IC50 data - a statistical analysis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e61007</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0061007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1371%2Fjournal.pone.0061007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23613770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e61007&author=T.+Kalliokoskiauthor=C.+Kramerauthor=A.+Vulpettiauthor=P.+Gedeck&title=Comparability+of+mixed+IC50+data+-+a+statistical+analysis&doi=10.1371%2Fjournal.pone.0061007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Comparability of mixed IC50 data - a statistical analysis</span></div><div class="casAuthors">Kalliokoski, Tuomo; Kramer, Christian; Vulpetti, Anna; Gedeck, Peter</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61007</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The biochem. half maximal inhibitory concn. (IC50) is the most commonly used metric for on-target activity in lead optimization.  It is used to guide lead optimization, build large-scale chemogenomics anal., off-target activity and toxicity models based on public data.  However, the use of public biochem. IC50 data is problematic, because they are assay specific and comparable only under certain conditions.  For large scale anal. it is not feasible to check each data entry manually and it is very tempting to mix all available IC50 values from public database even if assay information is not reported.  As previously reported for Ki database anal., we first analyzed the types of errors, the redundancy and the variability that can be found in ChEMBL IC50 database.  For assessing the variability of IC50 data independently measured in two different labs at least ten IC50 data for identical protein-ligand systems against the same target were searched in ChEMBL.  As a not sufficient no. of cases of this type are available, the variability of IC50 data was assessed by comparing all pairs of independent IC50 measurements on identical protein-ligand systems.  The std. deviation of IC50 data is only 25% larger than the std. deviation of Ki data, suggesting that mixing IC50 data from different assays, even not knowing assay conditions details, only adds a moderate amt. of noise to the overall data.  The std. deviation of public ChEMBL IC50 data, as expected, resulted greater than the std. deviation of inhouse intra-lab./inter-day IC50 data.  Augmenting mixed public IC50 data by public Ki data does not deteriorate the quality of the mixed IC50 data, if the Ki is cor. by an offset.  For a broad dataset such as ChEMBL database a Ki-IC50 conversion factor of 2 was found to be the most reasonable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq07UjgtQJyZ7Vg90H21EOLACvtfcHk0liUcdo6O9WsMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslSitrc%253D&md5=591144d98c123366e344688c74156e9e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061007%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DC.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DGedeck%26aufirst%3DP.%26atitle%3DComparability%2520of%2520mixed%2520IC50%2520data%2520-%2520a%2520statistical%2520analysis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De61007%26doi%3D10.1371%2Fjournal.pone.0061007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lexa, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazanov, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, H. A.</span></span> <span> </span><span class="NLM_article-title">CSAR benchmark exercise of 2010: selection of the protein-ligand complexes</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2036</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1021/ci200082t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200082t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1Cjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2036-2046&author=J.+B.+Dunbarauthor=R.+D.+Smithauthor=C.+Y.+Yangauthor=P.+M.+U.+Ungauthor=K.+W.+Lexaauthor=N.+A.+Khazanovauthor=J.+A.+Stuckeyauthor=S.+M.+Wangauthor=H.+A.+Carlson&title=CSAR+benchmark+exercise+of+2010%3A+selection+of+the+protein-ligand+complexes&doi=10.1021%2Fci200082t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes</span></div><div class="casAuthors">Dunbar, James B.; Smith, Richard D.; Yang, Chao-Yie; Ung, Peter Man-Un; Lexa, Katrina W.; Khazanov, Nickolay A.; Stuckey, Jeanne A.; Wang, Shaomeng; Carlson, Heather A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-2046</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major goal in drug design is the improvement of computational methods for docking and scoring.  The Community Structure Activity Resource (CSAR) aims to collect available data from industry and academia which may be used for this purpose (www.csardock.org).  Also, CSAR is charged with organizing community-wide exercises based on the collected data.  The first of these exercises was aimed to gauge the overall state of docking and scoring, using a large and diverse data set of protein-ligand complexes.  Participants were asked to calc. the affinity of the complexes as provided and then recalc. with changes which may improve their specific method.  This first data set was selected from existing PDB entries which had binding data (Kd or Ki) in Binding MOAD, augmented with entries from PDBbind.  The final data set contains 343 diverse protein-ligand complexes and spans 14 pKd.  Sixteen proteins have three or more complexes in the data set, from which a user could start an inspection of congeneric series.  Inherent exptl. error limits the possible correlation between scores and measured affinity; R2 is limited to ∼0.9 when fitting to the data set without over parametrizing.  R2 is limited to ∼0.8 when scoring the data set with a method trained on outside data.  The details of how the data set was initially selected, and the process by which it matured to better fit the needs of the community are presented.  Many groups generously participated in improving the data set, and this underscores the value of a supportive, collaborative effort in moving our field forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FcnvoLAJ07Vg90H21EOLACvtfcHk0liUcdo6O9WsMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1Cjur4%253D&md5=3a5e84d8428a2b214549d087e0d68489</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fci200082t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200082t%26sid%3Dliteratum%253Aachs%26aulast%3DDunbar%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DLexa%26aufirst%3DK.%2BW.%26aulast%3DKhazanov%26aufirst%3DN.%2BA.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%2BM.%26aulast%3DCarlson%26aufirst%3DH.%2BA.%26atitle%3DCSAR%2520benchmark%2520exercise%2520of%25202010%253A%2520selection%2520of%2520the%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2036%26epage%3D2046%26doi%3D10.1021%2Fci200082t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noren-Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Correa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestweber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">10606</span>– <span class="NLM_lpage">10611</span>, <span class="refDoi"> DOI: 10.1073/pnas.0601490103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0601490103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16809424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD28vhsVentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10606-10611&author=A.+Noren-Mullerauthor=I.+Reis-Correaauthor=H.+Prinzauthor=C.+Rosenbaumauthor=K.+Saxenaauthor=H.+J.+Schwalbeauthor=D.+Vestweberauthor=G.+Cagnaauthor=S.+Schunkauthor=O.+Schwarzauthor=H.+Schieweauthor=H.+Waldmann&title=Discovery+of+protein+phosphatase+inhibitor+classes+by+biology-oriented+synthesis&doi=10.1073%2Fpnas.0601490103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis</span></div><div class="casAuthors">Noren-Muller Andrea; Reis-Correa Ivan Jr; Prinz Heino; Rosenbaum Claudia; Saxena Krishna; Schwalbe Harald J; Vestweber Dietmar; Cagna Guiseppe; Schunk Stefan; Schwarz Oliver; Schiewe Hajo; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10606-11</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Protein phosphatases have very recently emerged as important targets for chemical biology and medicinal chemistry research, and new phosphatase inhibitor classes are in high demand.  The underlying frameworks of natural products represent the evolutionarily selected fractions of chemical space explored by nature so far and meet the criteria of relevance to nature and biological prevalidation most crucial to inhibitor development.  We refer to synthesis efforts and compound collection development based on these criteria as biology-oriented synthesis.  For the discovery of phosphatase inhibitor classes by means of this approach, four natural product-derived or -inspired medium-sized compound collections were synthesized and investigated for inhibition of the tyrosine phosphatases VE-PTP, Shp-2, PTP1B, MptpA, and MptpB and the dual-specificity phosphatases Cdc25A and VHR.  The screen yielded four unprecedented and selective phosphatase inhibitor classes for four phosphatases with high hit rates.  For VE-PTP and MptpB the first inhibitors were discovered.  These results demonstrate that biology-oriented synthesis is an efficient approach to the discovery of new compound classes for medicinal chemistry and chemical biology research that opens up new opportunities for the study of phosphatases, which may lead to the development of new drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNf4ONKii5590Q2ypr7jHkfW6udTcc2eaNh6giNsZo6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vhsVentg%253D%253D&md5=76f28f79227b8261fd23e7dbf3e2d8e7</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601490103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601490103%26sid%3Dliteratum%253Aachs%26aulast%3DNoren-Muller%26aufirst%3DA.%26aulast%3DReis-Correa%26aufirst%3DI.%26aulast%3DPrinz%26aufirst%3DH.%26aulast%3DRosenbaum%26aufirst%3DC.%26aulast%3DSaxena%26aufirst%3DK.%26aulast%3DSchwalbe%26aufirst%3DH.%2BJ.%26aulast%3DVestweber%26aufirst%3DD.%26aulast%3DCagna%26aufirst%3DG.%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DSchwarz%26aufirst%3DO.%26aulast%3DSchiewe%26aufirst%3DH.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520protein%2520phosphatase%2520inhibitor%2520classes%2520by%2520biology-oriented%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D10606%26epage%3D10611%26doi%3D10.1073%2Fpnas.0601490103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">47311</span>– <span class="NLM_lpage">47319</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106568200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M106568200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11584002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Gms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=47311-47319&author=K.+Shenauthor=Y.+F.+Kengauthor=L.+Wuauthor=X.+L.+Guoauthor=D.+S.+Lawrenceauthor=Z.+Y.+Zhang&title=Acquisition+of+a+specific+and+potent+PTP1B+inhibitor+from+a+novel+combinatorial+library+and+screening+procedure&doi=10.1074%2Fjbc.M106568200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure</span></div><div class="casAuthors">Shen, Kui; Keng, Yen-Fang; Wu, Li; Guo, Xiao-Ling; Lawrence, David S.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">47311-47319</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein-tyrosine phosphatases (PTPases) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Defective or inappropriate regulation of PTPase activity leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases including cancers and diabetes.  For example, recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  Thus, there is intense interest in obtaining specific and potent PTPase inhibitors for biol. studies and pharmacol. development.  However, given the highly conserved nature of the PTPase active site, it is unclear whether selectivity in PTPase inhibition can be achieved.  We describe a combinatorial approach that is designed to target both the active site and a unique peripheral site in PTP1B.  Compds. that can simultaneously assoc. with both sites are expected to exhibit enhanced affinity and specificity.  We also describe a novel affinity-based high-throughput assay procedure that can be used for PTPase inhibitor screening.  The combinatorial library/high-throughput screen protocols furnished a small mol. PTP1B inhibitor that is both potent (Ki = 2.4 nM) and selective (little or no activity against a panel of phosphatases including Yersinia PTPase, SHP1, SHP2, LAR, HePTP, PTPα, CD45, VHR, MKP3, Cdc25A, Stp1, and PP2C).  These results demonstrate that it is possible to acquire potent, yet highly selective inhibitors for individual members of the large PTPase family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCE0aWAjkRLrVg90H21EOLACvtfcHk0lh4Bwo6sEGr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Gms74%253D&md5=20d467b114c7d33f6dd6623bd1d35836</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106568200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106568200%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DK.%26aulast%3DKeng%26aufirst%3DY.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DX.%2BL.%26aulast%3DLawrence%26aufirst%3DD.%2BS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DAcquisition%2520of%2520a%2520specific%2520and%2520potent%2520PTP1B%2520inhibitor%2520from%2520a%2520novel%2520combinatorial%2520library%2520and%2520screening%2520procedure%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D47311%26epage%3D47319%26doi%3D10.1074%2Fjbc.M106568200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramphal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(03)00039-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0968-0896%2803%2900039-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12659770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlGjsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1835-1849&author=P.+Huangauthor=J.+Ramphalauthor=J.+Weiauthor=C.+X.+Liangauthor=B.+Jallalauthor=G.+McMahonauthor=C.+Tang&title=Structure-based+design+and+discovery+of+novel+inhibitors+of+protein+tyrosine+phosphatases&doi=10.1016%2FS0968-0896%2803%2900039-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases</span></div><div class="casAuthors">Huang, Ping; Ramphal, John; Wei, James; Liang, Congxin; Jallal, Bahija; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1835-1849</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are important in the regulation of signal transduction processes.  Certain enzymes of this class are considered as potential therapeutic targets in the treatment of a variety of diseases such as diabetes, inflammation, and cancer.  However, many PTP inhibitors identified to date are peptide-based and contain a highly charged phosphate-mimicking component.  These compds. usually lack membrane permeability and this limits their utility in the inhibition of intracellular phosphatases.  In the present study, we have used structure-based design and modeling techniques to explore catalytic-site directed, reversible inhibitors of PTPs.  Employing a non-charged phosphate mimic and non-peptidyl structural components, we have successfully designed and synthesized a novel series of trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compds. as PTP inhibitors.  This is the first time that an uncharged phosphate mimic is reported in the literature for general, reversible, and substrate-competitive inhibition of PTPs.  It is an important discovery because the finding may provide a paradigm for the development of phosphatase inhibitors that enter cells and modify signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeV_wY9vEvurVg90H21EOLACvtfcHk0liGiMwUDeQh2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlGjsL4%253D&md5=2071ba6cf7f98db86bfd54f0a3389b3f</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900039-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900039-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DC.%2BX.%26aulast%3DJallal%26aufirst%3DB.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DStructure-based%2520design%2520and%2520discovery%2520of%2520novel%2520inhibitors%2520of%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1835%26epage%3D1849%26doi%3D10.1016%2FS0968-0896%2803%2900039-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilander, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, J. A.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2925</span>, <span class="refDoi"> DOI: 10.1182/blood.V100.8.2917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood.V100.8.2917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12351403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVGht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=2917-2925&author=Y.+X.+Zhangauthor=M.+I.+Dawsonauthor=R.+Mohammadauthor=A.+K.+Rishiauthor=L.+Farhanaauthor=K.+C.+Fengauthor=M.+Leidauthor=V.+Petersonauthor=X.+K.+Zhangauthor=M.+Edelsteinauthor=D.+Eilanderauthor=S.+Biggarauthor=N.+Wallauthor=U.+Reichertauthor=J.+A.+Fontana&title=Induction+of+apoptosis+of+human+B-CLL+and+ALL+cells+by+a+novel+retinoid+and+its+nonretinoidal+analog&doi=10.1182%2Fblood.V100.8.2917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog</span></div><div class="casAuthors">Zhang, Yuxiang; Dawson, Marcia I.; Mohammad, Ramzi; Rishi, Arun K.; Farhana, Lulu; Feng, Kai-Chia; Leid, Mark; Peterson, Valerie; Zhang, Xiao-kun; Edelstein, Mark; Eilander, David; Biggar, Sandra; Wall, Nathan; Reichert, Uwe; Fontana, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2917-2925</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We have recently described a novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) that induces apoptosis in a no. of malignant cell types.  We now describe our studies examg. the effects of CD437 and a nonretinoidal analog (MM002) on the in vitro proliferation of the ALL-REH cell line, the in vitro and in vivo growth of a novel Epstein-Barr virus neg. (EBV-) B-cell chronic lymphocytic leukemia (B-CLL) cell line (WSU-CLL), and primary cultures of human B-CLL and acute lymphoblastic leukemia (ALL) cells.  CD437 and MM002 induce apoptosis in both cell lines, as indicated by the activation of caspase-2 and caspase-3, cleavage of poly(ADP-ribose) (poly(ADP-ribose)) polymerase, increase in annexin V binding, and subsequent nuclear fragmentation.  CD437-mediated apoptosis was not assocd. with the modulation of Bcl-2, Bax, or Mcl-1 levels, but was assocd. with the cleavage of the antiapoptotic protein Bcl-XL to a proapoptotic 18 kDa form.  This cleavage of Bcl-XL was dependent on caspase-3 activation since Bcl-XL cleavage and apoptosis were inhibited by the caspase-3 inhibitor Z-DVED-fmk.  CD437 markedly inhibited the growth of WSU-CLL cells in severe combined immunodeficiency (SCID) mice.  Tumor growth inhibition, growth delay, and log cell kill were 85.7%, 21 days, and 2.1, resp., in the treated mice.  Moreover, 1 of the 5 treated mice was tumor-free longer than 150 days and thus was considered cured.  Exposure of primary cultures of both B-CLL and ALL cells obtained from patients to CD437 and MM002 resulted in their apoptosis.  These results suggest that CD437 and MM002 analogs may have a potential role in the treatment of B-CLL and ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrggXBOhD9VhLVg90H21EOLACvtfcHk0liGiMwUDeQh2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVGht7w%253D&md5=20cc451a778d67804880eadca631a481</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood.V100.8.2917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V100.8.2917%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DDawson%26aufirst%3DM.%2BI.%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DFarhana%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DK.%2BC.%26aulast%3DLeid%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DX.%2BK.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DEilander%26aufirst%3DD.%26aulast%3DBiggar%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DN.%26aulast%3DReichert%26aufirst%3DU.%26aulast%3DFontana%26aufirst%3DJ.%2BA.%26atitle%3DInduction%2520of%2520apoptosis%2520of%2520human%2520B-CLL%2520and%2520ALL%2520cells%2520by%2520a%2520novel%2520retinoid%2520and%2520its%2520nonretinoidal%2520analog%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D2917%26epage%3D2925%26doi%3D10.1182%2Fblood.V100.8.2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhuiyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waleh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span> <span> </span><span class="NLM_article-title">Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of Src homology 2 domain-containing protein tyrosine phosphatase-2 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5650</span>– <span class="NLM_lpage">5662</span>, <span class="refDoi"> DOI: 10.1021/jm800456k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800456k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5650-5662&author=M.+I.+Dawsonauthor=Z.+B.+Xiaauthor=T.+Jiangauthor=M.+Yeauthor=J.+A.+Fontanaauthor=L.+Farhanaauthor=B.+Patelauthor=L.+P.+Xueauthor=M.+Bhuiyanauthor=R.+Pellicciariauthor=A.+Macchiaruloauthor=R.+Nutiauthor=X.+K.+Zhangauthor=Y.+H.+Hanauthor=L.+Tautzauthor=P.+D.+Hobbsauthor=L.+Jongauthor=N.+Walehauthor=W.+Chaoauthor=G.+S.+Fengauthor=Y.+H.+Pangauthor=Y.+Su&title=Adamantyl-substituted+retinoid-derived+molecules+that+interact+with+the+orphan+nuclear+receptor+small+heterodimer+partner%3A+Effects+of+replacing+the+1-adamantyl+or+hydroxyl+group+on+inhibition+of+cancer+cell+growth%2C+induction+of+cancer+cell+apoptosis%2C+and+inhibition+of+Src+homology+2+domain-containing+protein+tyrosine+phosphatase-2+activity&doi=10.1021%2Fjm800456k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl-Substituted Retinoid-Derived Molecules That Interact with the Orphan Nuclear Receptor Small Heterodimer Partner: Effects of Replacing the 1-Adamantyl or Hydroxyl Group on Inhibition of Cancer Cell Growth, Induction of Cancer Cell Apoptosis, and Inhibition of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase-2 Activity</span></div><div class="casAuthors">Dawson, Marcia I.; Xia, Zebin; Jiang, Tao; Ye, Mao; Fontana, Joseph A.; Farhana, Lulu; Patel, Bhaumik; Xue, Li Ping; Bhuiyan, Mohammad; Pellicciari, Roberto; Macchiarulo, Antonio; Nuti, Roberto; Zhang, Xiao-Kun; Han, Young-Hoon; Tautz, Lutz; Hobbs, Peter D.; Jong, Ling; Waleh, Nahid; Chao, Wan-ru; Feng, Gen-Sheng; Pang, Yuhong; Su, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5650-5662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells.  Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP).  Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression.  3-Cl-AHPC analogs having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis.  Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity.  Docking of 3-Cl-AHPC and its analogs to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity.  Inhibitory activity against Src homol. 2 domain-contg. protein tyrosine phosphatase 2 (Shp-2) was also assessed.  The most active Shp-2 inhibitor was found to be the 3'-(3,3-dimethylbutynyl) analog of 3-Cl-AHPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3EhNrmE1CAbVg90H21EOLACvtfcHk0lhunlIkw_pbMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbfE&md5=d083d7bfb6334fe98cf184b59af1dfec</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm800456k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800456k%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DM.%2BI.%26aulast%3DXia%26aufirst%3DZ.%2BB.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DFontana%26aufirst%3DJ.%2BA.%26aulast%3DFarhana%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DL.%2BP.%26aulast%3DBhuiyan%26aufirst%3DM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DNuti%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%2BK.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DTautz%26aufirst%3DL.%26aulast%3DHobbs%26aufirst%3DP.%2BD.%26aulast%3DJong%26aufirst%3DL.%26aulast%3DWaleh%26aufirst%3DN.%26aulast%3DChao%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DPang%26aufirst%3DY.%2BH.%26aulast%3DSu%26aufirst%3DY.%26atitle%3DAdamantyl-substituted%2520retinoid-derived%2520molecules%2520that%2520interact%2520with%2520the%2520orphan%2520nuclear%2520receptor%2520small%2520heterodimer%2520partner%253A%2520Effects%2520of%2520replacing%2520the%25201-adamantyl%2520or%2520hydroxyl%2520group%2520on%2520inhibition%2520of%2520cancer%2520cell%2520growth%252C%2520induction%2520of%2520cancer%2520cell%2520apoptosis%252C%2520and%2520inhibition%2520of%2520Src%2520homology%25202%2520domain-containing%2520protein%2520tyrosine%2520phosphatase-2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5650%26epage%3D5662%26doi%3D10.1021%2Fjm800456k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha,beta-unsaturated carbonyls with thiols via Hetero-Michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2Cbeta-unsaturated+carbonyls+with+thiols+via+Hetero-Michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0li_msorx2Wexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520Hetero-Michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/mol.106.025536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1124%2Fmol.106.025536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16717135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=562-570&author=L.+W.+Chenauthor=S.+S.+Sungauthor=M.+L.+R.+Yipauthor=H.+R.+Lawrenceauthor=Y.+Renauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Discovery+of+a+novel+Shp2+protein+tyrosine+phosphatase+inhibitor&doi=10.1124%2Fmol.106.025536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span></div><div class="casAuthors">Chen, Liwei; Sung, Shen-Shu; Yip, M. L. Richard; Lawrence, Harshani R.; Ren, Yuan; Guida, Wayne C.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">562-570</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Shp2 is a non-receptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene.  It is involved in growth factor-induced activation of mitogen-activated protein (MAP) kinases Erk1 and Erk2 (Erk1/2) and has been implicated in the pathogenicity of the oncogenic bacterium Helicobacter pylori.  Moreover, gain-of-function Shp2 mutations have been found in childhood leukemias and Noonan syndrome.  Thus, small mol. Shp2 PTP inhibitors are much needed reagents for evaluation of Shp2 as a therapeutic target and for chem. biol. studies of Shp2 function.  By screening the National Cancer Institute (NCI) Diversity Set chem. library, we identified 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877) as a potent Shp2 PTP inhibitor.  Mol. modeling and site-directed mutagenesis studies suggested that NSC-87877 binds to the catalytic cleft of Shp2 PTP.  NSC-87877 cross-inhibited Shp1 in vitro, but it was selective for Shp2 over other PTPs (PTP1B, HePTP, DEP1, CD45, and LAR).  It is noteworthy that NSC-87877 inhibited epidermal growth factor (EGF)-induced activation of Shp2 PTP, Ras, and Erk1/2 in cell cultures but did not block EGF-induced Gab1 tyrosine phosphorylation or Gab1-Shp2 assocn.  Furthermore, NSC-87877 inhibited Erk1/2 activation by a Gab1-Shp2 chimera but did not affect the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.  These results identified NSC-87877 as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect.  Our study also provides the first pharmacol. evidence that Shp2 mediates EGF-induced Erk1/2 MAP kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4XVGUjw3W7Vg90H21EOLACvtfcHk0li_msorx2Wexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D&md5=a2ce03150ecbe6937876bb292ced30dc</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025536%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Shp2%2520protein%2520tyrosine%2520phosphatase%2520inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D562%26epage%3D570%26doi%3D10.1124%2Fmol.106.025536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubeek, I.</span>; <span class="NLM_string-name">Cloos, J.</span>; <span class="NLM_string-name">Vojtekova, K.</span>; <span class="NLM_string-name">Broekhuizen, R.</span>; <span class="NLM_string-name">Loosdrecht, A.</span>; <span class="NLM_string-name">Berg, T. V. D.</span>; <span class="NLM_string-name">Zwaan, M.</span>; <span class="NLM_string-name">Kaspers, G.</span></span> <span> </span><span class="NLM_article-title">Cytotoxicity and combination studies with the SHP-2 inhibitor NSC87877 in AML</span>. Presented at the Annual Meeting of the American Association for Cancer Res (AACR), San Diego, CA, <span class="NLM_year">2008</span>; Abstract 5692.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Hubeek&author=J.+Cloos&author=K.+Vojtekova&author=R.+Broekhuizen&author=A.+Loosdrecht&author=T.+V.+D.+Berg&author=M.+Zwaan&author=G.+Kaspers&title=Cytotoxicity+and+combination+studies+with+the+SHP-2+inhibitor+NSC87877+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHubeek%26aufirst%3DI.%26atitle%3DCytotoxicity%2520and%2520combination%2520studies%2520with%2520the%2520SHP-2%2520inhibitor%2520NSC87877%2520in%2520AML%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Identification of Cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7212</span>– <span class="NLM_lpage">7221</span>, <span class="refDoi"> DOI: 10.1021/jm400474r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400474r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7212-7221&author=W.+Liuauthor=B.+Yuauthor=G.+Xuauthor=W.+R.+Xuauthor=M.+L.+Lohauthor=L.+D.+Tangauthor=C.+K.+Qu&title=Identification+of+Cryptotanshinone+as+an+inhibitor+of+oncogenic+protein+tyrosine+phosphatase+SHP2+%28PTPN11%29&doi=10.1021%2Fjm400474r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)</span></div><div class="casAuthors">Liu, Wei; Yu, Bing; Xu, Gang; Xu, Wei-Ren; Loh, Mignon L.; Tang, Li-Da; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7212-7221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations of PTPN11 (encoding the SHP2 phosphatase) are assocd. with Noonan syndrome, childhood leukemias, and sporadic solid tumors.  Virtual screening combined with exptl. assays was performed to identify inhibitors of SHP2 from a database of natural products.  This effort led to the identification of cryptotanshinone as an inhibitor of SHP2.  Cryptotanshinone inhibited SHP2 with an IC50 of 22.50 μM.  Fluorescence titrn. expts. confirmed that it directly bound to SHP2.  Enzymic kinetic analyses showed that cryptotanshinone was a mixed-type and irreversible inhibitor.  This drug was further verified for its ability to block SHP2-mediated cell signaling and cellular functions.  Furthermore, mouse myeloid progenitors and patient leukemic cells with the activating mutation E76K in PTPN11 were found to be sensitive to this inhibitor.  Since cryptotanshinone is used to treat cardiovascular diseases in Asian countries, this drug has a potential to be used directly or to be further developed to treat PTPN11-assocd. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYelS47QYHLVg90H21EOLACvtfcHk0lgVrnx78O5dTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurvN&md5=3bbbae68159ae4227bbf74d5573ca77a</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm400474r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400474r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DW.%2BR.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DIdentification%2520of%2520Cryptotanshinone%2520as%2520an%2520inhibitor%2520of%2520oncogenic%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520%2528PTPN11%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7212%26epage%3D7221%26doi%3D10.1021%2Fjm400474r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. S. S.</span></span> <span> </span><span class="NLM_article-title">Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1177/0091270005282630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1177%2F0091270005282630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16291709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=1345-1359&author=L.+M.+Zhouauthor=Z.+Zuoauthor=M.+S.+S.+Chow&title=Danshen%3A+An+overview+of+its+chemistry%2C+pharmacology%2C+pharmacokinetics%2C+and+clinical+use&doi=10.1177%2F0091270005282630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use</span></div><div class="casAuthors">Zhou, Limin; Zuo, Zhong; Chow, Moses Sing Sum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1345-1359</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Danshen, the dried root of Salvia miltiorrhiza, has been widely used in China and, to a lesser extent, in Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases.  In China, the specific clin. use is angina pectoris, hyperlipidemia, and acute ischemic stroke.  The current review covers its traditional uses, chem. constituents, pharmacol. activities, pharmacokinetics, clin. applications, and potential herb-drug interactions based on information obtained in both the English and Chinese literature.  Although numerous clin. trials have demonstrated that certain Danshen products in China are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality.  Therefore, large randomized clin. trials and further scientific research to det. its mechanism of actions will be necessary to ensure the safety, effectiveness, and better understanding of its action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSr_sWcH9VsbVg90H21EOLACvtfcHk0lgVrnx78O5dTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtrzL&md5=b2475589ba03dab9465808f6756dbce7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1177%2F0091270005282630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270005282630%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%2BM.%26aulast%3DZuo%26aufirst%3DZ.%26aulast%3DChow%26aufirst%3DM.%2BS.%2BS.%26atitle%3DDanshen%253A%2520An%2520overview%2520of%2520its%2520chemistry%252C%2520pharmacology%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520use%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26spage%3D1345%26epage%3D1359%26doi%3D10.1177%2F0091270005282630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Genome-wide transcriptional profiling of the response of staphylococcus aureus to cryptotanshinone</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">617509</span>, <span class="refDoi"> DOI: 10.1155/2009/617509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1155%2F2009%2F617509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19707532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD1MrotVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=617509&author=H.+H.+Fengauthor=H.+Xiangauthor=J.+Y.+Zhangauthor=G.+W.+Liuauthor=N.+Guoauthor=X.+L.+Wangauthor=X.+P.+Wuauthor=X.+M.+Dengauthor=L.+Yu&title=Genome-wide+transcriptional+profiling+of+the+response+of+staphylococcus+aureus+to+cryptotanshinone&doi=10.1155%2F2009%2F617509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cryptotanshinone</span></div><div class="casAuthors">Feng Haihua; Xiang Hua; Zhang Jiyu; Liu Guowen; Guo Na; Wang Xuelin; Wu Xiuping; Deng Xuming; Yu Lu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2009</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">617509</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Staphylococcus aureus (S. aureus) strains with multiple antibiotic resistances are increasingly widespread, and new agents are required for the treatment of S. aureus.  Cryptotanshinone (CT), a major tanshinone of medicinal plant Salvia miltiorrhiza Bunge, demonstrated effective in vitro antibacterial activity against all 21 S. aureus strains tested in this experiment.  Affymetrix GeneChips were utilized to determine the global transcriptional response of S. aureus ATCC 25923 to treatment with subinhibitory concentrations of CT.  Transcriptome profiling indicated that the antibacterial action of CT may be associated with its action as active oxygen radical generator; S. aureus undergoes an oxygen-limiting state upon exposure to CT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFRjSAM_h5TcERNNga7KD-fW6udTcc2eYIsEXaT2o7j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrotVCnuw%253D%253D&md5=1b377a1fb45ddc795fa78d3f5f8be591</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1155%2F2009%2F617509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2009%252F617509%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DH.%2BH.%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DG.%2BW.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DWu%26aufirst%3DX.%2BP.%26aulast%3DDeng%26aufirst%3DX.%2BM.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DGenome-wide%2520transcriptional%2520profiling%2520of%2520the%2520response%2520of%2520staphylococcus%2520aureus%2520to%2520cryptotanshinone%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2009%26spage%3D617509%26doi%3D10.1155%2F2009%2F617509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span> <span> </span><span class="NLM_article-title">Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-08-2575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19118003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=193-202&author=D.+S.+Shinauthor=H.+N.+Kimauthor=K.+D.+Shinauthor=Y.+J.+Yoonauthor=S.+J.+Kimauthor=D.+C.+Hanauthor=B.+M.+Kwon&title=Cryptotanshinone+inhibits+constitutive+signal+transducer+and+activator+of+transcription+3+function+through+blocking+the+dimerization+in+DU145+prostate+cancer+cells&doi=10.1158%2F0008-5472.CAN-08-2575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells</span></div><div class="casAuthors">Shin, Dae-Seop; Kim, Hye-Nan; Shin, Ki Deok; Yoon, Young Ju; Kim, Seung-Jun; Han, Dong Cho; Kwon, Byoung-Mog</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-202</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because signal transducer and activator of transcription 3 (STAT3) is constitutively activated in most human solid tumors and is involved in the proliferation, angiogenesis, immune evasion, and antiapoptosis of cancer cells, researchers have focused on STAT3 as a target for cancer therapy.  We screened for natural compds. that inhibit the activity of STAT3 using a dual-luciferase assay.  Cryptotanshinone was identified as a potent STAT3 inhibitor.  Cryptotanshinone rapidly inhibited STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells and the growth of the cells through 96 h of the treatment.  Inhibition of STAT3 Tyr705 phosphorylation in DU145 cells decreased the expression of STAT3 downstream target proteins such as cyclin D1, survivin, and Bcl-xL.  To investigate the cryptotanshinone inhibitory mechanism in DU145 cells, we analyzed proteins upstream of STAT3.  Although phosphorylation of Janus-activated kinase (JAK) 2 was inhibited by 7 μmol/L cryptotanshinone at 24 h, inhibition of STAT3 Tyr705 phosphorylation occurred within 30 min and the activity of the other proteins was not affected.  These results suggest that inhibition of STAT3 phosphorylation is caused by a JAK2-independent mechanism, with suppression of JAK2 phosphorylation as a secondary effect of cryptotanshinone treatment.  Continuing expts. revealed the possibility that cryptotanshinone might directly bind to STAT3 mols.  Cryptotanshinone was colocalized with STAT3 mols. in the cytoplasm and inhibited the formation of STAT3 dimers.  Computational modeling showed that cryptotanshinone could bind to the SH2 domain of STAT3.  These results suggest that cryptotanshinone is a potent anticancer agent targeting the activation STAT3 protein.  It is the first report that cryptotanshinone has antitumor activity through the inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2CVvIW5pBbVg90H21EOLACvtfcHk0lgz6nF5IKxnRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFCm&md5=f318d248355d742ef874136ccdc9c053</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2575%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BN.%26aulast%3DShin%26aufirst%3DK.%2BD.%26aulast%3DYoon%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DCryptotanshinone%2520inhibits%2520constitutive%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520function%2520through%2520blocking%2520the%2520dimerization%2520in%2520DU145%2520prostate%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D193%26epage%3D202%26doi%3D10.1158%2F0008-5472.CAN-08-2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7275</span>– <span class="NLM_lpage">7280</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710468105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0710468105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18480264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7275-7280&author=K.+Hellmuthauthor=S.+Grosskopfauthor=C.+T.+Lumauthor=M.+Wurteleauthor=N.+Roderauthor=J.+P.+von+Kriesauthor=M.+Rosarioauthor=J.+Rademannauthor=W.+Birchmeier&title=Specific+inhibitors+of+the+protein+tyrosine+phosphatase+Shp2+identified+by+high-throughput+docking&doi=10.1073%2Fpnas.0710468105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span></div><div class="casAuthors">Hellmuth, Klaus; Grosskopf, Stefanie; Lum, Ching Tung; Wuertele, Martin; Roeder, Nadine; von Kries, Jens Peter; Rosario, Marta; Rademann, Jorg; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7275-7280</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protein tyrosine phosphatase Shp2 is a pos. regulator of growth factor signaling.  Gain-of-function mutations in several types of leukemia define Shp2 as a bona fide oncogene.  We performed a high-throughput in silico screen for small-mol.-wt. compds. that bind the catalytic site of Shp2.  We have identified the phenylhydrazonopyrazolone sulfonate PHPS1 as a potent and cell-permeable inhibitor, which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1 B.  PHPS1 inhibits Shp2-dependent cellular events such as hepatocyte growth factor/scatter factor (HGF/SF)-induced epithelial cell scattering and branching morphogenesis.  PHPS1 also blocks Shp2-dependent downstream signaling, namely HGF/SF-induced sustained phosphorylation of the Erk1/2 MAP kinases and dephosphorylation of paxillin.  Furthermore, PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-assocd. Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.  The PHPS compd. class is therefore suitable for further development of therapeutics for the treatment of Shp2-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGponh1kw_h7jrVg90H21EOLACvtfcHk0lgz6nF5IKxnRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D&md5=39c7dda94e32134c305e135e4c48b9d1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710468105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710468105%26sid%3Dliteratum%253Aachs%26aulast%3DHellmuth%26aufirst%3DK.%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DWurtele%26aufirst%3DM.%26aulast%3DRoder%26aufirst%3DN.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DSpecific%2520inhibitors%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%2520identified%2520by%2520high-throughput%2520docking%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D7275%26epage%3D7280%26doi%3D10.1073%2Fpnas.0710468105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fcmdc.201500015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25877780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=815-826&author=S.+Grosskopfauthor=C.+Eckertauthor=C.+Arkonaauthor=S.+Radetzkiauthor=K.+Bohmauthor=U.+Heinemannauthor=G.+Wolberauthor=J.+P.+von+Kriesauthor=W.+Birchmeierauthor=J.+Rademann&title=Selective+inhibitors+of+the+protein+tyrosine+phosphatase+SHP2+block+cellular+motility+and+growth+of+cancer+cells+in+vitro+and+in+vivo&doi=10.1002%2Fcmdc.201500015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo</span></div><div class="casAuthors">Grosskopf, Stefanie; Eckert, Chris; Arkona, Christoph; Radetzki, Silke; Boehm, Kerstin; Heinemann, Udo; Wolber, Gerhard; von Kries, Jens-Peter; Birchmeier, Walter; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-826</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibitors of the protein tyrosine phosphatase SHP2 (src homol. region 2 domain phosphatase; PTPN11), an enzyme that is deregulated in numerous human tumors, were generated through a combination of chem. synthesis and structure-based rational design.  Seventy pyridazolon-4-ylidenehydrazinyl benzenesulfonates were prepd. and evaluated in enzyme assays.  The binding modes of active inhibitors were simulated in silico using a newly generated crystal structure of SHP2.  The most powerful compd. I inhibited SHP2 with an IC50 value of 71±15 nM in the enzyme assay and was 29- and 45-fold more active toward SHP2 than against related SHP1 and PTP1B.  In cell culture expts. compd. I was found to block hepatocyte growth factor (HGF)-stimulated epithelial-mesenchymal transition of human pancreatic adenocarcinoma (HPAF) cells, as indicated by a decrease in the min. neighbor distances of cells.  Moreover, I inhibited cell colony formation in the nonsmall-cell lung cancer cell line LXFA 526 L in soft agar.  Finally, I was obsd. to inhibit tumor growth in a murine xenograft model.  Therefore, the novel specific compd. I strengthens the hypothesis that SHP2 is a relevant protein target for the inhibition of mobility and invasiveness of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovDT-98edFurVg90H21EOLACvtfcHk0lgz6nF5IKxnRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D&md5=72fa2915b67c514076144b3005441b17</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500015%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRadetzki%26aufirst%3DS.%26aulast%3DBohm%26aufirst%3DK.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520block%2520cellular%2520motility%2520and%2520growth%2520of%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D815%26epage%3D826%26doi%3D10.1002%2Fcmdc.201500015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0lirJ8wBh-LdQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lirJ8wBh-LdQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanschagrin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span> <span> </span><span class="NLM_article-title">Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6177</span>– <span class="NLM_lpage">6196</span>, <span class="refDoi"> DOI: 10.1021/jm051256o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+Docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein-ligand+complexes&doi=10.1021%2Fjm051256o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes</span></div><div class="casAuthors">Friesner, Richard A.; Murphy, Robert B.; Repasky, Matthew P.; Frye, Leah L.; Greenwood, Jeremy R.; Halgren, Thomas A.; Sanschagrin, Paul C.; Mainz, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6177-6196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel scoring function to est. protein-ligand binding affinities has been developed and implemented as the Glide 4.0 XP scoring function and docking protocol.  In addn. to unique water desolvation energy terms, protein-ligand structural motifs leading to enhanced binding affinity are included:(1) hydrophobic enclosure where groups of lipophilic ligand atoms are enclosed on opposite faces by lipophilic protein atoms, (2) neutral-neutral single or correlated hydrogen bonds in a hydrophobically enclosed environment, and (3) five categories of charged-charged hydrogen bonds.  The XP scoring function and docking protocol have been developed to reproduce exptl. binding affinities for a set of 198 complexes (RMSDs of 2.26 and 1.73 kcal/mol over all and well-docked ligands, resp.) and to yield quality enrichments for a set of fifteen screens of pharmaceutical importance.  Enrichment results demonstrate the importance of the novel XP mol. recognition and water scoring in sepg. active and inactive ligands and avoiding false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZiwN12vaY7Vg90H21EOLACvtfcHk0lirJ8wBh-LdQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D&md5=ea428c82ead0d8c27f8c1a7b694a1edf</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520Docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6177%26epage%3D6196%26doi%3D10.1021%2Fjm051256o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugochukwu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, O. N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess-Brown, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19167335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=352-363&author=A.+J.+Barrauthor=E.+Ugochukwuauthor=W.+H.+Leeauthor=O.+N.+F.+Kingauthor=P.+Filippakopoulosauthor=I.+Alfanoauthor=P.+Savitskyauthor=N.+A.+Burgess-Brownauthor=S.+Mullerauthor=S.+Knapp&title=Large-scale+structural+analysis+of+the+classical+human+protein+tyrosine+phosphatome&doi=10.1016%2Fj.cell.2008.11.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span></div><div class="casAuthors">Barr, Alastair J.; Ugochukwu, Emilie; Lee, Wen Hwa; King, Oliver N. F.; Filippakopoulos, Panagis; Alfano, Ivan; Savitsky, Pavel; Burgess-Brown, Nicola A.; Muller, Susanne; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) play a crit. role in regulating cellular functions by selectively dephosphorylating their substrates.  Here we present 22 human PTP crystal structures that, together with prior structural knowledge, enable a comprehensive anal. of the classical PTP family.  Despite their largely conserved fold, surface properties of PTPs are strikingly diverse.  A potential secondary substrate-binding pocket is frequently found in phosphatases, and this has implications for both substrate recognition and development of selective inhibitors.  Structural comparison identified four diverse catalytic loop (WPD) conformations and suggested a mechanism for loop closure.  Enzymic assays revealed vast differences in PTP catalytic activity and identified PTPD1, PTPD2, and HDPTP as catalytically inert protein phosphatases.  We propose a "head-to-toe" dimerization model for RPTPγ/ζ that is distinct from the "inhibitory wedge" model and that provides a mol. basis for inhibitory regulation.  This phosphatome resource gives an expanded insight into intrafamily PTP diversity, catalytic activity, substrate recognition, and autoregulatory self-assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kaabM4U0LLVg90H21EOLACvtfcHk0ljPUiT6TOKoHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D&md5=f47994736342cc0490609596d66fd03e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DKing%26aufirst%3DO.%2BN.%2BF.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DBurgess-Brown%26aufirst%3DN.%2BA.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DLarge-scale%2520structural%2520analysis%2520of%2520the%2520classical%2520human%2520protein%2520tyrosine%2520phosphatome%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D352%26epage%3D363%26doi%3D10.1016%2Fj.cell.2008.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: Structure and function, substrate specificity, and inhibitor development</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.42.083001.144616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1146%2Fannurev.pharmtox.42.083001.144616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11807171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=209-234&author=Z.+Y.+Zhang&title=Protein+tyrosine+phosphatases%3A+Structure+and+function%2C+substrate+specificity%2C+and+inhibitor+development&doi=10.1146%2Fannurev.pharmtox.42.083001.144616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development</span></div><div class="casAuthors">Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-234</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are signaling enzymes that control a diverse array of cellular processes.  Malfunction of PTP activity is assocd. with a no. of human disorders.  Recent genetic and biochem. studies indicate that PTPs represent a novel platform for drug discovery.  Detailed knowledge of PTP substrate specificity and the wealth of structural data on PTPs provide a solid foundation for rational PTP inhibitor design.  This review summarizes a correlation of PTP structure and function from mutagenesis expts.  The mol. basis for PTP1B and MKP3 substrate recognition is discussed.  A powerful strategy is presented for creating specific and high-affinity bidentate PTP inhibitors that simultaneously bind both the active site and a unique adjacent site.  Finally, recent advances in the development of potent and selective inhibitors for PTP1B and Cdc25 are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkHsDd9nAT7Vg90H21EOLACvtfcHk0ljPUiT6TOKoHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFKnsbo%253D&md5=eb192ad4d7283c476947af0fbbcfcfb0</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.42.083001.144616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.42.083001.144616%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520Structure%2520and%2520function%252C%2520substrate%2520specificity%252C%2520and%2520inhibitor%2520development%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2002%26volume%3D42%26spage%3D209%26epage%3D234%26doi%3D10.1146%2Fannurev.pharmtox.42.083001.144616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goenka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span> <span> </span><span class="NLM_article-title">The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fleu.2012.308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23103841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Gns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=398-408&author=S.+C.+Nabingerauthor=X.+J.+Liauthor=B.+Ramdasauthor=Y.+Heauthor=X.+Zhangauthor=L.+Zengauthor=B.+Richineauthor=J.+D.+Bowlingauthor=S.+Fukudaauthor=S.+Goenkaauthor=Z.+Liuauthor=G.+S.+Fengauthor=M.+Yuauthor=G.+E.+Sanduskyauthor=H.+S.+Boswellauthor=Z.+Y.+Zhangauthor=R.+Kapurauthor=R.+J.+Chan&title=The+protein+tyrosine+phosphatase%2C+Shp2%2C+positively+contributes+to+FLT3-ITD-induced+hematopoietic+progenitor+hyperproliferation+and+malignant+disease+in+vivo&doi=10.1038%2Fleu.2012.308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo</span></div><div class="casAuthors">Nabinger, S. C.; Li, X. J.; Ramdas, B.; He, Y.; Zhang, X.; Zeng, L.; Richine, B.; Bowling, J. D.; Fukuda, S.; Goenka, S.; Liu, Z.; Feng, G.-S.; Yu, M.; Sandusky, G. E.; Boswell, H. S.; Zhang, Z.-Y.; Kapur, R.; Chan, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">398-408</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML).  We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation.  Co-immunopptn. demonstrated constitutive assocn. of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5.  Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells.  Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-d. mononuclear cells reduced proliferation and STAT5 activation.  In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy.  Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and pos. activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression.  Further, using a small mol. Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner.  These findings demonstrate that Shp2 pos. contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22BzHymkQ77Vg90H21EOLACvtfcHk0ljD0aPP8j-ArQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Gns70%253D&md5=5d1053444fa0b17bbc8719cf35646b13</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.308%26sid%3Dliteratum%253Aachs%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DRamdas%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DRichine%26aufirst%3DB.%26aulast%3DBowling%26aufirst%3DJ.%2BD.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DGoenka%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26aulast%3DBoswell%26aufirst%3DH.%2BS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520protein%2520tyrosine%2520phosphatase%252C%2520Shp2%252C%2520positively%2520contributes%2520to%2520FLT3-ITD-induced%2520hematopoietic%2520progenitor%2520hyperproliferation%2520and%2520malignant%2520disease%2520in%2520vivo%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D398%26epage%3D408%26doi%3D10.1038%2Fleu.2012.308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting the oncogenic SHP2 phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.+F.+Zengauthor=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=S.+J.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+J.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.+Y.+Zhang&title=Therapeutic+potential+of+targeting+the+oncogenic+SHP2+phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0ljD0aPP8j-ArQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520the%2520oncogenic%2520SHP2%2520phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVansr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=782-786&author=R.+J.+Heauthor=Z.+H.+Yuauthor=R.+Y.+Zhangauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=J.+S.+Shimauthor=L.+F.+Zengauthor=Y.+T.+Heauthor=L.+Chenauthor=C.+D.+Wellsauthor=J.+O.+Liuauthor=Z.+Y.+Zhang&title=Exploring+the+existing+drug+space+for+novel+pTyr+mimetic+and+SHP2+inhibitors&doi=10.1021%2Facsmedchemlett.5b00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors</span></div><div class="casAuthors">He, Rongjun; Yu, Zhi-Hong; Zhang, Ruo-Yu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Shim, Joong S.; Zeng, Li-Fan; He, Yantao; Chen, Lan; Wells, Clark D.; Liu, Jun O.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-786</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are potential therapeutic targets for many diseases.  Unfortunately, despite considerable drug discovery efforts devoted to PTPs, obtaining selective and cell permeable PTP inhibitors remains highly challenging.  The authors describe a strategy to explore the existing drug space for previously unknown PTP inhibitory activities.  This led to the discovery of cefsulodin as an inhibitor of SHP2, an oncogenic phosphatase in the PTP family.  Crystal structure anal. of SHP2 interaction with cefsulodin identified sulfophenyl acetic amide (SPAA) as a novel phosphotyrosine (pTyr) mimetic.  A structure-guided and SPAA fragment-based focused library approach produced several potent and selective SHP2 inhibitors, e.g. I.  Notably, these inhibitors blocked SHP2-mediated signaling events and proliferation in several cancer cell lines.  Thus, SPAA may serve as a new platform for developing chem. probes for other PTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHtl-WSr2zK7Vg90H21EOLACvtfcHk0ljD0aPP8j-ArQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVansr3F&md5=6374b80d7357c4b957afb432723d06dc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00118%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%2BJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DShim%26aufirst%3DJ.%2BS.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DExploring%2520the%2520existing%2520drug%2520space%2520for%2520novel%2520pTyr%2520mimetic%2520and%2520SHP2%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D782%26epage%3D786%26doi%3D10.1021%2Facsmedchemlett.5b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0049-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F1535-7163.MCT-13-0049-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23825065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1738-1748&author=B.+Yuauthor=W.+Liuauthor=W.+M.+Yuauthor=M.+L.+Lohauthor=S.+Alterauthor=O.+Guvenchauthor=A.+D.+MacKerellauthor=L.+D.+Tangauthor=C.+K.+Qu&title=Targeting+protein+tyrosine+phosphatase+SHP2+for+the+treatment+of+PTPN11-associated+malignancies&doi=10.1158%2F1535-7163.MCT-13-0049-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies</span></div><div class="casAuthors">Yu, Bing; Liu, Wei; Yu, Wen-Mei; Loh, Mignon L.; Alter, Shawn; Guvench, Olgun; MacKerell, Alexander D., Jr.; Tang, Li-Da; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1738-1748</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in PTPN11 (encoding SHP2), a protein tyrosine phosphatase (PTP) that plays an overall pos. role in growth factor and cytokine signaling, are directly assocd. with the pathogenesis of Noonan syndrome and childhood leukemias.  Identification of SHP2-selective inhibitors could lead to the development of new drugs that ultimately serve as treatments for PTPN11-assocd. diseases.  As the catalytic core of SHP2 shares extremely high homol. to those of SHP1 and other PTPs that play neg. roles in cell signaling, to identify selective inhibitors of SHP2 using computer-aided drug design, we targeted a protein surface pocket that is adjacent to the catalytic site, is predicted to be important for binding to phosphopeptide substrates, and has structural features unique to SHP2.  From computationally selected candidate compds., #220-324 effectively inhibited SHP2 activity with an IC50 of 14 μmol/L.  Fluorescence titrn. expts. confirmed its direct binding to SHP2.  This active compd. was further verified for its ability to inhibit SHP2-mediated cell signaling and cellular function with minimal off-target effects.  Furthermore, mouse myeloid progenitors with the activating mutation (E76K) in PTPN11 and patient leukemic cells with the same mutation were more sensitive to this inhibitor than wild-type cells.  This study provides evidence that SHP2 is a "druggable" target for the treatment of PTPN11-assocd. diseases.  As the small-mol. SHP2 inhibitor identified has a simple chem. structure, it represents an ideal lead compd. for the development of novel anti-SHP2 drugs.  Mol Cancer Ther; 12(9); 1738-48. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3UZZIk5H7LVg90H21EOLACvtfcHk0lj6HB2l5SZ4GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7M&md5=645bbea5d54c34844313f638b6fb0b7c</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0049-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0049-T%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%2BM.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DAlter%26aufirst%3DS.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DTargeting%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520for%2520the%2520treatment%2520of%2520PTPN11-associated%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1738%26epage%3D1748%26doi%3D10.1158%2F1535-7163.MCT-13-0049-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel inhibitor of the protein tyrosine phosphatase Shp2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17626</span>, <span class="refDoi"> DOI: 10.1038/srep17626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsrep17626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26626996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17626&author=C.+Chenauthor=M.+M.+Caoauthor=S.+Y.+Zhuauthor=C.+C.+Wangauthor=F.+Liangauthor=L.+L.+Yanauthor=D.+Q.+Luo&title=Discovery+of+a+novel+inhibitor+of+the+protein+tyrosine+phosphatase+Shp2&doi=10.1038%2Fsrep17626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span></div><div class="casAuthors">Chen, Chuan; Cao, Mengmeng; Zhu, Siyu; Wang, Cuicui; Liang, Fan; Yan, Leilei; Luo, Duqiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17626</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Shp2 is a ubiquitously expressed protein tyrosine phosphatase (PTP) related to adult acute myelogenous leukemia and human solid tumors.  In this report, we describe identification of a potent Shp2 inhibitor, Fumosorinone (Fumos) from entomogenous fungi, which shows selective inhibition of Shp2 over other tested PTPs.  Using a surface plasmon resonance anal., we further confirmed the phys. interaction between Shp2 and Fumos.  Fumos inhibits Shp2-dependent activation of the Ras/ERK signal pathway downstream of EGFR, and interrupts EGF-induced Gab1-Shp2 assocn.  As expected, Fumos shows little effects on the Shp2-independent ERK1/2 activation induced by PMA or oncogenic Ras.  Furthermore, Fumos down-regulates Src activation, inhibits phosphorylation of Paxillin and prevents tumor cell invasion.  These results suggest that Fumos can inhibit Shp2-dependent cell signaling in human cells and has a potential for treatment of Shp2-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswqt5Y98UCrVg90H21EOLACvtfcHk0lj6HB2l5SZ4GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN&md5=ae7d1a3adf914820e57a2862ade65cf7</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fsrep17626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17626%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DM.%2BM.%26aulast%3DZhu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DL.%2BL.%26aulast%3DLuo%26aufirst%3DD.%2BQ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520inhibitor%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17626%26doi%3D10.1038%2Fsrep17626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span> <span> </span><span class="NLM_article-title">Benzo c 1,2,5 thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5154</span>– <span class="NLM_lpage">5157</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmcl.2017.10.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29100798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKnsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5154-5157&author=W.+L.+Wangauthor=X.+Y.+Chenauthor=Y.+Gaoauthor=L.+X.+Gaoauthor=L.+Shengauthor=J.+Y.+Zhuauthor=L.+Xuauthor=Z.+Z.+Dingauthor=C.+Zhangauthor=J.+Y.+Liauthor=J.+Liauthor=Y.+B.+Zhou&title=Benzo+c+1%2C2%2C5+thiadiazole+derivatives%3A+A+new+class+of+potent+Src+homology-2+domain+containing+protein+tyrosine+phosphatase-2+%28SHP2%29+inhibitors&doi=10.1016%2Fj.bmcl.2017.10.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors</span></div><div class="casAuthors">Wang, Wen-Long; Chen, Xiao-Yu; Gao, Ya; Gao, Li-Xin; Sheng, Li; Zhu, Jingyu; Xu, Lei; Ding, Zhen-Zhong; Zhang, Chao; Li, Jing-Ya; Li, Jia; Zhou, Yu-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5154-5157</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase linked to various kinds of cancers.  Consequently, SHP2 has emerged as a promising target for novel anti-cancer agents.  Using scaffold-hopping strategy, a series of benzo[c][1,2,5]thiadiazole derivs. was designed from PTP1B inhibitors with 1H-2,3-Dihydroperimidine motif, synthesized and evaluated their biol. activities against PTP1B and SHP2.  Among them, the representative compd. I displayed SHP2 inhibitory activity with IC50 of 2.11 ± 0.99 μM, exhibited 2.02-fold and 25-fold selectivity for SHP2 over SHP1 and PTP1B resp. and had no visible activity against TCPTP.  These preliminary results could provide a possible opportunity for the development of novel SHP2 inhibitors with optimal potency and improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHEbzkGLAjKLVg90H21EOLACvtfcHk0lj6HB2l5SZ4GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKnsrzL&md5=ebc7fcb7c71a9ddbbbffc43898ab1d90</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.059%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DL.%2BX.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DZ.%2BZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26atitle%3DBenzo%2520c%25201%252C2%252C5%2520thiadiazole%2520derivatives%253A%2520A%2520new%2520class%2520of%2520potent%2520Src%2520homology-2%2520domain%2520containing%2520protein%2520tyrosine%2520phosphatase-2%2520%2528SHP2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5154%26epage%3D5157%26doi%3D10.1016%2Fj.bmcl.2017.10.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+G.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lj7x5n4B9gJqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%2BG.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Targeting protein tyrosine phosphatases for anticancer drug discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.2174/138161210791209027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2174%2F138161210791209027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=20337577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1843-1862&author=L.+M.+Scottauthor=H.+R.+Lawrenceauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Targeting+protein+tyrosine+phosphatases+for+anticancer+drug+discovery&doi=10.2174%2F138161210791209027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatases for anticancer drug discovery</span></div><div class="casAuthors">Scott, Latanya M.; Lawrence, Harshani R.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1843-1862</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome.  Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes.  While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase.  In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed.  Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHuBrNeSP0n7Vg90H21EOLACvtfcHk0lj7x5n4B9gJqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D&md5=17813d1fba0225fd5e54692b1159bc4a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F138161210791209027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791209027%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DTargeting%2520protein%2520tyrosine%2520phosphatases%2520for%2520anticancer%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1843%26epage%3D1862%26doi%3D10.2174%2F138161210791209027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Small molecule tools for functional interrogation of protein tyrosine phosphatases</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08718.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1742-4658.2012.08718.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22816879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=731-750&author=R.+J.+Heauthor=L.+F.+Zengauthor=Y.+T.+Heauthor=S.+Zhangauthor=Z.+Y.+Zhang&title=Small+molecule+tools+for+functional+interrogation+of+protein+tyrosine+phosphatases&doi=10.1111%2Fj.1742-4658.2012.08718.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule tools for functional interrogation of protein tyrosine phosphatases</span></div><div class="casAuthors">He, Rongjun; Zeng, Li-Fan; He, Yantao; Zhang, Sheng; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">731-750</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The importance of protein tyrosine phosphatases (PTPs) in the regulation of cellular signalling is well established.  Malfunction of PTP activity is also known to be assocd. with cancer, metabolic syndromes and autoimmune disorders, as well as neurodegenerative and infectious diseases.  However, a detailed understanding of the roles played by the PTPs in normal physiol. and in pathogenic conditions has been hampered by the absence of PTP-specific small mol. agents.  In addn., the therapeutic benefits of modulating this target class are underexplored as a result of a lack of suitable chem. probes.  Potent and specific PTP inhibitors could significantly facilitate functional anal. of the PTPs in complex cellular signal transduction pathways and may constitute valuable therapeutics in the treatment of several human diseases.  We highlight the current challenges to and opportunities for developing PTP-specific small mol. agents.  We also review available selective small mol. inhibitors developed for a no. of PTPs, including PTP1B, TC-PTP, SHP2, lymphoid-specific tyrosine phosphatase, hematopoietic protein tyrosine phosphatase, CD45, PTPβ, PTPγ, PTPRO, Vaccinia H1-related phosphatase, mitogen-activated protein kinase phosphatase-1, mitogen-activated protein kinase phosphatase-3, Cdc25, YopH, mPTPA and mPTPB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokl-YBrjLX1bVg90H21EOLACvtfcHk0lj7x5n4B9gJqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCls7Y%253D&md5=a30f63b9e20bcff3b00bf61e77a95bce</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08718.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08718.x%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSmall%2520molecule%2520tools%2520for%2520functional%2520interrogation%2520of%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D731%26epage%3D750%26doi%3D10.1111%2Fj.1742-4658.2012.08718.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Phosphatases start shedding their stigma of undruggability</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2018.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30482950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlalu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=847-849&author=A.+Mullard&title=Phosphatases+start+shedding+their+stigma+of+undruggability&doi=10.1038%2Fnrd.2018.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatases start shedding their stigma of undruggability</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">847-849</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Clin.-stage allosterically acting drugs are on track to unlock a stubborn class of targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLTXLIW9n5pLVg90H21EOLACvtfcHk0lhihaT9MCSabw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlalu7%252FL&md5=bf7083438604d9f88f530b2e260a49c3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.201%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DPhosphatases%2520start%2520shedding%2520their%2520stigma%2520of%2520undruggability%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D847%26epage%3D849%26doi%3D10.1038%2Fnrd.2018.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.+N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.+T.+Chenauthor=Z.+L.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.+X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+M.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Y.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Z.+Yangauthor=J.+Yuanauthor=J.+H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+inhibition+of+SHP2+phosphatase+inhibits+cancers+driven+by+receptor+tyrosine+kinases&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0lhihaT9MCSabw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BN.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BY.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%2BZ.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%2520inhibits%2520cancers%2520driven%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Grunenfelder, D.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Stams, T. M.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">1-Pyridazin-/Triazin-3-yl-piper(-azine)/Idine/Pyrolidine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107493 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.-T.+Chen&author=Z.+Chen&author=J.+G.+Fortanet&author=D.+Grunenfelder&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=T.+M.+Stams&author=S.+Williams&title=1-Pyridazin-%2FTriazin-3-yl-piper%28-azine%29%2FIdine%2FPyrolidine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26atitle%3D1-Pyridazin-%252FTriazin-3-yl-piper%2528-azine%2529%252FIdine%252FPyrolidine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+G.+Fortanetauthor=C.+H.+T.+Chenauthor=Y.+N.+P.+Chenauthor=Z.+L.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+M.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Y.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.+H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+inhibition+of+SHP2%3A+identification+of+a+potent%2C+selective%2C+and+orally+efficacious+phosphatase+inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DFortanet%26aufirst%3DJ.%2BG.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BN.%2BP.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BY.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%253A%2520identification%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520phosphatase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padua, R. A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitsawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiller, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, D.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4507</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06814-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41467-018-06814-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30375376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3cvkslemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4507&author=R.+A.+P.+Paduaauthor=Y.+Z.+Sunauthor=I.+Markoauthor=W.+Pitsawongauthor=J.+B.+Stillerauthor=R.+Ottenauthor=D.+Kern&title=Mechanism+of+activating+mutations+and+allosteric+drug+inhibition+of+the+phosphatase+SHP2&doi=10.1038%2Fs41467-018-06814-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2</span></div><div class="casAuthors">Padua Ricardo A P; Sun Yizhi; Marko Ingrid; Pitsawong Warintra; Stiller John B; Otten Renee; Kern Dorothee; Sun Yizhi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4507</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 functions as a key regulator of cell cycle control, and activating mutations cause several cancers.  Here, we dissect the energy landscape of wild-type SHP2 and the oncogenic mutation E76K.  NMR spectroscopy and X-ray crystallography reveal that wild-type SHP2 exchanges between closed, inactive and open, active conformations.  E76K mutation shifts this equilibrium toward the open state.  The previously unknown open conformation is characterized, including the active-site WPD loop in the inward and outward conformations.  Binding of the allosteric inhibitor SHP099 to E76K mutant, despite much weaker, results in an identical structure as the wild-type complex.  A conformational selection to the closed state reduces drug affinity which, combined with E76K's much higher activity, demands significantly greater SHP099 concentrations to restore wild-type  activity levels.  The differences in structural ensembles and drug-binding kinetics of cancer-associated SHP2 forms may stimulate innovative ideas for developing more potent inhibitors for activated SHP2 mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRglXfZMl481eR_TJajKxJDfW6udTcc2ebOItkwoWWs5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvkslemsg%253D%253D&md5=676e8c7d4c85cbb7ce2fa9f756106535</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06814-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06814-w%26sid%3Dliteratum%253Aachs%26aulast%3DPadua%26aufirst%3DR.%2BA.%2BP.%26aulast%3DSun%26aufirst%3DY.%2BZ.%26aulast%3DMarko%26aufirst%3DI.%26aulast%3DPitsawong%26aufirst%3DW.%26aulast%3DStiller%26aufirst%3DJ.%2BB.%26aulast%3DOtten%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DD.%26atitle%3DMechanism%2520of%2520activating%2520mutations%2520and%2520allosteric%2520drug%2520inhibition%2520of%2520the%2520phosphatase%2520SHP2%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4507%26doi%3D10.1038%2Fs41467-018-06814-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0020-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41375-018-0020-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29568093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1246-1249&author=X.+Sunauthor=Y.+Renauthor=S.+Gunawanauthor=P.+Tengauthor=Z.+Chenauthor=H.+R.+Lawrenceauthor=J.+Caiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Selective+inhibition+of+leukemia-associated+SHP2%28E69K%29+mutant+by+the+allosteric+SHP2+inhibitor+SHP099&doi=10.1038%2Fs41375-018-0020-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099</span></div><div class="casAuthors">Sun, X.; Ren, Y.; Gunawan, S.; Teng, P.; Chen, Z.; Lawrence, H. R.; Cai, J.; Lawrence, N. J.; Wu, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1246-1249</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The article studies selective inhibition of leukemia-assocd. SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.  Our findings here identify SHP2E69K as a SHP099-sensitive mutation, wherein three of four most common oncogenic SHP2 mutants studied here are resistant to SHP099.  Moreover, whether Noonan syndrome-assocd. SHP2 mutants are sensitive to SHP099 remained to be tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQzBW1E1YhLVg90H21EOLACvtfcHk0lieYtz5-7_F6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK&md5=2cb9342a2e06eac4b9d9043163e4095c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0020-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0020-5%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DTeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520leukemia-associated%2520SHP2%2528E69K%2529%2520mutant%2520by%2520the%2520allosteric%2520SHP2%2520inhibitor%2520SHP099%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1246%26epage%3D1249%26doi%3D10.1038%2Fs41375-018-0020-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.apsb.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30972278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=304-315&author=M.+X.+Zhaoauthor=W.+J.+Guoauthor=Y.+Y.+Wuauthor=C.+X.+Yangauthor=L.+Zhongauthor=G.+L.+Dengauthor=Y.+Y.+Zhuauthor=W.+Liuauthor=Y.+H.+Guauthor=Y.+Luauthor=L.+D.+Kongauthor=X.+B.+Mengauthor=Q.+Xuauthor=Y.+Sun&title=SHP2+inhibition+triggers+anti-tumor+immunity+and+synergizes+with+PD-1+blockade&doi=10.1016%2Fj.apsb.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span></div><div class="casAuthors">Zhao Mingxia; Guo Wenjie; Yang Chenxi; Deng Guoliang; Zhu Yuyu; Liu Wen; Kong Lingdong; Meng Xiangbao; Xu Qiang; Sun Yang; Wu Yuanyuan; Lu Yin; Zhong Liang; Meng Xiangbao; Gu Yanhong</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-315</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation.  Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo.  However, whether SHP099-mediated SHP2 inhibition retards tumor growth in vivo via anti-tumor immunity remains elusive.  To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099.  Consequently, SHP099 minimally affected CT-26 tumor growth in immuno-deficient nude mice, but significantly decreased the tumor burden in CT-26 tumor-bearing mice with intact immune system.  SHP099 augmented anti-tumor immunity, as shown by the elevated proportion of CD8(+)IFN-γ(+) T cells and the upregulation of cytotoxic T-cell related genes including Granzyme B andPerforin, which decreased the tumor load.  In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses.  Finally, the combination of SHP099 and anti-PD-1 antibody showed a higher therapeutic efficacy than either monotherapy in controlling tumor growth in two colon cancer xenograft models, indicating that these agents complement each other.  Our study suggests that SHP2 inhibitor SHP099 is a promising candidate drug for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB60VxKgx5l_h3YQQtAhNufW6udTcc2eYKZXbFsziuebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D&md5=759babe45705b88551f6ac62cb3cee2e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%2BX.%26aulast%3DGuo%26aufirst%3DW.%2BJ.%26aulast%3DWu%26aufirst%3DY.%2BY.%26aulast%3DYang%26aufirst%3DC.%2BX.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%2BH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%2BD.%26aulast%3DMeng%26aufirst%3DX.%2BB.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DSHP2%2520inhibition%2520triggers%2520anti-tumor%2520immunity%2520and%2520synergizes%2520with%2520PD-1%2520blockade%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.apsb.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">1-(Triazin-3-yl/Pyridazin-3-yl)-piper(-azine)dine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107494 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=S.+Williams&author=M.+Sendzik&title=1-%28Triazin-3-yl%2FPyridazin-3-yl%29-piper%28-azine%29dine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-%2528Triazin-3-yl%252FPyridazin-3-yl%2529-piper%2528-azine%2529dine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leila, D. A.</span>; <span class="NLM_string-name">Engelman, J. A.</span>; <span class="NLM_string-name">Hao, H.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combination Comprising an ALK Inhibitor and a SHP2 Inhibitor</span>. <span class="NLM_patent">WO 2018/130928 A1</span>, Jul 19, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+A.+Leila&author=J.+A.+Engelman&author=H.+Hao&author=F.+Li&author=M.+J.+Lamarche&author=H.+Wang&title=Pharmaceutical+Combination+Comprising+an+ALK+Inhibitor+and+a+SHP2+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeila%26aufirst%3DD.%2BA.%26atitle%3DPharmaceutical%2520Combination%2520Comprising%2520an%2520ALK%2520Inhibitor%2520and%2520a%2520SHP2%2520Inhibitor%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Giraldes, J. W.</span>; <span class="NLM_string-name">Toure, B.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">N-Azaspirocycloalkane Substituted N-heteroaryl Compounds and Compositions for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107495 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.+Chen&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=T.+D.+Smith&author=S.+Williams&author=J.+W.+Giraldes&author=B.+Toure&author=M.+Sendzik&title=N-Azaspirocycloalkane+Substituted+N-heteroaryl+Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DN-Azaspirocycloalkane%2520Substituted%2520N-heteroaryl%2520Compounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+L.+Chenauthor=Y.+N.+Chenauthor=H.+M.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+X.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+M.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Y.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+potent%2C+selective%2C+and+orally+efficacious+SHP2+inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0liiV9oViapsgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BN.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520SHP2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of fused bicyclic allosteric SHP2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+L.+Chenauthor=M.+Ackerauthor=Y.+N.+Chenauthor=H.+M.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+M.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Y.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+fused+bicyclic+allosteric+SHP2+inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0liiV9oViapsgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BN.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520fused%2520bicyclic%2520allosteric%2520SHP2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2016/203404 A1</span>, Dec 22, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+T.+Bagdanoff&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=M.+Kato&author=M.+J.+Lamarche&author=P.+J.+Sarver&author=M.+Shultz&author=T.+D.+Smith&author=S.+Williams&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Gili, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/013597 A1</span>, Jan 18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+S.+Koltun&author=A.+Gili&author=K.+Mellem&author=N.+Aay&author=A.+Buckl&author=C.+Semko&author=G.+Kiss&title=2%2C5-Disubstituted+3-Methyl+Pyrazines+and+2%2C5%2C6-Trisubstituted+3-Methyl+Pyrazines+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26atitle%3D2%252C5-Disubstituted%25203-Methyl%2520Pyrazines%2520and%25202%252C5%252C6-Trisubstituted%25203-Methyl%2520Pyrazines%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. A.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">Pyridine Compounds as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/136264 A1</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+A.+Gill&author=N.+Aay&author=K.+Mellem&author=A.+Buckl&author=E.+S.+Koltun&author=C.+Semko&author=G.+Kiss&title=Pyridine+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BA.%26atitle%3DPyridine%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B. R.</span>; <span class="NLM_string-name">Pitzen, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Won, W. S.</span>; <span class="NLM_string-name">Tzitzilonis, C.</span>; <span class="NLM_string-name">Li, J. J.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Kiss, G.</span>; <span class="NLM_string-name">Gill, A.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Compounds as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/136265 A1</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+R.+Blank&author=J.+Pitzen&author=G.+Wang&author=W.+S.+Won&author=C.+Tzitzilonis&author=J.+J.+Li&author=E.+S.+Koltun&author=N.+Aay&author=A.+Buckl&author=K.+Mellem&author=C.+Semko&author=A.+Jogalekar&author=G.+Kiss&author=A.+Gill&title=Bicyclic+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DB.%2BR.%26atitle%3DBicyclic%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, E.</span>; <span class="NLM_string-name">Mordec, K.</span>; <span class="NLM_string-name">Nichols, R. J.</span>; <span class="NLM_string-name">Wildes, D.</span>; <span class="NLM_string-name">Schulze, C. J.</span>; <span class="NLM_string-name">Myers, D. R.</span>; <span class="NLM_string-name">Singh, M.</span>; <span class="NLM_string-name">Koltun, E.</span>; <span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Kelsey, S.</span>; <span class="NLM_string-name">Goldsmith, M. A.</span>; <span class="NLM_string-name">Smith, J. A. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms</span>. Presented at the the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY, <span class="NLM_year">2018</span>; Abstract A103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Quintana&author=K.+Mordec&author=R.+J.+Nichols&author=D.+Wildes&author=C.+J.+Schulze&author=D.+R.+Myers&author=M.+Singh&author=E.+Koltun&author=A.+Gill&author=S.+Kelsey&author=M.+A.+Goldsmith&author=J.+A.+M.+Smith&title=Allosteric+inhibition+of+SHP2+induces+antitumor+immunity+in+PD-1-sensitive+tumors+through+modulation+of+both+innate+and+adaptive+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DE.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520induces%2520antitumor%2520immunity%2520in%2520PD-1-sensitive%2520tumors%2520through%2520modulation%2520of%2520both%2520innate%2520and%2520adaptive%2520mechanisms%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobvis Shifrin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belwafa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-3038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-19-3038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Quintanaauthor=C.+J.+Schulzeauthor=D.+R.+Myersauthor=T.+J.+Choyauthor=K.+Mordecauthor=D.+Wildesauthor=N.+Tobvis+Shifrinauthor=A.+Belwafaauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=S.+Kelseyauthor=M.+A.+Goldsmithauthor=R.+Nicholsauthor=J.+A.+M.+Smith&title=Allosteric+inhibition+of+SHP2+stimulates+anti-tumor+immunity+by+transforming+the+immunosuppressive+environment&doi=10.1158%2F0008-5472.CAN-19-3038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-3038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-3038%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DE.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DMyers%26aufirst%3DD.%2BR.%26aulast%3DChoy%26aufirst%3DT.%2BJ.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTobvis%2BShifrin%26aufirst%3DN.%26aulast%3DBelwafa%26aufirst%3DA.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKelsey%26aufirst%3DS.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520stimulates%2520anti-tumor%2520immunity%2520by%2520transforming%2520the%2520immunosuppressive%2520environment%26jtitle%3DCancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F0008-5472.CAN-19-3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2017/211303 A1</span>, Dec 14, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/172984 A1</span>, Sep 27, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">SHP2 Phosphatase Inhibitors and Methods of Use Thereof</span>. <span class="NLM_patent">WO 2018/057884 A1</span>, Mar 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+K.+Albrecht&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=W.+P.+Walters&title=SHP2+Phosphatase+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DSHP2%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Pipietro, L. V.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Therrien, E.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-B]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2018/081091 A1</span>, May 3, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=L.+V.+Pipietro&author=E.+H.+Kelley&author=A.+Lescarbeau&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=S.+Bhat&author=E.+Therrien&author=M.+K.+Dahlgeren&title=Pyrazolo%5B3%2C4-B%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26atitle%3DPyrazolo%255B3%252C4-B%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Tang, Y.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span>; <span class="NLM_string-name">Therrien, E.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-B]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2018/218133 A1</span>, Nov 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+M.+Taylor&author=A.+Lescarbeau&author=E.+H.+Kelley&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=Y.+Tang&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=S.+Bhat&author=M.+K.+Dahlgeren&author=E.+Therrien&title=Pyrazolo%5B3%2C4-B%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26atitle%3DPyrazolo%255B3%252C4-B%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Babiss, L. E.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2019/182960 A1</span>, Sep 26, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Xie&author=L.+E.+Babiss&title=SHP2+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26atitle%3DSHP2%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Mandal, P.</span>; <span class="NLM_string-name">Cross, J.</span></span> <span> </span><span class="NLM_article-title">6-(4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one Derivatives and Related Compounds as PTPN11 (SHP2) Inhibitors for Treating Cancer</span>. <span class="NLM_patent">WO 2020/033828 A1</span>, Feb 13, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+Jones&author=B.+Czako&author=C.+L.+Carroll&author=P.+Mandal&author=J.+Cross&title=6-%284-Amino-3-methyl-2-oxa-8-azaspiro%5B4.5%5Ddecan-8-yl%29-3-%282%2C3-dichlorophenyl%29-2-methylpyrimidin-4%283H%29-one+Derivatives+and+Related+Compounds+as+PTPN11+%28SHP2%29+Inhibitors+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3D6-%25284-Amino-3-methyl-2-oxa-8-azaspiro%255B4.5%255Ddecan-8-yl%2529-3-%25282%252C3-dichlorophenyl%2529-2-methylpyrimidin-4%25283H%2529-one%2520Derivatives%2520and%2520Related%2520Compounds%2520as%2520PTPN11%2520%2528SHP2%2529%2520Inhibitors%2520for%2520Treating%2520Cancer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Buck, I. M.</span>; <span class="NLM_string-name">Chessari, G.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">Fujiwara, H.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Hiscock, S. D.</span>; <span class="NLM_string-name">Holevy, R. S.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Liebeschuetz, J. w.</span>; <span class="NLM_string-name">Palmer, N. J.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Twigg, D. G.</span>; <span class="NLM_string-name">Woodhead, A. J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compounds</span>. <span class="NLM_patent">WO 2019/167000 A1</span>, Sep 6, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+N.+Johnson&author=I.+M.+Buck&author=G.+Chessari&author=J.+E.+H.+Day&author=H.+Fujiwara&author=C.+C.+F.+Hamlett&author=S.+D.+Hiscock&author=R.+S.+Holevy&author=S.+Howard&author=J.+w.+Liebeschuetz&author=N.+J.+Palmer&author=J.+D.+St+Denis&author=D.+G.+Twigg&author=A.+J.+Woodhead&title=Pharmaceutical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26atitle%3DPharmaceutical%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Boys, M. L.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Cook, A.</span>; <span class="NLM_string-name">Elsayed, M. S. A.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Hinklin, R. J.</span>; <span class="NLM_string-name">Mcnulty, O. T.</span>; <span class="NLM_string-name">Mejia, M. J.</span>; <span class="NLM_string-name">Rodriguez, M. E.</span>; <span class="NLM_string-name">Wong, C. E.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2020/081848 A1</span>, Apr 23, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+F.+Blake&author=M.+L.+Boys&author=M.+J.+Chicarelli&author=A.+Cook&author=M.+S.+A.+Elsayed&author=J.+B.+Fell&author=J.+P.+Fischer&author=R.+J.+Hinklin&author=O.+T.+Mcnulty&author=M.+J.+Mejia&author=M.+E.+Rodriguez&author=C.+E.+Wong&title=Protein+Tyrosine+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DProtein%2520Tyrosine%2520Phosphatase%2520Inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Bao, M.</span>; <span class="NLM_string-name">Yuan, Y.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Derivative Inhibitor, Preparation Method Therefor, and Application Thereof</span>. <span class="NLM_patent">WO 2020/073945 A1</span>, Apr 16, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Liu&author=M.+Bao&author=Y.+Yuan&author=Y.+Wang&author=Y.+Zhou&title=Bicyclic+Derivative+Inhibitor%2C+Preparation+Method+Therefor%2C+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DBicyclic%2520Derivative%2520Inhibitor%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Application%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10205</span>– <span class="NLM_lpage">10219</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10205-10219&author=J.+J.+Xieauthor=X.+J.+Siauthor=S.+L.+Guauthor=M.+L.+Wangauthor=J.+Shenauthor=H.+Y.+Liauthor=J.+Shenauthor=D.+Liauthor=Y.+J.+Fangauthor=C.+Liuauthor=J.+D.+Zhu&title=Allosteric+inhibitors+of+SHP2+with+therapeutic+potential+for+cancer+treatment&doi=10.1021%2Facs.jmedchem.7b01520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment</span></div><div class="casAuthors">Xie, Jingjing; Si, Xiaojia; Gu, Shoulai; Wang, Mingliang; Shen, Jian; Li, Haoyan; Li, Dan; Fang, Yanjia; Liu, Cong; Zhu, Jidong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10205-10219</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2, a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene, is involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways.  SHP2 has been shown to contribute to the progression of a no. of cancer types including leukemia, gastric, and breast cancers.  It also regulates T-cell activation by interacting with inhibitory immune checkpoint receptors such as the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA).  Thus, SHP2 inhibitors have drawn great attention by both inhibiting tumor cell proliferation and activating T cell immune responses toward cancer cells.  In this study, the authors report the identification of an allosteric SHP2 inhibitor I that locks SHP2 in a closed conformation by binding to the interface of the N-terminal SH2, C-terminal SH2, and phosphatase domains.  Compd. I suppresses MAPK signaling pathway and YAP transcriptional activity and shows antitumor activity in vivo.  The results indicate that allosteric inhibition of SHP2 could be a feasible approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWHA25LKpH7Vg90H21EOLACvtfcHk0likLuv7OhN1Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FM&md5=4aaabafae3250476b7bf3687d83cffd3</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01520%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BJ.%26aulast%3DSi%26aufirst%3DX.%2BJ.%26aulast%3DGu%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%2BD.%26atitle%3DAllosteric%2520inhibitors%2520of%2520SHP2%2520with%2520therapeutic%2520potential%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10205%26epage%3D10219%26doi%3D10.1021%2Facs.jmedchem.7b01520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argintaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual allosteric inhibition of SHP2 phosphatase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00980</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00980" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=647-656&author=M.+Fodorauthor=E.+Priceauthor=P.+Wangauthor=H.+Y.+Luauthor=A.+Argintaruauthor=Z.+L.+Chenauthor=M.+Glickauthor=H.+X.+Haoauthor=M.+Katoauthor=R.+Koenigauthor=J.+R.+LaRochelleauthor=G.+Liuauthor=E.+McNeillauthor=D.+Majumdarauthor=G.+A.+Nishiguchiauthor=L.+B.+Perezauthor=G.+Parisauthor=C.+M.+Quinnauthor=T.+Ramseyauthor=M.+Sendzikauthor=M.+D.+Shultzauthor=S.+L.+Williamsauthor=T.+Stamsauthor=S.+C.+Blacklowauthor=M.+G.+Ackerauthor=M.+J.+LaMarche&title=Dual+allosteric+inhibition+of+SHP2+phosphatase&doi=10.1021%2Facschembio.7b00980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dual allosteric inhibition of SHP2 phosphatase</span></div><div class="casAuthors">Fodor, Michelle; Price, Edmund; Wang, Ping; Lu, Hengyu; Argintaru, Andreea; Chen, Zhouliang; Glick, Meir; Hao, Huai-Xiang; Kato, Mitsunori; Koenig, Robert; La Rochelle, Jonathan R.; Liu, Gang; McNeill, Eric; Majumdar, Dyuti; Nishiguchi, Gisele A.; Perez, Lawrence B.; Paris, Gregory; Quinn, Christopher M.; Ramsey, Timothy; Sendzik, Martin; Shultz, Michael David; Williams, Sarah L.; Stams, Travis; Blacklow, Stephen C.; Acker, Michael G.; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival.  Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2.  SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small mol. inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2.  In this report, we describe further screening strategies that enabled the identification of a second, distinct small mol. allosteric site.  SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme.  X-ray crystallog. revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site-a cleft formed at the interface of the N-terminal SH2 and PTP domains.  Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochem. inhibition, and subsequent MAPK pathway modulation.  Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was obsd. in KYSE-520 cancer cells.  Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochem. inhibition expts. and X-ray crystallog.  Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacol. pathway inhibition in cells.  This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodol. and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdw7pTS6sOLVg90H21EOLACvtfcHk0lj3OArP4sJ2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D&md5=8e4de4c353b9fc196c81e1cb51e367df</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00980%26sid%3Dliteratum%253Aachs%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DH.%2BY.%26aulast%3DArgintaru%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DPerez%26aufirst%3DL.%2BB.%26aulast%3DParis%26aufirst%3DG.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DDual%2520allosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D647%26epage%3D656%26doi%3D10.1021%2Facschembio.7b00980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1125-1137&author=X.+Q.+Wuauthor=G.+Xuauthor=X.+B.+Liauthor=W.+R.+Xuauthor=Q.+J.+Liauthor=W.+Liuauthor=K.+A.+Kirbyauthor=M.+L.+Lohauthor=J.+Liauthor=S.+G.+Sarafianosauthor=C.+K.+Qu&title=Small+molecule+inhibitor+that+stabilizes+the+autoinhibited+conformation+of+the+oncogenic+tyrosine+phosphatase+SHP2&doi=10.1021%2Facs.jmedchem.8b00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span></div><div class="casAuthors">Wu Xiaoqin; Li Xiaobo; Li Qianjin; Qu Cheng-Kui; Xu Gang; Li Xiaobo; Xu Weiren; Liu Wei; Qu Cheng-Kui; Kirby Karen A; Sarafianos Stefan G; Loh Mignon L; Li Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1125-1137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias.  These mutations cause hyperactivation of SHP2 due to the disruption of the autoinhibitory conformation.  By targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor ( E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1 H-benzo[ d]imidazol-2(3 H)-one (LY6, 1) using computer-aided drug design database screening combined with cell-based assays.  This compound inhibited SHP2 with an IC50 value of 9.8 μM, 7-fold more selective for SHP2 than the highly related SHP1.  Fluorescence titration, thermal shift, and microscale thermophoresis quantitative binding assays confirmed its direct binding to SHP2.  This compound was further verified to effectively inhibit SHP2-mediated cell signaling and proliferation.  Furthermore, mouse and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than wild-type cells.  This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further optimization studies to develop novel anti-SHP2 therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0hz4mjYe4HMSzjBFCN0BJfW6udTcc2eZJj7yOz0oVwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D&md5=e05fd7589519ad6928eb769225b9a607</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00513%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%2BB.%26aulast%3DXu%26aufirst%3DW.%2BR.%26aulast%3DLi%26aufirst%3DQ.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DSmall%2520molecule%2520inhibitor%2520that%2520stabilizes%2520the%2520autoinhibited%2520conformation%2520of%2520the%2520oncogenic%2520tyrosine%2520phosphatase%2520SHP2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1125%26epage%3D1137%26doi%3D10.1021%2Facs.jmedchem.8b00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T.</span></span> <span> </span><span class="NLM_article-title">New method for fast and accurate binding-site identification and analysis</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00483.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1747-0285.2007.00483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17381729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=146-148&author=T.+Halgren&title=New+method+for+fast+and+accurate+binding-site+identification+and+analysis&doi=10.1111%2Fj.1747-0285.2007.00483.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">New method for fast and accurate binding-site identification and analysis</span></div><div class="casAuthors">Halgren, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-148</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset.  Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biol. effects or new class of compds.  It is also vital in lead optimization to clearly understand the degree to which known binders or docking hits satisfy or violate complementarity to the receptor.  SiteMap is a new technique for identifying potential binding sites and for predicting their druggability in lead-discovery applications and for characterizing binding sites and critically assessing prospective ligands in lead-optimization applications.  In large-scale validation tests, SiteMap correctly identifies the known binding site in > 96% of the cases, with best results (> 98%) coming for sites that bind ligands tightly.  It also accurately distinguishes between sites that bind ligands and sites that don't.  In binding-site anal., SiteMap provides a wealth of quant. and graphical information that can help guide efforts to modify ligand structure to enhance potency or improve phys. properties.  These attributes allow SiteMap to nicely complement techniques such as docking and computational lead optimization in structure-base drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr245hmZWXilrVg90H21EOLACvtfcHk0lj3OArP4sJ2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D&md5=c233276ba9580393b282f255781f9ce6</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00483.x%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%26atitle%3DNew%2520method%2520for%2520fast%2520and%2520accurate%2520binding-site%2520identification%2520and%2520analysis%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D69%26spage%3D146%26epage%3D148%26doi%3D10.1111%2Fj.1747-0285.2007.00483.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span> <span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0ljOkCWzXHCsHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faitg, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnamon, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnchembio.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24390428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=181-187&author=A.+G.+Gilmartinauthor=T.+H.+Faitgauthor=M.+Richterauthor=A.+Groyauthor=M.+A.+Seefeldauthor=M.+G.+Darcyauthor=X.+Pengauthor=K.+Federowiczauthor=J.+S.+Yangauthor=S.+Y.+Zhangauthor=E.+Minthornauthor=J.+P.+Jaworskiauthor=M.+Schaberauthor=S.+Martensauthor=D.+E.+McNultyauthor=R.+H.+Sinnamonauthor=H.+Zhangauthor=R.+B.+Kirkpatrickauthor=N.+Nevinsauthor=G.+L.+Cuiauthor=B.+Pietrakauthor=E.+Diazauthor=A.+Jonesauthor=M.+Brandtauthor=B.+Schwartzauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Allosteric+Wip1+phosphatase+inhibition+through+flap-subdomain+interaction&doi=10.1038%2Fnchembio.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span></div><div class="casAuthors">Gilmartin, Aidan G.; Faitg, Thomas H.; Richter, Mark; Groy, Arthur; Seefeld, Mark A.; Darcy, Michael G.; Peng, Xin; Federowicz, Kelly; Yang, Jingsong; Zhang, Shu-Yun; Minthorn, Elisabeth; Jaworski, Jon-Paul; Schaber, Michael; Martens, Stan; McNulty, Dean E.; Sinnamon, Robert H.; Zhang, Hong; Kirkpatrick, Robert B.; Nevins, Neysa; Cui, Guanglei; Pietrak, Beth; Diaz, Elsie; Jones, Amber; Brandt, Martin; Schwartz, Benjamin; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-187</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although therapeutic interventions of signal-transduction cascades with targeted kinase inhibitors are a well-established strategy, drug-discovery efforts to identify targeted phosphatase inhibitors have proven challenging.  Herein we report a series of allosteric, small-mol. inhibitors of wild-type p53-induced phosphatase (Wip1), an oncogenic phosphatase common to multiple cancers.  Compd. binding to Wip1 is dependent on a 'flap' subdomain located near the Wip1 catalytic site that renders Wip1 structurally divergent from other members of the protein phosphatase 2C (PP2C) family and that thereby confers selectivity for Wip1 over other phosphatases.  Treatment of tumor cells with the inhibitor GSK2830371 increases phosphorylation of Wip1 substrates and causes growth inhibition in both hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.  Oral administration of Wip1 inhibitors in mice results in expected pharmacodynamic effects and causes inhibition of lymphoma xenograft growth.  To our knowledge, GSK2830371 is the first orally active, allosteric inhibitor of Wip1 phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jXZXKTKTL7Vg90H21EOLACvtfcHk0ljOkCWzXHCsHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D&md5=47524caa70df233fb152a2d683417e7d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1427%26sid%3Dliteratum%253Aachs%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DFaitg%26aufirst%3DT.%2BH.%26aulast%3DRichter%26aufirst%3DM.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFederowicz%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%26aulast%3DJaworski%26aufirst%3DJ.%2BP.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DMartens%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DNevins%26aufirst%3DN.%26aulast%3DCui%26aufirst%3DG.%2BL.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DAllosteric%2520Wip1%2520phosphatase%2520inhibition%2520through%2520flap-subdomain%2520interaction%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D181%26epage%3D187%26doi%3D10.1038%2Fnchembio.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Selective detection of allosteric phosphatase inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">6838</span>– <span class="NLM_lpage">6841</span>, <span class="refDoi"> DOI: 10.1021/ja4030484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4030484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=6838-6841&author=R.+Schneiderauthor=C.+Beumerauthor=J.+R.+Simardauthor=C.+Grutterauthor=D.+Rauh&title=Selective+detection+of+allosteric+phosphatase+inhibitors&doi=10.1021%2Fja4030484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Detection of Allosteric Phosphatase Inhibitors</span></div><div class="casAuthors">Schneider, Ralf; Beumer, Claudia; Simard, Jeffrey R.; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6838-6841</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal cellular function, such as signal transduction, is largely controlled by the reversible phosphorylation of cellular proteins catalyzed by two major classes of enzymes, kinases and phosphatases.  A misbalance in this complex and dynamic interplay leads to a variety of severe diseases, such as cancer, inflammation, or autoimmune diseases.  This makes kinases as well as phosphatases equally attractive targets for therapeutic manipulation by small mols.  While the development of kinase inhibitors has resulted in several blockbuster drugs, such as imatinib, with remarkable success in the clinic and sales of many billions of U.S. dollars per yr, not a single phosphatase inhibitor has yet been approved for clin. use.  Similar to the kinase world, substrate-competitive phosphatase inhibitors have been developed but were not suitable for further development into clin. candidates due to their charge and limited selectivity.  Research efforts, therefore, have shifted to the exploitation of allosteric sites that can regulate phosphatase activity and may enable the discovery of novel modulators of phosphatase activity with much improved pharmacol. properties.  However, assay systems, which enable the straightforward discovery of these inhibitor types, are missing.  Here, we present a novel binding assay capable of detecting ligands of an allosteric pocket of the protein tyrosine phosphatase 1B.  This assay is suitable for high-throughput screening and selectively detects ligands which bind to this unique site with a clear discrimination from substrate-competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMMpcm8RfGWrVg90H21EOLACvtfcHk0ljOkCWzXHCsHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D&md5=49a980ad7f749718803f1afe1d8d1a04</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fja4030484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4030484%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBeumer%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DSelective%2520detection%2520of%2520allosteric%2520phosphatase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D6838%26epage%3D6841%26doi%3D10.1021%2Fja4030484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahr, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. K.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of protein tyrosine phosphatase 1B</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/nsmb803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnsmb803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15258570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=730-737&author=C.+Wiesmannauthor=K.+J.+Barrauthor=J.+Kungauthor=J.+Zhuauthor=D.+A.+Erlansonauthor=W.+Shenauthor=B.+J.+Fahrauthor=M.+Zhongauthor=L.+Taylorauthor=M.+Randalauthor=R.+S.+McDowellauthor=S.+K.+Hansen&title=Allosteric+inhibition+of+protein+tyrosine+phosphatase+1B&doi=10.1038%2Fnsmb803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Wiesmann, Christian; Barr, Kenneth J.; Kung, Jenny; Zhu, Jiang; Erlanson, Daniel A.; Shen, Wang; Fahr, Bruce J.; Zhong, Min; Taylor, Lisa; Randal, Mike; McDowell, Robert S.; Hansen, Stig K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Obesity and type II diabetes are closely linked metabolic syndromes that afflict >100 million people worldwide.  Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge.  Here we describe the discovery of an allosteric site in PTP1B.  Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located ∼20 Å from the catalytic site.  We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases.  Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells.  Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2mAdfb7Ou7Vg90H21EOLACvtfcHk0ljlNSMoNPm8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D&md5=abf4042d5dd49fa810ced16426d2bcb5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnsmb803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb803%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DKung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DFahr%26aufirst%3DB.%2BJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DR.%2BS.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D730%26epage%3D737%26doi%3D10.1038%2Fnsmb803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzosiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdardottir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolotti, A.</span></span> <span> </span><span class="NLM_article-title">Target-based discovery of an inhibitor of the regulatory phosphatase PPP1R15B</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2018.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30057111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2018&pages=1216-1228&author=A.+Krzyzosiakauthor=A.+Sigurdardottirauthor=L.+Luhauthor=M.+Carraraauthor=I.+Dasauthor=K.+Schneiderauthor=A.+Bertolotti&title=Target-based+discovery+of+an+inhibitor+of+the+regulatory+phosphatase+PPP1R15B&doi=10.1016%2Fj.cell.2018.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B</span></div><div class="casAuthors">Krzyzosiak, Agnieszka; Sigurdardottir, Anna; Luh, Laura; Carrara, Marta; Das, Indrajit; Schneider, Kim; Bertolotti, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1228.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein phosphorylation is a prevalent and ubiquitous mechanism of regulation.  Kinases are popular drug targets, but identifying selective phosphatase inhibitors has been challenging.  Here, we used surface plasmon resonance to design a method to enable target-based discovery of selective serine/threonine phosphatase inhibitors.  The method targeted a regulatory subunit of protein phosphatase 1, PPP1R15B, a neg. regulator of proteostasis.  This yielded Raphin1, a selective inhibitor of R15B.  In cells, Raphin1 caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis.  In vitro, Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment.  Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease.  This identifies R15B as a druggable target and provides a platform for target-based discovery of inhibitors of serine/threonine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnL1IexJPGE7Vg90H21EOLACvtfcHk0ljlNSMoNPm8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsLbL&md5=09415366927bac424f14e9cce05d9385</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DKrzyzosiak%26aufirst%3DA.%26aulast%3DSigurdardottir%26aufirst%3DA.%26aulast%3DLuh%26aufirst%3DL.%26aulast%3DCarrara%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DI.%26aulast%3DSchneider%26aufirst%3DK.%26aulast%3DBertolotti%26aufirst%3DA.%26atitle%3DTarget-based%2520discovery%2520of%2520an%2520inhibitor%2520of%2520the%2520regulatory%2520phosphatase%2520PPP1R15B%26jtitle%3DCell%26date%3D2018%26volume%3D174%26spage%3D1216%26epage%3D1228%26doi%3D10.1016%2Fj.cell.2018.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koveal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akshinthala, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kragelj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauss, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackledge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the disordered C terminus of PTP1B with an allosteric inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnchembio.1528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24845231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=558-566&author=N.+Krishnanauthor=D.+Kovealauthor=D.+H.+Millerauthor=B.+Xueauthor=S.+D.+Akshinthalaauthor=J.+Krageljauthor=M.+R.+Jensenauthor=C.+M.+Gaussauthor=R.+Pageauthor=M.+Blackledgeauthor=S.+K.+Muthuswamyauthor=W.+Petiauthor=N.+K.+Tonks&title=Targeting+the+disordered+C+terminus+of+PTP1B+with+an+allosteric+inhibitor&doi=10.1038%2Fnchembio.1528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the disordered C terminus of PTP1B with an allosteric inhibitor</span></div><div class="casAuthors">Krishnan, Navasona; Koveal, Dorothy; Miller, Daniel H.; Xue, Bin; Akshinthala, Sai Dipikaa; Kragelj, Jaka; Jensen, Malene Ringkjoebing; Gauss, Carla-Maria; Page, Rebecca; Blackledge, Martin; Muthuswamy, Senthil K.; Peti, Wolfgang; Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PTP1B, a validated therapeutic target for diabetes and obesity, has a crit. pos. role in HER2 signaling in breast tumorigenesis.  Efforts to develop therapeutic inhibitors of PTP1B have been frustrated by the chem. properties of the active site.  We define a new mechanism of allosteric inhibition that targets the C-terminal, noncatalytic segment of PTP1B.  We present what is to our knowledge the first ensemble structure of PTP1B contg. this intrinsically disordered segment, within which we identified a binding site for the small-mol. inhibitor MSI-1436.  We demonstrate binding to a second site close to the catalytic domain, with cooperative effects between the two sites locking PTP1B in an inactive state.  MSI-1436 antagonized HER2 signaling, inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2 mouse model of breast cancer, validating inhibition of PTP1B as a therapeutic strategy in breast cancer.  This new approach to inhibition of PTP1B emphasizes the potential of disordered segments of proteins as specific binding sites for therapeutic small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo526if7ja9XbVg90H21EOLACvtfcHk0lhOSBYPNg3VNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1ylsL8%253D&md5=10a460f3a5deafb9f7c206246d67a29b</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1528%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DN.%26aulast%3DKoveal%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BH.%26aulast%3DXue%26aufirst%3DB.%26aulast%3DAkshinthala%26aufirst%3DS.%2BD.%26aulast%3DKragelj%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DGauss%26aufirst%3DC.%2BM.%26aulast%3DPage%26aufirst%3DR.%26aulast%3DBlackledge%26aufirst%3DM.%26aulast%3DMuthuswamy%26aufirst%3DS.%2BK.%26aulast%3DPeti%26aufirst%3DW.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DTargeting%2520the%2520disordered%2520C%2520terminus%2520of%2520PTP1B%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D558%26epage%3D566%26doi%3D10.1038%2Fnchembio.1528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottini, N.</span></span> <span> </span><span class="NLM_article-title">Targeting tyrosine phosphatases: time to end the stigma</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.tips.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28412041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=524-540&author=S.+M.+Stanfordauthor=N.+Bottini&title=Targeting+tyrosine+phosphatases%3A+time+to+end+the+stigma&doi=10.1016%2Fj.tips.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tyrosine Phosphatases: Time to End the Stigma</span></div><div class="casAuthors">Stanford, Stephanie M.; Bottini, Nunzio</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">524-540</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are a family of enzymes essential for numerous cellular processes, and several PTPs have been validated as therapeutic targets for human diseases.  Historically, the development of drugs targeting PTPs has been highly challenging, leading to stigmatization of these enzymes as undruggable targets.  Despite these difficulties, efforts to drug PTPs have persisted, and recent years have seen an influx of new probes providing opportunities for biol. examn. of old and new PTP targets.  Here we discuss progress towards drugging PTPs with special emphasis on the development of selective probes with biol. activity.  We describe the development of new small-mol. orthosteric, allosteric, and oligomerization-inhibiting PTP inhibitors and discuss new studies targeting the receptor PTP (RPTP) subfamily with biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodaLAks9bm7LVg90H21EOLACvtfcHk0lhOSBYPNg3VNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWrtbc%253D&md5=539153cbe8845849b542a6d92bf2e7ed</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DS.%2BM.%26aulast%3DBottini%26aufirst%3DN.%26atitle%3DTargeting%2520tyrosine%2520phosphatases%253A%2520time%2520to%2520end%2520the%2520stigma%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D524%26epage%3D540%26doi%3D10.1016%2Fj.tips.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dempke, W. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uciechowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenchel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevassut, T.</span></span> <span> </span><span class="NLM_article-title">Targeting SHP-1, 2 and SHIP pathways: A novel strategy for cancer treatment?</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1159/000490106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1159%2F000490106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29925063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2018&pages=257-269&author=W.+C.+M.+Dempkeauthor=P.+Uciechowskiauthor=K.+Fenchelauthor=T.+Chevassut&title=Targeting+SHP-1%2C+2+and+SHIP+pathways%3A+A+novel+strategy+for+cancer+treatment%3F&doi=10.1159%2F000490106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?</span></div><div class="casAuthors">Dempke, Wolfram C. M.; Uciechowski, Peter; Fenchel, Klaus; Chevassut, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">257-269</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Well-balanced levels of tyrosine phosphorylation, maintained by the reversible and coordinated actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), are crit. for a wide range of cellular processes including growth, differentiation, metab., migration, and survival.  Aberrant tyrosine phosphorylation, as a result of a perturbed balance between the activities of PTKs and PTPs, is linked to the pathogenesis of numerous human diseases, including cancer, suggesting that PTPs may be innovative mol. targets for cancer treatment.  Two PTPs that have an important inhibitory role in haematopoietic cells are SHP-1 and SHP-2.  SHP-1, 2 promote cell growth and act by both upregulating pos. signaling pathways and by downregulating neg. signaling pathways.  SHIP is another inhibitory phosphatase that is specific for the inositol phospholipid phosphatidylinositol-3,4,5-trisphosphate (PIP3).  SHIP acts as a neg. regulator of immune response by hydrolyzing PIP3, and SHIP deficiency results in myeloproliferation and B-cell lymphoma in mice.  The validation of SHP-1, 2 and SHIP as oncol. targets has generated interest in the development of inhibitors as potential therapeutic agents for cancers; however, SHP-1, 2 and SHIP have proven to be an extremely difficult target for drug discovery, primarily due to the highly conserved and pos. charged nature of their PTP active site, and many PTP inhibitors lack either appro-priate selectivity or membrane permeability.  To overcome these caveats, novel techniques have been employed to synthesize new inhibitors that specifically attenuate the PTP-dependent signaling inside the cell and amongst them; some are already in clin. development which are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgI8vLcSbFQLVg90H21EOLACvtfcHk0lhOSBYPNg3VNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagur%252FP&md5=40b3d65498f4d5974235ef41b3fbc5a8</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1159%2F000490106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000490106%26sid%3Dliteratum%253Aachs%26aulast%3DDempke%26aufirst%3DW.%2BC.%2BM.%26aulast%3DUciechowski%26aufirst%3DP.%26aulast%3DFenchel%26aufirst%3DK.%26aulast%3DChevassut%26aufirst%3DT.%26atitle%3DTargeting%2520SHP-1%252C%25202%2520and%2520SHIP%2520pathways%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520treatment%253F%26jtitle%3DOncology%26date%3D2018%26volume%3D95%26spage%3D257%26epage%3D269%26doi%3D10.1159%2F000490106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulahannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T.</span></span> <span> </span><span class="NLM_article-title">The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a frst-in-man phase 1 clinical trial</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">S15</span>– <span class="NLM_lpage">S16</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.jtho.2019.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31864548" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=S15-S16&author=S.+I.+Ouauthor=M.+Koczywasauthor=S.+Ulahannanauthor=P.+Janneauthor=J.+Pachecoauthor=H.+Burrisauthor=C.+McCoachauthor=J.+S.+Wangauthor=M.+Gordonauthor=E.+Hauraauthor=J.+W.+Riessauthor=V.+Zhuauthor=K.+Ngauthor=S.+G.+Eckhardtauthor=A.+Capassoauthor=R.+Duaauthor=A.+Chenauthor=Z.+Wangauthor=J.+Hayesauthor=R.+Nicholsauthor=T.+Bivona&title=The+SHP2+inhibitor+RMC-4630+in+patients+with+KRAS-mutant+non-small+cell+lung+cancer%3A+preliminary+evaluation+of+a+frst-in-man+phase+1+clinical+trial&doi=10.1016%2Fj.jtho.2019.12.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DUlahannan%26aufirst%3DS.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DPacheco%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DRiess%26aufirst%3DJ.%2BW.%26aulast%3DZhu%26aufirst%3DV.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DCapasso%26aufirst%3DA.%26aulast%3DDua%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DR.%26aulast%3DBivona%26aufirst%3DT.%26atitle%3DThe%2520SHP2%2520inhibitor%2520RMC-4630%2520in%2520patients%2520with%2520KRAS-mutant%2520non-small%2520cell%2520lung%2520cancer%253A%2520preliminary%2520evaluation%2520of%2520a%2520frst-in-man%2520phase%25201%2520clinical%2520trial%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26spage%3DS15%26epage%3DS16%26doi%3D10.1016%2Fj.jtho.2019.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschhof, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembrough, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshetian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0022-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0022-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=968-977&author=G.+S.+Wongauthor=J.+Zhouauthor=J.+B.+Liuauthor=Z.+Wuauthor=X.+S.+Xuauthor=T.+X.+Liauthor=D.+Xuauthor=S.+E.+Schumacherauthor=J.+Puschhofauthor=J.+McFarlandauthor=C.+Zouauthor=A.+Dulakauthor=L.+Hendersonauthor=P.+Xuauthor=E.+O%E2%80%99Dayauthor=R.+Rendakauthor=W.+L.+Liaoauthor=F.+Cecchiauthor=T.+Hembroughauthor=S.+Schwartzauthor=C.+Szetoauthor=A.+K.+Rustgiauthor=K.+K.+Wongauthor=J.+A.+Diehlauthor=K.+Jensenauthor=F.+Grazianoauthor=A.+Ruzzoauthor=S.+Fereshetianauthor=P.+Mertinsauthor=S.+A.+Carrauthor=R.+Beroukhimauthor=K.+Nakamuraauthor=E.+Okiauthor=M.+Watanabeauthor=H.+Babaauthor=Y.+Imamuraauthor=D.+Catenacciauthor=A.+J.+Bass&title=Targeting+wild-type+KRAS-amplified+gastroesophageal+cancer+through+combined+MEK+and+SHP2+inhibition&doi=10.1038%2Fs41591-018-0022-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition</span></div><div class="casAuthors">Wong, Gabrielle S.; Zhou, Jin; Liu, Jie Bin; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven E.; Puschhof, Jens; McFarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit; Szeto, Christopher; Rustgi, Anil K.; Wong, Kwok-Kin; Diehl, J. Alan; Jensen, Karin; Graziano, Francesco; Ruzzo, Annamaria; Fereshetian, Shaunt; Mertins, Philipp; Carr, Steven A.; Beroukhim, Rameen; Nakamura, Kenichi; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo; Imamura, Yu; Catenacci, Daniel; Bass, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">968-977</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The role of KRAS, when activated through canonical mutations, has been well established in cancer1.  Here it explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations.  These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas2-4.  KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels.  Here it demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacol., can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings.  These data demonstrate the relevance of copy-no. amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTIe1Ygfy-ibVg90H21EOLACvtfcHk0lgdT-Gli0-ZoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvE&md5=9b0e728428d655cebea911300b5ed91a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0022-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0022-x%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DG.%2BS.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BB.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BX.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3DPuschhof%26aufirst%3DJ.%26aulast%3DMcFarland%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DDulak%26aufirst%3DA.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DE.%26aulast%3DRendak%26aufirst%3DR.%26aulast%3DLiao%26aufirst%3DW.%2BL.%26aulast%3DCecchi%26aufirst%3DF.%26aulast%3DHembrough%26aufirst%3DT.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DSzeto%26aufirst%3DC.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DDiehl%26aufirst%3DJ.%2BA.%26aulast%3DJensen%26aufirst%3DK.%26aulast%3DGraziano%26aufirst%3DF.%26aulast%3DRuzzo%26aufirst%3DA.%26aulast%3DFereshetian%26aufirst%3DS.%26aulast%3DMertins%26aufirst%3DP.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DOki%26aufirst%3DE.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DCatenacci%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520wild-type%2520KRAS-amplified%2520gastroesophageal%2520cancer%2520through%2520combined%2520MEK%2520and%2520SHP2%2520inhibition%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D968%26epage%3D977%26doi%3D10.1038%2Fs41591-018-0022-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wormann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, E. A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algul, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Y.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+Gorguluauthor=Z.+Dantesauthor=S.+M.+Wormannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Z.+van+der+Laanauthor=M.+P.+Lopez-Albercaauthor=M.+Nazareauthor=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Algul&title=Mutant+KRAS-driven+cancers+depend+on+PTPN11%2FSHP2+phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0ljVuKsZNks6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%2BY.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DGorgulu%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DWormann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%2BZ.%26aulast%3DLopez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlgul%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-driven%2520cancers%2520depend%2520on%2520PTPN11%252FSHP2%2520phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aaronson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2018.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30605687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=65-78&author=T.+A.+Ahmedauthor=C.+Adamopoulosauthor=Z.+Karouliaauthor=X.+W.+Wuauthor=R.+Sachidanandamauthor=S.+A.+Aaronsonauthor=P.+I.+Poulikakos&title=SHP2+Drives+Adaptive+Resistance+to+ERK+Signaling+Inhibition+in+Molecularly+Defined+Subsets+of+ERK-Dependent+Tumors&doi=10.1016%2Fj.celrep.2018.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors</span></div><div class="casAuthors">Ahmed, Tamer A.; Adamopoulos, Christos; Karoulia, Zoi; Wu, Xuewei; Sachidanandam, Ravi; Aaronson, Stuart A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pharmacol. targeting of components of ERK signaling in ERK-dependent tumors is often limited by adaptive resistance, frequently mediated by feedback-activation of RTK signaling and rebound of ERK activity.  Here, we show that combinatorial pharmacol. targeting of ERK signaling and the SHP2 phosphatase prevents adaptive resistance in defined subsets of ERK-dependent tumors.  In each tumor that was sensitive to combined treatment, p(Y542)SHP2 induction was obsd. in response to ERK signaling inhibition.  The strategy was broadly effective in TNBC models and tumors with RAS mutations at G12, whereas tumors with RAS(G13D) or RAS(Q61X) mutations were resistant.  In addn., we identified a subset of BRAF(V600E) tumors that were resistant to the combined treatment, in which FGFR was found to drive feedback-induced RAS activation, independently of SHP2.  Thus, we identify mol. determinants of response to combined ERK signaling and SHP2 inhibition in ERK-dependent tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqffbcbbR68qLVg90H21EOLACvtfcHk0ljVuKsZNks6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVegsg%253D%253D&md5=8c82efdc10ee2e0632d3ca9269bfb3d2</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DAdamopoulos%26aufirst%3DC.%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%2BW.%26aulast%3DSachidanandam%26aufirst%3DR.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DSHP2%2520Drives%2520Adaptive%2520Resistance%2520to%2520ERK%2520Signaling%2520Inhibition%2520in%2520Molecularly%2520Defined%2520Subsets%2520of%2520ERK-Dependent%2520Tumors%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D65%26epage%3D78%26doi%3D10.1016%2Fj.celrep.2018.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordjour, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbucher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1038/nm.4497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm.4497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29505033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=512-517&author=L.+Dardaeiauthor=H.+Q.+Wangauthor=M.+Singhauthor=P.+Fordjourauthor=K.+X.+Shawauthor=S.+Yodaauthor=G.+Kerrauthor=K.+Yuauthor=J.+S.+Liangauthor=Y.+C.+Caoauthor=Y.+Chenauthor=M.+S.+Lawrenceauthor=A.+Langenbucherauthor=J.+F.+Gainorauthor=L.+Fribouletauthor=I.+Dagogo-Jackauthor=D.+T.+Myersauthor=E.+Labrotauthor=D.+Ruddyauthor=M.+Parksauthor=D.+Leeauthor=R.+H.+DiCeccaauthor=S.+Moodyauthor=H.+X.+Haoauthor=M.+Mohseniauthor=M.+LaMarcheauthor=J.+Williamsauthor=K.+Hoffmasterauthor=G.+Caponigroauthor=A.+T.+Shawauthor=A.+N.+Hataauthor=C.+H.+Benesauthor=F.+Liauthor=J.+A.+Engelman&title=SHP2+inhibition+restores+sensitivity+in+ALK-rearranged+non-small-cell+lung+cancer+resistant+to+ALK+inhibitors&doi=10.1038%2Fnm.4497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors</span></div><div class="casAuthors">Dardaei, Leila; Wang, Hui Qin; Singh, Manrose; Fordjour, Paul; Shaw, Katherine X.; Yoda, Satoshi; Kerr, Grainne; Yu, Kristine; Liang, Jinsheng; Cao, Yichen; Chen, Yan; Lawrence, Michael S.; Langenbucher, Adam; Gainor, Justin F.; Friboulet, Luc; Dagogo-Jack, Ibiayi; Myers, David T.; Labrot, Emma; Ruddy, David; Parks, Melissa; Lee, Dana; Di Cecca, Richard H.; Moody, Susan; Hao, Huaixiang; Mohseni, Morvarid; LaMarche, Matthew; Williams, Juliet; Hoffmaster, Keith; Caponigro, Giordano; Shaw, Alice T.; Hata, Aaron N.; Benes, Cyril H.; Li, Fang; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-mol. ALK inhibitors, but drug resistance often develops.  Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approx. half harbor resistance mutations in ALK, while the other half have other mechanisms underlying resistance.  Members of the latter group often have activation of at least one of several different tyrosine kinases driving resistance.  Such tumors are not expected to respond to lorlatinib-a third-generation inhibitor targeting ALK that is able to overcome all clin. identified resistant mutations in ALK-and further therapeutic options are limited.  Herein, we deployed a shRNA screen of 1,000 genes in multiple ALK-inhibitor-resistant patient-derived cells (PDCs) to discover those that confer sensitivity to ALK inhibition.  This approach identified SHP2, a nonreceptor protein tyrosine phosphatase, as a common targetable resistance node in multiple PDCs.  SHP2 provides a parallel survival input downstream of multiple tyrosine kinases that promote resistance to ALK inhibitors.  Treatment with SHP099, the recently discovered small-mol. inhibitor of SHP2, in combination with the ALK tyrosine kinase inhibitor (TKI) ceritinib halted the growth of resistant PDCs through preventing compensatory RAS and ERK1 and ERK2 (ERK1/2) reactivation.  These findings suggest that combined ALK and SHP2 inhibition may be a promising therapeutic strategy for resistant cancers driven by several different ALK-independent mechanisms underlying resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBbW-AAzZ-grVg90H21EOLACvtfcHk0lg2avX4i1fvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu78%253D&md5=e40334532f10444b2df350345add9d0e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnm.4497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4497%26sid%3Dliteratum%253Aachs%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%2BQ.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DFordjour%26aufirst%3DP.%26aulast%3DShaw%26aufirst%3DK.%2BX.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DJ.%2BS.%26aulast%3DCao%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DLangenbucher%26aufirst%3DA.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DMyers%26aufirst%3DD.%2BT.%26aulast%3DLabrot%26aufirst%3DE.%26aulast%3DRuddy%26aufirst%3DD.%26aulast%3DParks%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DMoody%26aufirst%3DS.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DLaMarche%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DHoffmaster%26aufirst%3DK.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DSHP2%2520inhibition%2520restores%2520sensitivity%2520in%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520resistant%2520to%2520ALK%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D512%26epage%3D517%26doi%3D10.1038%2Fnm.4497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lg2avX4i1fvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0lgV6JDUHiZouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">What is the right dose? The elusive optimal biologic dose in phase I clinical trials</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4054</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.07.4658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1200%2FJCO.2006.07.4658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16943522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVantbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4054-4055&author=A.+A.+Adjei&title=What+is+the+right+dose%3F+The+elusive+optimal+biologic+dose+in+phase+I+clinical+trials&doi=10.1200%2FJCO.2006.07.4658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">What is the right dose? The elusive optimal biologic dose in phase I clinical trials</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4054-4055</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Carducci et al (2006) entitled "Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer" is reviewed with commentary and refs.  Carducci et al. found that total enzastaurin exposure increased with increasing concn. up to 240 mg and appeared to reach a plateau at 525 and 700 mg.  On the basis of plasma exposures, 525 mg was selected as the recommended phase II dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvHZhMTwjRg7Vg90H21EOLACvtfcHk0lgV6JDUHiZouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVantbzJ&md5=6aea6009e4816da5a024fac4fcba9d91</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.07.4658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.07.4658%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DWhat%2520is%2520the%2520right%2520dose%253F%2520The%2520elusive%2520optimal%2520biologic%2520dose%2520in%2520phase%2520I%2520clinical%2520trials%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4054%26epage%3D4055%26doi%3D10.1200%2FJCO.2006.07.4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berraondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etxeberria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilboa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melero, I.</span></span> <span> </span><span class="NLM_article-title">An RNA toolbox for cancer immunotherapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2018.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30190565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KksLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=751-767&author=F.+Pastorauthor=P.+Berraondoauthor=I.+Etxeberriaauthor=J.+Frederickauthor=U.+Sahinauthor=E.+Gilboaauthor=I.+Melero&title=An+RNA+toolbox+for+cancer+immunotherapy&doi=10.1038%2Fnrd.2018.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">An RNA toolbox for cancer immunotherapy</span></div><div class="casAuthors">Pastor, Fernando; Berraondo, Pedro; Etxeberria, Inaki; Frederick, Josh; Sahin, Ugur; Gilboa, Eli; Melero, Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-767</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has revolutionized oncol. practice.  However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety.  RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different mols.  These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches.  These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results.  RNA and RNA derivs. can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function.  Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogs, interference RNAs and protein-binding RNA aptamers.  These approaches are already in early clin. development with promising safety and efficacy results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfpXP7YjK3HLVg90H21EOLACvtfcHk0lgV6JDUHiZouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KksLvO&md5=8d6552734b7a329f0a6385519e343503</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.132%26sid%3Dliteratum%253Aachs%26aulast%3DPastor%26aufirst%3DF.%26aulast%3DBerraondo%26aufirst%3DP.%26aulast%3DEtxeberria%26aufirst%3DI.%26aulast%3DFrederick%26aufirst%3DJ.%26aulast%3DSahin%26aufirst%3DU.%26aulast%3DGilboa%26aufirst%3DE.%26aulast%3DMelero%26aufirst%3DI.%26atitle%3DAn%2520RNA%2520toolbox%2520for%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D751%26epage%3D767%26doi%3D10.1038%2Fnrd.2018.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jopling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geemen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hertog, J.</span></span> <span> </span><span class="NLM_article-title">Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2468</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.0030225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1371%2Fjournal.pgen.0030225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=2468-2476&author=C.+Joplingauthor=D.+van+Geemenauthor=J.+den+Hertog&title=Shp2+knockdown+and+Noonan%2FLEOPARD+mutant+Shp2-induced+gastrulation+defects&doi=10.1371%2Fjournal.pgen.0030225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects</span></div><div class="casAuthors">Jopling, Chris; van Geemen, Daphne; den Hertog, Jeroen</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2468-2476</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Shp2 is a cytoplasmic protein tyrosine phosphatase that is essential for normal development.  Activating and inactivating mutations have been identified in humans to cause the related Noonan and LEOPARD syndromes, resp.  The cell biol. cause of these syndromes remains to be detd.  The authors have used the zebrafish to assess the role of Shp2 in early development.  Here, the authors report that morpholino-mediated knockdown of Shp2 in zebrafish resulted in defects during gastrulation.  Cell tracing expts. demonstrated that Shp2 knockdown induced defects in convergence and extension cell movements.  In situ hybridization using a panel of markers indicated that cell fate was not affected by Shp2 knock down.  The Shp2 knockdown-induced defects were rescued by active Fyn and Yes and by active RhoA.  The authors generated mutants of Shp2 with mutations that were identified in human patients with Noonan or LEOPARD Syndrome and established that Noonan Shp2 was activated and LEOPARD Shp2 lacked catalytic protein tyrosine phosphatase activity.  Expression of Noonan or LEOPARD mutant Shp2 in zebrafish embryos induced convergence and extension cell movement defects without affecting cell fate.  Moreover, these embryos displayed craniofacial and cardiac defects, reminiscent of human symptoms.  Noonan and LEOPARD mutant Shp2s were not additive nor synergistic, consistent with the mutant Shp2s having activating and inactivating roles in the same signaling pathway.  The authors' results demonstrate that Shp2 is required for normal convergence and extension cell movements during gastrulation and that Src family kinases and RhoA were downstream of Shp2.  Expression of Noonan or LEOPARD Shp2 phenocopied the craniofacial and cardiac defects of human patients.  The finding that defective Shp2 signaling induced cell movement defects as early as gastrulation may have implications for the monitoring and diagnosis of Noonan and LEOPARD syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusv3uhpPLi7Vg90H21EOLACvtfcHk0lgBNhKTHZPXRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslajuw%253D%253D&md5=a64d91c3fe9b12589971d6bdabc1399c</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.0030225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.0030225%26sid%3Dliteratum%253Aachs%26aulast%3DJopling%26aufirst%3DC.%26aulast%3Dvan%2BGeemen%26aufirst%3DD.%26aulast%3Dden%2BHertog%26aufirst%3DJ.%26atitle%3DShp2%2520knockdown%2520and%2520Noonan%252FLEOPARD%2520mutant%2520Shp2-induced%2520gastrulation%2520defects%26jtitle%3DPLoS%2520Genet.%26date%3D2007%26volume%3D3%26spage%3D2468%26epage%3D2476%26doi%3D10.1371%2Fjournal.pgen.0030225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. S.</span></span> <span> </span><span class="NLM_article-title">Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro</span>. <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.oooo.2013.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.oooo.2013.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24439919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2czmvFertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=234-242&author=H.+J.+Xieauthor=S.+Y.+Huangauthor=W.+G.+Liauthor=H.+B.+Zhaoauthor=T.+Q.+Zhangauthor=D.+S.+Zhang&title=Upregulation+of+Src+homology+phosphotyrosyl+phosphatase+2+%28Shp2%29+expression+in+oral+cancer+and+knockdown+of+Shp2+expression+inhibit+tumor+cell+viability+and+invasion+in+vitro&doi=10.1016%2Fj.oooo.2013.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro</span></div><div class="casAuthors">Xie Hongjun; Huang Shengyun; Li Wengang; Zhao Hongbo; Zhang Tianqi; Zhang Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oral surgery, oral medicine, oral pathology and oral radiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">234-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study investigated the clinical significance of Shp2 protein expression in oral squamous cell carcinoma (OSCC) and elucidated its biologic significance in OSCC cells.  STUDY DESIGN:  A total of 88 OSCC cases were used to assess Shp2 expression, out of which 70 were for immunohistochemistry and 18 paired tumors vs normal tissues were for Western blot of Shp2 expression.  OSCC cells were used to assess the effects of Shp2 knockdown for cell viability, apoptosis, invasion, and protein expressions.  RESULTS:  Expression of Shp2 protein was significantly upregulated in OSCC tissues compared with the normal tissues, and Shp2 overexpression was associated with advanced tumor clinical stages and lymph node metastasis ex vivo.  Knockdown of Shp2 expression in vitro inhibited OSCC cell viability and invasion but induced apoptosis by regulating expression of the apoptosis-related proteins.  CONCLUSIONS:  The data indicated that Shp2 may play an important role in OSCC progression.  Further studies will investigate whether a target of Shp2 expression could be a novel therapeutic strategy for clinical control of OSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoyRSzjCk5vMK3uFsUIZtkfW6udTcc2eYUyxgvFZL837ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmvFertQ%253D%253D&md5=02f04e0fc7b5196b50ccb309146de287</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.oooo.2013.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oooo.2013.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DW.%2BG.%26aulast%3DZhao%26aufirst%3DH.%2BB.%26aulast%3DZhang%26aufirst%3DT.%2BQ.%26aulast%3DZhang%26aufirst%3DD.%2BS.%26atitle%3DUpregulation%2520of%2520Src%2520homology%2520phosphotyrosyl%2520phosphatase%25202%2520%2528Shp2%2529%2520expression%2520in%2520oral%2520cancer%2520and%2520knockdown%2520of%2520Shp2%2520expression%2520inhibit%2520tumor%2520cell%2520viability%2520and%2520invasion%2520in%2520vitro%26jtitle%3DOral%2520Surg.%2520Oral%2520Med.%2520Oral%2520Pathol.%2520Oral%2520Radiol.%26date%3D2014%26volume%3D117%26spage%3D234%26epage%3D242%26doi%3D10.1016%2Fj.oooo.2013.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R. F.</span></span> <span> </span><span class="NLM_article-title">Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">395</span>, <span class="refDoi"> DOI: 10.3390/ijms18020395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.3390%2Fijms18020395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=395&author=X.+Sunauthor=J.+Zhangauthor=Z.+Y.+Wangauthor=W.+Jiauthor=R.+Tianauthor=F.+Zhangauthor=R.+F.+Niu&title=Shp2+plays+a+critical+role+in+IL-6-induced+EMT+in+breast+cancer+cells&doi=10.3390%2Fijms18020395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells</span></div><div class="casAuthors">Sun, Xuan; Zhang, Jie; Wang, Zhiyong; Ji, Wei; Tian, Ran; Zhang, Fei; Niu, Ruifang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395/1-395/16</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Accumulative evidence demonstrates that the protein tyrosine phosphatase Shp2 functions as a powerful tumor promoter in many types of cancers.  Abnormal expression of Shp2 has been implicated in many human malignancies.  Overexpression of Shp2 in cancer tissues is correlated with cancer metastasis, resistance to targeted therapy, and poor prognosis.  The well-known function of Shp2 is its pos. role in regulating cellular signaling initiated by growth factors and cytokines, including interleukin-6 (IL-6).  Several recent studies have shown that Shp2 is required for epithelial-mesenchymal transition (EMT), triggered by growth factors.  However, whether Shp2 is involved in IL-6-signaling-promoted breast cancer EMT and progression, remains undefined.  In this study, we showed that exogenous and endogenous IL-6 can enhance breast cancer invasion and migration, through the promotion of EMT.  IL-6 also induces the activation of Erk1/2 and the phosphorylation of Shp2.  Knockdown of Shp2 attenuated the IL-6-induced downregulation of E-cadherin, as well as IL-6-promoted cell migration and invasion.  Moreover, by using Shp2 phosphatase mutants, phosphor-tyrosine mimicking, and deficiency mutants, we provided evidence that the phosphatase activity of Shp2 and its tyrosine phosphorylation, are necessary for the IL-6-induced downregulation of E-cadherin and the phosphorylation of Erk1/2.  Our findings uncover an important function that links Shp2 to IL-6-promoted breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozWl0u0pgApLVg90H21EOLACvtfcHk0li92LicE7viIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSgsLg%253D&md5=4b6ae20d32ee9a910efa433686b27a3b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms18020395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020395%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DJi%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DR.%2BF.%26atitle%3DShp2%2520plays%2520a%2520critical%2520role%2520in%2520IL-6-induced%2520EMT%2520in%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D395%26doi%3D10.3390%2Fijms18020395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0li92LicE7viIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0li92LicE7viIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macartney, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G. P.</span></span> <span> </span><span class="NLM_article-title">Targeting endogenous proteins for degradation through the affinity-directed protein missile system</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">170066</span>, <span class="refDoi"> DOI: 10.1098/rsob.170066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1098%2Frsob.170066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28490657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVaktLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=170066&author=L.+J.+Fulcherauthor=L.+D.+Hutchinsonauthor=T.+J.+Macartneyauthor=C.+Turnbullauthor=G.+P.+Sapkota&title=Targeting+endogenous+proteins+for+degradation+through+the+affinity-directed+protein+missile+system&doi=10.1098%2Frsob.170066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting endogenous proteins for degradation through the affinity-directed protein missile system</span></div><div class="casAuthors">Fulcher, Luke J.; Hutchinson, Luke D.; Macartney, Thomas J.; Turnbull, Craig; Sapkota, Gopal P.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">170066/1-170066/11</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics.  CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes.  Similarly, RNAinterference approaches necessitate prolonged treatments, can lead to incomplete knockdowns and are often assocd. with off-target effects.  Targeted proteolysis can overcome these limitations.  In this report,we describe an affinity-directed protein missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degrdn.  By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degrdn. of endogenous SHP2 and ASC in human cell lines.  We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biol.  This study demonstrates for the first time that small polypeptide binders that selectively recognize endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1fku-pJ3ORLVg90H21EOLACvtfcHk0lg8clDM6FM7ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVaktLzM&md5=3fcb8b661243ff13f9d8f6e2cca29125</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1098%2Frsob.170066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.170066%26sid%3Dliteratum%253Aachs%26aulast%3DFulcher%26aufirst%3DL.%2BJ.%26aulast%3DHutchinson%26aufirst%3DL.%2BD.%26aulast%3DMacartney%26aufirst%3DT.%2BJ.%26aulast%3DTurnbull%26aufirst%3DC.%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26atitle%3DTargeting%2520endogenous%2520proteins%2520for%2520degradation%2520through%2520the%2520affinity-directed%2520protein%2520missile%2520system%26jtitle%3DOpen%2520Biol.%26date%3D2017%26volume%3D7%26spage%3D170066%26doi%3D10.1098%2Frsob.170066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+D.+Shenauthor=W.+X.+Chenauthor=J.+L.+Zhuauthor=G.+F.+Wuauthor=R.+P.+Shenauthor=M.+Y.+Xiauthor=H.+P.+Sun&title=Therapeutic+potential+of+targeting+SHP2+in+human+developmental+disorders+and+cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0lg8clDM6FM7ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BD.%26aulast%3DChen%26aufirst%3DW.%2BX.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DG.%2BF.%26aulast%3DShen%26aufirst%3DR.%2BP.%26aulast%3DXi%26aufirst%3DM.%2BY.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520SHP2%2520in%2520human%2520developmental%2520disorders%2520and%2520cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Nattawadee Chaisan, Sureeporn Ruengsangtongkul, Jumreang Tummatorn, Somsak Ruchirawat, Kittipong Chainok, <span class="NLM_string-name hlFld-ContribAuthor">Charnsak Thongsornkleeb</span>. </span><span class="cited-content_cbyCitation_article-title">Dibrominative Spirocyclization of 2-Butynolyl Anilides: Synthesis of gem-Dibromospirocyclic Benzo[d][1,3]oxazines and Their Application in the Synthesis of 4H-Furo[3,2-b]indoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (6)
                                     , 4671-4698. <a href="https://doi.org/10.1021/acs.joc.1c00086" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00086%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDibrominative%252BSpirocyclization%252Bof%252B2-Butynolyl%252BAnilides%25253A%252BSynthesis%252Bof%252Bgem-Dibromospirocyclic%252BBenzo%25255Bd%25255D%25255B1%25252C3%25255Doxazines%252Band%252BTheir%252BApplication%252Bin%252Bthe%252BSynthesis%252Bof%252B4H-Furo%25255B3%25252C2-b%25255Dindoles%26aulast%3DChaisan%26aufirst%3DNattawadee%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D12012021%26date%3D10032021%26volume%3D86%26issue%3D6%26spage%3D4671%26epage%3D4698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yelena Mostinski, Guus J. J. E. Heynen, Maria Pascual López-Alberca, Jerome Paul, Sandra Miksche, Silke Radetzki, David Schaller, Elena Shanina, Carola Seyffarth, Yuliya Kolomeets, Nandor Ziebart, Judith de Schryver, Sylvia Oestreich, Martin Neuenschwander, Yvette Roske, Udo Heinemann, Christoph Rademacher, Andrea Volkamer, Jens Peter von Kries, Walter Birchmeier, <span class="NLM_string-name hlFld-ContribAuthor">Marc Nazaré</span>. </span><span class="cited-content_cbyCitation_article-title">From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14780-14804. <a href="https://doi.org/10.1021/acs.jmedchem.0c01265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01265%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BPyrazolones%252Bto%252BAzaindoles%25253A%252BEvolution%252Bof%252BActive-Site%252BSHP2%252BInhibitors%252BBased%252Bon%252BScaffold%252BHopping%252Band%252BBioisosteric%252BReplacement%26aulast%3DMostinski%26aufirst%3DYelena%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28072020%26date%3D19112020%26volume%3D63%26issue%3D23%26spage%3D14780%26epage%3D14804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yizhe  Wu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Zhichao  Pan</span>, <span class="hlFld-ContribAuthor ">Shichun  Zhong</span>, <span class="hlFld-ContribAuthor ">Xinxin  Jin</span>, <span class="hlFld-ContribAuthor ">Weihao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Sikang  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113637. <a href="https://doi.org/10.1016/j.ejmech.2021.113637" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113637%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bphenyl-linked%252Bsymmetric%252Bsmall%252Bmolecules%252Bas%252Binhibitors%252Bof%252Bthe%252Bprogrammed%252Bcell%252Bdeath-1%25252Fprogrammed%252Bcell%252Bdeath-ligand%252B1%252Binteraction%26aulast%3DWu%26aufirst%3DYizhe%26date%3D2021%26volume%3D223%26spage%3D113637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Yaping  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jianjun  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: From Catalytic Site Inhibitors to Allosteric Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (22)
                                     , 5504-5523. <a href="https://doi.org/10.1002/slct.202100186" title="DOI URL">https://doi.org/10.1002/slct.202100186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100186%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DCross%252Bthe%252BUndruggable%252BBarrier%25252C%252Bthe%252BDevelopment%252Bof%252BSHP2%252BInhibitors%25253A%252BFrom%252BCatalytic%252BSite%252BInhibitors%252Bto%252BAllosteric%252BInhibitors%26aulast%3DGuo%26aufirst%3DYu%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D22%26spage%3D5504%26epage%3D5523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyu Sic  You</span>, <span class="hlFld-ContribAuthor ">Yong Weon  Yi</span>, <span class="hlFld-ContribAuthor ">Jeonghee  Cho</span>, <span class="hlFld-ContribAuthor ">Jeong-Soo  Park</span>, <span class="hlFld-ContribAuthor ">Yeon-Sun  Seong</span>. </span><span class="cited-content_cbyCitation_article-title">Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (6)
                                     , 589. <a href="https://doi.org/10.3390/ph14060589" title="DOI URL">https://doi.org/10.3390/ph14060589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14060589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14060589%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DPotentiating%252BTherapeutic%252BEffects%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibition%252Bin%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DYou%26aufirst%3DKyu%2BSic%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D6%26spage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Nian</span>, <span class="hlFld-ContribAuthor ">Jinhao  Zeng</span>, <span class="hlFld-ContribAuthor ">Li  He</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fernando  Rodrigues-Lima</span>, <span class="hlFld-ContribAuthor ">Liyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Xuanlin  Feng</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>32 </em>
                                    (5)
                                     , 1645-1652. <a href="https://doi.org/10.1016/j.cclet.2021.01.002" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.01.002%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DA%252Bsmall%252Bmolecule%252Binhibitor%252Btargeting%252BSHP2%252Bmutations%252Bfor%252Bthe%252Blung%252Bcarcinoma%26aulast%3DNian%26aufirst%3DQing%26date%3D2021%26volume%3D32%26issue%3D5%26spage%3D1645%26epage%3D1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zeng</span>, <span class="hlFld-ContribAuthor ">Hongwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yunwei  Han</span>. </span><span class="cited-content_cbyCitation_article-title">The role of exosomal PD-L1 in tumor immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 101047. <a href="https://doi.org/10.1016/j.tranon.2021.101047" title="DOI URL">https://doi.org/10.1016/j.tranon.2021.101047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2021.101047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2021.101047%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DThe%252Brole%252Bof%252Bexosomal%252BPD-L1%252Bin%252Btumor%252Bimmunotherapy%26aulast%3DWang%26aufirst%3DJing%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D101047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Liu</span>, <span class="hlFld-ContribAuthor ">Shan  Gao</span>, <span class="hlFld-ContribAuthor ">Reham M.  Elhassan</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome drug resistance using SHP2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>27 </em><a href="https://doi.org/10.1016/j.apsb.2021.03.037" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.03.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.03.037%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DStrategies%252Bto%252Bovercome%252Bdrug%252Bresistance%252Busing%252BSHP2%252Binhibitors%26aulast%3DLiu%26aufirst%3DMeng%26date%3D2021%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaohe  Yang</span>, <span class="hlFld-ContribAuthor ">Yali  Wang</span>, <span class="hlFld-ContribAuthor ">Yueying  Yang</span>, <span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Lixia  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting SHP2 as a therapeutic strategy for inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113264. <a href="https://doi.org/10.1016/j.ejmech.2021.113264" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113264%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BSHP2%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Binflammatory%252Bdiseases%26aulast%3DLiu%26aufirst%3DYang%26date%3D2021%26volume%3D214%26spage%3D113264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Se Jeong  Kwon</span>, <span class="hlFld-ContribAuthor ">Dohee  Ahn</span>, <span class="hlFld-ContribAuthor ">Hyun-Mo  Yang</span>, <span class="hlFld-ContribAuthor ">Hyo Jin  Kang</span>, <span class="hlFld-ContribAuthor ">Sang J.  Chung</span>. </span><span class="cited-content_cbyCitation_article-title">Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2). </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (4)
                                     , 848. <a href="https://doi.org/10.3390/molecules26040848" title="DOI URL">https://doi.org/10.3390/molecules26040848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26040848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26040848%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPolyphyllin%252BD%252BShows%252BAnticancer%252BEffect%252Bthrough%252Ba%252BSelective%252BInhibition%252Bof%252BSrc%252BHomology%252BRegion%252B2-Containing%252BProtein%252BTyrosine%252BPhosphatase-2%252B%252528SHP2%252529%26aulast%3DKwon%26aufirst%3DSe%2BJeong%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D4%26spage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">祥东  孟</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Evaluation of Aminobenzoic Acid Derivatives against SHP2. </span><span class="cited-content_cbyCitation_journal-name">Hans Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>09 </em>
                                    (02)
                                     , 87-93. <a href="https://doi.org/10.12677/HJMCe.2021.92011" title="DOI URL">https://doi.org/10.12677/HJMCe.2021.92011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/HJMCe.2021.92011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FHJMCe.2021.92011%26sid%3Dliteratum%253Aachs%26jtitle%3DHans%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiological%252BEvaluation%252Bof%252BAminobenzoic%252BAcid%252BDerivatives%252Bagainst%252BSHP2%26aulast%3D%25E5%25AD%259F%26aufirst%3D%25E7%25A5%25A5%25E4%25B8%259C%26date%3D2021%26volume%3D09%26issue%3D02%26spage%3D87%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Tang</span>, <span class="hlFld-ContribAuthor ">Yao-Nan  Jia</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112657. <a href="https://doi.org/10.1016/j.ejmech.2020.112657" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112657</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112657%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252Bchemistry%252Bstrategies%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bprotein%252Btyrosine%252Bphosphatase%252BSHP2%252Binhibitors%252Band%252BPROTAC%252Bdegraders%26aulast%3DTang%26aufirst%3DKai%26date%3D2020%26volume%3D204%26spage%3D112657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Pardella</span>, <span class="hlFld-ContribAuthor ">Erica  Pranzini</span>, <span class="hlFld-ContribAuthor ">Angela  Leo</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Taddei</span>, <span class="hlFld-ContribAuthor ">Paolo  Paoli</span>, <span class="hlFld-ContribAuthor ">Giovanni  Raugei</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2799. <a href="https://doi.org/10.3390/cancers12102799" title="DOI URL">https://doi.org/10.3390/cancers12102799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102799%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DOncogenic%252BTyrosine%252BPhosphatases%25253A%252BNovel%252BTherapeutic%252BTargets%252Bfor%252BMelanoma%252BTreatment%26aulast%3DPardella%26aufirst%3DElisa%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Sequence alignment of SHP1 and SHP2 PTP catalytic domains. Identical and similar residues are red and pink. (B) Overview of the native human SHP2 domains. SHP2 contains two SH2 domains (N-SH2 and C-SH2), a PTP catalytic domain, and a C-terminal tail containing two tyrosine phosphorylation sites (Tyr542 and Tyr580).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Schematic illustration of SHP2 mutations in various cancers (e.g., AML, JMML, and ALL) and NS. (B) Frequency of missense mutations in SHP2 in 1182 of 1677 tumor samples (∼75.5%) curated in COSMIC v91 (<a href="https://cancer.sanger.ac.uk/cosmic" class="extLink">https://cancer.sanger.ac.uk/cosmic</a>). Purple and orange bars correspond to the amino acid mutations in cancer and NS listed in (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Schematic illustration of SHP2-associated growth factor dependent signaling pathways, RAS/Raf/ERK and PI3K/AKT. (B) Schematic illustration of SHP2-associated immune dependent signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Alignment of the PTP domain in SHP2 based on reported crystal structures (<i>n</i> = 50) of wild-type, mutant SHP2 with or without ligands at the binding sites. Some of the N-SH2 domain in SHP2 are not shown for clarity. (B) Same with (A) but the catalytic PTP domain of SHP1 (<i>n</i> = 9) is shown. (C) Comparison of the PTP domains between SHP1 (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PS5">3PS5</a><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) and SHP2 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP">2SHP</a><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a>). Residue differences between SHP1 and SHP2 are depicted in the stick model and labeled (top, SHP1; bottom, SHP2). A phosphate ion (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GRZ">4GRZ</a><a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a>) is shown to refer to the location of the phosphate group in the pTyr peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Alignment of 117 PTP1B structures with or without ligands and different temperatures reported by Fraser’s group.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> A PTP1B inhibitor (5b) is shown to indicate the binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T19">5T19</a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (B) Comparison of the PTP domain binding sites between SHP1 (orange), SHP2 (green), and PTP1B (cyan). The backbone structure of SHP1 is not shown for clarity. Residues differing between SHP1, SHP2, and PTP1B are depicted as the stick model and labeled. A PTP1B inhibitor (LZP-25, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EB1">3EB1</a>) is displayed for comparison.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Autoinhibitory conformation of SHP2. D′E loop of N-SH2 domain extends into the catalytic pocket of the PTP domain; D′E loop is cyan; pTyr loop is orange; P loop is magenta; WPD loop is blue; Q loop is green. (B) Hydrogen bond interactions between the residues in the PTP and N-SH2 domains. Hydrogen bonds are depicted in yellow dashed lines. (C) Inactive state of N-SH2 domain and the active state of N-SH2 domain. In the inactive state, the closure of the EF loop (66–68) and BG loop (89–92) blocks the binding site of the pTyr peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Organization of the N-SH2 (blue), the C-SH2 (red), and the PTP domain (green) in the autoinhibited (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMV">6BMV</a>) and activated (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O">3B7O</a>) state of SHP2. The structure of N-SH2 and the Gab1 peptide (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4QSY">4QSY</a>) is aligned with N-SH2, C-SH2 to show the binding sites of the pY motif. Activation via the signaling at the cell membrane is illustrated as an example. SHP2 can also be activated by cytosolic molecules or in the mitochondria. Y denotes a tyrosine residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mapped locations of reported amino acid mutations in hematological (yellow) and solid (purple) tumors in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A using the autoinhibited SHP2 structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and IC<sub>50</sub> values of compounds <b>1</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and IC<sub>50</sub> values of compounds <b>7</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Progressive development of compounds <b>11</b>–<b>17</b> and the binding model of <b>17</b> with SHP2. The binding model of <b>17</b> (green) with SHP2 (gray) is reproduced in reference to the work published by Grosskopf et al. using the crystal structure of SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3">3ZM3</a>) and the Glide program.<a onclick="showRef(event, 'ref115 ref116 ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117 ref118">(115−118)</a> Alignment of the crystal structure of malate (orange) with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O">3B7O</a>)<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3">3ZM3</a>) highlights the location of the potential phosphate group in pTyr. Hydrogen bonds are depicted by cyan dashed lines. The view of the model is oriented similarly to that reported in Grosskopf et al.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures and IC<sub>50</sub> values of <b>18</b>–<b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and IC<sub>50</sub> values of compounds <b>22</b>–<b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) X-ray crystallography structure of <b>23</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X">3O5X</a>). (B) Alignment of SHP2/23 with SHP1/JAK1<sub>AL</sub> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GS0">4GS0</a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> JAK1<sub>AL</sub> is a JAK1 activation loop peptide containing a difluorophosphonomethyl phenylalanine group mimicking phosphotyrosine. (C) X-ray crystallography structure of <b>11c-9</b> (an analog of <b>27</b>) with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PVG">4PVG</a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> (D) Alignment of SHP2/<b>11c-9</b> with SHP1/JAK1<sub>AL</sub>. The P, WPD, Q, pY loops, and the β5−β6 loop are colored in pink, blue, green, orange, light green, respectively. Amino acids interact with the ligands are shown in the stick models and labeled. Water molecules are depicted as red spheres. Hydrogen bonds are shown as cyan dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and IC<sub>50</sub> values of compounds <b>27</b>–<b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Structures and IC<sub>50</sub> values of <b>32</b>–<b>34</b>. (B) X-ray crystallography structure of <b>33</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RDD">4RDD</a><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a>). Water molecules are shown in red spheres, and hydrogen bonds are depicted as cyan dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures and IC<sub>50</sub> values of compounds <b>35</b>–<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures and IC<sub>50</sub> values of compounds <b>38</b>–<b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. (A) X-ray crystallography structure of <b>38</b> with SHP2 in the close conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a><a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>). (B) Binding mode of <b>38</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>). (C) Binding mode of <b>46</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures, IC<sub>50</sub> values, and development paths of compounds <b>49</b>–<b>55</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. (A) Structures, IC<sub>50</sub> values, and development paths of compounds <b>56</b>–<b>59</b>. (B) X-ray crystallography structure of <b>59</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDC">6MDC</a><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures and IC<sub>50</sub> values of <b>60</b>–<b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures and IC<sub>50</sub> values of compounds <b>63</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and IC<sub>50</sub> values of <b>71</b>–<b>77</b>. Novelty of the compounds is highlighted by the red color.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures and IC<sub>50</sub> values of <b>78</b>–<b>92</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Allosteric binding sites in the autoinhibitory conformation of SHP2. (B) Structures and IC<sub>50</sub> values of <b>93</b>–<b>96</b>. (C) X-ray crystallography structure of <b>93</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMR">6BMR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A) Larger potential allosteric binding site (cyan spheres) in SHP2 identified using the Sitemap program. This is reproduced by using the SHP2 structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR">5EHR</a><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a>) and the Sitemap program from the Schrodinger program suite in reference to Wu et al.’s work.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> (B) Identification of compounds <b>97</b>–<b>100</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/medium/jm0c00249_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and IC<sub>50</sub> values of compounds <b>101</b>–<b>104</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00249/20201019/images/large/jm0c00249_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00249&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 185 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Tyrosine-phosphorylation: thirty years and counting</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2009.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ceb.2009.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19269802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=140-146&author=T.+Hunter&title=Tyrosine-phosphorylation%3A+thirty+years+and+counting&doi=10.1016%2Fj.ceb.2009.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphorylation: thirty years and counting</span></div><div class="casAuthors">Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-146</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the 30 years since its discovery, tyrosine phosphorylation has emerged as a fundamentally important mechanism of signal transduction and regulation in all eukaryotic cells, governing many processes, including cell proliferation, cell cycle progression, metabolic homeostasis, transcriptional activation, neural transmission, differentiation and development, and aging.  Perturbations in tyrosine phosphorylation underlie many human diseases, and in particular cancer, and this has prompted the development of inhibitors of tyrosine kinases implicated in disease, a no. of which were approved for clin. use.  The following is a brief personal reflection on some of the salient findings over the past 30 years that led to the development of tyrosine kinase inhibitors for disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozf_yslNwApbVg90H21EOLACvtfcHk0ljEHjftRuNkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClurs%253D&md5=ef5dbec53a41f9691317cc5b1b47b3cb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DTyrosine-phosphorylation%253A%2520thirty%2520years%2520and%2520counting%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D140%26epage%3D146%26doi%3D10.1016%2Fj.ceb.2009.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: from genes, to function, to disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/nrm2039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrm2039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17057753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSms77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=833-846&author=N.+K.+Tonks&title=Protein+tyrosine+phosphatases%3A+from+genes%2C+to+function%2C+to+disease&doi=10.1038%2Fnrm2039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: from genes, to function, to disease</span></div><div class="casAuthors">Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">833-846</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The protein tyrosine phosphatase (PTP) superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signalling pathways that underlie a broad spectrum of fundamental physiol. processes.  In this review, I describe recent breakthroughs in our understanding of the role of the PTPs in the regulation of signal transduction and the etiol. of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5NdnwoKCC1bVg90H21EOLACvtfcHk0ljEHjftRuNkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSms77I&md5=20a078267093bb8415d9035a13b8ad17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm2039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2039%26sid%3Dliteratum%253Aachs%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520from%2520genes%252C%2520to%2520function%252C%2520to%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D833%26epage%3D846%26doi%3D10.1038%2Fnrm2039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: prospects for therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(00)00223-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS1367-5931%2800%2900223-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11470605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=416-423&author=Z.+Y.+Zhang&title=Protein+tyrosine+phosphatases%3A+prospects+for+therapeutics&doi=10.1016%2FS1367-5931%2800%2900223-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: prospects for therapeutics</span></div><div class="casAuthors">Zhang, Z.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Protein tyrosine phosphatases (PTPs) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  PTPs are also implicated in a wide variety of other disorders, including cancer.  Significant progress has been made in identifying small mols. that simultaneously bind both the active site and a unique adjacent site that enables specific inhibition of individual PTP isoenzymes.  As a consequence, there are compelling reasons to believe that PTP inhibitors may ultimately serve as powerful therapeutic weapons in the authors' arsenal for battling human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgujWWYVWfjbVg90H21EOLACvtfcHk0liussF-3D5pVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLs%253D&md5=eee42d18a57b314321cffca4e3892ac1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900223-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900223-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520prospects%2520for%2520therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D416%26epage%3D423%26doi%3D10.1016%2FS1367-5931%2800%2900223-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Julien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dube, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. L.</span></span> <span> </span><span class="NLM_article-title">Inside the human cancer tyrosine phosphatome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1038/nrc2980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrc2980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=21179176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WisrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=35-49&author=S.+G.+Julienauthor=N.+Dubeauthor=S.+Hardyauthor=M.+L.+Tremblay&title=Inside+the+human+cancer+tyrosine+phosphatome&doi=10.1038%2Fnrc2980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inside the human cancer tyrosine phosphatome</span></div><div class="casAuthors">Julien, Sofi G.; Dube, Nadia; Hardy, Serge; Tremblay, Michel L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-49</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the protein tyrosine phosphatase (Ptp) family dephosphorylate target proteins and counter the activities of protein tyrosine kinases that are involved in cellular phosphorylation and signalling.  As such, certain PTPs might be tumor suppressors.  Indeed, PTPs play an important part in the inhibition or control of growth, but accumulating evidence indicates that some PTPs may exert oncogenic functions.  Recent large-scale genetic analyses of various human tumors have highlighted the relevance of PTPs either as putative tumor suppressors or as candidate oncoproteins.  Progress in understanding the regulation and function of PTPs has provided insights into which PTPs might be potential therapeutic targets in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomjWFudpQjhLVg90H21EOLACvtfcHk0liussF-3D5pVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WisrbM&md5=ffd5f76f3d0b2d0ef220e5d398794f2e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2980%26sid%3Dliteratum%253Aachs%26aulast%3DJulien%26aufirst%3DS.%2BG.%26aulast%3DDube%26aufirst%3DN.%26aulast%3DHardy%26aufirst%3DS.%26aulast%3DTremblay%26aufirst%3DM.%2BL.%26atitle%3DInside%2520the%2520human%2520cancer%2520tyrosine%2520phosphatome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D35%26epage%3D49%26doi%3D10.1038%2Fnrc2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Munter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, M.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities in the development of protein phosphatase-directed therapeutics</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/cb300597g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300597g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSjurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=36-45&author=S.+De%0AMunterauthor=M.+Kohnauthor=M.+Bollen&title=Challenges+and+opportunities+in+the+development+of+protein+phosphatase-directed+therapeutics&doi=10.1021%2Fcb300597g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Opportunities in the Development of Protein Phosphatase-Directed Therapeutics</span></div><div class="casAuthors">De Munter, Sofie; Kohn, Maja; Bollen, Mathieu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-45</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein phosphatases have both protective and promoting roles in the etiol. of diseases.  A prominent example is the existence of oncogenic as well as tumor-suppressing protein phosphatases.  A few protein phosphatase activity modulators are already applied in therapies.  These were however not developed in target-directed approaches, and the recent discovery of phosphatase involvement followed their application in therapy.  Nevertheless, these examples demonstrate that small mols. can be generated that modulate the activity of protein phosphatases and are beneficial for the treatment of protein phosphorylation diseases.  We describe here strategies for the development of activators and inhibitors of protein phosphatases and clarify some long-standing misconceptions concerning the drug ability of these enzymes.  Recent developments suggest that it is feasible to design potent and selective protein phosphatase modulators with a therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTwo-BD9sHS7Vg90H21EOLACvtfcHk0liussF-3D5pVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSjurrF&md5=a6bccc84309271ecdec328d6b1b84294</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcb300597g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300597g%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMunter%26aufirst%3DS.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DBollen%26aufirst%3DM.%26atitle%3DChallenges%2520and%2520opportunities%2520in%2520the%2520development%2520of%2520protein%2520phosphatase-directed%2520therapeutics%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D36%26epage%3D45%26doi%3D10.1021%2Fcb300597g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebreda, Á. R.</span></span> <span> </span><span class="NLM_article-title">Protein kinases and phosphatases as therapeutic targets in cancer</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1007/s12094-006-0005-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1007%2Fs12094-006-0005-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16648114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=153-160&author=J.+J.+Venturaauthor=%C3%81.+R.+Nebreda&title=Protein+kinases+and+phosphatases+as+therapeutic+targets+in+cancer&doi=10.1007%2Fs12094-006-0005-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases and phosphatases as therapeutic targets in cancer</span></div><div class="casAuthors">Ventura, Juan-Jose; Nebreda, Angel R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Translational Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-160</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Instituto de Investigaciones Biomedicas CSIC/UAM</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation plays key roles in many physiol. processes and is often deregulated in pathol. conditions.  Our current understanding of how protein kinases and phosphatases orchestrate the phosphorylation changes that control cellular functions has made these enzymes potential drug targets for the treatment of many diseases.  The success of the tyrosine kinase inhibitor Gleevec in the treatment of some cancers has further invigorated the development of kinase inhibitors as anti-cancer drugs.  A large no. of these compds. are currently undergoing clin. trials and there is much expectation on the therapeutic potential of these mols., as more specific and less toxic drugs than currently used generic chemotherapeutic agents.  In this manuscript, we review the current status of more than 30 protein kinase inhibitors with proven or potential therapeutic value for cancer treatment.  These include inhibitors of receptor and cytosolic tyrosine kinases as well as compds. that target different families of serine/threonine kinases involved in signalling and cell cycle regulation.  We also briefly touch on the prospects of phosphatase inhibitors.  The combination of kinase inhibitors to target different components of signalling pathways that are found deregulated in tumors is also emerging as an interesting approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdO6Up4gp6n7Vg90H21EOLACvtfcHk0lioaK0mQwa70A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFentb0%253D&md5=57a09f7b6916b45b1154b608cd1f17af</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12094-006-0005-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-006-0005-0%26sid%3Dliteratum%253Aachs%26aulast%3DVentura%26aufirst%3DJ.%2BJ.%26aulast%3DNebreda%26aufirst%3D%25C3%2581.%2BR.%26atitle%3DProtein%2520kinases%2520and%2520phosphatases%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2006%26volume%3D8%26spage%3D153%26epage%3D160%26doi%3D10.1007%2Fs12094-006-0005-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span> <span> </span><span class="NLM_article-title">Chemical inhibitors of protein kinases</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">2541</span>– <span class="NLM_lpage">2571</span>, <span class="refDoi"> DOI: 10.1021/cr000250y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr000250y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2001&pages=2541-2571&author=A.+J.+Bridges&title=Chemical+inhibitors+of+protein+kinases&doi=10.1021%2Fcr000250y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical inhibitors of protein kinases</span></div><div class="casAuthors">Bridges, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2541-2571</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 258 refs. on development protein kinase inhibitors as potential antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWn7KO1AXzrVg90H21EOLACvtfcHk0lioaK0mQwa70A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWnt7k%253D&md5=05ee78880cc9dcf485684e05327108db</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr000250y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr000250y%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DChemical%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DChem.%2520Rev.%26date%3D2001%26volume%3D101%26spage%3D2541%26epage%3D2571%26doi%3D10.1021%2Fcr000250y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery - What’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery+-+What%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0lioaK0mQwa70A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%2520-%2520What%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinases as targets for cancer therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1056/NEJMra044389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+kinases+as+targets+for+cancer+therapy&doi=10.1056%2FNEJMra044389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0lioaK0mQwa70A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187%26doi%3D10.1056%2FNEJMra044389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">Mutational analysis of the tyrosine phosphatome in colorectal cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1126/science.1096096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.1096096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15155950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1164-1166&author=Z.+H.+Wangauthor=D.+Shenauthor=D.+W.+Parsonsauthor=A.+Bardelliauthor=J.+Sagerauthor=S.+Szaboauthor=J.+Ptakauthor=N.+Sillimanauthor=B.+A.+Petersauthor=M.+S.+van+der+Heijdenauthor=G.+Parmigianiauthor=H.+Yanauthor=T.+L.+Wangauthor=G.+Rigginsauthor=S.+M.+Powellauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=Mutational+analysis+of+the+tyrosine+phosphatome+in+colorectal+cancers&doi=10.1126%2Fscience.1096096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers</span></div><div class="casAuthors">Wang, Zhenghe; Shen, Dong; Parsons, D. Williams; Bardelli, Alberto; Sager, Jason; Szabo, Steve; Ptak, Janine; Silliman, Natalie; Peters, Brock A.; van der Heijden, Michiel S.; Parmigiani, Giovanni; Yan, Hai; Wang, Tian-Li; Riggins, Greg; Powell, Steven M.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5674</span>),
    <span class="NLM_cas:pages">1164-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis.  A mutational anal. of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a smaller fraction of lung, breast, and gastric cancers.  Fifteen mutations were nonsense, frameshift, or splice-site alterations predicted to result in truncated proteins lacking phosphatase activity.  Five missense mutations in the most commonly altered PTP (PTPRT) were biochem. examd. and found to reduce phosphatase activity.  Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth.  These observations suggest that the mutated tyrosine phosphatases are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9NQWiEUTTMbVg90H21EOLACvtfcHk0lj5uGLw2X1Crg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVyit7c%253D&md5=3466921b63561835ad9bf1f2f4f5d81e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096096%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DParsons%26aufirst%3DD.%2BW.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSager%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DM.%2BS.%26aulast%3DParmigiani%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%2BL.%26aulast%3DRiggins%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DMutational%2520analysis%2520of%2520the%2520tyrosine%2520phosphatome%2520in%2520colorectal%2520cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1164%26epage%3D1166%26doi%3D10.1126%2Fscience.1096096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2592</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1073/pnas.0914884107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0914884107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=20133777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1aksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=2592-2597&author=Y.+Q.+Zhaoauthor=X.+D.+Zhangauthor=K.+Gudaauthor=E.+Lawrenceauthor=Q.+Sunauthor=T.+Watanabeauthor=Y.+Iwakuraauthor=M.+Asanoauthor=L.+L.+Weiauthor=Z.+R.+Yangauthor=W.+P.+Zhengauthor=D.+Dawsonauthor=J.+Willisauthor=S.+D.+Markowitzauthor=M.+Satakeauthor=Z.+H.+Wang&title=Identification+and+functional+characterization+of+paxillin+as+a+target+of+protein+tyrosine+phosphatase+receptor+T&doi=10.1073%2Fpnas.0914884107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T</span></div><div class="casAuthors">Zhao, Yiqing; Zhang, Xiaodong; Guda, Kishore; Lawrence, Earl; Sun, Qun; Watanabe, Toshio; Iwakura, Yoichiro; Asano, Masahide; Wei, Lanlan; Yang, Zhirong; Zheng, Weiping; Dawson, Dawn; Willis, Joseph; Markowitz, Sanford D.; Satake, Masanobu; Wang, Zhenghe</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2592-2597, S2592/1-S2592/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase receptor-type T (PTPRT) is the most frequently mutated tyrosine phosphatase in human cancers.  However, the cell signaling pathways regulated by PTPRT largely remain to be elucidated.  Here, the authors show that paxillin is a direct substrate of PTPRT and that-PTPRT specifically regulates paxillin phosphorylation at tyrosine residue 88 (Y88) in colorectal cancer (CRC) cells.  The authors engineered CRC cells homozygous for a paxillin Y88F knock-in mutant and found that these cells exhibit significantly reduced cell migration and impaired anchorage-independent growth, fail to form xenograft tumors in nude mice, and have decreased phosphorylation of p130CAS, SHP2, and AKT.  PTPRT knockout mice that the authors generated exhibit increased levels of colonic paxillin phosphorylation at residue Y88 and are highly susceptible to carcinogen azoxymethane-induced colon tumor, providing crit. in vivo evidence that PTPRT normally functions as a tumor suppressor.  Moreover, similarly increased paxillin pY88 is also found as a common feature of human colon cancers.  These studies reveal an important signaling pathway that plays a crit. role in colorectal tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpXrtavoElLVg90H21EOLACvtfcHk0lj5uGLw2X1Crg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1aksLY%253D&md5=98e1034f41e18f0b21c0acc926dbdb8d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0914884107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0914884107%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DX.%2BD.%26aulast%3DGuda%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%2BR.%26aulast%3DZheng%26aufirst%3DW.%2BP.%26aulast%3DDawson%26aufirst%3DD.%26aulast%3DWillis%26aufirst%3DJ.%26aulast%3DMarkowitz%26aufirst%3DS.%2BD.%26aulast%3DSatake%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520paxillin%2520as%2520a%2520target%2520of%2520protein%2520tyrosine%2520phosphatase%2520receptor%2520T%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D2592%26epage%3D2597%26doi%3D10.1073%2Fpnas.0914884107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podsypanina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miliaresis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCombie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovanella, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tycko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibshoosh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span> <span> </span><span class="NLM_article-title">PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1126/science.275.5308.1943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.275.5308.1943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9072974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK2sXit1Wgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1943-1947&author=J.+Liauthor=C.+Yenauthor=D.+Liawauthor=K.+Podsypaninaauthor=S.+Boseauthor=S.+I.+Wangauthor=J.+Pucauthor=C.+Miliaresisauthor=L.+Rodgersauthor=R.+McCombieauthor=S.+H.+Bignerauthor=B.+C.+Giovanellaauthor=M.+Ittmannauthor=B.+Tyckoauthor=H.+Hibshooshauthor=M.+H.+Wiglerauthor=R.+Parsons&title=PTEN%2C+a+putative+protein+tyrosine+phosphatase+gene+mutated+in+human+brain%2C+breast%2C+and+prostate+cancer&doi=10.1126%2Fscience.275.5308.1943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</span></div><div class="casAuthors">Li, Jing; Yen, Clifford; Liaw, Danny; Podsypanina, Katrina; Bose, Shikha; Wang, Steven I.; Puc, Janusz; Miliaresis, Christa; Rodgers, Linda; McCombie, Richard; Bigner, Sandra H.; Giovanella, Beppino C.; Ittmann, Michael; Tycko, Ben; Hibshoosh, Hanina; Wigler, Michael H.; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">5308</span>),
    <span class="NLM_cas:pages">1943-1947</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers.  In preliminary screens, mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of prostate cancer cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas.  The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homol. to tensin, a protein that interacts with actin filaments at focal adhesions.  These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPNCE1bqsPNLVg90H21EOLACvtfcHk0ljkLAnJB82Zhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1Wgtbk%253D&md5=9b3810f68cbd7cbb882ff75e98a2f1bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.275.5308.1943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.275.5308.1943%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DC.%26aulast%3DLiaw%26aufirst%3DD.%26aulast%3DPodsypanina%26aufirst%3DK.%26aulast%3DBose%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BI.%26aulast%3DPuc%26aufirst%3DJ.%26aulast%3DMiliaresis%26aufirst%3DC.%26aulast%3DRodgers%26aufirst%3DL.%26aulast%3DMcCombie%26aufirst%3DR.%26aulast%3DBigner%26aufirst%3DS.%2BH.%26aulast%3DGiovanella%26aufirst%3DB.%2BC.%26aulast%3DIttmann%26aufirst%3DM.%26aulast%3DTycko%26aufirst%3DB.%26aulast%3DHibshoosh%26aufirst%3DH.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DPTEN%252C%2520a%2520putative%2520protein%2520tyrosine%2520phosphatase%2520gene%2520mutated%2520in%2520human%2520brain%252C%2520breast%252C%2520and%2520prostate%2520cancer%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1943%26epage%3D1947%26doi%3D10.1126%2Fscience.275.5308.1943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zbuk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, C.</span></span> <span> </span><span class="NLM_article-title">Cancer phenomics: RET and PTEN as illustrative models</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1038/nrc2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrc2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17167516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCht7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=35-45&author=K.+M.+Zbukauthor=C.+Eng&title=Cancer+phenomics%3A+RET+and+PTEN+as+illustrative+models&doi=10.1038%2Fnrc2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer phenomics: RET and PTEN as illustrative models</span></div><div class="casAuthors">Zbuk, Kevin M.; Eng, Charis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer phenomics, the systematic acquisition and objective documentation of host and/or somatic cancer phenotypic data at many levels, is a young field compared with other mol.-based 'omics'.  Two relatively advanced phenomic paradigms are assocd. with phosphatase and tensin homolog (PTEN) and rearranged during transfection (RET), genes that are assocd. with cancer predisposition syndromes in addn. to developmental disorders.  The phenomic characterization of PTEN and RET underscores the importance of incorporating robust phenomics into the host 'omic' profile, and shows that the evolution of phenomics will be crucial to the advancement of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOxv_KNE-ybVg90H21EOLACvtfcHk0ljkLAnJB82Zhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCht7nE&md5=60d58273a64e401da8eb23a23fe17e1f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2037%26sid%3Dliteratum%253Aachs%26aulast%3DZbuk%26aufirst%3DK.%2BM.%26aulast%3DEng%26aufirst%3DC.%26atitle%3DCancer%2520phenomics%253A%2520RET%2520and%2520PTEN%2520as%2520illustrative%2520models%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D35%26epage%3D45%26doi%3D10.1038%2Fnrc2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romans, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span> <span> </span><span class="NLM_article-title">PRL-3 expression in metastatic cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5607</span>– <span class="NLM_lpage">5615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14654542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVejtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5607-5615&author=A.+Bardelliauthor=S.+Sahaauthor=J.+A.+Sagerauthor=K.+E.+Romansauthor=B.+Z.+Xinauthor=S.+D.+Markowitzauthor=C.+Lengauerauthor=V.+E.+Velculescuauthor=K.+W.+Kinzlerauthor=B.+Vogelstein&title=PRL-3+expression+in+metastatic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3 expression in metastatic cancers</span></div><div class="casAuthors">Bardelli, Alberto; Saha, Saurabh; Sager, Jason A.; Romans, Kathy E.; Xin, Baozhong; Markowitz, Sanford D.; Lengauer, Christoph; Velculescu, Victor E.; Kinzler, Kenneth W.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5607-5615</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of the PRL-3 tyrosine phosphatase is elevated in liver metastases derived from colorectal cancer (CRC).  The authors sought to det. the cellular basis of this elevation and assess the expression of PRL-3 in metastatic lesions derived from cancers of the colon and other tissues.  The authors developed modifications of in situ hybridization methods that facilitated the study of paraffin-embedded sections.  They also evaluated PRL-3 gene copy nos. using fluorescence in situ hybridization and developed antibodies to assess PRL-3 subcellular localization.  PRL-3 mRNA expression was elevated in nearly all metastatic lesions derived from CRCs, regardless of the site of metastasis (liver, lung, brain, or ovary).  Expression was found in neoplastic cells, although tumor endothelium also expressed the gene.  In contrast, little or no PRL-3 expression was obsd. in normal colon, nonmetastatic primary cancers, or metastatic lesions derived from cancers other than those of the colon (pancreas, stomach, or esophagus).  Interphase fluorescence in situ hybridization confirmed that gene amplification was not the major cause of PRL-3 overexpression.  Immunohistochem. anal. with anti-PRL-3 antibodies showed a cell membrane localization, consistent with the predicted isoprenylation of the protein.  These studies establish an unexpected and unprecedented specificity in metastatic gene expression profiles: PRL-3 is apparently expressed in CRC metastases to any organ but is not expressed in metastases of other cancers to the same organs or in nonmetastatic CRCs.  PRL-3 is also expressed in tumor vasculature, regardless of the tumor source.  These data raise intriguing questions about the role of protein phosphorylation in angiogenesis and cell-type-specific metastatic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn3vWdorK4YrVg90H21EOLACvtfcHk0ljEq79g1XtJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVejtbY%253D&md5=da10edae1f3cbdb06792fc2f1a1fa72d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DSager%26aufirst%3DJ.%2BA.%26aulast%3DRomans%26aufirst%3DK.%2BE.%26aulast%3DXin%26aufirst%3DB.%2BZ.%26aulast%3DMarkowitz%26aufirst%3DS.%2BD.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DPRL-3%2520expression%2520in%2520metastatic%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5607%26epage%3D5615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemeyer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buechner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahlen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/ng1156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fng1156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12717436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=148-150&author=M.+Tartagliaauthor=C.+M.+Niemeyerauthor=A.+Fragaleauthor=X.+L.+Songauthor=J.+Buechnerauthor=A.+Jungauthor=K.+Hahlenauthor=H.+Hasleauthor=J.+D.+Lichtauthor=B.+D.+Gelb&title=Somatic+mutations+in+PTPN11+in+juvenile+myelomonocytic+leukemia%2C+myelodysplastic+syndromes+and+acute+myeloid+leukemia&doi=10.1038%2Fng1156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span></div><div class="casAuthors">Tartaglia, Marco; Niemeyer, Charlotte M.; Fragale, Alessandra; Song, Xiaoling; Buechner, Jochen; Jung, Andreas; Haehlen, Karel; Hasle, Henrik; Licht, Jonathan D.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-150</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML.  Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML).  Functional analyses documented that the two most common mutations in PTPN11 assocd. with JMML caused a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwFhlUQDJQLVg90H21EOLACvtfcHk0ljEq79g1XtJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D&md5=67d6900b46520ee461330bed95cbc890</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fng1156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1156%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DX.%2BL.%26aulast%3DBuechner%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DHahlen%26aufirst%3DK.%26aulast%3DHasle%26aufirst%3DH.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DSomatic%2520mutations%2520in%2520PTPN11%2520in%2520juvenile%2520myelomonocytic%2520leukemia%252C%2520myelodysplastic%2520syndromes%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2003%26volume%3D34%26spage%3D148%26epage%3D150%26doi%3D10.1038%2Fng1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellamy, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1002/jcb.23125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fjcb.23125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=21465528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslamtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2011&pages=2062-2071&author=W.+Wangauthor=L.+J.+Liuauthor=X.+Songauthor=Y.+Moauthor=C.+Kommaauthor=H.+D.+Bellamyauthor=Z.+J.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+human+protein+tyrosine+phosphatase+SHP-1+in+the+open+conformation&doi=10.1002%2Fjcb.23125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation</span></div><div class="casAuthors">Wang, Wei; Liu, Lijun; Song, Xi; Mo, Yi; Komma, Chandrasekhar; Bellamy, Henry D.; Zhao, Zhizhuang Joe; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2062-2071</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">SHP-1 belongs to the family of non-receptor protein tyrosine phosphatases (PTPs) and generally acts as a neg. regulator in a variety of cellular signaling pathways.  Previously, the crystal structures of tail-truncated SHP-1 and SHP-2 revealed an autoinhibitory conformation.  To understand the regulatory mechanism of SHP-1, the authors detd. the crystal structure of full-length SHP-1 at 3.1 Å.  Although the tail was disordered in the current structure, the huge conformational rearrangement of the N-SH2 domain and the incorporation of sulfate ions into the ligand-binding site of each domain indicated that SHP-1 was in the open conformation.  The N-SH2 domain in the current structure was shifted away from the active site of the PTP domain to the other side of the C-SH2 domain, resulting in exposure of the active site.  Meanwhile, the C-SH2 domain was twisted anti-clockwise by ∼110°.  In addn., a set of new interactions between 2 SH2 domains and between the N-SH2 and the catalytic domains was identified, which could be responsible for the stabilization of SHP-1 in the open conformation.  Based on the structural comparison, a model for the activation of SHP-1 was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbClbkZ-6vn7Vg90H21EOLACvtfcHk0ljEq79g1XtJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslamtLs%253D&md5=7da59a40ae5a36fb3842922de1135744</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fjcb.23125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.23125%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DKomma%26aufirst%3DC.%26aulast%3DBellamy%26aufirst%3DH.%2BD.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520human%2520protein%2520tyrosine%2520phosphatase%2520SHP-1%2520in%2520the%2520open%2520conformation%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2011%26volume%3D112%26spage%3D2062%26epage%3D2071%26doi%3D10.1002%2Fjcb.23125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">28199</span>– <span class="NLM_lpage">28207</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.43.28199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.273.43.28199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9774441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXntVClsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=28199-28207&author=J.+Yangauthor=X.+S.+Liangauthor=T.+Q.+Niuauthor=W.+Y.+Mengauthor=Z.+Z.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+the+catalytic+domain+of+protein-tyrosine+phosphatase+SHP-1&doi=10.1074%2Fjbc.273.43.28199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1</span></div><div class="casAuthors">Yang, Jian; Liang, Xiaoshan; Niu, Tianqi; Meng, Wuyi; Zhao, Zhizhuang; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">28199-28207</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structures of the phosphoprotein-tyrosine phosphatase (PTPase) SHP-1 catalytic domain and the complex formed with the substrate analog, tungstate, were detd. and refined to crystallog. R values of 0.209 at 2.5 Å resoln. and 0.207 at 2.8 Å resoln., resp.  Despite low sequence similarity, the catalytic domain of SHP-1 showed high similarity in secondary and tertiary structures with other PTPases.  In contrast to the conformational changes obsd. in the crystal structures of PTPase 1B and Yersinia PTPase, the WPD loop (Trp-419-Pro-428) in the catalytic domain of SHP-1 moved away from the substrate binding pocket after binding tungstate.  Sequence alignment and structural anal. suggested that the residues in the WPD loop, esp. the amino acid following Asp-421, are crit. for the movement of WPD loop on binding substrates and the specific activity of PTPases.  The authors' mutagenesis and kinetic measurements supported this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT1ZhDJzM3m7Vg90H21EOLACvtfcHk0ljQgRufGeUHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntVClsr8%253D&md5=363373fd7941078c2a3fb0b4f57c667e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.43.28199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.43.28199%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%2BS.%26aulast%3DNiu%26aufirst%3DT.%2BQ.%26aulast%3DMeng%26aufirst%3DW.%2BY.%26aulast%3DZhao%26aufirst%3DZ.%2BZ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520the%2520catalytic%2520domain%2520of%2520protein-tyrosine%2520phosphatase%2520SHP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D28199%26epage%3D28207%26doi%3D10.1074%2Fjbc.273.43.28199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/jm8002526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4948-4956&author=H.+R.+Lawrenceauthor=R.+Piredduauthor=L.+W.+Chenauthor=Y.+T.+Luoauthor=S.+S.+Sungauthor=A.+M.+Szymanskiauthor=M.+L.+R.+Yipauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=J.+Wuauthor=N.+J.+Lawrence&title=Inhibitors+of+Src+homology-2+domain+containing+protein+tyrosine+phosphatase-2+%28Shp2%29+based+on+oxindole+scaffolds&doi=10.1021%2Fjm8002526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds</span></div><div class="casAuthors">Lawrence, Harshani R.; Pireddu, Roberta; Chen, Liwei; Luo, Yunting; Sung, Shen-Shu; Szymanski, Ann Marie; Yip, M. L. Richard; Guida, Wayne C.; Sebti, Said M.; Wu, Jie; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4948-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of the NCI diversity set of compds. has led to the identification of NSC-117199, which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 μM.  A focused library incorporating an isatin scaffold was designed and evaluated for inhibition of Shp2 and Shp1 PTP activities.  Several compds. were identified that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar activity.  A model for the binding of the active compds. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqLAauyGNBbVg90H21EOLACvtfcHk0ljQgRufGeUHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2hu7o%253D&md5=572227c5a8cfffb108388616bd36fdfe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm8002526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002526%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DLuo%26aufirst%3DY.%2BT.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DSzymanski%26aufirst%3DA.%2BM.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DInhibitors%2520of%2520Src%2520homology-2%2520domain%2520containing%2520protein%2520tyrosine%2520phosphatase-2%2520%2528Shp2%2529%2520based%2520on%2520oxindole%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4948%26epage%3D4956%26doi%3D10.1021%2Fjm8002526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1128/MCB.19.3.2416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.19.3.2416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10022928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFCjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2416-2424&author=M.+Youauthor=D.+H.+Yuauthor=G.+S.+Feng&title=Shp-2+tyrosine+phosphatase+functions+as+a+negative+regulator+of+the+interferon-stimulated+Jak%2FSTAT+pathway&doi=10.1128%2FMCB.19.3.2416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway</span></div><div class="casAuthors">You, Min; Yu, De-Hua; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2416-2424</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Shp-2 is an SH2 domain-contg. protein tyrosine phosphatase.  Although the mechanism remains to be defined, substantial exptl. data suggest that Shp-2 is primarily a pos. regulator in cell growth and development.  The authors present evidence here that Shp-2, while acting to promote mitogenic signals, also functions as a neg. effector in interferon (IFN)-induced growth-inhibitory and apoptotic pathways.  Treatment of mouse fibroblast cells lacking a functional Shp-2 with IFN-α or IFN-γ resulted in an augmented suppression of cell viability compared to that of wild-type cells.  To dissect the mol. mechanism, the authors examd. IFN-induced activation of signal transducers and activators of transcription (STATs) by electrophoretic mobility shift assay, using a specific DNA probe (hSIE).  The amts. of STAT proteins bound to hSIE upon IFN-α or IFN-γ stimulation were increased in Shp-2-/- cells.  Consistently, tyrosine phosphorylation levels of Stat1 upon IFN-γ treatment and, to a lesser extent, upon IFN-α stimulation were markedly elevated in mutant cells.  Furthermore, IFN-γ induced a higher level of caspase 1 expression in Shp-2-/- cells than in wild-type cells.  Reintroduction of wild-type Shp-2 protein reversed the hypersensitivity of Shp-2-/- fibroblasts to the cytotoxic effect of IFN-α and IFN-γ.  Excessive activation of STATs by IFNs was also diminished in mutant cells in which Shp-2 had been reintroduced.  Thus, Shp-2 functions as a neg. regulator of the Jak/STAT pathway.  The authors propose that Shp-2 acts to promote cell growth and survival via 2 mechanisms, i.e., the stimulation of growth factor-initiated mitogenic pathways and the suppression of cytotoxic effect elicited by cytokines, such as IFNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiGe5yc6ZR-rVg90H21EOLACvtfcHk0ljyUXZ7kIe4_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFCjs7Y%253D&md5=ec6e07bdca1d8126e40cedda80358b7c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.2416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.2416%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DShp-2%2520tyrosine%2520phosphatase%2520functions%2520as%2520a%2520negative%2520regulator%2520of%2520the%2520interferon-stimulated%2520Jak%252FSTAT%2520pathway%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2416%26epage%3D2424%26doi%3D10.1128%2FMCB.19.3.2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapeau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">16064</span>– <span class="NLM_lpage">16069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0405041101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0405041101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15520383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGis7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=16064-16069&author=E.+E.+Zhangauthor=E.+Chapeauauthor=K.+Hagiharaauthor=G.+S.+Feng&title=Neuronal+Shp2+tyrosine+phosphatase+controls+energy+balance+and+metabolism&doi=10.1073%2Fpnas.0405041101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism</span></div><div class="casAuthors">Zhang, Eric E.; Chapeau, Emilie; Hagihara, Kazuki; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">16064-16069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Shp2, a Src homol. 2-contg. tyrosine phosphatase, has been implicated in a variety of growth factor or cytokine signaling pathways.  However, it is conceivable that this enzyme acts predominantly in one pathway vs. the others in a cell, depending on the cellular context.  To det. the putative functions of Shp2 in the adult brain, we selectively deleted Shp2 in postmitotic forebrain neurons by crossing CaMKIIα-Cre transgenic mice with a conditional Shp2 mutant (Shp2flox) strain.  Surprisingly, a prominent phenotype of the mutant (CaMKIIα-Cre:Shp2flox/flox or CaSKO) mice was the development of early-onset obesity, with increased serum levels of leptin, insulin, glucose, and triglycerides.  The mutant mice were not hyperphagic but developed enlarged and steatotic liver.  Consistent with previous in vitro data, we found that Shp2 down-regulates Jak2/Stat3 (signal transducer and activator of transcription 3) activation by leptin in the hypothalamus.  However, Jak2/Stat3 down-regulation is offset by a dominant Shp2 promotion of the leptin-stimulated Erk pathway, leading to induction rather than suppression of leptin resistance upon Shp2 deletion in the brain.  Collectively, these results suggest that a primary function of Shp2 in postmitotic forebrain neurons is to control energy balance and metab., and that this phosphatase is a crit. signaling component of leptin receptor ObRb in the hypothalamus.  Shp2 shows potential as a neuronal target for pharmaceutical sensitization of obese patients to leptin action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHDhmkfITz8bVg90H21EOLACvtfcHk0ljyUXZ7kIe4_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGis7zF&md5=bf9d1224a7e2703040ab2c8b73d19276</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405041101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405041101%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DE.%2BE.%26aulast%3DChapeau%26aufirst%3DE.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DNeuronal%2520Shp2%2520tyrosine%2520phosphatase%2520controls%2520energy%2520balance%2520and%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D16064%26epage%3D16069%26doi%3D10.1073%2Fpnas.0405041101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6018</span>– <span class="NLM_lpage">6025</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsj.onc.1204699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11593409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVCjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=6018-6025&author=C.+J.+Wuauthor=D.+M.+O%E2%80%99Rourkeauthor=G.+S.+Fengauthor=G.+R.+Johnsonauthor=Q.+Wangauthor=M.+I.+Greene&title=The+tyrosine+phosphatase+SHP-2+is+required+for+mediating+phosphatidylinositol+3-kinase%2FAkt+activation+by+growth+factors&doi=10.1038%2Fsj.onc.1204699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors</span></div><div class="casAuthors">Wu, Chuan-Jin; O'Rourke, Donald M.; Feng, Gen-Sheng; Johnson, Gibbes R.; Wang, Qiang; Greene, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6018-6025</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SHP-2 is a ubiquitously expressed non-transmembrane tyrosine phosphatase with two SH2 domains.  Multiple reverse-genetic studies have indicated that SHP-2 is a required component for organ and animal development.  SHP-2 wild-type and homozygous mutant mouse fibroblast cells in which the N-terminal SH2 domain was target-deleted were used to examine the function of SHP-2 in regulating phosphatidylinositol 3-kinase (PI3K) activation by growth factors.  In addn., SHP-2 and various mutants were introduced into human glioblastoma cells as well as SHP-2-/- mouse fibroblasts.  We found that EGF stimulation and EGFR oncoprotein (ΔEGFR) expression independently induced the co-immunopptn. of the p85 subunit of PI3K with SHP-2.  Targeted deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation.  Ectopic expression of SHP-2 in U87MG glioblastoma cells elevated EGF-induced Akt phosphorylation, and the effect was abolished by mutation of its N-terminal SH2 domain.  Likewise, the reconstitution of SHP-2 expression in the SHP-2-/- cells enhanced Akt phosphorylation induced by EGF while rescuing that induced by PDGF and IGF.  Further lipid kinase activity assays confirmed that SHP-2 modulation of Akt phosphorylation correlated with its regulation of PI3K activation.  Based on these results, we conclude that SHP-2 is required for mediating PI3K/Akt activation, and the N-terminal SH2 domain is critically important for a "pos." role of SHP-2 in regulating PI3K pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCyPto0sgBL7Vg90H21EOLACvtfcHk0lgWsUp-BdSz8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVCjsLs%253D&md5=d700f46c6127c929099ecc7c94b4d180</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204699%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DD.%2BM.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520SHP-2%2520is%2520required%2520for%2520mediating%2520phosphatidylinositol%25203-kinase%252FAkt%2520activation%2520by%2520growth%2520factors%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D6018%26epage%3D6025%26doi%3D10.1038%2Fsj.onc.1204699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsiaras, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4062</span>– <span class="NLM_lpage">4072</span>, <span class="refDoi"> DOI: 10.1128/MCB.22.12.4062-4072.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.22.12.4062-4072.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12024020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=4062-4072&author=S.+Q.+Zhangauthor=W.+G.+Tsiarasauthor=T.+Arakiauthor=G.+Y.+Wenauthor=L.+Minichielloauthor=R.+Kleinauthor=B.+G.+Neel&title=Receptor-specific+regulation+of+phosphatidylinositol+3%E2%80%B2-kinase+activation+by+the+protein+tyrosine+phosphatase+Shp2&doi=10.1128%2FMCB.22.12.4062-4072.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2</span></div><div class="casAuthors">Zhang, Si Qing; Tsiaras, William G.; Araki, Toshiyuki; Wen, Gengyun; Minichiello, Liliana; Klein, Ruediger; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4062-4072</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases (RTKs) play distinct roles in multiple biol. systems.  Many RTKs transmit similar signals, raising questions about how specificity is achieved.  One potential mechanism for RTK specificity is control of the magnitude and kinetics of activation of downstream pathways.  We have found that the protein tyrosine phosphatase Shp2 regulates the strength and duration of phosphatidylinositol 3'-kinase (PI3K) activation in the epidermal growth factor (EGF) receptor signaling pathway.  Shp2 mutant fibroblasts exhibit increased assocn. of the p85 subunit of PI3K with the scaffolding adapter Gab1 compared to that for wild-type (WT) fibroblasts or Shp2 mutant cells reconstituted with WT Shp2.  Far-Western anal. suggests increased phosphorylation of p85 binding sites on Gab1.  Gab1-assocd. PI3K activity is increased and PI3K-dependent downstream signals are enhanced in Shp2 mutant cells following EGF stimulation.  Analogous results are obtained in fibroblasts inducibly expressing dominant-neg. Shp2.  Our results suggest that, in addn. to its role as a pos. component of the Ras-Erk pathway, Shp2 neg. regulates EGF-dependent PI3K activation by dephosphorylating Gab1 p85 binding sites, thereby terminating a previously proposed Gab1-PI3K pos. feedback loop.  Activation of PI3K-dependent pathways following stimulation by other growth factors is unaffected or decreased in Shp2 mutant cells.  Thus, Shp2 regulates the kinetics and magnitude of RTK signaling in a receptor-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdw-2VHpyGFrVg90H21EOLACvtfcHk0lgWsUp-BdSz8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSmur8%253D&md5=abd02620597dc8ca097ba0b0d4d7ed8e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.12.4062-4072.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.12.4062-4072.2002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26aulast%3DTsiaras%26aufirst%3DW.%2BG.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DG.%2BY.%26aulast%3DMinichiello%26aufirst%3DL.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DReceptor-specific%2520regulation%2520of%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%2520activation%2520by%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D4062%26epage%3D4072%26doi%3D10.1128%2FMCB.22.12.4062-4072.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunnick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desponts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of the mitogen-activated protein kinase signaling pathway by SHP2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">9498</span>– <span class="NLM_lpage">9504</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110547200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M110547200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11779868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=9498-9504&author=J.+M.+Cunnickauthor=S.+S.+Mengauthor=Y.+Renauthor=C.+Despontsauthor=H.+G.+Wangauthor=J.+Y.+Djeuauthor=J.+Wu&title=Regulation+of+the+mitogen-activated+protein+kinase+signaling+pathway+by+SHP2&doi=10.1074%2Fjbc.M110547200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the mitogen-activated protein kinase signaling pathway by SHP2</span></div><div class="casAuthors">Cunnick, Jess M.; Meng, Songshu; Ren, Yuan; Desponts, Caroline; Wang, Hong-Gang; Djeu, Julie Y.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9498-9504</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Gab1-SHP2 assocn. is required for Erk mitogen-activated protein kinase activation by several growth factors.  Gab1-SHP2 interaction activates SHP2.  However, an activated SHP2 still needs to assoc. with Gab1 to mediate Erk activation.  It was unclear whether SHP2 is required to dephosphorylate a neg. phosphorylation site on Gab1 or whether SHP2 needs the Gab1 pleckstrin homol. (PH) domain to target it to the plasma membrane.  The authors found that expression of a fusion protein consisting of the Gab1 PH domain and an active SHP2 (Gab1PH-SHP2ΔN) induced constitutive Mek1 and Erk2 activation.  Linking the active SHP2ΔN to the PDK1 PH domain or the FRS2β myristoylation sequence also induced Mek1 activation.  Mek1 activation by Gab1PH-SHP2ΔN was inhibited by an Src inhibitor and by Csk.  Significantly, Gab1PH-SHP2ΔN induced Src activation.  Gab1PH-SHP2ΔN expression activated Ras, and the Gab1PH-SHP2ΔN-induced Mek1 activation was blocked by RasN17.  These findings suggest that Gab1PH-SHP2ΔN activated a signaling step upstream of Src and Ras.  The SHP2 tyrosine phosphatase activity is essential for the function of the fusion protein.  Together, these data show that the Gab1 sequence, besides the PH domain and SHP2 binding sites, is dispensable for Erk activation, suggesting that the primary role of Gab1 assocn. with an activated SHP2 is to target is to the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhARBgZq1OALVg90H21EOLACvtfcHk0licgOChROYxzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2kt7Y%253D&md5=9ee335040759d61b1bf0f706123cf24e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110547200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110547200%26sid%3Dliteratum%253Aachs%26aulast%3DCunnick%26aufirst%3DJ.%2BM.%26aulast%3DMeng%26aufirst%3DS.%2BS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DDesponts%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DDjeu%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520the%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520by%2520SHP2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D9498%26epage%3D9504%26doi%3D10.1074%2Fjbc.M110547200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naujokas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado-Madruga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8513</span>– <span class="NLM_lpage">8525</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.22.8513-8525.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.20.22.8513-8525.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11046147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFWrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=8513-8525&author=C.+R.+Marounauthor=M.+A.+Naujokasauthor=M.+Holgado-Madrugaauthor=A.+J.+Wongauthor=M.+Park&title=The+tyrosine+phosphatase+SHP-2+is+required+for+sustained+activation+of+extracellular+signal-regulated+kinase+and+epithelial+morphogenesis+downstream+from+the+Met+receptor+tyrosine+kinase&doi=10.1128%2FMCB.20.22.8513-8525.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase</span></div><div class="casAuthors">Maroun, Christiane R.; Naujokas, Monica A.; Holgado-Madruga, Marina; Wong, Albert J.; Park, Morag</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8513-8525</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Epithelial morphogenesis is crit. during development and wound healing, and alterations in this program contribute to neoplasia.  Met, the hepatocyte growth factor (HGF) receptor, promotes a morphogenic program in epithelial cell lines in matrix cultures.  Previous studies have identified Gab1, the major phosphorylated protein following Met activation, as important for the morphogenic response.  Gab1 is a docking protein that couples the Met receptor with multiple signaling proteins, including phosphatidylinositol-3 kinase, phospholipase Cγ, the adapter protein Crk, and the tyrosine specific phosphatase SHP-2.  HGF induces sustained phosphorylation of Gab1 and sustained activation of extracellular signal-regulated kinase (Erk) in epithelial Madin-Darby canine kidney cells.  In contrast, epidermal growth factor fails to promote a morphogenic program and induces transient Gab1 phosphorylation and Erk activation.  To elucidate the Gab1-dependent signals required for epithelial morphogenesis, the authors undertook a structure-function approach and demonstrate that assocn. of Gab1 with the tyrosine phosphatase SHP-2 is required for sustained Erk activation and for epithelial morphogenesis downstream from the Met receptor.  Epithelial cells expressing a Gab1 mutant protein unable to recruit SHP-2 elicit a transient activation of Erk in response to HGF.  Moreover, SHP-2 catalytic activity is required, since the expression of a catalytically inactive SHP-2 mutant, C/S, abrogates sustained activation of Erk and epithelial morphogenesis by the Met receptor.  These data identify SHP-2 as a pos. modulator of Erk activity and epithelial morphogenesis downstream from the Met receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Fb7TTQh5h7Vg90H21EOLACvtfcHk0licgOChROYxzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFWrtLk%253D&md5=11ac09ad73d32eb988e51100514bad38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.22.8513-8525.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.22.8513-8525.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26aulast%3DNaujokas%26aufirst%3DM.%2BA.%26aulast%3DHolgado-Madruga%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%2BJ.%26aulast%3DPark%26aufirst%3DM.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520SHP-2%2520is%2520required%2520for%2520sustained%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinase%2520and%2520epithelial%2520morphogenesis%2520downstream%2520from%2520the%2520Met%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D8513%26epage%3D8525%26doi%3D10.1128%2FMCB.20.22.8513-8525.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1128/MCB.20.5.1526-1536.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.20.5.1526-1536.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10669730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtF2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=1526-1536&author=Z.+Q.+Shiauthor=D.+H.+Yuauthor=M.+Parkauthor=M.+Marshallauthor=G.+S.+Feng&title=Molecular+mechanism+for+the+Shp-2+tyrosine+phosphatase+function+in+promoting+growth+factor+stimulation+of+Erk+activity&doi=10.1128%2FMCB.20.5.1526-1536.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity</span></div><div class="casAuthors">Shi, Zhong-Qing; Yu, De-Hua; Park, Morag; Marshall, Mark; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1526-1536</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We have previously shown that activation of extracellular signal-regulated kinase (Erk) by epidermal growth factor (EGF) treatment was significantly decreased in mouse fibroblast cells expressing a mutant Shp-2 mol. lacking 65 amino acids in the SH2-N domain, Shp-2Δ46-110.  To address the mol. mechanism for the pos. role of Shp-2 in mediating Erk induction, we evaluated the activation of signaling components upstream of Erk in Shp-2 mutant cells.  EGF-stimulated Ras, Raf, and Mek activation was significantly attenuated in Shp-2 mutant cells, suggesting that Shp-2 acts to promote Ras activation or to suppress the down-regulation of activated Ras.  Biochem. analyses indicate that upon EGF stimulation, Shp-2 is recruited into a multiprotein complex assembled on the Gab1 docking mol. and that Shp-2 seems to exert its biol. function by specifically dephosphorylating an unidentified mol. of 90 kDa in the complex.  The mutant Shp-2Δ46-110 mol. failed to participate in the Gab1-organized complex for dephosphorylation of p90, correlating with a defective activation of the Ras-Raf-Mek-Erk cascade in EGF-treated Shp-2 mutant cells.  Evidence is also presented that Shp-2 does not appear to modulate the signal relay from EGF receptor to Ras through the Shc, Grb2, and Sos proteins.  These results begin to elucidate the mechanism of Shp-2 function downstream of a receptor tyrosine kinase to promote the activation of the Ras-Erk pathway, with potential therapeutic applications in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs6Oeb8PVXK7Vg90H21EOLACvtfcHk0lg5xg0qJxfjCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtF2ntr4%253D&md5=6ce724c8a2cdbecd29fdfe1f30f00446</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.5.1526-1536.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.5.1526-1536.2000%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%2BQ.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DMolecular%2520mechanism%2520for%2520the%2520Shp-2%2520tyrosine%2520phosphatase%2520function%2520in%2520promoting%2520growth%2520factor%2520stimulation%2520of%2520Erk%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D1526%26epage%3D1536%26doi%3D10.1128%2FMCB.20.5.1526-1536.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildener-Leapman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span> <span> </span><span class="NLM_article-title">PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-14-1215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25480946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=508-518&author=J.+Liauthor=H.+B.+Jieauthor=Y.+Leiauthor=N.+Gildener-Leapmanauthor=S.+Trivediauthor=T.+Greenauthor=L.+P.+Kaneauthor=R.+L.+Ferris&title=PD-1%2FSHP-2+inhibits+Tc1%2FTh1+phenotypic+responses+and+the+activation+of+T+cells+in+the+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-14-1215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Li, Jing; Jie, Hyun-Bae; Lei, Yu; Gildener-Leapman, Neil; Trivedi, Sumita; Green, Tony; Kane, Lawrence P.; Ferris, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study addresses the mechanisms through which PD-1 antibody therapy restores the ability of the immune system to recognize and attack tumors by skewing intratumoral T cells toward a more potent activation phenotype that is assocd. with enhanced signaling and a reversal of their immunosuppressed phenotype.  Immune rejection of tumors is mediated by IFNγ prodn. and T-cell cytolytic activity.  These processes are impeded by PD-1, a coinhibitory mol. expressed on T cells that is elevated in tumor-infiltrating lymphocytes (TIL).  PD-1 elevation may reflect T-cell exhaustion marked by decreased proliferation, prodn. of type I cytokines, and poor cytolytic activity.  Although anti-PD-1 antibodies enhance IFNγ secretion after stimulation of the T-cell receptor (TCR), the mechanistic link between PD-1 and its effects on T-cell help (Tc1/Th1 skewing) remains unclear.  In prospectively collected cancer tissues, we found that TIL exhibited dampened Tc1/Th1 skewing and activation compared with peripheral blood lymphocytes (PBL).  When PD-1 bound its ligand PD-L1, we obsd. a marked suppression of crit. TCR target genes and Th1 cytokines.  Conversely, PD-1 blockade reversed these suppressive effects of PD-1:PD-L1 ligation.  We also found that the TCR-regulated phosphatase SHP-2 was expressed higher in TIL than in PBL, tightly correlating with PD-1 expression and neg. regulation of TCR target genes.  Overall, these results defined a PD-1/SHP-2/STAT1/T-bet signaling axis mediating the suppressive effects of PD-1 on Th1 immunity at tumor sites.  Our findings argue that PD-1 or SHP-2 blockade will be sufficient to restore robust Th1 immunity and T-cell activation and thereby reverse immunosuppression in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6jAWHNatvLVg90H21EOLACvtfcHk0lg5xg0qJxfjCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D&md5=695007f0715b5eee2b7e47deaf87ae23</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1215%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DH.%2BB.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DGildener-Leapman%26aufirst%3DN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DKane%26aufirst%3DL.%2BP.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26atitle%3DPD-1%252FSHP-2%2520inhibits%2520Tc1%252FTh1%2520phenotypic%2520responses%2520and%2520the%2520activation%2520of%2520T%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D508%26epage%3D518%26doi%3D10.1158%2F0008-5472.CAN-14-1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, R. D.</span></span> <span> </span><span class="NLM_article-title">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.aaf1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.aaf1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28280247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1428-1433&author=E.+F.+Huiauthor=J.+Cheungauthor=J.+Zhuauthor=X.+L.+Suauthor=M.+J.+Taylorauthor=H.+A.+Wallweberauthor=D.+K.+Sasmalauthor=J.+Huangauthor=J.+M.+Kimauthor=I.+Mellmanauthor=R.+D.+Vale&title=T+cell+costimulatory+receptor+CD28+is+a+primary+target+for+PD-1-mediated+inhibition&doi=10.1126%2Fscience.aaf1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span></div><div class="casAuthors">Hui, Enfu; Cheung, Jeanne; Zhu, Jing; Su, Xiaolei; Taylor, Marcus J.; Wallweber, Heidi A.; Sasmal, Dibyendu K.; Huang, Jun; Kim, Jeong M.; Mellman, Ira; Vale, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6332</span>),
    <span class="NLM_cas:pages">1428-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">PD-1-targeted therapies have been a breakthrough for treating certain tumors and can rejuvenate T cells to unleash the anticancer immune response (see the Perspective by Clouthier and Ohashi).  It is widely believed that PD-1 suppresses signaling through the T cell receptor (TCR).  However, Hui et al. find instead that the TCR costimulatory receptor, CD28, is the primary target of PD-1 signaling.  Independently, Kamphorst et al. show that CD28 is required for PD-1 therapies to kill cancer cells efficiently and eliminate chronic viral infections in mice.  Lung cancer patients that responded to PD-1 therapy had more CD28+ T cells, which suggests that CD28 may predict treatment response.  Science, ibid p. 1428, p. 1423; see also p. 1373.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_s4cf1lkxrVg90H21EOLACvtfcHk0lgHO-4qWvH5uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D&md5=69750b99b68316ee035a0b7eeddfb9fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf1292%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DE.%2BF.%26aulast%3DCheung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%2BL.%26aulast%3DTaylor%26aufirst%3DM.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BA.%26aulast%3DSasmal%26aufirst%3DD.%2BK.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DVale%26aufirst%3DR.%2BD.%26atitle%3DT%2520cell%2520costimulatory%2520receptor%2520CD28%2520is%2520a%2520primary%2520target%2520for%2520PD-1-mediated%2520inhibition%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1428%26epage%3D1433%26doi%3D10.1126%2Fscience.aaf1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Germ-line and somatic PTPN11 mutations in human disease. <i>Eur</i></span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejmg.2005.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ejmg.2005.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpsFKrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=81-96&author=M.+Tartagliaauthor=B.+D.+Gelb&title=Germ-line+and+somatic+PTPN11+mutations+in+human+disease.+Eur&doi=10.1016%2Fj.ejmg.2005.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Germ-line and somatic PTPN11 mutations in human disease</span></div><div class="casAuthors">Tartaglia Marco; Gelb Bruce D</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medical genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-96</span>
        ISSN:<span class="NLM_cas:issn">1769-7212</span>.
    </div><div class="casAbstract">Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream intracellular transducers is a major regulatory mechanism used to modulate cellular responses to extracellular stimuli, and its deregulation frequently drives aberrant cell proliferation, survival and/or differentiation.  SHP-2 is a cytoplasmic Src-homology 2 domain-containing protein tyrosine phosphatase that plays an important role in intracellular signaling and is required during development and hematopoiesis.  Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders.  More recently, a distinct class of missense mutations in the same gene has been identified to occur as a somatic event contributing to myeloid and lymphoid malignancies.  This review focuses on the role of SHP-2 in signal transduction, development and hematopoiesis, as well as on the consequences of SHP-2 gain-of-function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6C367GYPEDOxsqfvU0ziafW6udTcc2ebFcrtUCYDhMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpsFKrtQ%253D%253D&md5=b1972274ecf5d806bc83f435600d826b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmg.2005.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmg.2005.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DGerm-line%2520and%2520somatic%2520PTPN11%2520mutations%2520in%2520human%2520disease.%2520Eur%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2005%26volume%3D48%26spage%3D81%26epage%3D96%26doi%3D10.1016%2Fj.ejmg.2005.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R. F.</span></span> <span> </span><span class="NLM_article-title">Functions of Shp2 in cancer</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fjcmm.12618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26088100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=2075-2083&author=J.+Zhangauthor=F.+Zhangauthor=R.+F.+Niu&title=Functions+of+Shp2+in+cancer&doi=10.1111%2Fjcmm.12618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of Shp2 in cancer</span></div><div class="casAuthors">Zhang, Jie; Zhang, Fei; Niu, Ruifang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diagnostics and therapies have shown evident advances.  Tumor surgery, chemotherapy and radiotherapy are the main techniques in treat cancers.  Targeted therapy and drug resistance are the main focus in cancer research, but many mol. intracellular mechanisms remain unknown.  Src homol. region 2-contg. protein tyrosine phosphatase 2 (Shp2) is assocd. with breast cancer, leukemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.  Signalling pathways involving Shp2 have also been discovered.  Shp2 is related to many diseases.  Mutations in the ptpn11 gene cause Noonan syndrome, LEOPARD syndrome and childhood leukemia.  Shp2 is also involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance.  Based on the structure and function of Shp2, scientists have investigated specific mechanisms involved in cancer.  Shp2 may be a potential therapeutic target because this phosphatase is implicated in many aspects.  Furthermore, Shp2 inhibitors have been used in expts. to develop treatment strategies.  However, conflicting results related to Shp2 functions have been presented in the literature, and such results should be resolved in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozU4uZ0Uifx7Vg90H21EOLACvtfcHk0lgHO-4qWvH5uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtb%252FF&md5=fced523e7a96135ecd28883240ad7026</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12618%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DR.%2BF.%26atitle%3DFunctions%2520of%2520Shp2%2520in%2520cancer%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2015%26volume%3D19%26spage%3D2075%26epage%3D2083%26doi%3D10.1111%2Fjcmm.12618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiyama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akagi, T.</span></span> <span> </span><span class="NLM_article-title">Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6390</span>– <span class="NLM_lpage">6394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12438221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFOlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6390-6394&author=T.+Okaauthor=M.+Ouchidaauthor=M.+Koyamaauthor=Y.+Ogamaauthor=S.+Takadaauthor=Y.+Nakataniauthor=T.+Tanakaauthor=T.+Yoshinoauthor=K.+Hayashiauthor=N.+Oharaauthor=E.+Kondoauthor=K.+Takahashiauthor=J.+Tsuchiyamaauthor=M.+Tanimotoauthor=K.+Shimizuauthor=T.+Akagi&title=Gene+silencing+of+the+tyrosine+phosphatase+SHP1+gene+by+aberrant+methylation+in+leukemias%2Flymphomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas</span></div><div class="casAuthors">Oka, Takashi; Ouchida, Mamoru; Koyama, Maho; Ogama, Yoichiro; Takada, Shinichi; Nakatani, Yoko; Tanaka, Takehiro; Yoshino, Tadashi; Hayashi, Kazuhiko; Ohara, Nobuya; Kondo, Eisaku; Takahashi, Kiyoshi; Tsuchiyama, Junjiro; Tanimoto, Mitsune; Shimizu, Kenji; Akagi, Tadaatsu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6390-6394</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High-frequent silencing of hematopoietic cell-specific protein-tyrosine phosphatase SHP1 gene by promoter methylation was detected in various kinds of leukemias and lymphomas, as well as in many hematopoietic cell lines, which is supported by the authors' previous observation of strong decrease of SHP1 mRNA and protein.  The promoter methylation of the SHP1 gene was clearly correlated with the clin. stage.  Loss of heterozygosity with microsatellite markers near the SHP1 gene was shown in 79% of informative acute lymphoblastic leukemia cases.  These results suggest that functional loss of SHP1 is assocd. with the pathogenesis of leukemias/lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtl-YJLqbz7bVg90H21EOLACvtfcHk0lizljvqJHEdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFOlur4%253D&md5=8f9c6d58f20d8500eeb667b56e0d272c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DT.%26aulast%3DOuchida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DM.%26aulast%3DOgama%26aufirst%3DY.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DNakatani%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DOhara%26aufirst%3DN.%26aulast%3DKondo%26aufirst%3DE.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DTsuchiyama%26aufirst%3DJ.%26aulast%3DTanimoto%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DAkagi%26aufirst%3DT.%26atitle%3DGene%2520silencing%2520of%2520the%2520tyrosine%2520phosphatase%2520SHP1%2520gene%2520by%2520aberrant%2520methylation%2520in%2520leukemias%252Flymphomas%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6390%26epage%3D6394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecular weight inhibitors of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7396</span>– <span class="NLM_lpage">7404</span>, <span class="refDoi"> DOI: 10.1021/jm800229d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800229d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7396-7404&author=W.+M.+Yuauthor=O.+Guvenchauthor=A.+D.+MacKerellauthor=C.+K.+Qu&title=Identification+of+small+molecular+weight+inhibitors+of+Src+Homology+2+Domain-Containing+Tyrosine+Phosphatase+2+%28SHP-2%29+via+in+silico+database+screening+combined+with+experimental+assay&doi=10.1021%2Fjm800229d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small Molecular Weight Inhibitors of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 (SHP-2) via in Silico Database Screening Combined with Experimental Assay</span></div><div class="casAuthors">Yu, Wen-Mei; Guvench, Olgun; MacKerell, Alexander D.; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7396-7404</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Virtual screening methods combined with exptl. assays were used to identify low mol. wt. inhibitors for Src homol. 2 domain-contg. phosphatase 2 (SHP-2) that is mutated and hyperactivated in Noonan syndrome and a significant portion of childhood leukemias.  Virtual screening included multiple conformations of the protein, score normalization procedures, and chem. similarity considerations.  As the catalytic core of SHP-2 shares extremely high homol. to those of the related SHP-1 phosphatase and other tyrosine phosphatases, in order to identify selective inhibitors, we chose to target an adjacent protein surface pocket that is predicted to be important for binding to phosphopeptides and that has structural features unique to SHP-2.  From a database of 1.3 million compds., 9 out of 165 computationally selected compds. were shown to inhibit SHP-2 activity with IC50 values of ≈ 100 μM.  Two of the active compds. were further verified for their ability to inhibit SHP-2-mediated cellular functions.  Fluorescence titrn. expts. confirmed their direct binding to SHP-2.  Because of their simple chem. structures, these small org. compds. have the potential to act as lead compds. for the development of novel anti-SHP-2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Kw_2kNl-RbVg90H21EOLACvtfcHk0lizljvqJHEdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrfI&md5=915691bc2e64243286cf305314b3a470</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm800229d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800229d%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%2BM.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DIdentification%2520of%2520small%2520molecular%2520weight%2520inhibitors%2520of%2520Src%2520Homology%25202%2520Domain-Containing%2520Tyrosine%2520Phosphatase%25202%2520%2528SHP-2%2529%2520via%2520in%2520silico%2520database%2520screening%2520combined%2520with%2520experimental%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7396%26epage%3D7404%26doi%3D10.1021%2Fjm800229d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L.</span></span> <span> </span><span class="NLM_article-title">The ’Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0968-0004%2803%2900091-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12826400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=284-293&author=B.+G.+Neelauthor=H.+H.+Guauthor=L.+Pao&title=The+%E2%80%99Shp%E2%80%99ing+news%3A+SH2+domain-containing+tyrosine+phosphatases+in+cell+signaling&doi=10.1016%2FS0968-0004%2803%2900091-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span></div><div class="casAuthors">Neel, Benjamin G.; Gu, Haihua; Pao, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2 (SH2) domain-contg. phosphatases (Shps) are a small, highly conserved subfamily of protein tyrosine phosphatases, members of which are present in both vertebrates and invertebrates.  The mechanism of regulation of Shps by ligand binding is now well understood.  Much is also known about the normal signaling pathways regulated by each Shp and the consequences of Shp deficiency.  Recent studies have identified mutations in human Shp2 as the cause of the inherited disorder, Noonan syndrome.  Shp2 mutations might also contribute to the pathogenesis of some leukemias.  In addn., Shp2 might be a key virulence determinant for the important human pathogen, Helicobacter pylori.  Despite these efforts, however, the key targets of each Shp have remained elusive.  Identifying these substrates remains a major challenge for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zIEChntK0rVg90H21EOLACvtfcHk0lhi6dGoiUJB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D&md5=bce9fc3db0a41b29ba605251dc46c64f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%2BH.%26aulast%3DPao%26aufirst%3DL.%26atitle%3DThe%2520%25E2%2580%2599Shp%25E2%2580%2599ing%2520news%253A%2520SH2%2520domain-containing%2520tyrosine%2520phosphatases%2520in%2520cell%2520signaling%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26spage%3D284%26epage%3D293%26doi%3D10.1016%2FS0968-0004%2803%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">10472</span>– <span class="NLM_lpage">10482</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.450023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M113.450023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvV2qsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=10472-10482&author=Z.+H.+Yuauthor=J.+Xuauthor=C.+D.+Wallsauthor=L.+Chenauthor=S.+Zhangauthor=R.+Y.+Zhangauthor=L.+Wuauthor=L.+N.+Wangauthor=S.+J.+Liuauthor=Z.+Y.+Zhang&title=Structural+and+mechanistic+insights+into+LEOPARD+syndrome-associated+SHP2+mutations&doi=10.1074%2Fjbc.M113.450023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations</span></div><div class="casAuthors">Yu, Zhi-Hong; Xu, Jie; Walls, Chad D.; Chen, Lan; Zhang, Sheng; Zhang, Ruoyu; Wu, Li; Wang, Lina; Liu, Sijiu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">10472-10482</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SHP2 is an allosteric phosphatase essential for growth factor-mediated Ras activation.  Germ-line mutations in SHP2 cause clin. similar LEOPARD and Noonan syndromes, two of several autosomal-dominant conditions characterized by gain-of-function mutations in the Ras pathway.  Interestingly, Noonan syndrome SHP2 mutants are constitutively active, whereas LEOPARD syndrome SHP2 mutants exhibit reduced phosphatase activity.  How do catalytically impaired LEOPARD syndrome mutants engender gain-of-function phenotypes.  Our study reveals that LEOPARD syndrome mutations weaken the intramol. interaction between the N-SH2 and phosphatase domains, leading to a change in SHP2 mol. switching mechanism.  Consequently, LEOPARD syndrome SHP2 mutants bind upstream activators preferentially and are hypersensitive to growth factor stimulation.  They also stay longer with scaffolding adapters, thus prolonging substrate turnover, which compensates for the reduced phosphatase activity.  The study provides a solid framework for understanding how individual SHP2 mutations cause diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2FSxB8n8oKLVg90H21EOLACvtfcHk0lhi6dGoiUJB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvV2qsrg%253D&md5=eddf5aea52051f5471674ac917651298</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.450023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.450023%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWalls%26aufirst%3DC.%2BD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DStructural%2520and%2520mechanistic%2520insights%2520into%2520LEOPARD%2520syndrome-associated%2520SHP2%2520mutations%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D10472%26epage%3D10482%26doi%3D10.1074%2Fjbc.M113.450023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismat, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1038/nm1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15273746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=849-857&author=T.+Arakiauthor=M.+G.+Mohiauthor=F.+A.+Ismatauthor=R.+T.+Bronsonauthor=I.+R.+Williamsauthor=J.+L.+Kutokauthor=W.+T.+Yangauthor=L.+I.+Paoauthor=D.+G.+Gillilandauthor=J.+A.+Epsteinauthor=B.+G.+Neel&title=Mouse+model+of+Noonan+syndrome+reveals+cell+type-+and+gene+dosage-dependent+effects+of+Ptpn11+mutation&doi=10.1038%2Fnm1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</span></div><div class="casAuthors">Araki, Toshiyuki; Mohi, M. Golam; Ismat, Fraz A.; Bronson, Roderick T.; Williams, Ifor R.; Kutok, Jeffery L.; Yang, Wentian; Pao, Lily I.; Gilliland, D. Gary; Epstein, Jonathan A.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">849-857</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Noonan syndrome is a common human autosomal dominant birth defect, characterized by short stature, facial abnormalities, heart defects and possibly increased risk of leukemia.  Mutations of Ptpn11 (also known as Shp2), which encodes the protein-tyrosine phosphatase Shp2, occur in ∼50% of individuals with Noonan syndrome, but their mol., cellular and developmental effects, and the relationship between Noonan syndrome and leukemia, are unclear.  We generated mice expressing the Noonan syndrome-assocd. mutant D61G.  When homozygous, the D61G mutant is embryonic lethal, whereas heterozygotes have decreased viability.  Surviving Ptpn11D61G/+ embryos (∼50%) have short stature, craniofacial abnormalities similar to those in Noonan syndrome, and myeloproliferative disease.  Severely affected Ptpn11D61G/+ embryos (∼50%) have multiple cardiac defects similar to those in mice lacking the Ras-GAP protein neurofibromin.  Their endocardial cushions have increased Erk activation, but Erk hyperactivation is cell and pathway specific.  Our results clarify the relationship between Noonan syndrome and leukemia and show that a single Ptpn11 gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage-dependent and pathway-selective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsmxo_WGTel7Vg90H21EOLACvtfcHk0lhkIrkKmafBLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWrt78%253D&md5=69aae2a9730455356988fa32e7652c00</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnm1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1084%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DIsmat%26aufirst%3DF.%2BA.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DWilliams%26aufirst%3DI.%2BR.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DW.%2BT.%26aulast%3DPao%26aufirst%3DL.%2BI.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DEpstein%26aufirst%3DJ.%2BA.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DMouse%2520model%2520of%2520Noonan%2520syndrome%2520reveals%2520cell%2520type-%2520and%2520gene%2520dosage-dependent%2520effects%2520of%2520Ptpn11%2520mutation%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D849%26epage%3D857%26doi%3D10.1038%2Fnm1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leedy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munugalavadla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhorst, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span> <span> </span><span class="NLM_article-title">Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3737</span>– <span class="NLM_lpage">3742</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-10-4002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15644411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFejtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=3737-3742&author=R.+J.+Chanauthor=M.+B.+Leedyauthor=V.+Munugalavadlaauthor=C.+S.+Voorhorstauthor=Y.+J.+Liauthor=M.+G.+Yuauthor=R.+Kapur&title=Human+somatic+PTPN11+mutations+induce+hematopoietic-cell+hypersensitivity+to+granulocyte-macrophage+colony-stimulating+factor&doi=10.1182%2Fblood-2004-10-4002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor</span></div><div class="casAuthors">Chan, Rebecca J.; Leedy, Melissa B.; Munugalavadla, Veerendra; Voorhorst, Cara S.; Li, Yanjun; Yu, Menggang; Kapur, Reuben</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3737-3742</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Juvenile myelomonocytic leukemia (JMML) is a lethal disease of young children characterized by hypersensitivity of hematopoietic progenitors to granulocyte-macrophage colony-stimulating factor (GM-CSF).  Mutations in PTPN11, which encodes the protein tyrosine phosphatase Shp-2, are common in JMML.  We hypothesized that PTPN11 mutations induce hypersensitivity of hematopoietic progenitors to GM-CSF and confer increased GM-CSF-stimulated phospho-extracellular signal-regulated kinase (Erk) levels.  To test this hypothesis, the wild-type (WT) and 3 mutant Ptpn11 cDNAs (E76K, D61V, and D61Y) were transduced into murine bone marrow cells to examine GM-CSF-stimulated granulocyte-macrophage colony-forming unit (CFU-GM) growth, macrophage progenitor proliferation, and activation of the Ras signaling pathway.  Expression of the Shp-2 mutants induced progenitor cell hypersensitivity to GM-CSF compared with cells transduced with vector alone or WT Shp-2.  Macrophage progenitors expressing the Shp-2 mutants displayed both basal and GM-CSF-stimulated hyperproliferation compared with cells transduced with vector alone or WT Shp-2.  Consistently, macrophage progenitors transduced with the Shp-2 mutants demonstrated constitutively elevated phospho-Erk levels and sustained activation of phospho-Erk following GM-CSF stimulation compared with vector alone or WT Shp-2.  These data support the hypothesis that PTPN11 mutations induce hematopoietic progenitor hypersensitivity to GM-CSF due to hyperactivation of the Ras signaling axis and provide a basis for the GM-CSF signaling pathway as a target for rational drug design in JMML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDzelkPWl227Vg90H21EOLACvtfcHk0lhkIrkKmafBLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFejtLY%253D&md5=3120af906beb1ae08c2b6717a6030235</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4002%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DLeedy%26aufirst%3DM.%2BB.%26aulast%3DMunugalavadla%26aufirst%3DV.%26aulast%3DVoorhorst%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DM.%2BG.%26aulast%3DKapur%26aufirst%3DR.%26atitle%3DHuman%2520somatic%2520PTPN11%2520mutations%2520induce%2520hematopoietic-cell%2520hypersensitivity%2520to%2520granulocyte-macrophage%2520colony-stimulating%2520factor%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D3737%26epage%3D3742%26doi%3D10.1182%2Fblood-2004-10-4002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z. R.</span></span> <span> </span><span class="NLM_article-title">Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2639</span>– <span class="NLM_lpage">2643</span>, <span class="refDoi"> DOI: 10.3892/mmr.2016.5547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.3892%2Fmmr.2016.5547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27484170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSjtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2639-2643&author=J.+Zhangauthor=J.+W.+Shenauthor=R.+H.+Chengauthor=C.+Niauthor=J.+Y.+Liangauthor=M.+Liauthor=Z.+R.+Yao&title=Identification+of+a+PTPN11+hot+spot+mutation+in+a+child+with+atypical+LEOPARD+syndrome&doi=10.3892%2Fmmr.2016.5547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome</span></div><div class="casAuthors">Zhang, Jia; Shen, Jinwen; Cheng, Ruhong; Ni, Cheng; Liang, Jianying; Li, Ming; Yao, Zhirong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2639-2643</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">LEOPARD syndrome (LS) is an autosomal dominant inherited disorder primarily caused by mutations in the PTPN11, RAF1 and BRAF genes.  Characteristic features include lentigines, craniofacial dysmorphism, myocardium or valve abnormalities, eletrocardiog. conduction defects and deafness.  LS, neurofibromatosis type 1, Noonan syndrome and Legius syndrome are a group of highly overlapped disorders termed 'RASopathies'.  Therefore, clin. discrimination between these syndromes represents a huge challenge.  The present study reports a young child diagnosed with LS via identification of a common p.Thr468Met mutation in PTPN11.  Taking into account two Taiwanese LS cases with an identical mutation, Thr468Met is likely to be the most prevalent mutation in the Chinese population.  Furthermore, this study suggests that a clin. diagnosis of LS should be considered for individuals with congenital cardiac defects and atypical lentigines (i.e., light brown freckles) scattered particularly on the face.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWyNq3-2cy7Vg90H21EOLACvtfcHk0liO4W3QJOgPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSjtbvL&md5=dc00abe698beda2030812b6c49e9983a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5547%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%2BW.%26aulast%3DCheng%26aufirst%3DR.%2BH.%26aulast%3DNi%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DZ.%2BR.%26atitle%3DIdentification%2520of%2520a%2520PTPN11%2520hot%2520spot%2520mutation%2520in%2520a%2520child%2520with%2520atypical%2520LEOPARD%2520syndrome%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D2639%26epage%3D2643%26doi%3D10.3892%2Fmmr.2016.5547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarbaker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">8816</span>– <span class="NLM_lpage">8820</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-04-1923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15604238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOms7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=8816-8820&author=M.+Bentires-Aljauthor=J.+G.+Paezauthor=F.+S.+Davidauthor=H.+Keilhackauthor=B.+Halmosauthor=K.+Naokiauthor=J.+M.+Marisauthor=A.+Richardsonauthor=A.+Bardelliauthor=D.+J.+Sugarbakerauthor=W.+G.+Richardsauthor=J.+Y.+Duauthor=L.+Girardauthor=J.+D.+Minnaauthor=M.+L.+Lohauthor=D.+E.+Fisherauthor=V.+E.+Velculescuauthor=B.+Vogelsteinauthor=M.+Meyersonauthor=W.+R.+Sellersauthor=B.+G.+Neel&title=Activating+mutations+of+the+Noonan+syndrome-associated+SHP2%2FPTPN11+gene+in+human+solid+tumors+and+adult+acute+myelogenous+leukemia&doi=10.1158%2F0008-5472.CAN-04-1923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia</span></div><div class="casAuthors">Bentires-Alj, Mohamed; Paez, J. Guillermo; David, Frank S.; Keilhack, Heike; Halmos, Balazs; Naoki, Katsuhiko; Maris, John M.; Richardson, Andrea; Bardelli, Alberto; Sugarbaker, David J.; Richards, William G.; Du, Jinyan; Girard, Luc; Minna, John D.; Loh, Mignon L.; Fisher, David E.; Velculescu, Victor E.; Vogelstein, Bert; Meyerson, Matthew; Sellers, William R.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8816-8820</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The SH2 domain-contg. protein-tyrosine phosphatase PTPN11 (Shp2) is required for normal development and is an essential component of signaling pathways initiated by growth factors, cytokines, and extracellular matrix.  In many of these pathways, Shp2 acts upstream of Ras.  About 50% of patients with Noonan syndrome have germ-line PTPN11 gain of function mutations.  Assocns. between Noonan syndrome and an increased risk of some malignancies, notably leukemia and neuroblastoma, have been reported, and recent data indicate that somatic PTPN11 mutations occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia (AML).  Juvenile myelomonocytic leukemia patients without PTPN11 mutations have either homozygotic NF-1 deletion or activating RAS mutations.  Given the role of Shp2 in Ras activation and the frequent mutation of RAS in human tumors, these data raise the possibility that PTPN11 mutations play a broader role in cancer.  The authors asked whether PTPN11 mutations occur in other malignancies in which activating RAS mutations occur at low but significant frequency.  Sequencing of PTPN11 from 13 different human neoplasms including breast, lung, gastric, and neuroblastoma tumors and adult AML and acute lymphoblastic leukemia revealed 11 missense mutations.  Five are known mutations predicted to result in an activated form of Shp2, whereas six are new mutations.  Biochem. anal. confirmed that several of the new mutations result in increased Shp2 activity.  The data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, esp. neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3taKvDtHXBLVg90H21EOLACvtfcHk0liO4W3QJOgPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOms7fK&md5=f6f9fb8c6e9d5260901a03081db259c7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1923%26sid%3Dliteratum%253Aachs%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DDavid%26aufirst%3DF.%2BS.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DActivating%2520mutations%2520of%2520the%2520Noonan%2520syndrome-associated%2520SHP2%252FPTPN11%2520gene%2520in%2520human%2520solid%2520tumors%2520and%2520adult%2520acute%2520myelogenous%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D8816%26epage%3D8820%26doi%3D10.1158%2F0008-5472.CAN-04-1923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic acid based small molecule inhibitor for the oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+T.+Heauthor=S.+J.+Liuauthor=Z.+H.+Yuauthor=Z.+X.+Jiangauthor=Z.+Y.+Yangauthor=Y.+S.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+N.+Wangauthor=R.+J.+Chanauthor=Z.+Y.+Zhang&title=Salicylic+acid+based+small+molecule+inhibitor+for+the+oncogenic+Src+Homology-2+Domain+Containing+Protein+Tyrosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0lhXYlA88SfsJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DDong%26aufirst%3DY.%2BS.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSalicylic%2520acid%2520based%2520small%2520molecule%2520inhibitor%2520for%2520the%2520oncogenic%2520Src%2520Homology-2%2520Domain%2520Containing%2520Protein%2520Tyrosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+tyrosine+phosphatase+Shp2+%28PTPN11%29+in+cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lhXYlA88SfsJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520tyrosine%2520phosphatase%2520Shp2%2520%2528PTPN11%2529%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tate, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutselakis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jupe, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponting, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramshaw, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rye, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speedy, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefancsik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, S. A.</span></span> <span> </span><span class="NLM_article-title">COSMIC: the catalogue of somatic mutations in cancer</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D941</span>– <span class="NLM_lpage">D947</span>, <span class="refDoi"> DOI: 10.1093/nar/gky1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1093%2Fnar%2Fgky1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30371878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cgt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D941-D947&author=J.+G.+Tateauthor=S.+Bamfordauthor=H.+C.+Jubbauthor=Z.+Sondkaauthor=D.+M.+Beareauthor=N.+Bindalauthor=H.+Boutselakisauthor=C.+G.+Coleauthor=C.+Creatoreauthor=E.+Dawsonauthor=P.+Fishauthor=B.+Harshaauthor=C.+Hathawayauthor=S.+C.+Jupeauthor=C.+Y.+Kokauthor=K.+Nobleauthor=L.+Pontingauthor=C.+C.+Ramshawauthor=C.+E.+Ryeauthor=H.+E.+Speedyauthor=R.+Stefancsikauthor=S.+L.+Thompsonauthor=S.+C.+Wangauthor=S.+Wardauthor=P.+J.+Campbellauthor=S.+A.+Forbes&title=COSMIC%3A+the+catalogue+of+somatic+mutations+in+cancer&doi=10.1093%2Fnar%2Fgky1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">COSMIC: the Catalogue Of Somatic Mutations In Cancer</span></div><div class="casAuthors">Tate, John G.; Bamford, Sally; Jubb, Harry C.; Sondka, Zbyslaw; Beare, David M.; Bindal, Nidhi; Boutselakis, Harry; Cole, Charlotte G.; Creatore, Celestino; Dawson, Elisabeth; Fish, Peter; Harsha, Bhavana; Hathaway, Charlie; Jupe, Steve C.; Kok, Chai Yin; Noble, Kate; Ponting, Laura; Ramshaw, Christopher C.; Rye, Claire E.; Speedy, Helen E.; Stefancsik, Ray; Thompson, Sam L.; Wang, Shicai; Ward, Sari; Campbell, Peter J.; Forbes, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D941-D947</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">COSMIC, the Catalog Of Somatic Mutations In Cancer (https://cancer.sanger.ac.uk) is the most detailed and comprehensive resource for exploring the effect of somatic mutations in human cancer.  The latest release, COSMIC v86 (August 2018), includes almost 6 million coding mutations across 1.4 million tumor samples, curated from over 26,000 publications.  In addn. to coding mutations, COSMIC covers all the genetic mechanisms by which somatic mutations promote cancer, including non-coding mutations, gene fusions, copy-no. variants and drug resistance mutations.  COSMIC is primarily handcurated, ensuring quality, accuracy and descriptive data capture.  Building on our manual curation processes, we are introducing new initiatives that allow us to prioritize key genes and diseases, and to react more quickly and comprehensively to new findings in the literature.  Alongside improvements to the public website and data-download systems, new functionality in COSMIC-3D allows exploration of mutations within three-dimensional protein structures, their protein structural and functional impacts, and implications for druggability.  In parallel with COSMIC's deep and broad variant coverage, the Cancer Gene Census (CGC) describes a curated catalog of genes driving every form of human cancer.  Currently describing 719 genes, the CGC has recently introduced functional descriptions of how each gene drives disease, summarized into the 10 cancer Hallmarks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyWHUT512HAbVg90H21EOLACvtfcHk0li0UKY4RXaEjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cgt7bM&md5=56574cedbe9adc54c097a5af5fe41eb8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1015%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DJ.%2BG.%26aulast%3DBamford%26aufirst%3DS.%26aulast%3DJubb%26aufirst%3DH.%2BC.%26aulast%3DSondka%26aufirst%3DZ.%26aulast%3DBeare%26aufirst%3DD.%2BM.%26aulast%3DBindal%26aufirst%3DN.%26aulast%3DBoutselakis%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DC.%2BG.%26aulast%3DCreatore%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DE.%26aulast%3DFish%26aufirst%3DP.%26aulast%3DHarsha%26aufirst%3DB.%26aulast%3DHathaway%26aufirst%3DC.%26aulast%3DJupe%26aufirst%3DS.%2BC.%26aulast%3DKok%26aufirst%3DC.%2BY.%26aulast%3DNoble%26aufirst%3DK.%26aulast%3DPonting%26aufirst%3DL.%26aulast%3DRamshaw%26aufirst%3DC.%2BC.%26aulast%3DRye%26aufirst%3DC.%2BE.%26aulast%3DSpeedy%26aufirst%3DH.%2BE.%26aulast%3DStefancsik%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DWard%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DForbes%26aufirst%3DS.%2BA.%26atitle%3DCOSMIC%253A%2520the%2520catalogue%2520of%2520somatic%2520mutations%2520in%2520cancer%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD941%26epage%3DD947%26doi%3D10.1093%2Fnar%2Fgky1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span>; <span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Noonan syndrome and related disorders: Genetics and pathogenesis</span>. In  <i>Annual Review of Genomics and Human Genetics</i>; <span class="NLM_publisher-name">Annual Reviews</span>: <span class="NLM_publisher-loc">Palo Alto, CA</span>, <span class="NLM_year">2005</span>; Vol.  <span class="NLM_volume">6</span>, pp  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">68</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1146%2Fannurev.genom.6.080604.162305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=45-68&author=M.+Tartaglia&author=B.+D.+Gelb&title=Annual+Review+of+Genomics+and+Human+Genetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1146%2Fannurev.genom.6.080604.162305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1146%252Fannurev.genom.6.080604.162305%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26atitle%3DNoonan%2520syndrome%2520and%2520related%2520disorders%253A%2520Genetics%2520and%2520pathogenesis%26btitle%3DAnnual%2520Review%2520of%2520Genomics%2520and%2520Human%2520Genetics%26pub%3DAnnual%2520Reviews%26date%3D2005%26volume%3D6%26spage%3D45%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The role of Shp2 (PTPN11) in cancer</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2006.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.gde.2006.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17227708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=23-30&author=M.+G.+Mohiauthor=B.+G.+Neel&title=The+role+of+Shp2+%28PTPN11%29+in+cancer&doi=10.1016%2Fj.gde.2006.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Mohi, M. Golam; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes.  Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer.  Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene.  We now know that at least one other PTP, the SH2 domain-contg. phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors.  Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0V_cNPfFwLVg90H21EOLACvtfcHk0li0UKY4RXaEjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOgtQ%253D%253D&md5=a571192d3fffdff69ddfc264bb9108ce</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520role%2520of%2520Shp2%2520%2528PTPN11%2529%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.gde.2006.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span> <span> </span><span class="NLM_article-title">Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-14-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1186%2F1472-6807-14-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24628801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCmsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=10&author=W.+Qiuauthor=X.+N.+Wangauthor=V.+Romanovauthor=A.+Hutchinsonauthor=A.+Linauthor=M.+Ruzanovauthor=K.+P.+Battaileauthor=E.+F.+Paiauthor=B.+G.+Neelauthor=N.+Y.+Chirgadze&title=Structural+insights+into+Noonan%2FLEOPARD+syndrome-related+mutants+of+protein-tyrosine+phosphatase+SHP2+%28PTPN11%29&doi=10.1186%2F1472-6807-14-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)</span></div><div class="casAuthors">Qiu, Wei; Wang, Xiaonan; Romanov, Vladimir; Hutchinson, Ashley; Lin, Andres; Ruzanov, Maxim; Battaile, Kevin P.; Pai, Emil F.; Neel, Benjamin G.; Chirgadze, Nickolay Y.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Structural Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">BSBMBB</span>;
        ISSN:<span class="NLM_cas:issn">1472-6807</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The ubiquitous non-receptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) plays a key role in RAS/ERK signaling downstream of most, if not all growth factors, cytokines and integrins, although its major substrates remain controversial.  Mutations in PTPN11 lead to several distinct human diseases.  Germ-line PTPN11 mutations cause about 50% of Noonan Syndrome (NS), which is among the most common autosomal dominant disorders.  LEOPARD Syndrome (LS) is an acronym for its major syndromic manifestations: multiple Lentigines, Electrocardiog. abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormalities of genitalia, Retardation of growth, and sensorineural Deafness.  Frequently, LS patients have hypertrophic cardiomyopathy, and they might also have an increased risk of neuroblastoma (NS) and acute myeloid leukemia (AML).  Consistent with the distinct pathogenesis of NS and LS, different types of PTPN11 mutations cause these disorders.  Although multiple studies have reported the biochem. and biol. consequences of NS- and LS-assocd. PTPN11 mutations, their structural consequences have not been analyzed fully.  Here we report the crystal structures of WT SHP2 and five NS/LS-assocd. SHP2 mutants.  These findings enable direct structural comparisons of the local conformational changes caused by each mutation.  Our structural anal. agrees with, and provides addnl. mechanistic insight into, the previously reported catalytic properties of these mutants.  The results of our research provide new information regarding the structure-function relationship of this medically important target, and should serve as a solid foundation for structure-based drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbrX4o8Z0i8rVg90H21EOLACvtfcHk0lhJv54E6amAYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCmsrbP&md5=d6830509c6a36e299806f872570c51a6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-14-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-14-10%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%2BN.%26aulast%3DRomanov%26aufirst%3DV.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26atitle%3DStructural%2520insights%2520into%2520Noonan%252FLEOPARD%2520syndrome-related%2520mutants%2520of%2520protein-tyrosine%2520phosphatase%2520SHP2%2520%2528PTPN11%2529%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2014%26volume%3D14%26spage%3D10%26doi%3D10.1186%2F1472-6807-14-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-10-4057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16030196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3142-3149&author=R.+Z.+Xuauthor=Y.+Yuauthor=S.+Zhengauthor=X.+Y.+Zhaoauthor=Q.+H.+Dongauthor=Z.+W.+Heauthor=Y.+Liangauthor=Q.+H.+Luauthor=Y.+M.+Fangauthor=X.+X.+Ganauthor=X.+H.+Xuauthor=S.+Z.+Zhangauthor=Q.+Dongauthor=X.+H.+Zhangauthor=G.+S.+Feng&title=Overexpression+of+Shp2+tyrosine+phosphatase+is+implicated+in+leukemogenesis+in+adult+human+leukemia&doi=10.1182%2Fblood-2004-10-4057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia</span></div><div class="casAuthors">Xu, Rongzhen; Yu, Yingzi; Zheng, Shu; Zhao, Xiaoying; Dong, Qinghua; He, Zhiwen; Liang, Yun; Lu, Qinghua; Fang, Yongmin; Gan, Xiaoxian; Xu, Xiaohua; Zhang, Suzhan; Dong, Qi; Zhang, Xiaohong; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3142-3149</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Shp2 tyrosine phosphatase plays a crit. role in hematopoiesis, and dominant active mutations were detected in the human gene PTPN11, encoding Shp2, in child leukemia patients.  The authors report here that although no such mutations were detected in 44 adult leukemia patients screened, Shp2 expression levels were significantly elevated in primary leukemia cells and leukemia cell lines, as compared with normal hematopoietic progenitor cells.  The Shp2 protein amts. correlated well with the hyperproliferative capacity but were inversely assocd. with the differentiation degree of leukemia cells.  Suppression of Shp2 expression induced apoptosis and inhibition of leukemic cell clonogenic growth.  Notably, the majority of Shp2 was preferentially localized to the plasma membrane and was constitutively phosphorylated on tyrosine in leukemia cells, and also in normal hematopoietic cells following mitogenic stimulation.  Based on these results, the authors propose that aberrantly increased expression of Shp2 may contribute, collaboratively with other factors, to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBjdoCIKiqrVg90H21EOLACvtfcHk0lhJv54E6amAYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr3I&md5=22c0a22421a9fa0b7faca326b61f0c27</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4057%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%2BY.%26aulast%3DDong%26aufirst%3DQ.%2BH.%26aulast%3DHe%26aufirst%3DZ.%2BW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DQ.%2BH.%26aulast%3DFang%26aufirst%3DY.%2BM.%26aulast%3DGan%26aufirst%3DX.%2BX.%26aulast%3DXu%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DS.%2BZ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DOverexpression%2520of%2520Shp2%2520tyrosine%2520phosphatase%2520is%2520implicated%2520in%2520leukemogenesis%2520in%2520adult%2520human%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3142%26epage%3D3149%26doi%3D10.1182%2Fblood-2004-10-4057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzaniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giarin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrangeli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorcini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span> <span> </span><span class="NLM_article-title">Somatic PTPN11 mutations in childhood acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2005.05457.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1365-2141.2005.05457.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15842656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlWntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=333-339&author=M.+Tartagliaauthor=S.+Martinelliauthor=I.+Iavaroneauthor=G.+Cazzanigaauthor=M.+Spinelliauthor=E.+Giarinauthor=V.+Petrangeliauthor=C.+Cartaauthor=R.+Masettiauthor=M.+Aricoauthor=F.+Locatelliauthor=G.+Bassoauthor=M.+Sorciniauthor=A.+Pessionauthor=A.+Biondi&title=Somatic+PTPN11+mutations+in+childhood+acute+myeloid+leukaemia&doi=10.1111%2Fj.1365-2141.2005.05457.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic PTPN11 mutations in childhood acute myeloid leukaemia</span></div><div class="casAuthors">Tartaglia, Marco; Martinelli, Simone; Iavarone, Ivano; Cazzaniga, Giovanni; Spinelli, Monica; Giarin, Emanuela; Petrangeli, Valentina; Carta, Claudio; Masetti, Riccardo; Arico, Maurizio; Locatelli, Franco; Basso, Giuseppe; Sorcini, Mariella; Pession, Andrea; Biondi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-339</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukemogenesis.  In a recent study of 69 children and adolescents with de novo acute myeloid leukemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes.  Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases).  Here, we report on the results of a mol. screening performed on 181 addnl. unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clin. relevance.  We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4·4%), although they recur in a considerable percentage of patients with FAB-M5 (18%).  PTPN11 lesions rarely occur in other subtypes.  Within the FAB-M5 group no clear assocn. of PTPN11 mutations with any clin. variable was evident.  Nearly two third of the patients with this subtype were found to harbor an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUZ4vnyzIembVg90H21EOLACvtfcHk0ljlPmzujhwRXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlWntL8%253D&md5=d43133a39091c175b1f0e7355ec0c96f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2005.05457.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2005.05457.x%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DS.%26aulast%3DIavarone%26aufirst%3DI.%26aulast%3DCazzaniga%26aufirst%3DG.%26aulast%3DSpinelli%26aufirst%3DM.%26aulast%3DGiarin%26aufirst%3DE.%26aulast%3DPetrangeli%26aufirst%3DV.%26aulast%3DCarta%26aufirst%3DC.%26aulast%3DMasetti%26aufirst%3DR.%26aulast%3DArico%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DSorcini%26aufirst%3DM.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26atitle%3DSomatic%2520PTPN11%2520mutations%2520in%2520childhood%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2005%26volume%3D129%26spage%3D333%26epage%3D339%26doi%3D10.1111%2Fj.1365-2141.2005.05457.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span> <span> </span><span class="NLM_article-title">A role for the scaffolding adapter GAB2 in breast cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nm1341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm1341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16369543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=114-121&author=M.+Bentires-Aljauthor=S.+G.+Gilauthor=R.+Chanauthor=Z.+G.+C.+Wangauthor=Y.+P.+Wangauthor=N.+Imanakaauthor=L.+N.+Harrisauthor=A.+Richardsonauthor=B.+G.+Neelauthor=H.+H.+Gu&title=A+role+for+the+scaffolding+adapter+GAB2+in+breast+cancer&doi=10.1038%2Fnm1341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A role for the scaffolding adapter GAB2 in breast cancer</span></div><div class="casAuthors">Bentires-Alj, Mohamed; Gil, Susana G.; Chan, Richard; Wang, Zhigang C.; Wang, Yongping; Imanaka, Naoko; Harris, Lyndsay N.; Richardson, Andrea; Neel, Benjamin G.; Gu, Haihua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-121</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The scaffolding adapter GAB2 maps to a region (11q13-14) commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and primary tumors, but its functional role in mammary carcinogenesis has remained unexplored.  We found that overexpression of GAB2 (Grb2-assocd. binding protein 2) increases proliferation of MCF10A mammary cells in three-dimensional culture.  Coexpression of GAB2 with antiapoptotic oncogenes causes lumenal filling, whereas coexpression with Neu (also known as ErbB2 and HER2) results in an invasive phenotype.  These effects of GAB2 are mediated by hyperactivation of the Shp2-Erk pathway.  Furthermore, overexpression of Gab2 potentiates, whereas deficiency of Gab2 ameliorates, Neu-evoked breast carcinogenesis in mice.  Finally, GAB2 is amplified in some GAB2-overexpressing human breast tumors.  Our data suggest that GAB2 may be a key gene within an 11q13 amplicon in human breast cancer and propose a role for overexpression of GAB2 in mammary carcinogenesis.  Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTgOzDFXnf37Vg90H21EOLACvtfcHk0ljlPmzujhwRXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KmsA%253D%253D&md5=d1cad81db61467b25fecd674ed6cdc8c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnm1341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1341%26sid%3Dliteratum%253Aachs%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DS.%2BG.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DZ.%2BG.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DImanaka%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%2BH.%26atitle%3DA%2520role%2520for%2520the%2520scaffolding%2520adapter%2520GAB2%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D114%26epage%3D121%26doi%3D10.1038%2Fnm1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bocanegra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajput, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langerod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntsman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borresen-Dale, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span> <span> </span><span class="NLM_article-title">Focal amplification and oncogene dependency of GAB2 in breast cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fonc.2009.364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19881546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=774-779&author=M.+Bocanegraauthor=A.+Bergamaschiauthor=Y.+H.+Kimauthor=M.+A.+Millerauthor=A.+B.+Rajputauthor=J.+Kaoauthor=A.+Langerodauthor=W.+Hanauthor=D.+Y.+Nohauthor=S.+S.+Jeffreyauthor=D.+G.+Huntsmanauthor=A.+L.+Borresen-Daleauthor=J.+R.+Pollack&title=Focal+amplification+and+oncogene+dependency+of+GAB2+in+breast+cancer&doi=10.1038%2Fonc.2009.364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Focal amplification and oncogene dependency of GAB2 in breast cancer</span></div><div class="casAuthors">Bocanegra, M.; Bergamaschi, A.; Kim, Y. H.; Miller, M. A.; Rajput, A. B.; Kao, J.; Langerod, A.; Han, W.; Noh, D.-Y.; Jeffrey, S. S.; Huntsman, D. G.; Borresen-Dale, A.-L.; Pollack, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addn. to cyclin D1 (CCND1).  One such candidate, the scaffolding adapter protein, GRB2-assocd. binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer.  However, the amplification status and function of GAB2 in the context of amplification remain undefined.  In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we obsd. focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role.  Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling.  GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2.  Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKkR4hV7pYArVg90H21EOLACvtfcHk0ljHm-CdtLgU0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7nE&md5=2151d9c9c72ea83e0888d658d6ae63e5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.364%26sid%3Dliteratum%253Aachs%26aulast%3DBocanegra%26aufirst%3DM.%26aulast%3DBergamaschi%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DRajput%26aufirst%3DA.%2BB.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DLangerod%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DNoh%26aufirst%3DD.%2BY.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DHuntsman%26aufirst%3DD.%2BG.%26aulast%3DBorresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26atitle%3DFocal%2520amplification%2520and%2520oncogene%2520dependency%2520of%2520GAB2%2520in%2520breast%2520cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D774%26epage%3D779%26doi%3D10.1038%2Fonc.2009.364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducatman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agazie, Y. M.</span></span> <span> </span><span class="NLM_article-title">SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis</span>. <i>Histopathology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2559.2008.03103.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1365-2559.2008.03103.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18643929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2008&pages=389-402&author=X.+Zhouauthor=J.+Coadauthor=B.+Ducatmanauthor=Y.+M.+Agazie&title=SHP2+is+up-regulated+in+breast+cancer+cells+and+in+infiltrating+ductal+carcinoma+of+the+breast%2C+implying+its+involvement+in+breast+oncogenesis&doi=10.1111%2Fj.1365-2559.2008.03103.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis</span></div><div class="casAuthors">Zhou X; Coad J; Ducatman B; Agazie Y M</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-402</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  To determine whether Src homology phosphotyrosyl phosphatase 2 (SHP2) is up-regulated in breast cancer and, if so, to determine whether its up-regulation has any relationship with clinical variables of breast cancer.  METHODS AND RESULTS:  Immunoblotting, immunohistochemistry and immunofluorescence microscopy were used to assess the state of SHP2 expression in breast cancer cells and in infiltrating ductal carcinoma (IDC) of breast.  The possible role of SHP2 in breast cancer cell transformation was determined by dominant-negative expression and anchorage-independent growth assays.  All of the breast cancer cell lines tested and 72% of IDC breast tumours analysed had increased amounts of the SHP2 protein.  In support of its positive role, dominant-negative SHP2 blocked anchorage-independent growth of breast cancer cells.  Furthermore, overexpression of SHP2 seemed to have a positive relationship to HER2 overexpression, nuclear accumulation of hormone receptors, higher tumour grade and lymph node metastasis, but not to age of breast cancer patients.  CONCLUSION:  SHP2 is a widely overexpressed signalling protein in IDC breast tumours.  Given SHP2's positive role in cell growth, transformation and stem cell survival, the positive relationship of its overexpression to lymph node metastasis, nuclear accumulation of hormone receptors and higher tumour grade suggests that SHP2 promotes breast oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIF5GvxYY_9-cVm4E2RlLfW6udTcc2eb4AI0M-cLnCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhsFyksA%253D%253D&md5=83c19a6cc4a7b70d8accd75f9b83a169</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2008.03103.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2008.03103.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DCoad%26aufirst%3DJ.%26aulast%3DDucatman%26aufirst%3DB.%26aulast%3DAgazie%26aufirst%3DY.%2BM.%26atitle%3DSHP2%2520is%2520up-regulated%2520in%2520breast%2520cancer%2520cells%2520and%2520in%2520infiltrating%2520ductal%2520carcinoma%2520of%2520the%2520breast%252C%2520implying%2520its%2520involvement%2520in%2520breast%2520oncogenesis%26jtitle%3DHistopathology%26date%3D2008%26volume%3D53%26spage%3D389%26epage%3D402%26doi%3D10.1111%2Fj.1365-2559.2008.03103.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausgruber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkhaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidatzis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzarol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confalonieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balwierz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachkov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nimwegen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentires-Alj, M.</span></span> <span> </span><span class="NLM_article-title">Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1038/nm.2645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm.2645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22388088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1yisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=529-537&author=N.+Acetoauthor=N.+Sausgruberauthor=H.+Brinkhausauthor=D.+Gaidatzisauthor=G.+Martiny-Baronauthor=G.+Mazzarolauthor=S.+Confalonieriauthor=M.+Quartoauthor=G.+Huauthor=P.+J.+Balwierzauthor=M.+Pachkovauthor=S.+J.+Elledgeauthor=E.+van+Nimwegenauthor=M.+B.+Stadlerauthor=M.+Bentires-Alj&title=Tyrosine+phosphatase+SHP2+promotes+breast+cancer+progression+and+maintains+tumor-initiating+cells+via+activation+of+key+transcription+factors+and+a+positive+feedback+signaling+loop&doi=10.1038%2Fnm.2645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop</span></div><div class="casAuthors">Aceto, Nicola; Sausgruber, Nina; Brinkhaus, Heike; Gaidatzis, Dimos; Martiny-Baron, Georg; Mazzarol, Giovanni; Confalonieri, Stefano; Quarto, Micaela; Hu, Guang; Balwierz, Piotr J.; Pachkov, Mikhail; Elledge, Stephen J.; van Nimwegen, Erik; Stadler, Michael B.; Bentires-Alj, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New cancer therapies are likely to arise from an in-depth understanding of the signaling networks influencing tumor initiation, progression and metastasis.  We show a fundamental role for Src-homol. 2 domain-contg. phosphatase 2 (SHP2) in these processes in human epidermal growth factor receptor 2 (HER2)-pos. and triple-neg. breast cancers.  Knockdown of SHP2 eradicated breast tumor-initiating cells in xenograft models, and SHP2 depletion also prevented invasion in three-dimensional cultures and in a transductal invasion assay in vivo.  Notably, SHP2 knockdown in established breast tumors blocked their growth and reduced metastasis.  Mechanistically, SHP2 activated stemness-assocd. transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.  We found these genes to be simultaneously activated in a large subset of human primary breast tumors that are assocd. with invasive behavior and poor prognosis.  These results provide new insights into the signaling cascades influencing tumor-initiating cells as well as a rationale for targeting SHP2 in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBsjLtiOIWbVg90H21EOLACvtfcHk0ljVur0hdnyC2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1yisrg%253D&md5=ea1d756b2f9d21771ca5f25d2dfda798</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm.2645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2645%26sid%3Dliteratum%253Aachs%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DSausgruber%26aufirst%3DN.%26aulast%3DBrinkhaus%26aufirst%3DH.%26aulast%3DGaidatzis%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMazzarol%26aufirst%3DG.%26aulast%3DConfalonieri%26aufirst%3DS.%26aulast%3DQuarto%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DBalwierz%26aufirst%3DP.%2BJ.%26aulast%3DPachkov%26aufirst%3DM.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3Dvan%2BNimwegen%26aufirst%3DE.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DBentires-Alj%26aufirst%3DM.%26atitle%3DTyrosine%2520phosphatase%2520SHP2%2520promotes%2520breast%2520cancer%2520progression%2520and%2520maintains%2520tumor-initiating%2520cells%2520via%2520activation%2520of%2520key%2520transcription%2520factors%2520and%2520a%2520positive%2520feedback%2520signaling%2520loop%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D529%26epage%3D537%26doi%3D10.1038%2Fnm.2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 phosphatase as a novel therapeutic target for melanoma treatment</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73817</span>– <span class="NLM_lpage">73829</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.18632%2Foncotarget.12074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27650545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2svisVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73817-73829&author=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=L.+F.+Zengauthor=S.+Zhangauthor=Y.+P.+Baiauthor=J.+M.+Miaoauthor=L.+Chenauthor=J.+W.+Xieauthor=Z.+Y.+Zhang&title=SHP2+phosphatase+as+a+novel+therapeutic+target+for+melanoma+treatment&doi=10.18632%2Foncotarget.12074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 phosphatase as a novel therapeutic target for melanoma treatment</span></div><div class="casAuthors">Zhang Ruo-Yu; Yu Zhi-Hong; Zhang Sheng; Bai Yunpeng; Miao Jinmin; Chen Lan; Zhang Zhong-Yin; Zeng Lifan; Xie Jingwu; Zhang Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">73817-73829</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Melanoma ranks among the most aggressive and deadly human cancers.  Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses.  Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment.  Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis.  We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways.  We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation.  Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis.  Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5ZzG02x4ZGROk4JA3soTqfW6udTcc2eZJkN4KC4c3v7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svisVGqsQ%253D%253D&md5=374e0635fe58c11dcda57c24ef17b43a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12074%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%2BP.%26aulast%3DMiao%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSHP2%2520phosphatase%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520melanoma%2520treatment%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D73817%26epage%3D73829%26doi%3D10.18632%2Foncotarget.12074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+is+a+central+node+in+intrinsic+and+acquired+resistance+to+targeted+cancer+drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0lhZoScJe0KD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520is%2520a%2520central%2520node%2520in%2520intrinsic%2520and%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneeberger, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luetteke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6191</span>– <span class="NLM_lpage">6202</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.18632%2Foncotarget.3356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25730908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2MrpvFOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6191-6202&author=V.+E.+Schneebergerauthor=Y.+Renauthor=N.+Luettekeauthor=Q.+L.+Huangauthor=L.+W.+Chenauthor=H.+R.+Lawrenceauthor=N.+J.+Lawrenceauthor=E.+B.+Hauraauthor=J.+M.+Koomenauthor=D.+Coppolaauthor=J.+Wu&title=Inhibition+of+Shp2+suppresses+mutant+EGFR-induced+lung+tumors+in+transgenic+mouse+model+of+lung+adenocarcinoma&doi=10.18632%2Foncotarget.3356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma</span></div><div class="casAuthors">Schneeberger Valentina E; Ren Yuan; Huang Qingling; Chen Liwei; Koomen John M; Wu Jie; Schneeberger Valentina E; Koomen John M; Wu Jie; Luetteke Noreen; Lawrence Harshani R; Lawrence Nicholas J; Lawrence Nicholas J; Haura Eric B; Koomen John M; Coppola Domenico; Wu Jie; Haura Eric B; Coppola Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6191-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy.  However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active.  Thus, it is important to uncover mediators of EGFR mutant-driven lung tumors to develop new treatment strategies.  The protein tyrosine phosphatase (PTP) Shp2 mediates EGF signaling.  Nevertheless, it is unclear if Shp2 is activated by oncogenic EGFR mutants in lung carcinoma or if inhibiting the Shp2 PTP activity can suppress EGFR mutant-induced lung adenocarcinoma.  Here, we generated transgenic mice containing a doxycycline (Dox)-inducible PTP-defective Shp2 mutant (tetO-Shp2CSDA).  Using the rat Clara cell secretory protein (CCSP)-rtTA-directed transgene expression in the type II lung pneumocytes of transgenic mice, we found that the Gab1-Shp2 pathway was activated by EGFRL858R in the lungs of transgenic mice.  Consistently, the Gab1-Shp2 pathway was activated in human lung adenocarcinoma cells containing mutant EGFR.  Importantly, Shp2CSDA inhibited EGFRL858R-induced lung adenocarcinoma in transgenic animals.  Analysis of lung tissues showed that Shp2CSDA suppressed Gab1 tyrosine phosphorylation and Gab1-Shp2 association, suggesting that Shp2 modulates a positive feedback loop to regulate its own activity.  These results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJtlG99S4uDhpyrDyM_m9cfW6udTcc2eayn5-bwBMiALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrpvFOntg%253D%253D&md5=925fbaa74576c95ccd76a3ce0afd959c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3356%26sid%3Dliteratum%253Aachs%26aulast%3DSchneeberger%26aufirst%3DV.%2BE.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DLuetteke%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DQ.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DCoppola%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Shp2%2520suppresses%2520mutant%2520EGFR-induced%2520lung%2520tumors%2520in%2520transgenic%2520mouse%2520model%2520of%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D6191%26epage%3D6202%26doi%3D10.18632%2Foncotarget.3356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-Sanchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Goncalves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+required+for+growth+of+KRAS-mutant+non-small-cell+lung+cancer+in+vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0lj49xzSpPtazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-Sanchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGoncalves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520required%2520for%2520growth%2520of%2520KRAS-mutant%2520non-small-cell%2520lung%2520cancer%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracht, J. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldeguer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bruno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ebiom.2018.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30473379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3crksV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=207-214&author=N.+Karachaliouauthor=A.+F.+Cardonaauthor=J.+W.+P.+Brachtauthor=E.+Aldeguerauthor=A.+Drozdowskyjauthor=M.+Fernandez-Brunoauthor=I.+Chaibauthor=J.+Berenguerauthor=M.+Santarpiaauthor=M.+Itoauthor=J.+Codony-Servatauthor=R.+Rosell&title=Integrin-linked+kinase+%28ILK%29+and+src+homology+2+domain-containing+phosphatase+2+%28SHP2%29%3A+Novel+targets+in+EGFR-mutation+positive+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1016%2Fj.ebiom.2018.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Karachaliou Niki; Cardona Andres Felipe; Bracht Jillian Wilhelmina Paulina; Aldeguer Erika; Berenguer Jordi; Ito Masaoki; Codony-Servat Jordi; Drozdowskyj Ana; Fernandez-Bruno Manuel; Chaib Imane; Santarpia Mariacarmela; Rosell Rafael</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The activation of multiple signaling pathways jeopardizes the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutation positive non-small cell lung cancer (NSCLC).  Integrin-linked kinase (ILK) regulates the interactions between tumor cells and extracellular environment to activate signaling pathways and promote cell proliferation, migration, and epithelial-mesenchymal transition.  Src homology 2 domain-containing phosphatase 2 (SHP2) is essential for receptor tyrosine kinase signaling and mitogen-activated protein kinase (MAPK) pathway activation.  METHODS:  We analyzed tumor ILK, β-receptor subunit glycoprotein 130 (gp130), SHP2, and stromal hepatocyte growth factor (HGF) and interleukin-6 (IL-6) mRNA expression in baseline tumor specimens of advanced EGFR-mutation positive NSCLC patients treated with EGFR TKIs.  RESULTS:  ILK, when highly expressed, was an independent poor prognostic factor for the progression-free survival of the patients, both in the univariate (hazard ratio [HR for disease progression, 2.49; 95% CI, 1.37-4.52; P = .0020]) and in the multivariate (HR 3.74; 95% CI, 1.33-10.56; P = .0126) Cox regression model.  Patients with high SHP2 expression had an almost 13-month shorter progression-free survival (P = .0094) and an 18-month shorter overall survival (P = .0182) in comparison to those with low SHP2 mRNA expression.  INTERPRETATION:  The levels of ILK and SHP2 could be predictive for upfront combinatory therapy of EGFR TKIs plus SHP2 or ILK inhibitors.  FUND: A grant from La Caixa Foundation, an Instituto de Salud Carlos III grant (RESPONSE, PIE16/00011), an Instituto de Salud Carlos III grant (PI14/01678), a Marie Sklodowska-Curie Innovative Training Networks European Grant (ELBA No 765492) and a Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDk6kgt3Zd7BItaL1WaVAfW6udTcc2eZLY0P6GlUgzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksV2mtA%253D%253D&md5=02e23573d10225a1d365e777ca55bcfa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DCardona%26aufirst%3DA.%2BF.%26aulast%3DBracht%26aufirst%3DJ.%2BW.%2BP.%26aulast%3DAldeguer%26aufirst%3DE.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DFernandez-Bruno%26aufirst%3DM.%26aulast%3DChaib%26aufirst%3DI.%26aulast%3DBerenguer%26aufirst%3DJ.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DIntegrin-linked%2520kinase%2520%2528ILK%2529%2520and%2520src%2520homology%25202%2520domain-containing%2520phosphatase%25202%2520%2528SHP2%2529%253A%2520Novel%2520targets%2520in%2520EGFR-mutation%2520positive%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D39%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.ebiom.2018.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simanshu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissley, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">RAS proteins and their regulators in human disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2017.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28666118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=17-33&author=D.+K.+Simanshuauthor=D.+V.+Nissleyauthor=F.+McCormick&title=RAS+proteins+and+their+regulators+in+human+disease&doi=10.1016%2Fj.cell.2017.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">RAS Proteins and their regulators in human disease</span></div><div class="casAuthors">Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-33</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  RAS proteins are binary switches, cycling between ON and OFF states during signal transduction.  These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active.  The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear.  All RAS biol. occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoH9cHufj4FLVg90H21EOLACvtfcHk0likL5riEN2WoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP&md5=638a0c0efac88f2873c352715e332a92</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DSimanshu%26aufirst%3DD.%2BK.%26aulast%3DNissley%26aufirst%3DD.%2BV.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DRAS%2520proteins%2520and%2520their%2520regulators%2520in%2520human%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D17%26epage%3D33%26doi%3D10.1016%2Fj.cell.2017.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanafusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span> <span> </span><span class="NLM_article-title">Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">22992</span>– <span class="NLM_lpage">22995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M312498200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M312498200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15031289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=22992-22995&author=H.+Hanafusaauthor=S.+Toriiauthor=T.+Yasunagaauthor=K.+Matsumotoauthor=E.+Nishida&title=Shp2%2C+an+SH2-containing+protein-tyrosine+phosphatase%2C+positively+regulates+receptor+tyrosine+kinase+signaling+by+dephosphorylating+and+inactivating+the+inhibitor+sprouty&doi=10.1074%2Fjbc.M312498200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty</span></div><div class="casAuthors">Hanafusa, Hiroshi; Torii, Satoru; Yasunaga, Takayuki; Matsumoto, Kunihiro; Nishida, Eisuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">22992-22995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SH2 domain-contg. phosphotyrosine phosphatase Shp2 functions as a pos. effector in receptor tyrosine kinase (RTK) signaling immediately proximal to activated receptors.  However, neither its physiol. substrate(s) nor its mechanism of action in RTK signaling has been defined.  Here, the authors demonstrate that protein Sprouty (Spry), an inhibitor of the Ras-MAP kinase signaling pathway, is a possible target of Shp2.  Spry acts as a conserved inhibitor of RTK signaling, and tyrosine phosphorylation of Spry is indispensable for its inhibitory activity.  Shp2 was able to dephosphorylate fibroblast growth factor (FGF) receptor-induced phosphotyrosines on Spry both in vivo and in vitro.  Shp2-mediated dephosphorylation of Spry resulted in dissocn. of Spry from protein Grb2.  Furthermore, Shp2 could reverse the inhibitory effect of Spry on FGF-induced neurite outgrowth and MAP kinase activation.  These findings suggest that Shp2 acts as a pos. regulator in RTK signaling by dephosphorylating and inactivating Spry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GxPH8eSOr7Vg90H21EOLACvtfcHk0likL5riEN2WoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gisro%253D&md5=7b08119acef72fe735bf39c972beb70d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M312498200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M312498200%26sid%3Dliteratum%253Aachs%26aulast%3DHanafusa%26aufirst%3DH.%26aulast%3DTorii%26aufirst%3DS.%26aulast%3DYasunaga%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DE.%26atitle%3DShp2%252C%2520an%2520SH2-containing%2520protein-tyrosine%2520phosphatase%252C%2520positively%2520regulates%2520receptor%2520tyrosine%2520kinase%2520signaling%2520by%2520dephosphorylating%2520and%2520inactivating%2520the%2520inhibitor%2520sprouty%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D22992%26epage%3D22995%26doi%3D10.1074%2Fjbc.M312498200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Langhe, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Moral, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellusci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span> <span> </span><span class="NLM_article-title">A novel function for the protein tyrosine phosphatase Shp2 during lung branching morphogenesis</span>. <i>Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.ydbio.2005.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ydbio.2005.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15950607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFSqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2005&pages=422-431&author=D.+Tefftauthor=S.+P.+De+Langheauthor=P.+M.+Del+Moralauthor=F.+Salaauthor=W.+Shiauthor=S.+Bellusciauthor=D.+Warburton&title=A+novel+function+for+the+protein+tyrosine+phosphatase+Shp2+during+lung+branching+morphogenesis&doi=10.1016%2Fj.ydbio.2005.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel function for the protein tyrosine phosphatase Shp2 during lung branching morphogenesis</span></div><div class="casAuthors">Tefft, Denise; De Langhe, Stijn P.; Del Moral, Pierre-Marie; Sala, Frederic; Shi, Wei; Bellusci, Saverio; Warburton, David</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Biology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">422-431</span>CODEN:
                <span class="NLM_cas:coden">DEBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0012-1606</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Branching morphogenesis of many organs, including the embryonic lung, is a dynamic process in which growth factor mediated tyrosine kinase receptor activation is required, but must be tightly regulated to direct ramifications of the terminal branches.  However, the specific regulators that modulate growth factor signaling downstream of the tyrosine kinase receptor remain to be detd.  Herein, we demonstrate for the first time an important function for the intracellular protein tyrosine phosphatase Shp2 in directing embryonic lung epithelial morphogenesis.  We show that Shp2 is specifically expressed in embryonic lung epithelial buds, and that loss of function by the suppression of Shp2 mRNA expression results in a 53% redn. in branching morphogenesis.  Furthermore, by intra-tracheal microinjection of a catalytically inactive adenoviral Shp2 construct, we provide direct evidence that the catalytic activity of Shp2 is required for proper embryonic lung branch formation.  We demonstrate that Shp2 activity is required for FGF10 induced endodermal budding.  Furthermore, a loss of Shp2 catalytic activity in the embryonic lung was assocd. with a redn. in ERK phosphorylation and epithelial cell proliferation.  However, epithelial cell differentiation was not affected.  Our results show that the protein tyrosine phosphatase Shp2 plays an essential role in modulating growth factor mediated tyrosine kinase receptor activation in early embryonic lung branching morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNk_74RxcILVg90H21EOLACvtfcHk0likL5riEN2WoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFSqs74%253D&md5=144c67aaf99bb63a4c4b5c46b3276463</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ydbio.2005.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ydbio.2005.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DTefft%26aufirst%3DD.%26aulast%3DDe%2BLanghe%26aufirst%3DS.%2BP.%26aulast%3DDel%2BMoral%26aufirst%3DP.%2BM.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DWarburton%26aufirst%3DD.%26atitle%3DA%2520novel%2520function%2520for%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%2520during%2520lung%2520branching%2520morphogenesis%26jtitle%3DDev.%2520Biol.%26date%3D2005%26volume%3D282%26spage%3D422%26epage%3D431%26doi%3D10.1016%2Fj.ydbio.2005.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellusci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span> <span> </span><span class="NLM_article-title">mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins</span>. <i>Am. J. Physiol.-Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">L700</span>– <span class="NLM_lpage">L706</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00372.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1152%2Fajplung.00372.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12225946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2002&pages=L700-L706&author=D.+Tefftauthor=M.+Leeauthor=S.+Smithauthor=D.+L.+Croweauthor=S.+Bellusciauthor=D.+Warburton&title=mSprouty2+inhibits+FGF10-activated+MAP+kinase+by+differentially+binding+to+upstream+target+proteins&doi=10.1152%2Fajplung.00372.2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00372.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00372.2001%26sid%3Dliteratum%253Aachs%26aulast%3DTefft%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DD.%2BL.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DWarburton%26aufirst%3DD.%26atitle%3DmSprouty2%2520inhibits%2520FGF10-activated%2520MAP%2520kinase%2520by%2520differentially%2520binding%2520to%2520upstream%2520target%2520proteins%26jtitle%3DAm.%2520J.%2520Physiol.-Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2002%26volume%3D283%26spage%3DL700%26epage%3DL706%26doi%3D10.1152%2Fajplung.00372.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064-1073&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+P.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+nucleotide+cycling+underlies+the+SHP2+phosphatase+dependence+of+mutant+BRAF-%2C+NF1-and+RAS-driven+cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0li1hvcuyRLSQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520nucleotide%2520cycling%2520underlies%2520the%2520SHP2%2520phosphatase%2520dependence%2520of%2520mutant%2520BRAF-%252C%2520NF1-and%2520RAS-driven%2520cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieteska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalverda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladbury, J. E.</span></span> <span> </span><span class="NLM_article-title">Grb2 binding induces phosphorylation-independent activation of Shp2</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1101/859108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1101%2F859108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.-C.+Linauthor=L.+Wieteskaauthor=K.+M.+Suenauthor=A.+Kalverdaauthor=Z.+Ahmedauthor=J.+E.+Ladbury&title=Grb2+binding+induces+phosphorylation-independent+activation+of+Shp2&doi=10.1101%2F859108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1101%2F859108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F859108%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DWieteska%26aufirst%3DL.%26aulast%3DSuen%26aufirst%3DK.%2BM.%26aulast%3DKalverda%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DZ.%26aulast%3DLadbury%26aufirst%3DJ.%2BE.%26atitle%3DGrb2%2520binding%2520induces%2520phosphorylation-independent%2520activation%2520of%2520Shp2%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F859108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8859&author=S.+Bundaauthor=K.+Burrellauthor=P.+Heirauthor=L.+F.+Zengauthor=A.+Alamsahebpourauthor=Y.+Kanoauthor=B.+Raughtauthor=Z.+Y.+Zhangauthor=G.+Zadehauthor=M.+Ohh&title=Inhibition+of+SHP2-mediated+dephosphorylation+of+Ras+suppresses+oncogenesis&doi=10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0li1hvcuyRLSQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520SHP2-mediated%2520dephosphorylation%2520of%2520Ras%2520suppresses%2520oncogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agazie, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayman, M. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7875</span>– <span class="NLM_lpage">7886</span>, <span class="refDoi"> DOI: 10.1128/MCB.23.21.7875-7886.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1128%2FMCB.23.21.7875-7886.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14560030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=7875-7886&author=Y.+M.+Agazieauthor=M.+J.+Hayman&title=Molecular+mechanism+for+a+role+of+SHP2+in+epidermal+growth+factor+receptor+signaling&doi=10.1128%2FMCB.23.21.7875-7886.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling</span></div><div class="casAuthors">Agazie, Yehenew M.; Hayman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7875-7886</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Src homol. 2-contg. phosphotyrosine phosphatase (SHP2) is primarily a pos. effector of receptor tyrosine kinase signaling.  However, the mol. mechanism by which SHP2 effects its biol. function is unknown.  The authors provide evidence that defines the mol. mechanism and site of action of SHP2 in the epidermal growth factor-induced mitogenic pathway.  The authors demonstrate that SHP2 acts upstream of Ras and functions by increasing the half-life of activated Ras (GTP-Ras) in the cell by interfering with the process of Ras inactivation catalyzed by Ras GTPase-activating protein (RasGAP).  It does so by inhibition of tyrosine phosphorylation-dependent translocation of RasGAP to the plasma membrane, to its substrate (GTP-Ras) microdomain.  Inhibition is achieved through the dephosphorylation of RasGAP binding sites at the level of the plasma membrane.  The authors have identified Tyr 992 of the epidermal growth factor receptor (EGFR) to be one such site, since its mutation to Phe renders the EGFR refractory to the effect of dominant-neg. SHP2.  To the authors' knowledge, this is the first report to outline the site and mol. mechanism of action of SHP2 in EGFR signaling, which may also serve as a model to describe its role in other receptor tyrosine kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5SXQ45HAFrVg90H21EOLACvtfcHk0liBw4KrSMN_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOgtLo%253D&md5=23e83e2e6ea24b006daa799b15a95981</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FMCB.23.21.7875-7886.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.23.21.7875-7886.2003%26sid%3Dliteratum%253Aachs%26aulast%3DAgazie%26aufirst%3DY.%2BM.%26aulast%3DHayman%26aufirst%3DM.%2BJ.%26atitle%3DMolecular%2520mechanism%2520for%2520a%2520role%2520of%2520SHP2%2520in%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D7875%26epage%3D7886%26doi%3D10.1128%2FMCB.23.21.7875-7886.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">A treatment strategy for KRAS-driven tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0111-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0111-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29988139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=902-904&author=T.+T.+Maiauthor=P.+Lito&title=A+treatment+strategy+for+KRAS-driven+tumors&doi=10.1038%2Fs41591-018-0111-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A treatment strategy for KRAS-driven tumors</span></div><div class="casAuthors">Mai, Trang T.; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">902-904</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgaFi5mnw3KrVg90H21EOLACvtfcHk0liBw4KrSMN_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK&md5=03c6ec6d34bac76f8826e1f783dac0a7</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0111-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0111-x%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DA%2520treatment%2520strategy%2520for%2520KRAS-driven%2520tumors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D902%26epage%3D904%26doi%3D10.1038%2Fs41591-018-0111-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattoon, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1741-7007-2-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1186%2F1741-7007-2-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15550174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD2M7lsVKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=24&author=D.+R.+Mattoonauthor=B.+Lamotheauthor=I.+Laxauthor=J.+Schlessinger&title=The+docking+protein+Gab1+is+the+primary+mediator+of+EGF-stimulated+activation+of+the+PI-3K%2FAkt+cell+survival+pathway&doi=10.1186%2F1741-7007-2-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway</span></div><div class="casAuthors">Mattoon Dawn R; Lamothe Betty; Lax Irit; Schlessinger Joseph</div><div class="citationInfo"><span class="NLM_cas:title">BMC biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gab1 is a docking protein that recruits phosphatidylinositol-3 kinase (PI-3 kinase) and other effector proteins in response to the activation of many receptor tyrosine kinases (RTKs).  As the autophosphorylation sites on EGF-receptor (EGFR) do not include canonical PI-3 kinase binding sites, it is thought that EGF stimulation of PI-3 kinase and its downstream effector Akt is mediated by an indirect mechanism.  RESULTS:  We used fibroblasts isolated from Gab1-/- mouse embryos to explore the mechanism of EGF stimulation of the PI-3 kinase/Akt anti-apoptotic cell signaling pathway.  We demonstrate that Gab1 is essential for EGF stimulation of PI-3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85, the regulatory subunit of PI-3 kinase, and three canonical tyrosine phosphorylation sites on Gab1.  Furthermore, complex formation between Gab1 and the protein tyrosine phosphatase Shp2 negatively regulates Gab1 mediated PI-3 kinase and Akt activation following EGF-receptor stimulation.  We also demonstrate that tyrosine phosphorylation of ErbB3 may lead to recruitment and activation of PI-3 kinase and Akt in Gab1-/- MEFs.  CONCLUSIONS:  The primary mechanism of EGF-induced stimulation of the PI-3 kinase/Akt anti-apoptotic pathway occurs via the docking protein Gab1.  However, in cells expressing ErbB3, EGF and neuroregulin can stimulate PI-3 kinase and Akt activation in a Gab1-dependent or Gab1-independent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTvj5p-QMRX0Q0lWbKiCflfW6udTcc2eZeO8U1mmA5t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7lsVKisQ%253D%253D&md5=b41b39d518429d4a1f71718588ea6914</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-2-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-2-24%26sid%3Dliteratum%253Aachs%26aulast%3DMattoon%26aufirst%3DD.%2BR.%26aulast%3DLamothe%26aufirst%3DB.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520docking%2520protein%2520Gab1%2520is%2520the%2520primary%2520mediator%2520of%2520EGF-stimulated%2520activation%2520of%2520the%2520PI-3K%252FAkt%2520cell%2520survival%2520pathway%26jtitle%3DBMC%2520Biol.%26date%3D2004%26volume%3D2%26spage%3D24%26doi%3D10.1186%2F1741-7007-2-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitkopf, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontaridis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrimon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span> <span> </span><span class="NLM_article-title">A cross-species study of PI3K protein-protein interactions reveals the direct interaction of p85 and SHP2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20471</span>, <span class="refDoi"> DOI: 10.1038/srep20471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsrep20471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26839216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFant7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=20471&author=S.+B.+Breitkopfauthor=X.+M.+Yangauthor=M.+J.+Begleyauthor=M.+Kulkarniauthor=Y.+H.+Chiuauthor=A.+B.+Turkeauthor=J.+Lauriolauthor=M.+Yuanauthor=J.+Qiauthor=J.+A.+Engelmanauthor=P.+Y.+Hongauthor=M.+I.+Kontaridisauthor=L.+C.+Cantleyauthor=N.+Perrimonauthor=J.+M.+Asara&title=A+cross-species+study+of+PI3K+protein-protein+interactions+reveals+the+direct+interaction+of+p85+and+SHP2&doi=10.1038%2Fsrep20471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2</span></div><div class="casAuthors">Breitkopf, Susanne B.; Yang, Xuemei; Begley, Michael J.; Kulkarni, Meghana; Chiu, Yu-Hsin; Turke, Alexa B.; Lauriol, Jessica; Yuan, Min; Qi, Jie; Engelman, Jeffrey A.; Hong, Pengyu; Kontaridis, Maria I.; Cantley, Lewis C.; Perrimon, Norbert; Asara, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20471</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using a series of immunopptn. (IP) - tandem mass spectrometry (LC-MS/MS) expts. and reciprocal BLAST, we conducted a fly-human cross-species comparison of the phosphoinositide-3-kinase (PI3K) interactome in a drosophila S2R+ cell line and several NSCLC and human multiple myeloma cell lines to identify conserved interacting proteins to PI3K, a crit. signaling regulator of the AKT pathway.  Using H929 human cancer cells and drosophila S2R+ cells, our data revealed an unexpected direct binding of Corkscrew, the drosophila ortholog of the non-receptor protein tyrosine phosphatase type II (SHP2) to the Pi3k21B (p60) regulatory subunit of PI3K (p50/p85 human ortholog) but no assocn. with Pi3k92e, the human ortholog of the p110 catalytic subunit.  The p85-SHP2 assocn. was validated in human cell lines, and formed a ternary regulatory complex with GRB2-assocd.-binding protein 2 (GAB2).  Validation expts. with knockdown of GAB2 and Far-Western blots proved the direct interaction of SHP2 with p85, independent of adaptor proteins and transfected FLAG-p85 provided evidence that SHP2 binding on p85 occurred on the SH2 domains.  A disruption of the SHP2-p85 complex took place after insulin/IGF1 stimulation or imatinib treatment, suggesting that the direct SHP2-p85 interaction was both independent of AKT activation and pos. regulates the ERK signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKh6nokwivmrVg90H21EOLACvtfcHk0lgVE9B65Xj3Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFant7o%253D&md5=93d27c2a1d84db990ddaa959a67d6170</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsrep20471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep20471%26sid%3Dliteratum%253Aachs%26aulast%3DBreitkopf%26aufirst%3DS.%2BB.%26aulast%3DYang%26aufirst%3DX.%2BM.%26aulast%3DBegley%26aufirst%3DM.%2BJ.%26aulast%3DKulkarni%26aufirst%3DM.%26aulast%3DChiu%26aufirst%3DY.%2BH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DLauriol%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHong%26aufirst%3DP.%2BY.%26aulast%3DKontaridis%26aufirst%3DM.%2BI.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPerrimon%26aufirst%3DN.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26atitle%3DA%2520cross-species%2520study%2520of%2520PI3K%2520protein-protein%2520interactions%2520reveals%2520the%2520direct%2520interaction%2520of%2520p85%2520and%2520SHP2%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D20471%26doi%3D10.1038%2Fsrep20471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, M.</span></span> <span> </span><span class="NLM_article-title">SHP2: a new target for pro-senescence cancer therapies</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.15252/embj.201591616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.15252%2Fembj.201591616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25916826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1439-1441&author=M.+Serrano&title=SHP2%3A+a+new+target+for+pro-senescence+cancer+therapies&doi=10.15252%2Fembj.201591616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2: a new target for pro-senescence cancer therapies</span></div><div class="casAuthors">Serrano, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1439-1441</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cellular senescence is a response to stress that disables cell proliferation and orchestrates an inflammatory process that eliminates damaged cells.  The first pro-senescence drugs for cancer treatment are now a clin. reality, but still few targets have been identified whose inactivation results in cancer cell senescence.  Current work published in this issue of The EMBO Journal makes an important contribution to this area by discovering that pharmacol. inhibition of the tyrosine phosphatase SHP2 blocks mouse mammary cancer through the induction of senescence (Lan et al, ).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlsVG2_5YQQLVg90H21EOLACvtfcHk0lgVE9B65Xj3Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCnsrk%253D&md5=14b20256721d963f581dfd0d1c7977e4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.15252%2Fembj.201591616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201591616%26sid%3Dliteratum%253Aachs%26aulast%3DSerrano%26aufirst%3DM.%26atitle%3DSHP2%253A%2520a%2520new%2520target%2520for%2520pro-senescence%2520cancer%2520therapies%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D1439%26epage%3D1441%26doi%3D10.15252%2Fembj.201591616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, M.</span></span> <span> </span><span class="NLM_article-title">YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2013.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.devcel.2013.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24035415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=658-665&author=R.+Tsutsumiauthor=M.+Masoudiauthor=A.+Takahashiauthor=Y.+Fujiiauthor=T.+Hayashiauthor=I.+Kikuchiauthor=Y.+Satouauthor=M.+Tairaauthor=M.+Hatakeyama&title=YAP+and+TAZ%2C+Hippo+signaling+targets%2C+act+as+a+rheostat+for+nuclear+SHP2+function&doi=10.1016%2Fj.devcel.2013.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 Function</span></div><div class="casAuthors">Tsutsumi, Ryouhei; Masoudi, Mohammad; Takahashi, Atsushi; Fujii, Yumiko; Hayashi, Takeru; Kikuchi, Ippei; Satou, Yumeko; Taira, Masanori; Hatakeyama, Masanori</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">658-665</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SHP2 is a ubiquitously expressed protein tyrosine phosphatase, deregulation of which is assocd. with malignant neoplasms and developmental disorders.  SHP2 is required for full activation of RAS-Erk signaling in the cytoplasm and is also present in the nucleus, where it promotes Wnt target gene activation through dephosphorylation of parafibromin.  SHP2 is distributed both to the cytoplasm and nucleus at low cell d. but is excluded from the nucleus at high cell d.  Here, we show that SHP2 phys. interacts with transcriptional coactivators YAP and TAZ, targets of the cell-d.-sensing Hippo signal.  Through the interaction, nonphosphorylated YAP/TAZ promote nuclear translocalization of SHP2, which in turn stimulates TCF/LEF- and TEAD-regulated genes via parafibromin dephosphorylation.  Conversely, YAP/TAZ phosphorylated by Hippo signaling sequester SHP2 in the cytoplasm, thereby preventing nuclear accumulation of SHP2.  Hence, YAP/TAZ serve as a rheostat for nuclear SHP2 function, which is switched off by the Hippo signal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqYS_cEzmS8rVg90H21EOLACvtfcHk0li3cGSS4zfklg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCls7bJ&md5=a97dc2ed314db28cb3594244fff2f5ff</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2013.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2013.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsumi%26aufirst%3DR.%26aulast%3DMasoudi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DI.%26aulast%3DSatou%26aufirst%3DY.%26aulast%3DTaira%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DM.%26atitle%3DYAP%2520and%2520TAZ%252C%2520Hippo%2520signaling%2520targets%252C%2520act%2520as%2520a%2520rheostat%2520for%2520nuclear%2520SHP2%2520function%26jtitle%3DDev.%2520Cell%26date%3D2013%26volume%3D26%26spage%3D658%26epage%3D665%26doi%3D10.1016%2Fj.devcel.2013.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases in the JAK/STAT pathway</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4925</span>– <span class="NLM_lpage">4932</span>, <span class="refDoi"> DOI: 10.2741/3051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2741%2F3051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18508557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=4925-4932&author=D.+Xuauthor=C.+K.+Qu&title=Protein+tyrosine+phosphatases+in+the+JAK%2FSTAT+pathway&doi=10.2741%2F3051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases in the JAK/STAT pathway</span></div><div class="casAuthors">Xu, Dan; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4925-4932</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is crucial in controlling cellular activities in response to extracellular cytokines.  Dysfunctions of the JAK/STAT pathway result in various hematopoietic and immune disorders.  The central events in regulating this pathway are tyrosine phosphorylation and dephosphorylation of the signaling components, which are carried out by protein tyrosine kinases and protein tyrosine phosphatases (PTP), resp.  Here, we review recent advances in the regulatory roles of PTPs, in particular, SHP2 phosphatase, in the JAK/STAT signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1iYtqQyD_7Vg90H21EOLACvtfcHk0li3cGSS4zfklg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOjtrs%253D&md5=d3f84b6306220659ef34e4bf43cab87e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2741%2F3051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F3051%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DProtein%2520tyrosine%2520phosphatases%2520in%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D4925%26epage%3D4932%26doi%3D10.2741%2F3051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0li3cGSS4zfklg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyershaeuser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorausch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, T.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of SHP2 activation by PD-1 stimulation</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">eaay4458</span>, <span class="refDoi"> DOI: 10.1126/sciadv.aay4458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fsciadv.aay4458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32064351" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=eaay4458&author=M.+Marascoauthor=A.+Berteottiauthor=J.+Weyershaeuserauthor=N.+Thorauschauthor=J.+Sikorskaauthor=J.+Krauszeauthor=H.+J.+Brandtauthor=J.+Kirkpatrickauthor=P.+Riosauthor=W.+W.+Schamelauthor=M.+Kohnauthor=T.+Carlomagno&title=Molecular+mechanism+of+SHP2+activation+by+PD-1+stimulation&doi=10.1126%2Fsciadv.aay4458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay4458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay4458%26sid%3Dliteratum%253Aachs%26aulast%3DMarasco%26aufirst%3DM.%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DWeyershaeuser%26aufirst%3DJ.%26aulast%3DThorausch%26aufirst%3DN.%26aulast%3DSikorska%26aufirst%3DJ.%26aulast%3DKrausze%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DH.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DJ.%26aulast%3DRios%26aufirst%3DP.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DKohn%26aufirst%3DM.%26aulast%3DCarlomagno%26aufirst%3DT.%26atitle%3DMolecular%2520mechanism%2520of%2520SHP2%2520activation%2520by%2520PD-1%2520stimulation%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26spage%3Deaay4458%26doi%3D10.1126%2Fsciadv.aay4458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokosuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi-Imanishi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto-Tane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span> <span> </span><span class="NLM_article-title">Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.1084/jem.20112741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1084%2Fjem.20112741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22641383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslShsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=1201-1217&author=T.+Yokosukaauthor=M.+Takamatsuauthor=W.+Kobayashi-Imanishiauthor=A.+Hashimoto-Taneauthor=M.+Azumaauthor=T.+Saito&title=Programmed+cell+death+1+forms+negative+costimulatory+microclusters+that+directly+inhibit+T+cell+receptor+signaling+by+recruiting+phosphatase+SHP2&doi=10.1084%2Fjem.20112741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2</span></div><div class="casAuthors">Yokosuka, Tadashi; Takamatsu, Masako; Kobayashi-Imanishi, Wakana; Hashimoto-Tane, Akiko; Azuma, Miyuki; Saito, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1201-1217</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death 1 (PD-1) is a neg. costimulatory receptor crit. for the suppression of T cell activation in vitro and in vivo.  Single cell imaging elucidated a mol. mechanism of PD-1-mediated suppression.  PD-1 becomes clustered with T cell receptors (TCRs) upon binding to its ligand PD-L1 and is transiently assocd. with the phosphatase SHP2 (Src homol. 2 domain-contg. tyrosine phosphatase 2).  These neg. costimulatory microclusters induce the dephosphorylation of the proximal TCR signaling mols.  This results in the suppression of T cell activation and blockade of the TCR-induced stop signal.  In addn. to PD-1 clustering, PD-1-TCR colocalization within microclusters is required for efficient PD-1-mediated suppression.  This inhibitory mechanism also functions in PD-1hi T cells generated in vivo and can be overridden by a neutralizing anti-PD-L1 antibody.  Therefore, PD-1 microcluster formation is important for regulation of T cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfykLUUjaIbVg90H21EOLACvtfcHk0ljznGpzfcJNtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslShsr4%253D&md5=5c1fad62b4e3e69e177be5718ce92d41</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1084%2Fjem.20112741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20112741%26sid%3Dliteratum%253Aachs%26aulast%3DYokosuka%26aufirst%3DT.%26aulast%3DTakamatsu%26aufirst%3DM.%26aulast%3DKobayashi-Imanishi%26aufirst%3DW.%26aulast%3DHashimoto-Tane%26aufirst%3DA.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DT.%26atitle%3DProgrammed%2520cell%2520death%25201%2520forms%2520negative%2520costimulatory%2520microclusters%2520that%2520directly%2520inhibit%2520T%2520cell%2520receptor%2520signaling%2520by%2520recruiting%2520phosphatase%2520SHP2%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D1201%26epage%3D1217%26doi%3D10.1084%2Fjem.20112741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauken, K. E.</span></span> <span> </span><span class="NLM_article-title">The diverse functions of the PD1 inhibitory pathway</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnri.2017.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28990585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=153-167&author=A.+H.+Sharpeauthor=K.+E.+Pauken&title=The+diverse+functions+of+the+PD1+inhibitory+pathway&doi=10.1038%2Fnri.2017.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse functions of the PD1 inhibitory pathway</span></div><div class="casAuthors">Sharpe, Arlene H.; Pauken, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-167</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">T cell activation is a highly regulated process involving peptide-MHC engagement of the T cell receptor and pos. costimulatory signals.  Upon activation, coinhibitory 'checkpoints', including programmed cell death protein 1 (PD1), become induced to regulate T cells.  PD1 has an essential role in balancing protective immunity and immunopathol., homeostasis and tolerance.  However, during responses to chronic pathogens and tumors, PD1 expression can limit protective immunity.  Recently developed PD1 pathway inhibitors have revolutionized cancer treatment for some patients, but the majority of patients do not show complete responses, and adverse events have been noted.  This Review discusses the diverse roles of the PD1 pathway in regulating immune responses and how this knowledge can improve cancer immunotherapy as well as restore and/or maintain tolerance during autoimmunity and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVq0k2Iq6v-rVg90H21EOLACvtfcHk0lh4MX6XpO2CtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfP&md5=304a93c872e4beaa8f249390d516527e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.108%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DPauken%26aufirst%3DK.%2BE.%26atitle%3DThe%2520diverse%2520functions%2520of%2520the%2520PD1%2520inhibitory%2520pathway%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D153%26epage%3D167%26doi%3D10.1038%2Fnri.2017.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rota, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niogret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonta, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarda, G.</span></span> <span> </span><span class="NLM_article-title">Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29617671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=39-49&author=G.+Rotaauthor=C.+Niogretauthor=A.+T.+Dangauthor=C.+R.+Barrosauthor=N.+P.+Fontaauthor=F.+Alfeiauthor=L.+Morgadoauthor=D.+Zehnauthor=W.+Birchmeierauthor=E.+Vivierauthor=G.+Guarda&title=Shp-2+is+dispensable+for+establishing+T+cell+exhaustion+and+for+PD-1+signaling+in+vivo&doi=10.1016%2Fj.celrep.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo</span></div><div class="casAuthors">Rota, Giorgia; Niogret, Charlene; Dang, Anh Thu; Barros, Cristina Ramon; Fonta, Nicolas Pierre; Alfei, Francesca; Morgado, Leonor; Zehn, Dietmar; Birchmeier, Walter; Vivier, Eric; Guarda, Greta</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In chronic infection and cancer, T cells acquire a dysfunctional state characterized by the expression of inhibitory receptors.  In vitro studies implicated the phosphatase Shp-2 downstream of these receptors, including PD-1.  However, whether Shp-2 is responsible in vivo for such dysfunctional responses remains elusive.  To address this, we generated T cell-specific Shp-2-deficient mice.  These mice did not show differences in controlling chronic viral infections.  In this context, Shp-2-deleted CD8+ T lymphocytes expanded moderately better but were less polyfunctional than control cells.  Mice with Shp-2-deficient T cells also showed no significant improvement in controlling immunogenic tumors and responded similarly to controls to a-PD-1 treatment.  We therefore showed that Shp-2 is dispensable in T cells for globally establishing exhaustion and for PD-1 signaling in vivo.  These results reveal the existence of redundant mechanisms downstream of inhibitory receptors and represent the foundation for defining these relevant mol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PfFYT7Ao57Vg90H21EOLACvtfcHk0lh4MX6XpO2CtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsbo%253D&md5=a11d6aefd737036c5e5533674c83b8c3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DRota%26aufirst%3DG.%26aulast%3DNiogret%26aufirst%3DC.%26aulast%3DDang%26aufirst%3DA.%2BT.%26aulast%3DBarros%26aufirst%3DC.%2BR.%26aulast%3DFonta%26aufirst%3DN.%2BP.%26aulast%3DAlfei%26aufirst%3DF.%26aulast%3DMorgado%26aufirst%3DL.%26aulast%3DZehn%26aufirst%3DD.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DGuarda%26aufirst%3DG.%26atitle%3DShp-2%2520is%2520dispensable%2520for%2520establishing%2520T%2520cell%2520exhaustion%2520and%2520for%2520PD-1%2520signaling%2520in%2520vivo%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D39%26epage%3D49%26doi%3D10.1016%2Fj.celrep.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine phosphatase SHP-2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80938-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0092-8674%2800%2980938-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9491886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=441-450&author=P.+Hofauthor=S.+Pluskeyauthor=S.+Dhe-Paganonauthor=M.+J.+Eckauthor=S.+E.+Shoelson&title=Crystal+structure+of+the+tyrosine+phosphatase+SHP-2&doi=10.1016%2FS0092-8674%2800%2980938-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Hof, Peter; Pluskey, Scott; Dhe-Paganon, Sirano; Eck, Michael J.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The structure of the SHP-2 tyrosine phosphatase, detd. at 2.0 Å resoln., shows how its catalytic activity is regulated by its two SH2 domains.  In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site.  This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft.  Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface.  Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme.  Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcAryHYl6D5bVg90H21EOLACvtfcHk0lh4MX6XpO2CtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D&md5=ea99b7adb90b5db07754c0be75a63c66</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980938-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980938-1%26sid%3Dliteratum%253Aachs%26aulast%3DHof%26aufirst%3DP.%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520phosphatase%2520SHP-2%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D441%26epage%3D450%26doi%3D10.1016%2FS0092-8674%2800%2980938-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1038/nature01680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature01680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12802338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2003&pages=769-773&author=A.+Salmeenauthor=J.+N.+Andersenauthor=M.+P.+Myersauthor=T.+C.+Mengauthor=J.+A.+Hinksauthor=N.+K.+Tonksauthor=D.+Barford&title=Redox+regulation+of+protein+tyrosine+phosphatase+1B+involves+a+sulphenyl-amide+intermediate&doi=10.1038%2Fnature01680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate</span></div><div class="casAuthors">Salmeen, Annette; Andersen, Jannik N.; Myers, Michael P.; Meng, Tzu-Ching; Hinks, John A.; Tonks, Nicholas K.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">6941</span>),
    <span class="NLM_cas:pages">769-773</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The second messenger hydrogen peroxide is required for optimal activation of numerous signal transduction pathways, particularly those mediated by protein tyrosine kinases.  One mechanism by which hydrogen peroxide regulates cellular processes is the transient inhibition of protein tyrosine phosphatases through the reversible oxidization of their catalytic cysteine, which suppresses protein dephosphorylation.  Here the authors describe a structural anal. of the redox-dependent regulation of protein tyrosine phosphatase 1B (PTP1B), which is reversibly inhibited by oxidn. after cells are stimulated with insulin and epidermal growth factor.  The sulfenic acid intermediate produced in response to PTP1B oxidn. is rapidly converted into a previously unknown sulfenyl-amide species, in which the sulfur atom of the catalytic cysteine is covalently linked to the main chain nitrogen of an adjacent residue.  Oxidn. of PTP1B to the sulfenyl-amide form is accompanied by large conformational changes in the catalytic site that inhibit substrate binding.  The authors propose that this unusual protein modification both protects the active-site cysteine residue of PTP1B from irreversible oxidn. to sulfonic acid and permits redox regulation of the enzyme by promoting its reversible redn. by thiols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxAoJy80dnLVg90H21EOLACvtfcHk0liDNnckAINnog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2itrc%253D&md5=b46983eaf49248015cbb0c87e77129b6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnature01680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01680%26sid%3Dliteratum%253Aachs%26aulast%3DSalmeen%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DJ.%2BN.%26aulast%3DMyers%26aufirst%3DM.%2BP.%26aulast%3DMeng%26aufirst%3DT.%2BC.%26aulast%3DHinks%26aufirst%3DJ.%2BA.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DRedox%2520regulation%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%2520involves%2520a%2520sulphenyl-amide%2520intermediate%26jtitle%3DNature%26date%3D2003%26volume%3D423%26spage%3D769%26epage%3D773%26doi%3D10.1038%2Fnature01680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Montfort, R. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1038/nature01681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature01681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12802339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2003&pages=773-777&author=R.+L.+M.+van%0AMontfortauthor=M.+Congreveauthor=D.+Tisiauthor=R.+Carrauthor=H.+Jhoti&title=Oxidation+state+of+the+active-site+cysteine+in+protein+tyrosine+phosphatase+1B&doi=10.1038%2Fnature01681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B</span></div><div class="casAuthors">van Montfort, Rob L. M.; Congreve, Miles; Tisi, Dominic; Carr, Robin; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">6941</span>),
    <span class="NLM_cas:pages">773-777</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases regulate signal transduction pathways involving tyrosine phosphorylation and have been implicated in the development of cancer, diabetes, rheumatoid arthritis and hypertension.  Increasing evidence suggests that the cellular redox state is involved in regulating tyrosine phosphatase activity through the reversible oxidization of the catalytic cysteine to sulfenic acid (Cys-SOH).  But how further oxidn. to the irreversible sulfinic (Cys-SO2H) and sulfonic (Cys-SO3H) forms is prevented remains unclear.  Here the authors report the crystal structures of the regulatory sulfenic and irreversible sulfinic and sulfonic acids of protein tyrosine phosphatase 1B (PTP1B), an important enzyme in the neg. regulation of the insulin receptor and a therapeutic target in type II diabetes and obesity.  The authors also identify a sulfenyl-amide species that is formed through oxidn. of its catalytic cysteine.  Formation of the sulfenyl-amide causes large changes in the PTP1B active site, which are reversible by redn. with the cellular reducing agent glutathione.  The sulfenyl-amide is a protective intermediate in the oxidative inhibition of PTP1B.  In addn., it may facilitate reactivation of PTP1B by biol. thiols and signal a unique state of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL3MjGivrjqbVg90H21EOLACvtfcHk0liDNnckAINnog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2it74%253D&md5=90490439b3be879e480badfce2651bc6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature01681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01681%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DOxidation%2520state%2520of%2520the%2520active-site%2520cysteine%2520in%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNature%26date%3D2003%26volume%3D423%26spage%3D773%26epage%3D777%26doi%3D10.1038%2Fnature01681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, K. G.</span></span> <span> </span><span class="NLM_article-title">Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: Evidence for a sulfenic acid intermediate and implications for redox regulation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5633</span>– <span class="NLM_lpage">5642</span>, <span class="refDoi"> DOI: 10.1021/bi973035t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi973035t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXislGht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=5633-5642&author=J.+M.+Denuauthor=K.+G.+Tanner&title=Specific+and+reversible+inactivation+of+protein+tyrosine+phosphatases+by+hydrogen+peroxide%3A+Evidence+for+a+sulfenic+acid+intermediate+and+implications+for+redox+regulation&doi=10.1021%2Fbi973035t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Specific and Reversible Inactivation of Protein Tyrosine Phosphatases by Hydrogen Peroxide: Evidence for a Sulfenic Acid Intermediate and Implications for Redox Regulation</span></div><div class="casAuthors">Denu, John M.; Tanner, Kirk G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5633-5642</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) catalyze the hydrolysis of phosphotyrosine from specific signal-transducing proteins.  Although regulatory mechanisms for protein kinases have been described, no general mechanism for controlling PTPs has been demonstrated.  Numerous reports have shown that cellular redox status plays an important role in tyrosine phosphorylation-dependent signal transduction pathways.  This study explores the proposal that PTPs may be regulated by reversible redn./oxidn. involving cellular oxidants such as hydrogen peroxide (H2O2).  Recent reports indicated that H2O2 is transiently generated during growth factor stimulation and that H2O2 prodn. is concomitant with relevant tyrosine phosphorylation.  By use of recombinant enzymes, the effects of H2O2 on three PTPs (PTP1, LAR, and VHR) and three distinct serine/threonine protein phosphatases (PPs: PP2Cα, calcineurin, and λ phosphatase) were detd.  Hydrogen peroxide had no apparent effect on PP activity.  In contrast, PTPs were rapidly inactivated (kinact = 10-20 M-1 s-1) with low micromolar concns. of H2O2 but not with large alkyl hydroperoxides.  PTP inactivation was fully reversible with glutathione and other thiols.  Because of the slower rate of redn., modification occurred even in the presence of physiol. thiol concns.  By utilization of a variety of biochem. techniques including chem. modification, pH kinetic studies, and mutagenesis, the catalytic cysteine thiolate of PTPs was detd. to be the selective target of oxidn. by H2O2.  By use of the electrophilic reagent 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl), it was shown that a cysteine sulfenic acid intermediate (Cys-SOH) is formed after attack of the catalytic thiolate on H2O2.  A chem. mechanism for reversible inactivation involving a cysteine sulfenic acid intermediate is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpk7IfuQALDbVg90H21EOLACvtfcHk0liDNnckAINnog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislGht7k%253D&md5=0d7c3e14505b4e57c37f38cf76d5f745</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fbi973035t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi973035t%26sid%3Dliteratum%253Aachs%26aulast%3DDenu%26aufirst%3DJ.%2BM.%26aulast%3DTanner%26aufirst%3DK.%2BG.%26atitle%3DSpecific%2520and%2520reversible%2520inactivation%2520of%2520protein%2520tyrosine%2520phosphatases%2520by%2520hydrogen%2520peroxide%253A%2520Evidence%2520for%2520a%2520sulfenic%2520acid%2520intermediate%2520and%2520implications%2520for%2520redox%2520regulation%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D5633%26epage%3D5642%26doi%3D10.1021%2Fbi973035t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T. C.</span></span> <span> </span><span class="NLM_article-title">Cysteine S-nitrosylation protects protein-tyrosine phosphatase 1B against oxidation-induced permanent inactivation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">35265</span>– <span class="NLM_lpage">35272</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805287200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M805287200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18840608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35265-35272&author=Y.+Y.+Chenauthor=H.+M.+Chuauthor=K.+T.+Panauthor=C.+H.+Tengauthor=D.+L.+Wangauthor=A.+H.+J.+Wangauthor=K.+H.+Khooauthor=T.+C.+Meng&title=Cysteine+S-nitrosylation+protects+protein-tyrosine+phosphatase+1B+against+oxidation-induced+permanent+inactivation&doi=10.1074%2Fjbc.M805287200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine S-Nitrosylation Protects Protein-tyrosine Phosphatase 1B against Oxidation-induced Permanent Inactivation</span></div><div class="casAuthors">Chen, Yi-Yun; Chu, Hsing-Mao; Pan, Kuan-Ting; Teng, Chun-Hung; Wang, Danny-Ling; Wang, Andrew H.-J.; Khoo, Kay-Hooi; Meng, Tzu-Ching</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35265-35272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein S-nitrosylation mediated by cellular nitric oxide (NO) plays a primary role in executing biol. functions in cGMP-independent NO signaling.  Although S-nitrosylation appears similar to Cys oxidn. induced by reactive oxygen species, the mol. mechanism and biol. consequence remain unclear.  We investigated the structural process of S-nitrosylation of protein-tyrosine phosphatase 1B (PTP1B).  We treated PTP1B with various NO donors, including S-nitrosothiol reagents and compd.-releasing NO radicals, to produce site-specific Cys S-nitrosylation identified using advanced mass spectrometry (MS) techniques.  Quant. MS showed that the active site Cys-215 was the primary residue susceptible to S-nitrosylation.  The crystal structure of NO donor-reacted PTP1B at 2.6 Å resoln. revealed that the S-NO state at Cys-215 had no discernible irreversibly oxidized forms, whereas other Cys residues remained in their free thiol states.  We further demonstrated that S-nitrosylation of the Cys-215 residue protected PTP1B from subsequent H2O2-induced irreversible oxidn.  Increasing the level of cellular NO by pretreating cells with an NO donor or by activating ectopically expressed NO synthase inhibited reactive oxygen species-induced irreversible oxidn. of endogenous PTP1B.  These findings suggest that S-nitrosylation might prevent PTPs from permanent inactivation caused by oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWEIujim9PN7Vg90H21EOLACvtfcHk0ljsAJ9XiGmGWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt73K&md5=287181eba0751b89c7b06e7d2969275a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805287200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805287200%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DChu%26aufirst%3DH.%2BM.%26aulast%3DPan%26aufirst%3DK.%2BT.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DD.%2BL.%26aulast%3DWang%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKhoo%26aufirst%3DK.%2BH.%26aulast%3DMeng%26aufirst%3DT.%2BC.%26atitle%3DCysteine%2520S-nitrosylation%2520protects%2520protein-tyrosine%2520phosphatase%25201B%2520against%2520oxidation-induced%2520permanent%2520inactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D35265%26epage%3D35272%26doi%3D10.1074%2Fjbc.M805287200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alicea-Velazquez, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakoncic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.jsb.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23296072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2013&pages=243-251&author=N.+L.+Alicea-Velazquezauthor=J.+Jakoncicauthor=T.+J.+Boggon&title=Structure-guided+studies+of+the+SHP-1%2FJAK1+interaction+provide+new+insights+into+phosphatase+catalytic+domain+substrate+recognition&doi=10.1016%2Fj.jsb.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Jakoncic, Jean; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-251</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SHP-1 (PTPN6) is a member of the SHP sub-family of protein tyrosine phosphatases and plays a crit. role in the regulation of the JAK/STAT signaling pathway.  Previous studies suggested that SHP-1 contains a PTP1B-like second phosphotyrosine pocket that allows for binding of tandem phosphotyrosine residues, such as those found in the activation loop of JAK kinases.  To discover the structural nature of the interaction between SHP-1 and the JAK family member, JAK1, we detd. the 1.8 Å co-crystal structure of the SHP-1 catalytic domain and a JAK1-derived substrate peptide.  This structure reveals electron d. for only one bound phosphotyrosine residue.  To investigate the role of the predicted second site pocket we detd. the structures of SHP-1 in complex with phosphate and sulfate to 1.37 Å and 1.7 Å, resp., and performed anomalous scattering expts. for a selenate-soaked crystal.  These crystallog. data suggest that SHP-1 does not contain a PTP1B-like second site pocket.  This conclusion is further supported by anal. of the relative dephosphorylation and binding affinities of mono- and tandem-phosphorylated peptide substrates.  The crystal structures instead indicate that SHP-1 contains an extended C-terminal helix α2' incompatible with the predicted second phosphotyrosine binding site.  This study suggests that SHP-1 defines a new category of PTP1B-like protein tyrosine phosphatases with a hindered second phosphotyrosine pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokfZ66Q6-mkrVg90H21EOLACvtfcHk0ljsAJ9XiGmGWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCitb4%253D&md5=c492b2b2b725f30d5f9d336777bf039d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Velazquez%26aufirst%3DN.%2BL.%26aulast%3DJakoncic%26aufirst%3DJ.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DStructure-guided%2520studies%2520of%2520the%2520SHP-1%252FJAK1%2520interaction%2520provide%2520new%2520insights%2520into%2520phosphatase%2520catalytic%2520domain%2520substrate%2520recognition%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D181%26spage%3D243%26epage%3D251%26doi%3D10.1016%2Fj.jsb.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2333</span>– <span class="NLM_lpage">2344</span>, <span class="refDoi"> DOI: 10.1021/jm901090b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901090b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFektLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2333-2344&author=A.+P.+Combs&title=Recent+advances+in+the+discovery+of+competitive+protein+tyrosine+phosphatase+1B+inhibitors+for+the+treatment+of+diabetes%2C+obesity%2C+and+cancer&doi=10.1021%2Fjm901090b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of Diabetes, Obesity, and Cancer</span></div><div class="casAuthors">Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2333-2344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5P49bITC_bVg90H21EOLACvtfcHk0lhfSVfifqL5Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFektLzJ&md5=700b2a519c670e1bd9cb41af271d62ae</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm901090b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901090b%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520competitive%2520protein%2520tyrosine%2520phosphatase%25201B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520diabetes%252C%2520obesity%252C%2520and%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2333%26epage%3D2344%26doi%3D10.1021%2Fjm901090b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowarah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V. P.</span></span> <span> </span><span class="NLM_article-title">Anti-diabetic drugs recent approaches and advancements</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115263</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmc.2019.115263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32008883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFCjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115263&author=J.+Dowarahauthor=V.+P.+Singh&title=Anti-diabetic+drugs+recent+approaches+and+advancements&doi=10.1016%2Fj.bmc.2019.115263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-diabetic drugs recent approaches and advancements</span></div><div class="casAuthors">Dowarah, Jayanta; Singh, Ved Prakash</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">115263</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Diabetes is one of the major diseases worldwide and is the third leading cause of death in the United States.  Anti-diabetic drugs are used in the treatment of diabetes mellitus to control glucose levels in the blood.  Most of the drugs are administered orally, except for a few of them, such as insulin, exenatide, and pramlintide.  In this review, we are going to discuss seven major types of anti-diabetic drugs: Peroxisome proliferator-activated receptor (PPAR) agonist, protein tyrosine phosphatase 1B (PTP1B) inhibitors, aldose reductase inhibitors, α-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, G protein-coupled receptor (GPCR) agonists and sodium-glucose co-transporter (SGLT) inhibitors.  Here, we are also discussing some of the recently reported anti-diabetic agents with its multi-target pharmacol. actions.  This review summarises recent approaches and advancement in anti-diabetes treatment concerning characteristics, structure-activity relationships, functional mechanisms, expression regulation, and applications in medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YJxN_zZgZLVg90H21EOLACvtfcHk0lhfSVfifqL5Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFCjsr0%253D&md5=6ca9b8ebb4723bea4cb31188811053eb</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115263%26sid%3Dliteratum%253Aachs%26aulast%3DDowarah%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DV.%2BP.%26atitle%3DAnti-diabetic%2520drugs%2520recent%2520approaches%2520and%2520advancements%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115263%26doi%3D10.1016%2Fj.bmc.2019.115263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmouni, S.</span></span> <span> </span><span class="NLM_article-title">Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">2797</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmc.2015.03.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25921264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVamsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2786-2797&author=L.+Tautzauthor=Y.+A.+Senisauthor=C.+Ouryauthor=S.+Rahmouni&title=Perspective%3A+Tyrosine+phosphatases+as+novel+targets+for+antiplatelet+therapy&doi=10.1016%2Fj.bmc.2015.03.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy</span></div><div class="casAuthors">Tautz, Lutz; Senis, Yotis A.; Oury, Cecile; Rahmouni, Souad</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2786-2797</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Arterial thrombosis is the primary cause of most cases of myocardial infarction and stroke, the leading causes of death in the developed world.  Platelets, highly specialized cells of the circulatory system, are key contributors to thrombotic events.  Antiplatelet drugs, which prevent platelets from aggregating, have been very effective in reducing the mortality and morbidity of these conditions.  However, approved antiplatelet therapies have adverse side effects, most notably the increased risk of bleeding.  Moreover, there remains a considerable incidence of arterial thrombosis in a subset of patients receiving currently available drugs.  Thus, there is a pressing medical need for novel antiplatelet agents with a more favorable safety profile and less patient resistance.  The discovery of novel antiplatelet targets is the matter of intense ongoing research.  Recent findings demonstrate the potential of targeting key signaling mols., including kinases and phosphatases, to prevent platelet activation and aggregation.  Here, we offer perspectives to targeting members of the protein tyrosine phosphatase (PTP) superfamily, a major class of enzymes in signal transduction.  We give an overview of previously identified PTPs in platelet signaling, and discuss their potential as antiplatelet drug targets.  We also introduce VHR (DUSP3), a PTP that we recently identified as a major player in platelet biol. and thrombosis.  We review our data on genetic deletion as well as pharmacol. inhibition of VHR, providing proof-of-principle for a novel and potentially safer VHR-based antiplatelet therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9sT_F5AJ_bVg90H21EOLACvtfcHk0lhfSVfifqL5Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVamsbg%253D&md5=3ed965e9c4c6b3e0c403abbb1cad941f</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.075%26sid%3Dliteratum%253Aachs%26aulast%3DTautz%26aufirst%3DL.%26aulast%3DSenis%26aufirst%3DY.%2BA.%26aulast%3DOury%26aufirst%3DC.%26aulast%3DRahmouni%26aufirst%3DS.%26atitle%3DPerspective%253A%2520Tyrosine%2520phosphatases%2520as%2520novel%2520targets%2520for%2520antiplatelet%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2786%26epage%3D2797%26doi%3D10.1016%2Fj.bmc.2015.03.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">17075</span>– <span class="NLM_lpage">17084</span>, <span class="refDoi"> DOI: 10.1021/ja8068177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8068177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=17075-17084&author=S.+J.+Liuauthor=L.+F.+Zengauthor=L.+Wuauthor=X.+Yuauthor=T.+Xueauthor=A.+M.+Gunawanauthor=Y.+Q.+Longauthor=Z.+Y.+Zhang&title=Targeting+inactive+enzyme+conformation%3A+aryl+diketoacid+derivatives+as+a+new+class+of+PTP1B+inhibitors&doi=10.1021%2Fja8068177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Inactive Enzyme Conformation: Aryl Diketoacid Derivatives as a New Class of PTP1B Inhibitors</span></div><div class="casAuthors">Liu, Sijiu; Zeng, Li-Fan; Wu, Li; Yu, Xiao; Xue, Ting; Gunawan, Andrea M.; Long, Ya-Qiu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">17075-17084</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There has been considerable interest in protein tyrosine phosphatase 1B (PTP1B) as a therapeutic target for diabetes, obesity, as well as cancer.  Identifying inhibitory compds. with good bioavailability is a major challenge of drug discovery programs targeted toward PTPs.  Most current PTP active site-directed pharmacophores are neg. charged pTyr mimetics which cannot readily enter the cell.  This lack of cell permeability limits the utility of such compds. in signaling studies and further therapeutic development.  Aryl diketoacids were identified as novel pTyr surrogates and neutral amide-linked aryl diketoacid dimers were shown to exhibit excellent PTP inhibitory activity.  Kinetic studies establish that these aryl diketoacid derivs. act as noncompetitive inhibitors of PTP1B.  Crystal structures of ligand-bound PTP1B reveal that both the aryl diketoacid and its dimeric deriv. bind PTP1B at the active site, albeit with distinct modes of interaction, in the catalytically inactive, WPD loop open conformation.  Furthermore, dimeric aryl diketoacids are cell permeable and enhance insulin signaling in hepatoma cells, suggesting that targeting the inactive conformation may provide a unique opportunity for creating active site-directed PTP1B inhibitors with improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojCtLQmIhqo7Vg90H21EOLACvtfcHk0lgMj2xcBMYqaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb7K&md5=6b6748cc05e8d08ad1a2f5ba317f7baa</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fja8068177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8068177%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTargeting%2520inactive%2520enzyme%2520conformation%253A%2520aryl%2520diketoacid%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520PTP1B%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D17075%26epage%3D17084%26doi%3D10.1021%2Fja8068177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.6b00537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.6b00537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=122-129&author=Z.+Y.+Zhang&title=Drugging+the+undruggable%3A+therapeutic+potential+of+targeting+protein+tyrosine+phosphatases&doi=10.1021%2Facs.accounts.6b00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases</span></div><div class="casAuthors">Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are essential signaling enzymes that, together with protein tyrosine kinases, regulate tyrosine phosphorylation inside the cell.  Proper level of tyrosine phosphorylation is important for a diverse array of cellular processes, such as proliferation, metab., motility, and survival.  Aberrant tyrosine phosphorylation, resulting from alteration of PTP expression, misregulation, and mutation, has been linked to the etiol. of many human ailments including cancer, diabetes/obesity, autoimmune disorders and infectious diseases.  However, despite the fact that PTPs have been garnering attention as compelling drug targets, they remain a largely under-exploited resource for therapeutic intervention.  Indeed, PTPs have been widely dismissed as "undruggable", due to concerns that the highly conserved active site (i.e., pTyr-binding pocket) makes it difficult to achieve inhibitor selectivity among closely related family members, and the pos.-charged active site prefers neg. charged mols., which usually lack cell permeability.  To address the issue of selectivity, the authors advanced a novel paradigm for the acquisition of highly potent and selective PTP inhibitors through generation of bivalent ligands that interact with both PTP active site and adjacent unique peripheral pockets.  To overcome the bioavailability issue, the authors have identified nonhydrolyzable pTyr mimetics that are sufficiently polar to bind the PTP active site, yet still capable of efficiently penetrating cell membranes.  The authors show that these pTyr mimetics interact in the desired inhibitory fashion with the PTP active site and tethering them to appropriate mol. fragments to engage less conserved interactions outside of PTP active site can increase PTP inhibitor potency and selectivity.  The authors demonstrate through three pTyr mimetics fragment-based approaches that it is completely feasible to obtain highly potent and selective PTP inhibitors with robust in vivo efficacy in animal models of oncol., diabetes/obesity, autoimmune disorders, and tuberculosis.  The authors hope that these results will help dispel concerns about the druggability of PTPs and entice further effort in fostering a PTP-based drug discovery enterprise.  Well-characterized, potent, selective and bioactive inhibitors are essential tools for functional interrogation of PTPs in disease biol. and target validation.  They will also play a crit. role in illuminating the druggability of PTPs and provide the groundwork for new therapies for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoBcljiHogLVg90H21EOLACvtfcHk0lgMj2xcBMYqaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyitbfL&md5=67c8e7a9f57dd733eb97df590d55d583</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.6b00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.6b00537%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DDrugging%2520the%2520undruggable%253A%2520therapeutic%2520potential%2520of%2520targeting%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D122%26epage%3D129%26doi%3D10.1021%2Facs.accounts.6b00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Crystal-structure of human protein-tyrosine phosphatase-1B</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1126/science.8128219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1126%2Fscience.8128219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=8128219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFyhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1397-1404&author=D.+Barfordauthor=A.+J.+Flintauthor=N.+K.+Tonks&title=Crystal-structure+of+human+protein-tyrosine+phosphatase-1B&doi=10.1126%2Fscience.8128219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Barford, David; Flint, Andrew J.; Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5152</span>),
    <span class="NLM_cas:pages">1397-404</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) constitute a family of receptor-like and cytoplasmic signal transducing enzymes that catalyze the dephosphorylation of phosphotyrosine residues and are characterized by homologous catalytic domains.  The crystal structure of a representative member of this family, the 37-kilodalton form (residues 1 to 321) of PTP1B, has been detd. at 2.8 Å resoln.  The enzyme consists of a single domain with the catalytic site located at the base of a shallow cleft.  The phosphate recognition site is created from a loop that is located at the amino-terminus of an α helix.  This site is formed from an 11-residue sequence motif that is diagnostic of PTPs and the dual specificity phosphatases and that contains the catalytically essential cysteine and arginine residues.  The position of the invariant cysteine residue within the phosphate binding site is consistent with its role as a nucleophile in the catalytic reaction.  The structure of PTP1B should serve as a model for other members of the PTP family and as a framework for understanding the mechanism of tyrosine dephosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcmeGL76vbrVg90H21EOLACvtfcHk0lhcXPrsohNXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFyhsLo%253D&md5=cf529916cc8aabaa7d28402465dd6de4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.8128219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8128219%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DFlint%26aufirst%3DA.%2BJ.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DCrystal-structure%2520of%2520human%2520protein-tyrosine%2520phosphatase-1B%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1397%26epage%3D1404%26doi%3D10.1126%2Fscience.8128219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">17773</span>– <span class="NLM_lpage">17783</span>, <span class="refDoi"> DOI: 10.1021/bi9816958</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9816958" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXnslWqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=17773-17783&author=M.+R.+Grovesauthor=Z.+J.+Yaoauthor=P.+P.+Rollerauthor=T.+R.+Burkeauthor=D.+Barford&title=Structural+basis+for+inhibition+of+the+protein+tyrosine+phosphatase+1B+by+phosphotyrosine+peptide+mimetics&doi=10.1021%2Fbi9816958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics</span></div><div class="casAuthors">Groves, Matthew R.; Yao, Zhu-Jun; Roller, Peter P.; Burke, Terrence R., Jr.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">17773-17783</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases regulate diverse cellular processes and represent important targets for therapeutic intervention in a no. of diseases.  The crystal structures of protein tyrosine phosphatase 1B (PTP1B) in complex with small mol. inhibitors based upon two classes of phosphotyrosine mimetics, the (difluoronaphthylmethyl)phosphonic acids and the fluoromalonyl tyrosines, have been detd. to resolns. greater than 2.3 Å.  The fluoromalonyl tyrosine residue was incorporated within a cyclic hexapeptide modeled on an autophosphorylation site of the epidermal growth factor receptor.  The structure of this inhibitor bound to PTP1B represents the first crystal structure of a non-phosphonate-contg. inhibitor and reveals the mechanism of phosphotyrosine mimicry by the fluoromalonyl tyrosine residue and the nature of its interactions within the catalytic site of PTP1B.  In contrast to complexes of PTP1B with phosphotyrosine-contg. peptides, binding of the fluoromalonyl tyrosine residue to the catalytic site of PTP1B is not accompanied by closure of the catalytic site WPD loop.  Structures of PTP1B in complex with the (difluoronaphthylmethyl)phosphonic acid derivs. reveal that substitutions of the naphthalene ring modulate the mode of inhibitor binding to the catalytic site and provide the potential for enhanced inhibitor affinity and the generation of PTP-specific inhibitors.  These results provide a framework for the rational design of higher affinity and more specific phosphotyrosine mimetic inhibitors of not only protein tyrosine phosphatases but also SH2 and PTB domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9c6iDLueKGbVg90H21EOLACvtfcHk0liy-OagBG8ISA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnslWqtL0%253D&md5=8253e0d166692041e3fae452f6d38cd3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fbi9816958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9816958%26sid%3Dliteratum%253Aachs%26aulast%3DGroves%26aufirst%3DM.%2BR.%26aulast%3DYao%26aufirst%3DZ.%2BJ.%26aulast%3DRoller%26aufirst%3DP.%2BP.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DStructural%2520basis%2520for%2520inhibition%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%25201B%2520by%2520phosphotyrosine%2520peptide%2520mimetics%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D17773%26epage%3D17783%26doi%3D10.1021%2Fbi9816958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biel, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmaier, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandao-Neto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span> <span> </span><span class="NLM_article-title">An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e36307</span>, <span class="refDoi"> DOI: 10.7554/eLife.36307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.7554%2FeLife.36307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29877794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e36307&author=D.+A.+Keedyauthor=Z.+B.+Hillauthor=J.+T.+Bielauthor=E.+Kangauthor=T.+J.+Rettenmaierauthor=J.+Brandao-Netoauthor=N.+M.+Pearceauthor=F.+von+Delftauthor=J.+A.+Wellsauthor=J.+S.+Fraser&title=An+expanded+allosteric+network+in+PTP1B+by+multitemperature+crystallography%2C+fragment+screening%2C+and+covalent+tethering&doi=10.7554%2FeLife.36307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.7554%2FeLife.36307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.36307%26sid%3Dliteratum%253Aachs%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DHill%26aufirst%3DZ.%2BB.%26aulast%3DBiel%26aufirst%3DJ.%2BT.%26aulast%3DKang%26aufirst%3DE.%26aulast%3DRettenmaier%26aufirst%3DT.%2BJ.%26aulast%3DBrandao-Neto%26aufirst%3DJ.%26aulast%3DPearce%26aufirst%3DN.%2BM.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520expanded%2520allosteric%2520network%2520in%2520PTP1B%2520by%2520multitemperature%2520crystallography%252C%2520fragment%2520screening%252C%2520and%2520covalent%2520tethering%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26spage%3De36307%26doi%3D10.7554%2FeLife.36307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Punthasee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laciak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddraraju, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, K. S.</span></span> <span> </span><span class="NLM_article-title">Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=2051-2060&author=P.+Punthaseeauthor=A.+R.+Laciakauthor=A.+H.+Cummingsauthor=K.+V.+Ruddrarajuauthor=S.+M.+Lewisauthor=R.+Hillebrandauthor=H.+Singhauthor=J.+J.+Tannerauthor=K.+S.+Gates&title=Covalent+allosteric+inactivation+of+protein+tyrosine+phosphatase+1B+%28PTP1B%29+by+an+inhibitor-electrophile+conjugate&doi=10.1021%2Facs.biochem.7b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate</span></div><div class="casAuthors">Punthasee, Puminan; Laciak, Adrian R.; Cummings, Andrea H.; Ruddraraju, Kasi Viswanatharaju; Lewis, Sarah M.; Hillebrand, Roman; Singh, Harkewal; Tanner, John J.; Gates, Kent S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2051-2060</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase 1B (PTP1B) is a validated drug target, but it has proven difficult to develop medicinally useful, reversible inhibitors of this enzyme.  Here, we explored covalent strategies for the inactivation of PTP1B using a conjugate composed of an active site-directed 5-aryl-1,2,5-thiadiazolidin-3-one 1,1-dioxide inhibitor connected via a short linker to an electrophilic α-bromoacetamide moiety.  The inhibitor-electrophile conjugate caused time-dependent loss of PTP1B activity consistent with a covalent inactivation mechanism.  The inactivation occurred with a 2nd-order rate const. of 1.7 × 102 M-1 min-1.  Mass spectrometric anal. of the inactivated enzyme indicated that the primary site of modification was Cys-121, a residue distant from the active site.  Previous work provided evidence that covalent modification of allosteric residue Cys-121 could cause inactivation of PTP1B.  Overall, the results were consistent with an unusual enzyme inactivation process in which noncovalent binding of the inhibitor-electrophile conjugate to the active site of PTP1B protects the nucleophilic catalytic Cys-215 residue from covalent modification, thus allowing inactivation of the enzyme via selective modification of allosteric residue Cys-121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWbjBooNxw5bVg90H21EOLACvtfcHk0liy-OagBG8ISA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7c%253D&md5=f6d56427bbc06b14c5316b222c9be164</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00151%26sid%3Dliteratum%253Aachs%26aulast%3DPunthasee%26aufirst%3DP.%26aulast%3DLaciak%26aufirst%3DA.%2BR.%26aulast%3DCummings%26aufirst%3DA.%2BH.%26aulast%3DRuddraraju%26aufirst%3DK.%2BV.%26aulast%3DLewis%26aufirst%3DS.%2BM.%26aulast%3DHillebrand%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DTanner%26aufirst%3DJ.%2BJ.%26aulast%3DGates%26aufirst%3DK.%2BS.%26atitle%3DCovalent%2520allosteric%2520inactivation%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%2520%2528PTP1B%2529%2520by%2520an%2520inhibitor-electrophile%2520conjugate%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D2051%26epage%3D2060%26doi%3D10.1021%2Facs.biochem.7b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+mechanisms+for+SH2+domain+mediated+regulation+of+the+protein+tyrosine+phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0lhJ8DXZZpim1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520mechanisms%2520for%2520SH2%2520domain%2520mediated%2520regulation%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human protein-tyrosine phosphatase SHP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6520</span>, <span class="refDoi"> DOI: 10.1074/jbc.M210430200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M210430200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12482860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1ejsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=6516-6520&author=J.+Yangauthor=L.+J.+Liuauthor=D.+D.+Heauthor=X.+Songauthor=X.+S.+Liangauthor=Z.+Z.+J.+Zhaoauthor=G.+W.+Zhou&title=Crystal+structure+of+human+protein-tyrosine+phosphatase+SHP-1&doi=10.1074%2Fjbc.M210430200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Human Protein-tyrosine Phosphatase SHP-1</span></div><div class="casAuthors">Yang, Jian; Liu, Lijun; He, Dandan; Song, Xi; Liang, Xiaoshan; Zhao, Zhizhuang Joe; Zhou, G. Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6516-6520</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SHP-1 is a cytosolic protein tyrosine phosphatase that behaves as a neg. regulator in eukaryotic cellular signaling pathways.  To understand its regulatory mechanism, we have detd. the crystal structure of the C-terminally truncated human SHP-1 in the inactive conformation at 2.8-Å resoln. and refined the structure to a crystallog. R-factor of 24.0%.  The three-dimensional structure shows that the ligand-free SHP-1 has an auto-inhibited conformation.  Its N-SH2 domain blocks the catalytic domain and keeps the enzyme in the inactive conformation, which supports that the phosphatase activity of SHP-1 is primarily regulated by the N-SH2 domain.  In addn., the C-SH2 domain of SHP-1 has a different orientation and is more flexible than that of SHP-2, which enables us to propose an enzymic activation mechanism in which the C-SH2 domains of SHPs could be involved in searching for phosphotyrosine activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxRxIm18VVxrVg90H21EOLACvtfcHk0lhJ8DXZZpim1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1ejsLk%253D&md5=944cdc74889eb9dbf3783d5b99d03163</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210430200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210430200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DHe%26aufirst%3DD.%2BD.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DX.%2BS.%26aulast%3DZhao%26aufirst%3DZ.%2BZ.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520human%2520protein-tyrosine%2520phosphatase%2520SHP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D6516%26epage%3D6520%26doi%3D10.1074%2Fjbc.M210430200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiemer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoluzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesareni, G.</span></span> <span> </span><span class="NLM_article-title">The SH2 domain interaction landscape</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2013.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23545499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1293-1305&author=M.+Tintiauthor=L.+Kiemerauthor=S.+Costaauthor=M.+L.+Millerauthor=F.+Saccoauthor=J.+V.+Olsenauthor=M.+Carducciauthor=S.+Paoluziauthor=F.+Langoneauthor=C.+T.+Workmanauthor=N.+Blomauthor=K.+Machidaauthor=C.+M.+Thompsonauthor=M.+Schutkowskiauthor=S.+Brunakauthor=M.+Mannauthor=B.+J.+Mayerauthor=L.+Castagnoliauthor=G.+Cesareni&title=The+SH2+domain+interaction+landscape&doi=10.1016%2Fj.celrep.2013.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The SH2 Domain Interaction Landscape</span></div><div class="casAuthors">Tinti, Michele; Kiemer, Lars; Costa, Stefano; Miller, Martin L.; Sacco, Francesca; Olsen, Jesper V.; Carducci, Martina; Paoluzi, Serena; Langone, Francesca; Workman, Christopher T.; Blom, Nikolaj; Machida, Kazuya; Thompson, Christopher M.; Schutkowski, Mike; Brunak, Soeren; Mann, Matthias; Mayer, Bruce J.; Castagnoli, Luisa; Cesareni, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1305</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Members of the SH2 domain family modulate signal transduction by binding to short peptides contg. phosphorylated tyrosines.  Each domain displays a distinct preference for the sequence context of the phosphorylated residue.  We have developed a high-d. peptide chip technol. that allows for probing of the affinity of most SH2 domains for a large fraction of the entire complement of tyrosine phosphopeptides in the human proteome.  Using this technique, we have exptl. identified thousands of putative SH2-peptide interactions for more than 70 different SH2 domains.  By integrating this rich data set with orthogonal context-specific information, we have assembled an SH2-mediated probabilistic interaction network, which we make available as a community resource in the PepspotDB database.  A predicted dynamic interaction between the SH2 domains of the tyrosine phosphatase SHP2 and the phosphorylated tyrosine in the extracellular signal-regulated kinase activation loop was validated by expts. in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Fe2t6V8ZqLVg90H21EOLACvtfcHk0litzZvtBB3J3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCru7Y%253D&md5=5b72648ef1cb45c434c226a23cbe715a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTinti%26aufirst%3DM.%26aulast%3DKiemer%26aufirst%3DL.%26aulast%3DCosta%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DSacco%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DPaoluzi%26aufirst%3DS.%26aulast%3DLangone%26aufirst%3DF.%26aulast%3DWorkman%26aufirst%3DC.%2BT.%26aulast%3DBlom%26aufirst%3DN.%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DC.%2BM.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBrunak%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DB.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DL.%26aulast%3DCesareni%26aufirst%3DG.%26atitle%3DThe%2520SH2%2520domain%2520interaction%2520landscape%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1293%26epage%3D1305%26doi%3D10.1016%2Fj.celrep.2013.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablonowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkkainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renkema, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B. J.</span></span> <span> </span><span class="NLM_article-title">High-throughput phosphotyrosine profiling using SH2 domains</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.molcel.2007.05.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17588523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFSqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=899-915&author=K.+Machidaauthor=C.+M.+Thompsonauthor=K.+Dierckauthor=K.+Jablonowskiauthor=S.+Karkkainenauthor=B.+Liuauthor=H.+M.+Zhangauthor=P.+D.+Nashauthor=D.+K.+Newmanauthor=P.+Nollauauthor=T.+Pawsonauthor=G.+H.+Renkemaauthor=K.+Sakselaauthor=M.+R.+Schillerauthor=D.+G.+Shinauthor=B.+J.+Mayer&title=High-throughput+phosphotyrosine+profiling+using+SH2+domains&doi=10.1016%2Fj.molcel.2007.05.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput phosphotyrosine profiling using SH2 domains</span></div><div class="casAuthors">Machida, Kazuya; Thompson, Christopher M.; Dierck, Kevin; Jablonowski, Karl; Karkkainen, Satu; Liu, Bernard; Zhang, Haimin; Nash, Piers D.; Newman, Debra K.; Nollau, Peter; Pawson, Tony; Renkema, G. Herma; Saksela, Kalle; Schiller, Martin R.; Shin, Dong-Guk; Mayer, Bruce J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">899-915</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphorylation controls many aspects of signaling in multicellular organisms.  One of the major consequences of tyrosine phosphorylation is the creation of binding sites for proteins contg. Src homol. 2 (SH2) domains.  To profile the global tyrosine phosphorylation state of the cell, we have developed proteomic binding assays encompassing nearly the full complement of human SH2 domains.  Here we provide a global view of SH2 domain binding to cellular proteins based on large-scale far-western analyses.  We also use reverse-phase protein arrays to generate comprehensive, quant. SH2 binding profiles for phosphopeptides, recombinant proteins, and entire proteomes.  As an example, we profiled the adhesion-dependent SH2 binding interactions in fibroblasts and identified specific focal adhesion complex proteins whose tyrosine phosphorylation and binding to SH2 domains are modulated by adhesion.  These results demonstrate that high-throughput comprehensive SH2 profiling provides valuable mechanistic insights into tyrosine kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRaADjUvBnFLVg90H21EOLACvtfcHk0litzZvtBB3J3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFSqsrw%253D&md5=0d2ebb55c613469e13f256a6fda8bbe1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DMachida%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DC.%2BM.%26aulast%3DDierck%26aufirst%3DK.%26aulast%3DJablonowski%26aufirst%3DK.%26aulast%3DKarkkainen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DNash%26aufirst%3DP.%2BD.%26aulast%3DNewman%26aufirst%3DD.%2BK.%26aulast%3DNollau%26aufirst%3DP.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DRenkema%26aufirst%3DG.%2BH.%26aulast%3DSaksela%26aufirst%3DK.%26aulast%3DSchiller%26aufirst%3DM.%2BR.%26aulast%3DShin%26aufirst%3DD.%2BG.%26aulast%3DMayer%26aufirst%3DB.%2BJ.%26atitle%3DHigh-throughput%2520phosphotyrosine%2520profiling%2520using%2520SH2%2520domains%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D26%26spage%3D899%26epage%3D915%26doi%3D10.1016%2Fj.molcel.2007.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wavreille, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Decoding protein-protein interactions through combinatorial chemistry: Sequence specificity of SHP-1, SHP-2, and SHIPSH2 domains</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">14932</span>– <span class="NLM_lpage">14947</span>, <span class="refDoi"> DOI: 10.1021/bi051408h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi051408h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFaltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=14932-14947&author=M.+C.+Sweeneyauthor=A.+S.+Wavreilleauthor=J.+Parkauthor=J.+P.+Butcharauthor=S.+Tridandapaniauthor=D.+Pei&title=Decoding+protein-protein+interactions+through+combinatorial+chemistry%3A+Sequence+specificity+of+SHP-1%2C+SHP-2%2C+and+SHIPSH2+domains&doi=10.1021%2Fbi051408h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding Protein-Protein Interactions through Combinatorial Chemistry: Sequence Specificity of SHP-1, SHP-2, and SHIP SH2 Domains</span></div><div class="casAuthors">Sweeney, Michael C.; Wavreille, Anne-Sophie; Park, Junguk; Butchar, Jonathan P.; Tridandapani, Susheela; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">14932-14947</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general, combinatorial library method for the rapid identification of high-affinity peptide ligands of protein modular domains is reported.  The validity of this method has been demonstrated by detg. the sequence specificity of four Src homol. 2 (SH2) domains derived from protein tyrosine phosphatase SHP-1 and SHP-2 and inositol phosphatase SHIP.  A phosphotyrosyl (pY) peptide library was screened against the SH2 domains, and the beads that carry high-affinity ligands of the SH2 domains were identified and peptides were sequenced by partial Edman degrdn. and mass spectrometry.  The results reveal that the N-terminal SH2 domain of SHP-2 is capable of recognizing four different classes of pY peptides.  Binding competition studies suggest that the four classes of pY peptides all bind to the same site on the SH2 domain surface.  The C-terminal SH2 domains of SHP-1 and SHP-2 and the SHIP SH2 domain each bind to pY peptides of a single consensus sequence.  Database searches using the consensus sequences identified most of the known as well as many potential interacting proteins of SHP-1 and/or SHP-2.  Several proteins are found to bind to the SH2 domains of SHP-1 and SHP-2 through a new, nonclassical ITIM motif, (V/I/L)XpY(M/L/F)XP, which corresponds to the class IV peptides selected from the pY library.  The combinatorial library method should be generally applicable to other protein domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNRV8GxxQyW7Vg90H21EOLACvtfcHk0lg8bzyLdtEZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFaltbzM&md5=31deef0dc3947db23e64d986a666e8e3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fbi051408h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi051408h%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DM.%2BC.%26aulast%3DWavreille%26aufirst%3DA.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DTridandapani%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DDecoding%2520protein-protein%2520interactions%2520through%2520combinatorial%2520chemistry%253A%2520Sequence%2520specificity%2520of%2520SHP-1%252C%2520SHP-2%252C%2520and%2520SHIPSH2%2520domains%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D14932%26epage%3D14947%26doi%3D10.1021%2Fbi051408h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wavreille, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D. H.</span></span> <span> </span><span class="NLM_article-title">Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains - Critical roles of residues beyond the pY+3 position</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">20271</span>– <span class="NLM_lpage">20282</span>, <span class="refDoi"> DOI: 10.1074/jbc.M601047200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M601047200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16702225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFeqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=20271-20282&author=D.+Imhofauthor=A.+S.+Wavreilleauthor=A.+Mayauthor=M.+Zachariasauthor=S.+Tridandapaniauthor=D.+H.+Pei&title=Sequence+specificity+of+SHP-1+and+SHP-2+Src+homology+2+domains+-+Critical+roles+of+residues+beyond+the+pY%2B3+position&doi=10.1074%2Fjbc.M601047200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence Specificity of SHP-1 and SHP-2 Src Homology 2 Domains. Critical Roles of Residues Beyond the pY+3 Position</span></div><div class="casAuthors">Imhof, Diana; Wavreille, Anne-Sophie; May, Andreas; Zacharias, Martin; Tridandapani, Susheela; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">20271-20282</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A combinatorial phosphotyrosyl (pY) peptide library was screened to det. the amino acid preferences at the pY+4 to pY+6 positions for the four SH2 domains of protein tyrosine phosphatases SHP-1 and SHP-2.  Individual binding sequences selected from the library were resynthesized and their binding affinities and specificities to various SH2 domains were further evaluated by SPR studies, stimulation of SHP-1 and SHP-2 phosphatase activity, and in vitro pulldown assays.  These studies reveal that binding of a pY peptide to the N-SH2 domain of SHP-2 is greatly enhanced by a large hydrophobic residue (Trp, Tyr, Met, or Phe) at the pY+4 and/or pY+5 positions, whereas binding to SHP-1 N-SH2 domain is enhanced by either hydrophobic or pos. charged residues (Arg, Lys, or His) at these positions.  Similar residues at the pY+4 to pY+6 positions are also preferred by SHP-1 and SHP-2 C-SH2 domains, although their influence on the overall binding affinities is much smaller compared with the N-SH2 domains.  A structural model was generated to qual. interpret the contribution of the pY+4 and pY+5 residues to the overall binding affinity.  Examn. of pY motifs from known SHP-1 and SHP-2-binding proteins shows that many of the pY motifs contain a hydrophobic or pos. charged residue(s) at the pY+4 and pY+5 positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottCrfP57BlrVg90H21EOLACvtfcHk0lg8bzyLdtEZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFeqt7c%253D&md5=8b12fed8412f591e3309a9a7722d022b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M601047200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M601047200%26sid%3Dliteratum%253Aachs%26aulast%3DImhof%26aufirst%3DD.%26aulast%3DWavreille%26aufirst%3DA.%2BS.%26aulast%3DMay%26aufirst%3DA.%26aulast%3DZacharias%26aufirst%3DM.%26aulast%3DTridandapani%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%2BH.%26atitle%3DSequence%2520specificity%2520of%2520SHP-1%2520and%2520SHP-2%2520Src%2520homology%25202%2520domains%2520-%2520Critical%2520roles%2520of%2520residues%2520beyond%2520the%2520pY%252B3%2520position%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D20271%26epage%3D20282%26doi%3D10.1074%2Fjbc.M601047200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Diverse biochemical properties of Shp2 mutants</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">30984</span>– <span class="NLM_lpage">30993</span>, <span class="refDoi"> DOI: 10.1074/jbc.M504699200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M504699200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15987685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=30984-30993&author=H.+Keilhackauthor=F.+S.+Davidauthor=M.+McGregorauthor=L.+C.+Cantleyauthor=B.+G.+Neel&title=Diverse+biochemical+properties+of+Shp2+mutants&doi=10.1074%2Fjbc.M504699200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse Biochemical Properties of Shp2 Mutants: implications for disease phenotypes</span></div><div class="casAuthors">Keilhack, Heike; David, Frank S.; McGregor, Malcolm; Cantley, Lewis C.; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">30984-30993</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mutations in the Src homol. 2 (SH2)-contg. protein-tyrosine phosphatase Shp2 (PTPN11) underlie half of the cases of the autosomal dominant genetic disorder Noonan syndrome, and somatic Shp2 mutations are found in several hematol. and solid malignancies.  Earlier studies of small nos. of mutants suggested that disease-assocd. mutations cause constitutive (SH2 binding-independent) activation and that cancer-assocd. mutants are more active than those assocd. with Noonan syndrome.  We have characterized a larger panel of Shp2 mutants and find that this "activity-centric" model cannot explain the behaviors of all pathogenic Shp2 mutations.  Instead, enzymic, structural, and math. modeling analyses show that these mutants can affect basal activation, SH2 domain-phosphopeptide affinity, and/or substrate specificity to varying degrees.  Furthermore, there is no abs. correlation between the mutants' extents of basal activation and the diseases they induce.  We propose that activated mutants of Shp2 modulate signaling from specific stimuli to a subset of effectors and provide a theor. framework for understanding the complex relationship between Shp2 activation, intracellular signaling, and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJx5YZGoBn6bVg90H21EOLACvtfcHk0lg8bzyLdtEZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtL8%253D&md5=649d6897855861aa0e6aaaff4ed57125</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M504699200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M504699200%26sid%3Dliteratum%253Aachs%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DDavid%26aufirst%3DF.%2BS.%26aulast%3DMcGregor%26aufirst%3DM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DDiverse%2520biochemical%2520properties%2520of%2520Shp2%2520mutants%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D30984%26epage%3D30993%26doi%3D10.1074%2Fjbc.M504699200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieuw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. M.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-11-4207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood-2004-11-4207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15761018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=311-317&author=S.+Schubbertauthor=K.+Lieuwauthor=S.+L.+Roweauthor=C.+M.+Leeauthor=X.+X.+Liauthor=M.+L.+Lohauthor=D.+W.+Clappauthor=K.+M.+Shannon&title=Functional+analysis+of+leukemia-associated+PTPN11+mutations+in+primary+hematopoietic+cells&doi=10.1182%2Fblood-2004-11-4207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells</span></div><div class="casAuthors">Schubbert, Suzanne; Lieuw, Kenneth; Rowe, Sara L.; Lee, Connie M.; Li, XiaXin; Loh, Mignon L.; Clapp, D. Wade; Shannon, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">PTPN11 encodes the protein tyrosine phosphatase SHP-2, which relays signals from growth factor receptors to Ras and other effectors.  Germline PTPN11 mutations underlie about 50% of Noonan syndrome (NS), a developmental disorder that is assocd. with an elevated risk of juvenile myelomonocytic leukemia (JMML).  Somatic PTPN11 mutations were recently identified in about 35% of patients with JMML; these mutations introduce amino acid substitutions that are largely distinct from those found in NS.  We assessed the functional consequences of leukemia-assocd. PTPN11 mutations in murine hematopoietic cells.  Expressing an E76K SHP-2 protein induced a hypersensitive pattern of granulocyte-macrophage colony-forming unit (CFU-GM) colony growth in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) that was dependent on SHP-2 catalytic activity.  E76K SHP-2 expression also enhanced the growth of immature progenitor cells with high replating potential, perturbed erythroid growth, and impaired normal differentiation in liq. cultures.  In addn., leukemia-assocd. SHP-2 mutations conferred a stronger phenotype than a germline mutation found in patients with NS.  Mutant SHP-2 proteins induce aberrant growth in multiple hematopoietic compartments, which supports a primary role of hyperactive Ras in the pathogenesis of JMML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodGp2TL7I53LVg90H21EOLACvtfcHk0lhrM5gKtvDxkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrk%253D&md5=bb0309533d245fd69d069a8b69e67a35</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-11-4207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-11-4207%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DLieuw%26aufirst%3DK.%26aulast%3DRowe%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DX.%2BX.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DShannon%26aufirst%3DK.%2BM.%26atitle%3DFunctional%2520analysis%2520of%2520leukemia-associated%2520PTPN11%2520mutations%2520in%2520primary%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D311%26epage%3D317%26doi%3D10.1182%2Fblood-2004-11-4207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. F.</span></span> <span> </span><span class="NLM_article-title">The landscape of protein tyrosine phosphatase (Shp2) and cancer</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3767</span>– <span class="NLM_lpage">3777</span>, <span class="refDoi"> DOI: 10.2174/1381612824666181106100837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2174%2F1381612824666181106100837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=3767-3777&author=A.+U.+Rehmanauthor=M.+U.+Rahmanauthor=M.+T.+Khanauthor=S.+Saudauthor=H.+Liuauthor=D.+Songauthor=P.+Sultanaauthor=A.+Wadoodauthor=H.+F.+Chen&title=The+landscape+of+protein+tyrosine+phosphatase+%28Shp2%29+and+cancer&doi=10.2174%2F1381612824666181106100837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2174%2F1381612824666181106100837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612824666181106100837%26sid%3Dliteratum%253Aachs%26aulast%3DRehman%26aufirst%3DA.%2BU.%26aulast%3DRahman%26aufirst%3DM.%2BU.%26aulast%3DKhan%26aufirst%3DM.%2BT.%26aulast%3DSaud%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DSultana%26aufirst%3DP.%26aulast%3DWadood%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%2BF.%26atitle%3DThe%2520landscape%2520of%2520protein%2520tyrosine%2520phosphatase%2520%2528Shp2%2529%2520and%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2019%26volume%3D24%26spage%3D3767%26epage%3D3777%26doi%3D10.2174%2F1381612824666181106100837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durzynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2277</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2269-2277&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=X.+Xuauthor=I.+Durzynskaauthor=L.+Fanauthor=T.+Stamsauthor=H.+M.+Chanauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=P.+Wangauthor=P.+D.+Fortinauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+and+functional+consequences+of+three+cancer-associated+mutations+of+the+oncogenic+phosphatase+SHP2&doi=10.1021%2Facs.biochem.5b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span></div><div class="casAuthors">LaRochelle, Jonathan R.; Fodor, Michelle; Xu, Xiang; Durzynska, Izabela; Fan, Lixin; Stams, Travis; Chan, Ho Man; LaMarche, Matthew J.; Chopra, Rajiv; Wang, Ping; Fortin, Pascal D.; Acker, Michael G.; Blacklow, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2269-2277</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proto-oncogene PTPN11 encodes a cytoplasmic protein tyrosine phosphatase, SHP2, which is required for normal development and sustained activation of the Ras-MAPK signaling pathway.  Germline mutations in SHP2 cause developmental disorders, and somatic mutations have been identified in childhood and adult cancers and drive leukemia in mice.  Despite our knowledge of the PTPN11 variations assocd. with pathol., the structural and functional consequences of many disease-assocd. mutants remain poorly understood.  Here, we combine X-ray crystallog., small-angle X-ray scattering, and biochem. to elucidate structural and mechanistic features of three cancer-assocd. SHP2 variants harboring single point mutations within the N-SH2:PTP interdomain autoinhibitory interface.  Our findings directly compare the impact of each mutation on autoinhibition of the phosphatase and advance the development of structure-guided and mutation-specific SHP2 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIaFVGm5lArVg90H21EOLACvtfcHk0lhrM5gKtvDxkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D&md5=720b3dd9b18edde2c443d488cfb90dfc</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDurzynska%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520functional%2520consequences%2520of%2520three%2520cancer-associated%2520mutations%2520of%2520the%2520oncogenic%2520phosphatase%2520SHP2%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2269%26epage%3D2277%26doi%3D10.1021%2Facs.biochem.5b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1002/humu.20005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fhumu.20005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=14974085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFegur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=267-277&author=A.+Fragaleauthor=M.+Tartagliaauthor=J.+Wuauthor=B.+D.+Gelb&title=Noonan+syndrome-associated+SHP2%2FPTPN11+mutants+cause+EGF-dependent+prolonged+GAB1+binding+and+sustained+ERK2%2FMAPK1+activation&doi=10.1002%2Fhumu.20005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation</span></div><div class="casAuthors">Fragale, Alessandra; Tartaglia, Marco; Wu, Jie; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-277</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations.  PTPN11 encodes Src homol. 2 domain-contg. tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors.  We compared the functional effects of 3 Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction.  All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation.  Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent.  Binding of SHP2 mutants to Grb2-assocd. binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged.  Coexpression of Grb2-assocd. binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic redn. of extracellular signal-regulated kinase 2 activation.  Taken together, these results document that Noonan syndrome-assocd. PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homol. 2 and protein tyrosine phosphatase domains are altered.  The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-assocd. binder-1 (GAB1), leading to increased cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SbZpUF3L77Vg90H21EOLACvtfcHk0lg_BHz01BS0vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFegur4%253D&md5=696e3e6507da38f135546e2ad4f6d8e4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20005%26sid%3Dliteratum%253Aachs%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DNoonan%2520syndrome-associated%2520SHP2%252FPTPN11%2520mutants%2520cause%2520EGF-dependent%2520prolonged%2520GAB1%2520binding%2520and%2520sustained%2520ERK2%252FMAPK1%2520activation%26jtitle%3DHum.%2520Mutat.%26date%3D2004%26volume%3D23%26spage%3D267%26epage%3D277%26doi%3D10.1002%2Fhumu.20005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span> <span> </span><span class="NLM_article-title">Comparability of mixed IC50 data - a statistical analysis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e61007</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0061007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1371%2Fjournal.pone.0061007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23613770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e61007&author=T.+Kalliokoskiauthor=C.+Kramerauthor=A.+Vulpettiauthor=P.+Gedeck&title=Comparability+of+mixed+IC50+data+-+a+statistical+analysis&doi=10.1371%2Fjournal.pone.0061007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Comparability of mixed IC50 data - a statistical analysis</span></div><div class="casAuthors">Kalliokoski, Tuomo; Kramer, Christian; Vulpetti, Anna; Gedeck, Peter</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61007</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The biochem. half maximal inhibitory concn. (IC50) is the most commonly used metric for on-target activity in lead optimization.  It is used to guide lead optimization, build large-scale chemogenomics anal., off-target activity and toxicity models based on public data.  However, the use of public biochem. IC50 data is problematic, because they are assay specific and comparable only under certain conditions.  For large scale anal. it is not feasible to check each data entry manually and it is very tempting to mix all available IC50 values from public database even if assay information is not reported.  As previously reported for Ki database anal., we first analyzed the types of errors, the redundancy and the variability that can be found in ChEMBL IC50 database.  For assessing the variability of IC50 data independently measured in two different labs at least ten IC50 data for identical protein-ligand systems against the same target were searched in ChEMBL.  As a not sufficient no. of cases of this type are available, the variability of IC50 data was assessed by comparing all pairs of independent IC50 measurements on identical protein-ligand systems.  The std. deviation of IC50 data is only 25% larger than the std. deviation of Ki data, suggesting that mixing IC50 data from different assays, even not knowing assay conditions details, only adds a moderate amt. of noise to the overall data.  The std. deviation of public ChEMBL IC50 data, as expected, resulted greater than the std. deviation of inhouse intra-lab./inter-day IC50 data.  Augmenting mixed public IC50 data by public Ki data does not deteriorate the quality of the mixed IC50 data, if the Ki is cor. by an offset.  For a broad dataset such as ChEMBL database a Ki-IC50 conversion factor of 2 was found to be the most reasonable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq07UjgtQJyZ7Vg90H21EOLACvtfcHk0lg_BHz01BS0vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslSitrc%253D&md5=591144d98c123366e344688c74156e9e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061007%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DC.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DGedeck%26aufirst%3DP.%26atitle%3DComparability%2520of%2520mixed%2520IC50%2520data%2520-%2520a%2520statistical%2520analysis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De61007%26doi%3D10.1371%2Fjournal.pone.0061007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lexa, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazanov, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, H. A.</span></span> <span> </span><span class="NLM_article-title">CSAR benchmark exercise of 2010: selection of the protein-ligand complexes</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2036</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1021/ci200082t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200082t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1Cjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2036-2046&author=J.+B.+Dunbarauthor=R.+D.+Smithauthor=C.+Y.+Yangauthor=P.+M.+U.+Ungauthor=K.+W.+Lexaauthor=N.+A.+Khazanovauthor=J.+A.+Stuckeyauthor=S.+M.+Wangauthor=H.+A.+Carlson&title=CSAR+benchmark+exercise+of+2010%3A+selection+of+the+protein-ligand+complexes&doi=10.1021%2Fci200082t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes</span></div><div class="casAuthors">Dunbar, James B.; Smith, Richard D.; Yang, Chao-Yie; Ung, Peter Man-Un; Lexa, Katrina W.; Khazanov, Nickolay A.; Stuckey, Jeanne A.; Wang, Shaomeng; Carlson, Heather A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-2046</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major goal in drug design is the improvement of computational methods for docking and scoring.  The Community Structure Activity Resource (CSAR) aims to collect available data from industry and academia which may be used for this purpose (www.csardock.org).  Also, CSAR is charged with organizing community-wide exercises based on the collected data.  The first of these exercises was aimed to gauge the overall state of docking and scoring, using a large and diverse data set of protein-ligand complexes.  Participants were asked to calc. the affinity of the complexes as provided and then recalc. with changes which may improve their specific method.  This first data set was selected from existing PDB entries which had binding data (Kd or Ki) in Binding MOAD, augmented with entries from PDBbind.  The final data set contains 343 diverse protein-ligand complexes and spans 14 pKd.  Sixteen proteins have three or more complexes in the data set, from which a user could start an inspection of congeneric series.  Inherent exptl. error limits the possible correlation between scores and measured affinity; R2 is limited to ∼0.9 when fitting to the data set without over parametrizing.  R2 is limited to ∼0.8 when scoring the data set with a method trained on outside data.  The details of how the data set was initially selected, and the process by which it matured to better fit the needs of the community are presented.  Many groups generously participated in improving the data set, and this underscores the value of a supportive, collaborative effort in moving our field forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FcnvoLAJ07Vg90H21EOLACvtfcHk0lio500fkPTXeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1Cjur4%253D&md5=3a5e84d8428a2b214549d087e0d68489</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fci200082t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200082t%26sid%3Dliteratum%253Aachs%26aulast%3DDunbar%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DLexa%26aufirst%3DK.%2BW.%26aulast%3DKhazanov%26aufirst%3DN.%2BA.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%2BM.%26aulast%3DCarlson%26aufirst%3DH.%2BA.%26atitle%3DCSAR%2520benchmark%2520exercise%2520of%25202010%253A%2520selection%2520of%2520the%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2036%26epage%3D2046%26doi%3D10.1021%2Fci200082t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noren-Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Correa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestweber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">10606</span>– <span class="NLM_lpage">10611</span>, <span class="refDoi"> DOI: 10.1073/pnas.0601490103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0601490103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16809424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD28vhsVentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10606-10611&author=A.+Noren-Mullerauthor=I.+Reis-Correaauthor=H.+Prinzauthor=C.+Rosenbaumauthor=K.+Saxenaauthor=H.+J.+Schwalbeauthor=D.+Vestweberauthor=G.+Cagnaauthor=S.+Schunkauthor=O.+Schwarzauthor=H.+Schieweauthor=H.+Waldmann&title=Discovery+of+protein+phosphatase+inhibitor+classes+by+biology-oriented+synthesis&doi=10.1073%2Fpnas.0601490103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis</span></div><div class="casAuthors">Noren-Muller Andrea; Reis-Correa Ivan Jr; Prinz Heino; Rosenbaum Claudia; Saxena Krishna; Schwalbe Harald J; Vestweber Dietmar; Cagna Guiseppe; Schunk Stefan; Schwarz Oliver; Schiewe Hajo; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10606-11</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Protein phosphatases have very recently emerged as important targets for chemical biology and medicinal chemistry research, and new phosphatase inhibitor classes are in high demand.  The underlying frameworks of natural products represent the evolutionarily selected fractions of chemical space explored by nature so far and meet the criteria of relevance to nature and biological prevalidation most crucial to inhibitor development.  We refer to synthesis efforts and compound collection development based on these criteria as biology-oriented synthesis.  For the discovery of phosphatase inhibitor classes by means of this approach, four natural product-derived or -inspired medium-sized compound collections were synthesized and investigated for inhibition of the tyrosine phosphatases VE-PTP, Shp-2, PTP1B, MptpA, and MptpB and the dual-specificity phosphatases Cdc25A and VHR.  The screen yielded four unprecedented and selective phosphatase inhibitor classes for four phosphatases with high hit rates.  For VE-PTP and MptpB the first inhibitors were discovered.  These results demonstrate that biology-oriented synthesis is an efficient approach to the discovery of new compound classes for medicinal chemistry and chemical biology research that opens up new opportunities for the study of phosphatases, which may lead to the development of new drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNf4ONKii5590Q2ypr7jHkfW6udTcc2eYsbroX3FEH37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vhsVentg%253D%253D&md5=76f28f79227b8261fd23e7dbf3e2d8e7</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601490103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601490103%26sid%3Dliteratum%253Aachs%26aulast%3DNoren-Muller%26aufirst%3DA.%26aulast%3DReis-Correa%26aufirst%3DI.%26aulast%3DPrinz%26aufirst%3DH.%26aulast%3DRosenbaum%26aufirst%3DC.%26aulast%3DSaxena%26aufirst%3DK.%26aulast%3DSchwalbe%26aufirst%3DH.%2BJ.%26aulast%3DVestweber%26aufirst%3DD.%26aulast%3DCagna%26aufirst%3DG.%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DSchwarz%26aufirst%3DO.%26aulast%3DSchiewe%26aufirst%3DH.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520protein%2520phosphatase%2520inhibitor%2520classes%2520by%2520biology-oriented%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D10606%26epage%3D10611%26doi%3D10.1073%2Fpnas.0601490103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">47311</span>– <span class="NLM_lpage">47319</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106568200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1074%2Fjbc.M106568200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11584002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Gms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=47311-47319&author=K.+Shenauthor=Y.+F.+Kengauthor=L.+Wuauthor=X.+L.+Guoauthor=D.+S.+Lawrenceauthor=Z.+Y.+Zhang&title=Acquisition+of+a+specific+and+potent+PTP1B+inhibitor+from+a+novel+combinatorial+library+and+screening+procedure&doi=10.1074%2Fjbc.M106568200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure</span></div><div class="casAuthors">Shen, Kui; Keng, Yen-Fang; Wu, Li; Guo, Xiao-Ling; Lawrence, David S.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">47311-47319</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein-tyrosine phosphatases (PTPases) form a large family of enzymes that serve as key regulatory components in signal transduction pathways.  Defective or inappropriate regulation of PTPase activity leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases including cancers and diabetes.  For example, recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery.  Thus, there is intense interest in obtaining specific and potent PTPase inhibitors for biol. studies and pharmacol. development.  However, given the highly conserved nature of the PTPase active site, it is unclear whether selectivity in PTPase inhibition can be achieved.  We describe a combinatorial approach that is designed to target both the active site and a unique peripheral site in PTP1B.  Compds. that can simultaneously assoc. with both sites are expected to exhibit enhanced affinity and specificity.  We also describe a novel affinity-based high-throughput assay procedure that can be used for PTPase inhibitor screening.  The combinatorial library/high-throughput screen protocols furnished a small mol. PTP1B inhibitor that is both potent (Ki = 2.4 nM) and selective (little or no activity against a panel of phosphatases including Yersinia PTPase, SHP1, SHP2, LAR, HePTP, PTPα, CD45, VHR, MKP3, Cdc25A, Stp1, and PP2C).  These results demonstrate that it is possible to acquire potent, yet highly selective inhibitors for individual members of the large PTPase family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCE0aWAjkRLrVg90H21EOLACvtfcHk0lh4hgLnAGYExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Gms74%253D&md5=20d467b114c7d33f6dd6623bd1d35836</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106568200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106568200%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DK.%26aulast%3DKeng%26aufirst%3DY.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DX.%2BL.%26aulast%3DLawrence%26aufirst%3DD.%2BS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DAcquisition%2520of%2520a%2520specific%2520and%2520potent%2520PTP1B%2520inhibitor%2520from%2520a%2520novel%2520combinatorial%2520library%2520and%2520screening%2520procedure%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D47311%26epage%3D47319%26doi%3D10.1074%2Fjbc.M106568200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramphal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(03)00039-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2FS0968-0896%2803%2900039-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12659770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlGjsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1835-1849&author=P.+Huangauthor=J.+Ramphalauthor=J.+Weiauthor=C.+X.+Liangauthor=B.+Jallalauthor=G.+McMahonauthor=C.+Tang&title=Structure-based+design+and+discovery+of+novel+inhibitors+of+protein+tyrosine+phosphatases&doi=10.1016%2FS0968-0896%2803%2900039-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases</span></div><div class="casAuthors">Huang, Ping; Ramphal, John; Wei, James; Liang, Congxin; Jallal, Bahija; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1835-1849</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are important in the regulation of signal transduction processes.  Certain enzymes of this class are considered as potential therapeutic targets in the treatment of a variety of diseases such as diabetes, inflammation, and cancer.  However, many PTP inhibitors identified to date are peptide-based and contain a highly charged phosphate-mimicking component.  These compds. usually lack membrane permeability and this limits their utility in the inhibition of intracellular phosphatases.  In the present study, we have used structure-based design and modeling techniques to explore catalytic-site directed, reversible inhibitors of PTPs.  Employing a non-charged phosphate mimic and non-peptidyl structural components, we have successfully designed and synthesized a novel series of trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compds. as PTP inhibitors.  This is the first time that an uncharged phosphate mimic is reported in the literature for general, reversible, and substrate-competitive inhibition of PTPs.  It is an important discovery because the finding may provide a paradigm for the development of phosphatase inhibitors that enter cells and modify signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeV_wY9vEvurVg90H21EOLACvtfcHk0lh4hgLnAGYExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlGjsL4%253D&md5=2071ba6cf7f98db86bfd54f0a3389b3f</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900039-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900039-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DC.%2BX.%26aulast%3DJallal%26aufirst%3DB.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DStructure-based%2520design%2520and%2520discovery%2520of%2520novel%2520inhibitors%2520of%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1835%26epage%3D1849%26doi%3D10.1016%2FS0968-0896%2803%2900039-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilander, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, J. A.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2925</span>, <span class="refDoi"> DOI: 10.1182/blood.V100.8.2917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1182%2Fblood.V100.8.2917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=12351403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVGht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=2917-2925&author=Y.+X.+Zhangauthor=M.+I.+Dawsonauthor=R.+Mohammadauthor=A.+K.+Rishiauthor=L.+Farhanaauthor=K.+C.+Fengauthor=M.+Leidauthor=V.+Petersonauthor=X.+K.+Zhangauthor=M.+Edelsteinauthor=D.+Eilanderauthor=S.+Biggarauthor=N.+Wallauthor=U.+Reichertauthor=J.+A.+Fontana&title=Induction+of+apoptosis+of+human+B-CLL+and+ALL+cells+by+a+novel+retinoid+and+its+nonretinoidal+analog&doi=10.1182%2Fblood.V100.8.2917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog</span></div><div class="casAuthors">Zhang, Yuxiang; Dawson, Marcia I.; Mohammad, Ramzi; Rishi, Arun K.; Farhana, Lulu; Feng, Kai-Chia; Leid, Mark; Peterson, Valerie; Zhang, Xiao-kun; Edelstein, Mark; Eilander, David; Biggar, Sandra; Wall, Nathan; Reichert, Uwe; Fontana, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2917-2925</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We have recently described a novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) that induces apoptosis in a no. of malignant cell types.  We now describe our studies examg. the effects of CD437 and a nonretinoidal analog (MM002) on the in vitro proliferation of the ALL-REH cell line, the in vitro and in vivo growth of a novel Epstein-Barr virus neg. (EBV-) B-cell chronic lymphocytic leukemia (B-CLL) cell line (WSU-CLL), and primary cultures of human B-CLL and acute lymphoblastic leukemia (ALL) cells.  CD437 and MM002 induce apoptosis in both cell lines, as indicated by the activation of caspase-2 and caspase-3, cleavage of poly(ADP-ribose) (poly(ADP-ribose)) polymerase, increase in annexin V binding, and subsequent nuclear fragmentation.  CD437-mediated apoptosis was not assocd. with the modulation of Bcl-2, Bax, or Mcl-1 levels, but was assocd. with the cleavage of the antiapoptotic protein Bcl-XL to a proapoptotic 18 kDa form.  This cleavage of Bcl-XL was dependent on caspase-3 activation since Bcl-XL cleavage and apoptosis were inhibited by the caspase-3 inhibitor Z-DVED-fmk.  CD437 markedly inhibited the growth of WSU-CLL cells in severe combined immunodeficiency (SCID) mice.  Tumor growth inhibition, growth delay, and log cell kill were 85.7%, 21 days, and 2.1, resp., in the treated mice.  Moreover, 1 of the 5 treated mice was tumor-free longer than 150 days and thus was considered cured.  Exposure of primary cultures of both B-CLL and ALL cells obtained from patients to CD437 and MM002 resulted in their apoptosis.  These results suggest that CD437 and MM002 analogs may have a potential role in the treatment of B-CLL and ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrggXBOhD9VhLVg90H21EOLACvtfcHk0lguI2dbjSM8iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVGht7w%253D&md5=20cc451a778d67804880eadca631a481</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood.V100.8.2917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V100.8.2917%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DDawson%26aufirst%3DM.%2BI.%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DFarhana%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DK.%2BC.%26aulast%3DLeid%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DX.%2BK.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DEilander%26aufirst%3DD.%26aulast%3DBiggar%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DN.%26aulast%3DReichert%26aufirst%3DU.%26aulast%3DFontana%26aufirst%3DJ.%2BA.%26atitle%3DInduction%2520of%2520apoptosis%2520of%2520human%2520B-CLL%2520and%2520ALL%2520cells%2520by%2520a%2520novel%2520retinoid%2520and%2520its%2520nonretinoidal%2520analog%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D2917%26epage%3D2925%26doi%3D10.1182%2Fblood.V100.8.2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhuiyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waleh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span> <span> </span><span class="NLM_article-title">Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of Src homology 2 domain-containing protein tyrosine phosphatase-2 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5650</span>– <span class="NLM_lpage">5662</span>, <span class="refDoi"> DOI: 10.1021/jm800456k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800456k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5650-5662&author=M.+I.+Dawsonauthor=Z.+B.+Xiaauthor=T.+Jiangauthor=M.+Yeauthor=J.+A.+Fontanaauthor=L.+Farhanaauthor=B.+Patelauthor=L.+P.+Xueauthor=M.+Bhuiyanauthor=R.+Pellicciariauthor=A.+Macchiaruloauthor=R.+Nutiauthor=X.+K.+Zhangauthor=Y.+H.+Hanauthor=L.+Tautzauthor=P.+D.+Hobbsauthor=L.+Jongauthor=N.+Walehauthor=W.+Chaoauthor=G.+S.+Fengauthor=Y.+H.+Pangauthor=Y.+Su&title=Adamantyl-substituted+retinoid-derived+molecules+that+interact+with+the+orphan+nuclear+receptor+small+heterodimer+partner%3A+Effects+of+replacing+the+1-adamantyl+or+hydroxyl+group+on+inhibition+of+cancer+cell+growth%2C+induction+of+cancer+cell+apoptosis%2C+and+inhibition+of+Src+homology+2+domain-containing+protein+tyrosine+phosphatase-2+activity&doi=10.1021%2Fjm800456k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl-Substituted Retinoid-Derived Molecules That Interact with the Orphan Nuclear Receptor Small Heterodimer Partner: Effects of Replacing the 1-Adamantyl or Hydroxyl Group on Inhibition of Cancer Cell Growth, Induction of Cancer Cell Apoptosis, and Inhibition of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase-2 Activity</span></div><div class="casAuthors">Dawson, Marcia I.; Xia, Zebin; Jiang, Tao; Ye, Mao; Fontana, Joseph A.; Farhana, Lulu; Patel, Bhaumik; Xue, Li Ping; Bhuiyan, Mohammad; Pellicciari, Roberto; Macchiarulo, Antonio; Nuti, Roberto; Zhang, Xiao-Kun; Han, Young-Hoon; Tautz, Lutz; Hobbs, Peter D.; Jong, Ling; Waleh, Nahid; Chao, Wan-ru; Feng, Gen-Sheng; Pang, Yuhong; Su, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5650-5662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells.  Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP).  Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression.  3-Cl-AHPC analogs having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis.  Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity.  Docking of 3-Cl-AHPC and its analogs to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity.  Inhibitory activity against Src homol. 2 domain-contg. protein tyrosine phosphatase 2 (Shp-2) was also assessed.  The most active Shp-2 inhibitor was found to be the 3'-(3,3-dimethylbutynyl) analog of 3-Cl-AHPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3EhNrmE1CAbVg90H21EOLACvtfcHk0lguI2dbjSM8iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbfE&md5=d083d7bfb6334fe98cf184b59af1dfec</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm800456k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800456k%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DM.%2BI.%26aulast%3DXia%26aufirst%3DZ.%2BB.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DFontana%26aufirst%3DJ.%2BA.%26aulast%3DFarhana%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DL.%2BP.%26aulast%3DBhuiyan%26aufirst%3DM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DNuti%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%2BK.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DTautz%26aufirst%3DL.%26aulast%3DHobbs%26aufirst%3DP.%2BD.%26aulast%3DJong%26aufirst%3DL.%26aulast%3DWaleh%26aufirst%3DN.%26aulast%3DChao%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DPang%26aufirst%3DY.%2BH.%26aulast%3DSu%26aufirst%3DY.%26atitle%3DAdamantyl-substituted%2520retinoid-derived%2520molecules%2520that%2520interact%2520with%2520the%2520orphan%2520nuclear%2520receptor%2520small%2520heterodimer%2520partner%253A%2520Effects%2520of%2520replacing%2520the%25201-adamantyl%2520or%2520hydroxyl%2520group%2520on%2520inhibition%2520of%2520cancer%2520cell%2520growth%252C%2520induction%2520of%2520cancer%2520cell%2520apoptosis%252C%2520and%2520inhibition%2520of%2520Src%2520homology%25202%2520domain-containing%2520protein%2520tyrosine%2520phosphatase-2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5650%26epage%3D5662%26doi%3D10.1021%2Fjm800456k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha,beta-unsaturated carbonyls with thiols via Hetero-Michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2Cbeta-unsaturated+carbonyls+with+thiols+via+Hetero-Michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0lipR2sroZmboQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520Hetero-Michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/mol.106.025536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1124%2Fmol.106.025536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16717135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=562-570&author=L.+W.+Chenauthor=S.+S.+Sungauthor=M.+L.+R.+Yipauthor=H.+R.+Lawrenceauthor=Y.+Renauthor=W.+C.+Guidaauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Discovery+of+a+novel+Shp2+protein+tyrosine+phosphatase+inhibitor&doi=10.1124%2Fmol.106.025536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor</span></div><div class="casAuthors">Chen, Liwei; Sung, Shen-Shu; Yip, M. L. Richard; Lawrence, Harshani R.; Ren, Yuan; Guida, Wayne C.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">562-570</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Shp2 is a non-receptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene.  It is involved in growth factor-induced activation of mitogen-activated protein (MAP) kinases Erk1 and Erk2 (Erk1/2) and has been implicated in the pathogenicity of the oncogenic bacterium Helicobacter pylori.  Moreover, gain-of-function Shp2 mutations have been found in childhood leukemias and Noonan syndrome.  Thus, small mol. Shp2 PTP inhibitors are much needed reagents for evaluation of Shp2 as a therapeutic target and for chem. biol. studies of Shp2 function.  By screening the National Cancer Institute (NCI) Diversity Set chem. library, we identified 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877) as a potent Shp2 PTP inhibitor.  Mol. modeling and site-directed mutagenesis studies suggested that NSC-87877 binds to the catalytic cleft of Shp2 PTP.  NSC-87877 cross-inhibited Shp1 in vitro, but it was selective for Shp2 over other PTPs (PTP1B, HePTP, DEP1, CD45, and LAR).  It is noteworthy that NSC-87877 inhibited epidermal growth factor (EGF)-induced activation of Shp2 PTP, Ras, and Erk1/2 in cell cultures but did not block EGF-induced Gab1 tyrosine phosphorylation or Gab1-Shp2 assocn.  Furthermore, NSC-87877 inhibited Erk1/2 activation by a Gab1-Shp2 chimera but did not affect the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.  These results identified NSC-87877 as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect.  Our study also provides the first pharmacol. evidence that Shp2 mediates EGF-induced Erk1/2 MAP kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4XVGUjw3W7Vg90H21EOLACvtfcHk0lipR2sroZmboQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnslyjsrk%253D&md5=a2ce03150ecbe6937876bb292ced30dc</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025536%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BW.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DYip%26aufirst%3DM.%2BL.%2BR.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Shp2%2520protein%2520tyrosine%2520phosphatase%2520inhibitor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D562%26epage%3D570%26doi%3D10.1124%2Fmol.106.025536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubeek, I.</span>; <span class="NLM_string-name">Cloos, J.</span>; <span class="NLM_string-name">Vojtekova, K.</span>; <span class="NLM_string-name">Broekhuizen, R.</span>; <span class="NLM_string-name">Loosdrecht, A.</span>; <span class="NLM_string-name">Berg, T. V. D.</span>; <span class="NLM_string-name">Zwaan, M.</span>; <span class="NLM_string-name">Kaspers, G.</span></span> <span> </span><span class="NLM_article-title">Cytotoxicity and combination studies with the SHP-2 inhibitor NSC87877 in AML</span>. Presented at the Annual Meeting of the American Association for Cancer Res (AACR), San Diego, CA, <span class="NLM_year">2008</span>; Abstract 5692.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Hubeek&author=J.+Cloos&author=K.+Vojtekova&author=R.+Broekhuizen&author=A.+Loosdrecht&author=T.+V.+D.+Berg&author=M.+Zwaan&author=G.+Kaspers&title=Cytotoxicity+and+combination+studies+with+the+SHP-2+inhibitor+NSC87877+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHubeek%26aufirst%3DI.%26atitle%3DCytotoxicity%2520and%2520combination%2520studies%2520with%2520the%2520SHP-2%2520inhibitor%2520NSC87877%2520in%2520AML%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Identification of Cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7212</span>– <span class="NLM_lpage">7221</span>, <span class="refDoi"> DOI: 10.1021/jm400474r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400474r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7212-7221&author=W.+Liuauthor=B.+Yuauthor=G.+Xuauthor=W.+R.+Xuauthor=M.+L.+Lohauthor=L.+D.+Tangauthor=C.+K.+Qu&title=Identification+of+Cryptotanshinone+as+an+inhibitor+of+oncogenic+protein+tyrosine+phosphatase+SHP2+%28PTPN11%29&doi=10.1021%2Fjm400474r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)</span></div><div class="casAuthors">Liu, Wei; Yu, Bing; Xu, Gang; Xu, Wei-Ren; Loh, Mignon L.; Tang, Li-Da; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7212-7221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations of PTPN11 (encoding the SHP2 phosphatase) are assocd. with Noonan syndrome, childhood leukemias, and sporadic solid tumors.  Virtual screening combined with exptl. assays was performed to identify inhibitors of SHP2 from a database of natural products.  This effort led to the identification of cryptotanshinone as an inhibitor of SHP2.  Cryptotanshinone inhibited SHP2 with an IC50 of 22.50 μM.  Fluorescence titrn. expts. confirmed that it directly bound to SHP2.  Enzymic kinetic analyses showed that cryptotanshinone was a mixed-type and irreversible inhibitor.  This drug was further verified for its ability to block SHP2-mediated cell signaling and cellular functions.  Furthermore, mouse myeloid progenitors and patient leukemic cells with the activating mutation E76K in PTPN11 were found to be sensitive to this inhibitor.  Since cryptotanshinone is used to treat cardiovascular diseases in Asian countries, this drug has a potential to be used directly or to be further developed to treat PTPN11-assocd. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYelS47QYHLVg90H21EOLACvtfcHk0liYOuq7Ot-wkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurvN&md5=3bbbae68159ae4227bbf74d5573ca77a</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm400474r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400474r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DW.%2BR.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DIdentification%2520of%2520Cryptotanshinone%2520as%2520an%2520inhibitor%2520of%2520oncogenic%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520%2528PTPN11%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7212%26epage%3D7221%26doi%3D10.1021%2Fjm400474r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. S. S.</span></span> <span> </span><span class="NLM_article-title">Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1177/0091270005282630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1177%2F0091270005282630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16291709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=1345-1359&author=L.+M.+Zhouauthor=Z.+Zuoauthor=M.+S.+S.+Chow&title=Danshen%3A+An+overview+of+its+chemistry%2C+pharmacology%2C+pharmacokinetics%2C+and+clinical+use&doi=10.1177%2F0091270005282630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use</span></div><div class="casAuthors">Zhou, Limin; Zuo, Zhong; Chow, Moses Sing Sum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1345-1359</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Danshen, the dried root of Salvia miltiorrhiza, has been widely used in China and, to a lesser extent, in Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases.  In China, the specific clin. use is angina pectoris, hyperlipidemia, and acute ischemic stroke.  The current review covers its traditional uses, chem. constituents, pharmacol. activities, pharmacokinetics, clin. applications, and potential herb-drug interactions based on information obtained in both the English and Chinese literature.  Although numerous clin. trials have demonstrated that certain Danshen products in China are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality.  Therefore, large randomized clin. trials and further scientific research to det. its mechanism of actions will be necessary to ensure the safety, effectiveness, and better understanding of its action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSr_sWcH9VsbVg90H21EOLACvtfcHk0liYOuq7Ot-wkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtrzL&md5=b2475589ba03dab9465808f6756dbce7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1177%2F0091270005282630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270005282630%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%2BM.%26aulast%3DZuo%26aufirst%3DZ.%26aulast%3DChow%26aufirst%3DM.%2BS.%2BS.%26atitle%3DDanshen%253A%2520An%2520overview%2520of%2520its%2520chemistry%252C%2520pharmacology%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520use%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26spage%3D1345%26epage%3D1359%26doi%3D10.1177%2F0091270005282630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Genome-wide transcriptional profiling of the response of staphylococcus aureus to cryptotanshinone</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">617509</span>, <span class="refDoi"> DOI: 10.1155/2009/617509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1155%2F2009%2F617509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19707532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BD1MrotVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=617509&author=H.+H.+Fengauthor=H.+Xiangauthor=J.+Y.+Zhangauthor=G.+W.+Liuauthor=N.+Guoauthor=X.+L.+Wangauthor=X.+P.+Wuauthor=X.+M.+Dengauthor=L.+Yu&title=Genome-wide+transcriptional+profiling+of+the+response+of+staphylococcus+aureus+to+cryptotanshinone&doi=10.1155%2F2009%2F617509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cryptotanshinone</span></div><div class="casAuthors">Feng Haihua; Xiang Hua; Zhang Jiyu; Liu Guowen; Guo Na; Wang Xuelin; Wu Xiuping; Deng Xuming; Yu Lu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2009</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">617509</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Staphylococcus aureus (S. aureus) strains with multiple antibiotic resistances are increasingly widespread, and new agents are required for the treatment of S. aureus.  Cryptotanshinone (CT), a major tanshinone of medicinal plant Salvia miltiorrhiza Bunge, demonstrated effective in vitro antibacterial activity against all 21 S. aureus strains tested in this experiment.  Affymetrix GeneChips were utilized to determine the global transcriptional response of S. aureus ATCC 25923 to treatment with subinhibitory concentrations of CT.  Transcriptome profiling indicated that the antibacterial action of CT may be associated with its action as active oxygen radical generator; S. aureus undergoes an oxygen-limiting state upon exposure to CT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFRjSAM_h5TcERNNga7KD-fW6udTcc2eYcyCVgHPoFVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrotVCnuw%253D%253D&md5=1b377a1fb45ddc795fa78d3f5f8be591</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1155%2F2009%2F617509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2009%252F617509%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DH.%2BH.%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DG.%2BW.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DWu%26aufirst%3DX.%2BP.%26aulast%3DDeng%26aufirst%3DX.%2BM.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DGenome-wide%2520transcriptional%2520profiling%2520of%2520the%2520response%2520of%2520staphylococcus%2520aureus%2520to%2520cryptotanshinone%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2009%26spage%3D617509%26doi%3D10.1155%2F2009%2F617509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span> <span> </span><span class="NLM_article-title">Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-08-2575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19118003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=193-202&author=D.+S.+Shinauthor=H.+N.+Kimauthor=K.+D.+Shinauthor=Y.+J.+Yoonauthor=S.+J.+Kimauthor=D.+C.+Hanauthor=B.+M.+Kwon&title=Cryptotanshinone+inhibits+constitutive+signal+transducer+and+activator+of+transcription+3+function+through+blocking+the+dimerization+in+DU145+prostate+cancer+cells&doi=10.1158%2F0008-5472.CAN-08-2575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells</span></div><div class="casAuthors">Shin, Dae-Seop; Kim, Hye-Nan; Shin, Ki Deok; Yoon, Young Ju; Kim, Seung-Jun; Han, Dong Cho; Kwon, Byoung-Mog</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-202</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because signal transducer and activator of transcription 3 (STAT3) is constitutively activated in most human solid tumors and is involved in the proliferation, angiogenesis, immune evasion, and antiapoptosis of cancer cells, researchers have focused on STAT3 as a target for cancer therapy.  We screened for natural compds. that inhibit the activity of STAT3 using a dual-luciferase assay.  Cryptotanshinone was identified as a potent STAT3 inhibitor.  Cryptotanshinone rapidly inhibited STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells and the growth of the cells through 96 h of the treatment.  Inhibition of STAT3 Tyr705 phosphorylation in DU145 cells decreased the expression of STAT3 downstream target proteins such as cyclin D1, survivin, and Bcl-xL.  To investigate the cryptotanshinone inhibitory mechanism in DU145 cells, we analyzed proteins upstream of STAT3.  Although phosphorylation of Janus-activated kinase (JAK) 2 was inhibited by 7 μmol/L cryptotanshinone at 24 h, inhibition of STAT3 Tyr705 phosphorylation occurred within 30 min and the activity of the other proteins was not affected.  These results suggest that inhibition of STAT3 phosphorylation is caused by a JAK2-independent mechanism, with suppression of JAK2 phosphorylation as a secondary effect of cryptotanshinone treatment.  Continuing expts. revealed the possibility that cryptotanshinone might directly bind to STAT3 mols.  Cryptotanshinone was colocalized with STAT3 mols. in the cytoplasm and inhibited the formation of STAT3 dimers.  Computational modeling showed that cryptotanshinone could bind to the SH2 domain of STAT3.  These results suggest that cryptotanshinone is a potent anticancer agent targeting the activation STAT3 protein.  It is the first report that cryptotanshinone has antitumor activity through the inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2CVvIW5pBbVg90H21EOLACvtfcHk0lhxTUN_2cLx3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFCm&md5=f318d248355d742ef874136ccdc9c053</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2575%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BN.%26aulast%3DShin%26aufirst%3DK.%2BD.%26aulast%3DYoon%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DCryptotanshinone%2520inhibits%2520constitutive%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520function%2520through%2520blocking%2520the%2520dimerization%2520in%2520DU145%2520prostate%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D193%26epage%3D202%26doi%3D10.1158%2F0008-5472.CAN-08-2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span> <span> </span><span class="NLM_article-title">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7275</span>– <span class="NLM_lpage">7280</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710468105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1073%2Fpnas.0710468105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=18480264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7275-7280&author=K.+Hellmuthauthor=S.+Grosskopfauthor=C.+T.+Lumauthor=M.+Wurteleauthor=N.+Roderauthor=J.+P.+von+Kriesauthor=M.+Rosarioauthor=J.+Rademannauthor=W.+Birchmeier&title=Specific+inhibitors+of+the+protein+tyrosine+phosphatase+Shp2+identified+by+high-throughput+docking&doi=10.1073%2Fpnas.0710468105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking</span></div><div class="casAuthors">Hellmuth, Klaus; Grosskopf, Stefanie; Lum, Ching Tung; Wuertele, Martin; Roeder, Nadine; von Kries, Jens Peter; Rosario, Marta; Rademann, Jorg; Birchmeier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7275-7280</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protein tyrosine phosphatase Shp2 is a pos. regulator of growth factor signaling.  Gain-of-function mutations in several types of leukemia define Shp2 as a bona fide oncogene.  We performed a high-throughput in silico screen for small-mol.-wt. compds. that bind the catalytic site of Shp2.  We have identified the phenylhydrazonopyrazolone sulfonate PHPS1 as a potent and cell-permeable inhibitor, which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1 B.  PHPS1 inhibits Shp2-dependent cellular events such as hepatocyte growth factor/scatter factor (HGF/SF)-induced epithelial cell scattering and branching morphogenesis.  PHPS1 also blocks Shp2-dependent downstream signaling, namely HGF/SF-induced sustained phosphorylation of the Erk1/2 MAP kinases and dephosphorylation of paxillin.  Furthermore, PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-assocd. Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.  The PHPS compd. class is therefore suitable for further development of therapeutics for the treatment of Shp2-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGponh1kw_h7jrVg90H21EOLACvtfcHk0lhxTUN_2cLx3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLs%253D&md5=39c7dda94e32134c305e135e4c48b9d1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710468105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710468105%26sid%3Dliteratum%253Aachs%26aulast%3DHellmuth%26aufirst%3DK.%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DWurtele%26aufirst%3DM.%26aulast%3DRoder%26aufirst%3DN.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DSpecific%2520inhibitors%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%2520identified%2520by%2520high-throughput%2520docking%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D7275%26epage%3D7280%26doi%3D10.1073%2Fpnas.0710468105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosskopf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kries, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1002%2Fcmdc.201500015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=25877780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=815-826&author=S.+Grosskopfauthor=C.+Eckertauthor=C.+Arkonaauthor=S.+Radetzkiauthor=K.+Bohmauthor=U.+Heinemannauthor=G.+Wolberauthor=J.+P.+von+Kriesauthor=W.+Birchmeierauthor=J.+Rademann&title=Selective+inhibitors+of+the+protein+tyrosine+phosphatase+SHP2+block+cellular+motility+and+growth+of+cancer+cells+in+vitro+and+in+vivo&doi=10.1002%2Fcmdc.201500015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo</span></div><div class="casAuthors">Grosskopf, Stefanie; Eckert, Chris; Arkona, Christoph; Radetzki, Silke; Boehm, Kerstin; Heinemann, Udo; Wolber, Gerhard; von Kries, Jens-Peter; Birchmeier, Walter; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-826</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibitors of the protein tyrosine phosphatase SHP2 (src homol. region 2 domain phosphatase; PTPN11), an enzyme that is deregulated in numerous human tumors, were generated through a combination of chem. synthesis and structure-based rational design.  Seventy pyridazolon-4-ylidenehydrazinyl benzenesulfonates were prepd. and evaluated in enzyme assays.  The binding modes of active inhibitors were simulated in silico using a newly generated crystal structure of SHP2.  The most powerful compd. I inhibited SHP2 with an IC50 value of 71±15 nM in the enzyme assay and was 29- and 45-fold more active toward SHP2 than against related SHP1 and PTP1B.  In cell culture expts. compd. I was found to block hepatocyte growth factor (HGF)-stimulated epithelial-mesenchymal transition of human pancreatic adenocarcinoma (HPAF) cells, as indicated by a decrease in the min. neighbor distances of cells.  Moreover, I inhibited cell colony formation in the nonsmall-cell lung cancer cell line LXFA 526 L in soft agar.  Finally, I was obsd. to inhibit tumor growth in a murine xenograft model.  Therefore, the novel specific compd. I strengthens the hypothesis that SHP2 is a relevant protein target for the inhibition of mobility and invasiveness of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovDT-98edFurVg90H21EOLACvtfcHk0ljtSns2pgEmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFers7g%253D&md5=72fa2915b67c514076144b3005441b17</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500015%26sid%3Dliteratum%253Aachs%26aulast%3DGrosskopf%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRadetzki%26aufirst%3DS.%26aulast%3DBohm%26aufirst%3DK.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3Dvon%2BKries%26aufirst%3DJ.%2BP.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520block%2520cellular%2520motility%2520and%2520growth%2520of%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D815%26epage%3D826%26doi%3D10.1002%2Fcmdc.201500015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0ljtSns2pgEmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lhLXOVv4aefYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanschagrin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span> <span> </span><span class="NLM_article-title">Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6177</span>– <span class="NLM_lpage">6196</span>, <span class="refDoi"> DOI: 10.1021/jm051256o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+Docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein-ligand+complexes&doi=10.1021%2Fjm051256o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes</span></div><div class="casAuthors">Friesner, Richard A.; Murphy, Robert B.; Repasky, Matthew P.; Frye, Leah L.; Greenwood, Jeremy R.; Halgren, Thomas A.; Sanschagrin, Paul C.; Mainz, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6177-6196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel scoring function to est. protein-ligand binding affinities has been developed and implemented as the Glide 4.0 XP scoring function and docking protocol.  In addn. to unique water desolvation energy terms, protein-ligand structural motifs leading to enhanced binding affinity are included:(1) hydrophobic enclosure where groups of lipophilic ligand atoms are enclosed on opposite faces by lipophilic protein atoms, (2) neutral-neutral single or correlated hydrogen bonds in a hydrophobically enclosed environment, and (3) five categories of charged-charged hydrogen bonds.  The XP scoring function and docking protocol have been developed to reproduce exptl. binding affinities for a set of 198 complexes (RMSDs of 2.26 and 1.73 kcal/mol over all and well-docked ligands, resp.) and to yield quality enrichments for a set of fifteen screens of pharmaceutical importance.  Enrichment results demonstrate the importance of the novel XP mol. recognition and water scoring in sepg. active and inactive ligands and avoiding false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZiwN12vaY7Vg90H21EOLACvtfcHk0lhLXOVv4aefYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D&md5=ea428c82ead0d8c27f8c1a7b694a1edf</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520Docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6177%26epage%3D6196%26doi%3D10.1021%2Fjm051256o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugochukwu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, O. N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess-Brown, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=19167335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=352-363&author=A.+J.+Barrauthor=E.+Ugochukwuauthor=W.+H.+Leeauthor=O.+N.+F.+Kingauthor=P.+Filippakopoulosauthor=I.+Alfanoauthor=P.+Savitskyauthor=N.+A.+Burgess-Brownauthor=S.+Mullerauthor=S.+Knapp&title=Large-scale+structural+analysis+of+the+classical+human+protein+tyrosine+phosphatome&doi=10.1016%2Fj.cell.2008.11.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span></div><div class="casAuthors">Barr, Alastair J.; Ugochukwu, Emilie; Lee, Wen Hwa; King, Oliver N. F.; Filippakopoulos, Panagis; Alfano, Ivan; Savitsky, Pavel; Burgess-Brown, Nicola A.; Muller, Susanne; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) play a crit. role in regulating cellular functions by selectively dephosphorylating their substrates.  Here we present 22 human PTP crystal structures that, together with prior structural knowledge, enable a comprehensive anal. of the classical PTP family.  Despite their largely conserved fold, surface properties of PTPs are strikingly diverse.  A potential secondary substrate-binding pocket is frequently found in phosphatases, and this has implications for both substrate recognition and development of selective inhibitors.  Structural comparison identified four diverse catalytic loop (WPD) conformations and suggested a mechanism for loop closure.  Enzymic assays revealed vast differences in PTP catalytic activity and identified PTPD1, PTPD2, and HDPTP as catalytically inert protein phosphatases.  We propose a "head-to-toe" dimerization model for RPTPγ/ζ that is distinct from the "inhibitory wedge" model and that provides a mol. basis for inhibitory regulation.  This phosphatome resource gives an expanded insight into intrafamily PTP diversity, catalytic activity, substrate recognition, and autoregulatory self-assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kaabM4U0LLVg90H21EOLACvtfcHk0lgq-5oKWOwYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D&md5=f47994736342cc0490609596d66fd03e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DKing%26aufirst%3DO.%2BN.%2BF.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DBurgess-Brown%26aufirst%3DN.%2BA.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DLarge-scale%2520structural%2520analysis%2520of%2520the%2520classical%2520human%2520protein%2520tyrosine%2520phosphatome%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D352%26epage%3D363%26doi%3D10.1016%2Fj.cell.2008.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine phosphatases: Structure and function, substrate specificity, and inhibitor development</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.42.083001.144616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1146%2Fannurev.pharmtox.42.083001.144616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=11807171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=209-234&author=Z.+Y.+Zhang&title=Protein+tyrosine+phosphatases%3A+Structure+and+function%2C+substrate+specificity%2C+and+inhibitor+development&doi=10.1146%2Fannurev.pharmtox.42.083001.144616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development</span></div><div class="casAuthors">Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-234</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are signaling enzymes that control a diverse array of cellular processes.  Malfunction of PTP activity is assocd. with a no. of human disorders.  Recent genetic and biochem. studies indicate that PTPs represent a novel platform for drug discovery.  Detailed knowledge of PTP substrate specificity and the wealth of structural data on PTPs provide a solid foundation for rational PTP inhibitor design.  This review summarizes a correlation of PTP structure and function from mutagenesis expts.  The mol. basis for PTP1B and MKP3 substrate recognition is discussed.  A powerful strategy is presented for creating specific and high-affinity bidentate PTP inhibitors that simultaneously bind both the active site and a unique adjacent site.  Finally, recent advances in the development of potent and selective inhibitors for PTP1B and Cdc25 are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkHsDd9nAT7Vg90H21EOLACvtfcHk0lgq-5oKWOwYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFKnsbo%253D&md5=eb192ad4d7283c476947af0fbbcfcfb0</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.42.083001.144616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.42.083001.144616%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DProtein%2520tyrosine%2520phosphatases%253A%2520Structure%2520and%2520function%252C%2520substrate%2520specificity%252C%2520and%2520inhibitor%2520development%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2002%26volume%3D42%26spage%3D209%26epage%3D234%26doi%3D10.1146%2Fannurev.pharmtox.42.083001.144616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goenka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span> <span> </span><span class="NLM_article-title">The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fleu.2012.308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23103841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Gns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=398-408&author=S.+C.+Nabingerauthor=X.+J.+Liauthor=B.+Ramdasauthor=Y.+Heauthor=X.+Zhangauthor=L.+Zengauthor=B.+Richineauthor=J.+D.+Bowlingauthor=S.+Fukudaauthor=S.+Goenkaauthor=Z.+Liuauthor=G.+S.+Fengauthor=M.+Yuauthor=G.+E.+Sanduskyauthor=H.+S.+Boswellauthor=Z.+Y.+Zhangauthor=R.+Kapurauthor=R.+J.+Chan&title=The+protein+tyrosine+phosphatase%2C+Shp2%2C+positively+contributes+to+FLT3-ITD-induced+hematopoietic+progenitor+hyperproliferation+and+malignant+disease+in+vivo&doi=10.1038%2Fleu.2012.308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo</span></div><div class="casAuthors">Nabinger, S. C.; Li, X. J.; Ramdas, B.; He, Y.; Zhang, X.; Zeng, L.; Richine, B.; Bowling, J. D.; Fukuda, S.; Goenka, S.; Liu, Z.; Feng, G.-S.; Yu, M.; Sandusky, G. E.; Boswell, H. S.; Zhang, Z.-Y.; Kapur, R.; Chan, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">398-408</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML).  We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation.  Co-immunopptn. demonstrated constitutive assocn. of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5.  Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells.  Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-d. mononuclear cells reduced proliferation and STAT5 activation.  In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy.  Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and pos. activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression.  Further, using a small mol. Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner.  These findings demonstrate that Shp2 pos. contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22BzHymkQ77Vg90H21EOLACvtfcHk0lgq-5oKWOwYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Gns70%253D&md5=5d1053444fa0b17bbc8719cf35646b13</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.308%26sid%3Dliteratum%253Aachs%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DRamdas%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DRichine%26aufirst%3DB.%26aulast%3DBowling%26aufirst%3DJ.%2BD.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DGoenka%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26aulast%3DBoswell%26aufirst%3DH.%2BS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520protein%2520tyrosine%2520phosphatase%252C%2520Shp2%252C%2520positively%2520contributes%2520to%2520FLT3-ITD-induced%2520hematopoietic%2520progenitor%2520hyperproliferation%2520and%2520malignant%2520disease%2520in%2520vivo%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D398%26epage%3D408%26doi%3D10.1038%2Fleu.2012.308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting the oncogenic SHP2 phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.+F.+Zengauthor=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=S.+J.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+J.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.+Y.+Zhang&title=Therapeutic+potential+of+targeting+the+oncogenic+SHP2+phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0lgrtZYbh0oZJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520the%2520oncogenic%2520SHP2%2520phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVansr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=782-786&author=R.+J.+Heauthor=Z.+H.+Yuauthor=R.+Y.+Zhangauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=J.+S.+Shimauthor=L.+F.+Zengauthor=Y.+T.+Heauthor=L.+Chenauthor=C.+D.+Wellsauthor=J.+O.+Liuauthor=Z.+Y.+Zhang&title=Exploring+the+existing+drug+space+for+novel+pTyr+mimetic+and+SHP2+inhibitors&doi=10.1021%2Facsmedchemlett.5b00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors</span></div><div class="casAuthors">He, Rongjun; Yu, Zhi-Hong; Zhang, Ruo-Yu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Shim, Joong S.; Zeng, Li-Fan; He, Yantao; Chen, Lan; Wells, Clark D.; Liu, Jun O.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-786</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are potential therapeutic targets for many diseases.  Unfortunately, despite considerable drug discovery efforts devoted to PTPs, obtaining selective and cell permeable PTP inhibitors remains highly challenging.  The authors describe a strategy to explore the existing drug space for previously unknown PTP inhibitory activities.  This led to the discovery of cefsulodin as an inhibitor of SHP2, an oncogenic phosphatase in the PTP family.  Crystal structure anal. of SHP2 interaction with cefsulodin identified sulfophenyl acetic amide (SPAA) as a novel phosphotyrosine (pTyr) mimetic.  A structure-guided and SPAA fragment-based focused library approach produced several potent and selective SHP2 inhibitors, e.g. I.  Notably, these inhibitors blocked SHP2-mediated signaling events and proliferation in several cancer cell lines.  Thus, SPAA may serve as a new platform for developing chem. probes for other PTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHtl-WSr2zK7Vg90H21EOLACvtfcHk0lgrtZYbh0oZJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVansr3F&md5=6374b80d7357c4b957afb432723d06dc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00118%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%2BJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DShim%26aufirst%3DJ.%2BS.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DExploring%2520the%2520existing%2520drug%2520space%2520for%2520novel%2520pTyr%2520mimetic%2520and%2520SHP2%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D782%26epage%3D786%26doi%3D10.1021%2Facsmedchemlett.5b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0049-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F1535-7163.MCT-13-0049-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=23825065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1738-1748&author=B.+Yuauthor=W.+Liuauthor=W.+M.+Yuauthor=M.+L.+Lohauthor=S.+Alterauthor=O.+Guvenchauthor=A.+D.+MacKerellauthor=L.+D.+Tangauthor=C.+K.+Qu&title=Targeting+protein+tyrosine+phosphatase+SHP2+for+the+treatment+of+PTPN11-associated+malignancies&doi=10.1158%2F1535-7163.MCT-13-0049-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies</span></div><div class="casAuthors">Yu, Bing; Liu, Wei; Yu, Wen-Mei; Loh, Mignon L.; Alter, Shawn; Guvench, Olgun; MacKerell, Alexander D., Jr.; Tang, Li-Da; Qu, Cheng-Kui</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1738-1748</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in PTPN11 (encoding SHP2), a protein tyrosine phosphatase (PTP) that plays an overall pos. role in growth factor and cytokine signaling, are directly assocd. with the pathogenesis of Noonan syndrome and childhood leukemias.  Identification of SHP2-selective inhibitors could lead to the development of new drugs that ultimately serve as treatments for PTPN11-assocd. diseases.  As the catalytic core of SHP2 shares extremely high homol. to those of SHP1 and other PTPs that play neg. roles in cell signaling, to identify selective inhibitors of SHP2 using computer-aided drug design, we targeted a protein surface pocket that is adjacent to the catalytic site, is predicted to be important for binding to phosphopeptide substrates, and has structural features unique to SHP2.  From computationally selected candidate compds., #220-324 effectively inhibited SHP2 activity with an IC50 of 14 μmol/L.  Fluorescence titrn. expts. confirmed its direct binding to SHP2.  This active compd. was further verified for its ability to inhibit SHP2-mediated cell signaling and cellular function with minimal off-target effects.  Furthermore, mouse myeloid progenitors with the activating mutation (E76K) in PTPN11 and patient leukemic cells with the same mutation were more sensitive to this inhibitor than wild-type cells.  This study provides evidence that SHP2 is a "druggable" target for the treatment of PTPN11-assocd. diseases.  As the small-mol. SHP2 inhibitor identified has a simple chem. structure, it represents an ideal lead compd. for the development of novel anti-SHP2 drugs.  Mol Cancer Ther; 12(9); 1738-48. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3UZZIk5H7LVg90H21EOLACvtfcHk0lh-NsCGyqU6Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7M&md5=645bbea5d54c34844313f638b6fb0b7c</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0049-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0049-T%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%2BM.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DAlter%26aufirst%3DS.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DTargeting%2520protein%2520tyrosine%2520phosphatase%2520SHP2%2520for%2520the%2520treatment%2520of%2520PTPN11-associated%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1738%26epage%3D1748%26doi%3D10.1158%2F1535-7163.MCT-13-0049-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel inhibitor of the protein tyrosine phosphatase Shp2</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17626</span>, <span class="refDoi"> DOI: 10.1038/srep17626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fsrep17626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=26626996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17626&author=C.+Chenauthor=M.+M.+Caoauthor=S.+Y.+Zhuauthor=C.+C.+Wangauthor=F.+Liangauthor=L.+L.+Yanauthor=D.+Q.+Luo&title=Discovery+of+a+novel+inhibitor+of+the+protein+tyrosine+phosphatase+Shp2&doi=10.1038%2Fsrep17626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2</span></div><div class="casAuthors">Chen, Chuan; Cao, Mengmeng; Zhu, Siyu; Wang, Cuicui; Liang, Fan; Yan, Leilei; Luo, Duqiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17626</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Shp2 is a ubiquitously expressed protein tyrosine phosphatase (PTP) related to adult acute myelogenous leukemia and human solid tumors.  In this report, we describe identification of a potent Shp2 inhibitor, Fumosorinone (Fumos) from entomogenous fungi, which shows selective inhibition of Shp2 over other tested PTPs.  Using a surface plasmon resonance anal., we further confirmed the phys. interaction between Shp2 and Fumos.  Fumos inhibits Shp2-dependent activation of the Ras/ERK signal pathway downstream of EGFR, and interrupts EGF-induced Gab1-Shp2 assocn.  As expected, Fumos shows little effects on the Shp2-independent ERK1/2 activation induced by PMA or oncogenic Ras.  Furthermore, Fumos down-regulates Src activation, inhibits phosphorylation of Paxillin and prevents tumor cell invasion.  These results suggest that Fumos can inhibit Shp2-dependent cell signaling in human cells and has a potential for treatment of Shp2-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswqt5Y98UCrVg90H21EOLACvtfcHk0lh-NsCGyqU6Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGms7bN&md5=ae7d1a3adf914820e57a2862ade65cf7</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fsrep17626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17626%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DM.%2BM.%26aulast%3DZhu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DL.%2BL.%26aulast%3DLuo%26aufirst%3DD.%2BQ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520inhibitor%2520of%2520the%2520protein%2520tyrosine%2520phosphatase%2520Shp2%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17626%26doi%3D10.1038%2Fsrep17626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span> <span> </span><span class="NLM_article-title">Benzo c 1,2,5 thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5154</span>– <span class="NLM_lpage">5157</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.bmcl.2017.10.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29100798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKnsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5154-5157&author=W.+L.+Wangauthor=X.+Y.+Chenauthor=Y.+Gaoauthor=L.+X.+Gaoauthor=L.+Shengauthor=J.+Y.+Zhuauthor=L.+Xuauthor=Z.+Z.+Dingauthor=C.+Zhangauthor=J.+Y.+Liauthor=J.+Liauthor=Y.+B.+Zhou&title=Benzo+c+1%2C2%2C5+thiadiazole+derivatives%3A+A+new+class+of+potent+Src+homology-2+domain+containing+protein+tyrosine+phosphatase-2+%28SHP2%29+inhibitors&doi=10.1016%2Fj.bmcl.2017.10.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors</span></div><div class="casAuthors">Wang, Wen-Long; Chen, Xiao-Yu; Gao, Ya; Gao, Li-Xin; Sheng, Li; Zhu, Jingyu; Xu, Lei; Ding, Zhen-Zhong; Zhang, Chao; Li, Jing-Ya; Li, Jia; Zhou, Yu-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5154-5157</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase linked to various kinds of cancers.  Consequently, SHP2 has emerged as a promising target for novel anti-cancer agents.  Using scaffold-hopping strategy, a series of benzo[c][1,2,5]thiadiazole derivs. was designed from PTP1B inhibitors with 1H-2,3-Dihydroperimidine motif, synthesized and evaluated their biol. activities against PTP1B and SHP2.  Among them, the representative compd. I displayed SHP2 inhibitory activity with IC50 of 2.11 ± 0.99 μM, exhibited 2.02-fold and 25-fold selectivity for SHP2 over SHP1 and PTP1B resp. and had no visible activity against TCPTP.  These preliminary results could provide a possible opportunity for the development of novel SHP2 inhibitors with optimal potency and improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHEbzkGLAjKLVg90H21EOLACvtfcHk0lgy9bMSa0wgDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKnsrzL&md5=ebc7fcb7c71a9ddbbbffc43898ab1d90</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.059%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DL.%2BX.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DZ.%2BZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26atitle%3DBenzo%2520c%25201%252C2%252C5%2520thiadiazole%2520derivatives%253A%2520A%2520new%2520class%2520of%2520potent%2520Src%2520homology-2%2520domain%2520containing%2520protein%2520tyrosine%2520phosphatase-2%2520%2528SHP2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5154%26epage%3D5157%26doi%3D10.1016%2Fj.bmcl.2017.10.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+G.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lgy9bMSa0wgDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%2BG.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Targeting protein tyrosine phosphatases for anticancer drug discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.2174/138161210791209027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.2174%2F138161210791209027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=20337577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1843-1862&author=L.+M.+Scottauthor=H.+R.+Lawrenceauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Targeting+protein+tyrosine+phosphatases+for+anticancer+drug+discovery&doi=10.2174%2F138161210791209027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatases for anticancer drug discovery</span></div><div class="casAuthors">Scott, Latanya M.; Lawrence, Harshani R.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1843-1862</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome.  Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes.  While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase.  In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed.  Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHuBrNeSP0n7Vg90H21EOLACvtfcHk0lgy9bMSa0wgDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D&md5=17813d1fba0225fd5e54692b1159bc4a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F138161210791209027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791209027%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DTargeting%2520protein%2520tyrosine%2520phosphatases%2520for%2520anticancer%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1843%26epage%3D1862%26doi%3D10.2174%2F138161210791209027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Small molecule tools for functional interrogation of protein tyrosine phosphatases</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08718.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1742-4658.2012.08718.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=22816879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=731-750&author=R.+J.+Heauthor=L.+F.+Zengauthor=Y.+T.+Heauthor=S.+Zhangauthor=Z.+Y.+Zhang&title=Small+molecule+tools+for+functional+interrogation+of+protein+tyrosine+phosphatases&doi=10.1111%2Fj.1742-4658.2012.08718.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule tools for functional interrogation of protein tyrosine phosphatases</span></div><div class="casAuthors">He, Rongjun; Zeng, Li-Fan; He, Yantao; Zhang, Sheng; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">731-750</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The importance of protein tyrosine phosphatases (PTPs) in the regulation of cellular signalling is well established.  Malfunction of PTP activity is also known to be assocd. with cancer, metabolic syndromes and autoimmune disorders, as well as neurodegenerative and infectious diseases.  However, a detailed understanding of the roles played by the PTPs in normal physiol. and in pathogenic conditions has been hampered by the absence of PTP-specific small mol. agents.  In addn., the therapeutic benefits of modulating this target class are underexplored as a result of a lack of suitable chem. probes.  Potent and specific PTP inhibitors could significantly facilitate functional anal. of the PTPs in complex cellular signal transduction pathways and may constitute valuable therapeutics in the treatment of several human diseases.  We highlight the current challenges to and opportunities for developing PTP-specific small mol. agents.  We also review available selective small mol. inhibitors developed for a no. of PTPs, including PTP1B, TC-PTP, SHP2, lymphoid-specific tyrosine phosphatase, hematopoietic protein tyrosine phosphatase, CD45, PTPβ, PTPγ, PTPRO, Vaccinia H1-related phosphatase, mitogen-activated protein kinase phosphatase-1, mitogen-activated protein kinase phosphatase-3, Cdc25, YopH, mPTPA and mPTPB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokl-YBrjLX1bVg90H21EOLACvtfcHk0lhchX0aWLQhqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCls7Y%253D&md5=a30f63b9e20bcff3b00bf61e77a95bce</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08718.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08718.x%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSmall%2520molecule%2520tools%2520for%2520functional%2520interrogation%2520of%2520protein%2520tyrosine%2520phosphatases%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D731%26epage%3D750%26doi%3D10.1111%2Fj.1742-4658.2012.08718.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Phosphatases start shedding their stigma of undruggability</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2018.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30482950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlalu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=847-849&author=A.+Mullard&title=Phosphatases+start+shedding+their+stigma+of+undruggability&doi=10.1038%2Fnrd.2018.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatases start shedding their stigma of undruggability</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">847-849</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Clin.-stage allosterically acting drugs are on track to unlock a stubborn class of targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLTXLIW9n5pLVg90H21EOLACvtfcHk0lhchX0aWLQhqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlalu7%252FL&md5=bf7083438604d9f88f530b2e260a49c3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.201%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DPhosphatases%2520start%2520shedding%2520their%2520stigma%2520of%2520undruggability%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D847%26epage%3D849%26doi%3D10.1038%2Fnrd.2018.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.+N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.+T.+Chenauthor=Z.+L.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.+X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+M.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Y.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Z.+Yangauthor=J.+Yuanauthor=J.+H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+inhibition+of+SHP2+phosphatase+inhibits+cancers+driven+by+receptor+tyrosine+kinases&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0liK2VrVS9oDkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BN.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BY.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%2BZ.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%2520inhibits%2520cancers%2520driven%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Grunenfelder, D.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Stams, T. M.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">1-Pyridazin-/Triazin-3-yl-piper(-azine)/Idine/Pyrolidine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107493 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.-T.+Chen&author=Z.+Chen&author=J.+G.+Fortanet&author=D.+Grunenfelder&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=T.+M.+Stams&author=S.+Williams&title=1-Pyridazin-%2FTriazin-3-yl-piper%28-azine%29%2FIdine%2FPyrolidine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26atitle%3D1-Pyridazin-%252FTriazin-3-yl-piper%2528-azine%2529%252FIdine%252FPyrolidine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+G.+Fortanetauthor=C.+H.+T.+Chenauthor=Y.+N.+P.+Chenauthor=Z.+L.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+M.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Y.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.+H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+inhibition+of+SHP2%3A+identification+of+a+potent%2C+selective%2C+and+orally+efficacious+phosphatase+inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DFortanet%26aufirst%3DJ.%2BG.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BN.%2BP.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BY.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%253A%2520identification%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520phosphatase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padua, R. A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitsawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiller, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, D.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4507</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06814-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41467-018-06814-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30375376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3cvkslemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4507&author=R.+A.+P.+Paduaauthor=Y.+Z.+Sunauthor=I.+Markoauthor=W.+Pitsawongauthor=J.+B.+Stillerauthor=R.+Ottenauthor=D.+Kern&title=Mechanism+of+activating+mutations+and+allosteric+drug+inhibition+of+the+phosphatase+SHP2&doi=10.1038%2Fs41467-018-06814-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2</span></div><div class="casAuthors">Padua Ricardo A P; Sun Yizhi; Marko Ingrid; Pitsawong Warintra; Stiller John B; Otten Renee; Kern Dorothee; Sun Yizhi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4507</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 functions as a key regulator of cell cycle control, and activating mutations cause several cancers.  Here, we dissect the energy landscape of wild-type SHP2 and the oncogenic mutation E76K.  NMR spectroscopy and X-ray crystallography reveal that wild-type SHP2 exchanges between closed, inactive and open, active conformations.  E76K mutation shifts this equilibrium toward the open state.  The previously unknown open conformation is characterized, including the active-site WPD loop in the inward and outward conformations.  Binding of the allosteric inhibitor SHP099 to E76K mutant, despite much weaker, results in an identical structure as the wild-type complex.  A conformational selection to the closed state reduces drug affinity which, combined with E76K's much higher activity, demands significantly greater SHP099 concentrations to restore wild-type  activity levels.  The differences in structural ensembles and drug-binding kinetics of cancer-associated SHP2 forms may stimulate innovative ideas for developing more potent inhibitors for activated SHP2 mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRglXfZMl481eR_TJajKxJDfW6udTcc2eZTUbWcozImRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvkslemsg%253D%253D&md5=676e8c7d4c85cbb7ce2fa9f756106535</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06814-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06814-w%26sid%3Dliteratum%253Aachs%26aulast%3DPadua%26aufirst%3DR.%2BA.%2BP.%26aulast%3DSun%26aufirst%3DY.%2BZ.%26aulast%3DMarko%26aufirst%3DI.%26aulast%3DPitsawong%26aufirst%3DW.%26aulast%3DStiller%26aufirst%3DJ.%2BB.%26aulast%3DOtten%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DD.%26atitle%3DMechanism%2520of%2520activating%2520mutations%2520and%2520allosteric%2520drug%2520inhibition%2520of%2520the%2520phosphatase%2520SHP2%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4507%26doi%3D10.1038%2Fs41467-018-06814-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0020-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41375-018-0020-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29568093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1246-1249&author=X.+Sunauthor=Y.+Renauthor=S.+Gunawanauthor=P.+Tengauthor=Z.+Chenauthor=H.+R.+Lawrenceauthor=J.+Caiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Selective+inhibition+of+leukemia-associated+SHP2%28E69K%29+mutant+by+the+allosteric+SHP2+inhibitor+SHP099&doi=10.1038%2Fs41375-018-0020-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099</span></div><div class="casAuthors">Sun, X.; Ren, Y.; Gunawan, S.; Teng, P.; Chen, Z.; Lawrence, H. R.; Cai, J.; Lawrence, N. J.; Wu, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1246-1249</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The article studies selective inhibition of leukemia-assocd. SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.  Our findings here identify SHP2E69K as a SHP099-sensitive mutation, wherein three of four most common oncogenic SHP2 mutants studied here are resistant to SHP099.  Moreover, whether Noonan syndrome-assocd. SHP2 mutants are sensitive to SHP099 remained to be tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQzBW1E1YhLVg90H21EOLACvtfcHk0liLOR7BnxvESQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrrK&md5=2cb9342a2e06eac4b9d9043163e4095c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0020-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0020-5%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DTeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520leukemia-associated%2520SHP2%2528E69K%2529%2520mutant%2520by%2520the%2520allosteric%2520SHP2%2520inhibitor%2520SHP099%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1246%26epage%3D1249%26doi%3D10.1038%2Fs41375-018-0020-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.apsb.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30972278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=304-315&author=M.+X.+Zhaoauthor=W.+J.+Guoauthor=Y.+Y.+Wuauthor=C.+X.+Yangauthor=L.+Zhongauthor=G.+L.+Dengauthor=Y.+Y.+Zhuauthor=W.+Liuauthor=Y.+H.+Guauthor=Y.+Luauthor=L.+D.+Kongauthor=X.+B.+Mengauthor=Q.+Xuauthor=Y.+Sun&title=SHP2+inhibition+triggers+anti-tumor+immunity+and+synergizes+with+PD-1+blockade&doi=10.1016%2Fj.apsb.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span></div><div class="casAuthors">Zhao Mingxia; Guo Wenjie; Yang Chenxi; Deng Guoliang; Zhu Yuyu; Liu Wen; Kong Lingdong; Meng Xiangbao; Xu Qiang; Sun Yang; Wu Yuanyuan; Lu Yin; Zhong Liang; Meng Xiangbao; Gu Yanhong</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-315</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation.  Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo.  However, whether SHP099-mediated SHP2 inhibition retards tumor growth in vivo via anti-tumor immunity remains elusive.  To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099.  Consequently, SHP099 minimally affected CT-26 tumor growth in immuno-deficient nude mice, but significantly decreased the tumor burden in CT-26 tumor-bearing mice with intact immune system.  SHP099 augmented anti-tumor immunity, as shown by the elevated proportion of CD8(+)IFN-γ(+) T cells and the upregulation of cytotoxic T-cell related genes including Granzyme B andPerforin, which decreased the tumor load.  In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses.  Finally, the combination of SHP099 and anti-PD-1 antibody showed a higher therapeutic efficacy than either monotherapy in controlling tumor growth in two colon cancer xenograft models, indicating that these agents complement each other.  Our study suggests that SHP2 inhibitor SHP099 is a promising candidate drug for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB60VxKgx5l_h3YQQtAhNufW6udTcc2eZstDRtVR6y67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D&md5=759babe45705b88551f6ac62cb3cee2e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%2BX.%26aulast%3DGuo%26aufirst%3DW.%2BJ.%26aulast%3DWu%26aufirst%3DY.%2BY.%26aulast%3DYang%26aufirst%3DC.%2BX.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%2BH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%2BD.%26aulast%3DMeng%26aufirst%3DX.%2BB.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DSHP2%2520inhibition%2520triggers%2520anti-tumor%2520immunity%2520and%2520synergizes%2520with%2520PD-1%2520blockade%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.apsb.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">1-(Triazin-3-yl/Pyridazin-3-yl)-piper(-azine)dine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107494 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=S.+Williams&author=M.+Sendzik&title=1-%28Triazin-3-yl%2FPyridazin-3-yl%29-piper%28-azine%29dine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-%2528Triazin-3-yl%252FPyridazin-3-yl%2529-piper%2528-azine%2529dine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leila, D. A.</span>; <span class="NLM_string-name">Engelman, J. A.</span>; <span class="NLM_string-name">Hao, H.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combination Comprising an ALK Inhibitor and a SHP2 Inhibitor</span>. <span class="NLM_patent">WO 2018/130928 A1</span>, Jul 19, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+A.+Leila&author=J.+A.+Engelman&author=H.+Hao&author=F.+Li&author=M.+J.+Lamarche&author=H.+Wang&title=Pharmaceutical+Combination+Comprising+an+ALK+Inhibitor+and+a+SHP2+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeila%26aufirst%3DD.%2BA.%26atitle%3DPharmaceutical%2520Combination%2520Comprising%2520an%2520ALK%2520Inhibitor%2520and%2520a%2520SHP2%2520Inhibitor%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Giraldes, J. W.</span>; <span class="NLM_string-name">Toure, B.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">N-Azaspirocycloalkane Substituted N-heteroaryl Compounds and Compositions for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2015/107495 A1</span>, Jul 23, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.+Chen&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+Lamarche&author=L.+B.+Perez&author=T.+D.+Smith&author=S.+Williams&author=J.+W.+Giraldes&author=B.+Toure&author=M.+Sendzik&title=N-Azaspirocycloalkane+Substituted+N-heteroaryl+Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DN-Azaspirocycloalkane%2520Substituted%2520N-heteroaryl%2520Compounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+L.+Chenauthor=Y.+N.+Chenauthor=H.+M.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+X.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+M.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Y.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+potent%2C+selective%2C+and+orally+efficacious+SHP2+inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0lhLXB3qfO1EmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BN.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520SHP2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of fused bicyclic allosteric SHP2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+L.+Chenauthor=M.+Ackerauthor=Y.+N.+Chenauthor=H.+M.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+M.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Y.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+fused+bicyclic+allosteric+SHP2+inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0lhLXB3qfO1EmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BN.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%2BM.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520fused%2520bicyclic%2520allosteric%2520SHP2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">Lamarche, M. J.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. <span class="NLM_patent">WO 2016/203404 A1</span>, Dec 22, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+T.+Bagdanoff&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=M.+Kato&author=M.+J.+Lamarche&author=P.+J.+Sarver&author=M.+Shultz&author=T.+D.+Smith&author=S.+Williams&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Gili, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/013597 A1</span>, Jan 18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+S.+Koltun&author=A.+Gili&author=K.+Mellem&author=N.+Aay&author=A.+Buckl&author=C.+Semko&author=G.+Kiss&title=2%2C5-Disubstituted+3-Methyl+Pyrazines+and+2%2C5%2C6-Trisubstituted+3-Methyl+Pyrazines+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26atitle%3D2%252C5-Disubstituted%25203-Methyl%2520Pyrazines%2520and%25202%252C5%252C6-Trisubstituted%25203-Methyl%2520Pyrazines%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. A.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">Pyridine Compounds as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/136264 A1</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+A.+Gill&author=N.+Aay&author=K.+Mellem&author=A.+Buckl&author=E.+S.+Koltun&author=C.+Semko&author=G.+Kiss&title=Pyridine+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BA.%26atitle%3DPyridine%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B. R.</span>; <span class="NLM_string-name">Pitzen, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Won, W. S.</span>; <span class="NLM_string-name">Tzitzilonis, C.</span>; <span class="NLM_string-name">Li, J. J.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Kiss, G.</span>; <span class="NLM_string-name">Gill, A.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Compounds as Allosteric SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/136265 A1</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+R.+Blank&author=J.+Pitzen&author=G.+Wang&author=W.+S.+Won&author=C.+Tzitzilonis&author=J.+J.+Li&author=E.+S.+Koltun&author=N.+Aay&author=A.+Buckl&author=K.+Mellem&author=C.+Semko&author=A.+Jogalekar&author=G.+Kiss&author=A.+Gill&title=Bicyclic+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DB.%2BR.%26atitle%3DBicyclic%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, E.</span>; <span class="NLM_string-name">Mordec, K.</span>; <span class="NLM_string-name">Nichols, R. J.</span>; <span class="NLM_string-name">Wildes, D.</span>; <span class="NLM_string-name">Schulze, C. J.</span>; <span class="NLM_string-name">Myers, D. R.</span>; <span class="NLM_string-name">Singh, M.</span>; <span class="NLM_string-name">Koltun, E.</span>; <span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Kelsey, S.</span>; <span class="NLM_string-name">Goldsmith, M. A.</span>; <span class="NLM_string-name">Smith, J. A. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms</span>. Presented at the the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY, <span class="NLM_year">2018</span>; Abstract A103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Quintana&author=K.+Mordec&author=R.+J.+Nichols&author=D.+Wildes&author=C.+J.+Schulze&author=D.+R.+Myers&author=M.+Singh&author=E.+Koltun&author=A.+Gill&author=S.+Kelsey&author=M.+A.+Goldsmith&author=J.+A.+M.+Smith&title=Allosteric+inhibition+of+SHP2+induces+antitumor+immunity+in+PD-1-sensitive+tumors+through+modulation+of+both+innate+and+adaptive+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DE.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520induces%2520antitumor%2520immunity%2520in%2520PD-1-sensitive%2520tumors%2520through%2520modulation%2520of%2520both%2520innate%2520and%2520adaptive%2520mechanisms%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobvis Shifrin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belwafa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-3038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1158%2F0008-5472.CAN-19-3038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Quintanaauthor=C.+J.+Schulzeauthor=D.+R.+Myersauthor=T.+J.+Choyauthor=K.+Mordecauthor=D.+Wildesauthor=N.+Tobvis+Shifrinauthor=A.+Belwafaauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=S.+Kelseyauthor=M.+A.+Goldsmithauthor=R.+Nicholsauthor=J.+A.+M.+Smith&title=Allosteric+inhibition+of+SHP2+stimulates+anti-tumor+immunity+by+transforming+the+immunosuppressive+environment&doi=10.1158%2F0008-5472.CAN-19-3038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-3038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-3038%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DE.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DMyers%26aufirst%3DD.%2BR.%26aulast%3DChoy%26aufirst%3DT.%2BJ.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTobvis%2BShifrin%26aufirst%3DN.%26aulast%3DBelwafa%26aufirst%3DA.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKelsey%26aufirst%3DS.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520stimulates%2520anti-tumor%2520immunity%2520by%2520transforming%2520the%2520immunosuppressive%2520environment%26jtitle%3DCancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F0008-5472.CAN-19-3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2017/211303 A1</span>, Dec 14, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. <span class="NLM_patent">WO 2018/172984 A1</span>, Sep 27, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">SHP2 Phosphatase Inhibitors and Methods of Use Thereof</span>. <span class="NLM_patent">WO 2018/057884 A1</span>, Mar 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+K.+Albrecht&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=W.+P.+Walters&title=SHP2+Phosphatase+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DSHP2%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Pipietro, L. V.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Therrien, E.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-B]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2018/081091 A1</span>, May 3, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=L.+V.+Pipietro&author=E.+H.+Kelley&author=A.+Lescarbeau&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=S.+Bhat&author=E.+Therrien&author=M.+K.+Dahlgeren&title=Pyrazolo%5B3%2C4-B%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26atitle%3DPyrazolo%255B3%252C4-B%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Tang, Y.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span>; <span class="NLM_string-name">Therrien, E.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-B]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2018/218133 A1</span>, Nov 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+M.+Taylor&author=A.+Lescarbeau&author=E.+H.+Kelley&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=Y.+Tang&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=S.+Bhat&author=M.+K.+Dahlgeren&author=E.+Therrien&title=Pyrazolo%5B3%2C4-B%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26atitle%3DPyrazolo%255B3%252C4-B%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Babiss, L. E.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2019/182960 A1</span>, Sep 26, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Xie&author=L.+E.+Babiss&title=SHP2+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26atitle%3DSHP2%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Mandal, P.</span>; <span class="NLM_string-name">Cross, J.</span></span> <span> </span><span class="NLM_article-title">6-(4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one Derivatives and Related Compounds as PTPN11 (SHP2) Inhibitors for Treating Cancer</span>. <span class="NLM_patent">WO 2020/033828 A1</span>, Feb 13, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+Jones&author=B.+Czako&author=C.+L.+Carroll&author=P.+Mandal&author=J.+Cross&title=6-%284-Amino-3-methyl-2-oxa-8-azaspiro%5B4.5%5Ddecan-8-yl%29-3-%282%2C3-dichlorophenyl%29-2-methylpyrimidin-4%283H%29-one+Derivatives+and+Related+Compounds+as+PTPN11+%28SHP2%29+Inhibitors+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3D6-%25284-Amino-3-methyl-2-oxa-8-azaspiro%255B4.5%255Ddecan-8-yl%2529-3-%25282%252C3-dichlorophenyl%2529-2-methylpyrimidin-4%25283H%2529-one%2520Derivatives%2520and%2520Related%2520Compounds%2520as%2520PTPN11%2520%2528SHP2%2529%2520Inhibitors%2520for%2520Treating%2520Cancer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Buck, I. M.</span>; <span class="NLM_string-name">Chessari, G.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">Fujiwara, H.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Hiscock, S. D.</span>; <span class="NLM_string-name">Holevy, R. S.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Liebeschuetz, J. w.</span>; <span class="NLM_string-name">Palmer, N. J.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Twigg, D. G.</span>; <span class="NLM_string-name">Woodhead, A. J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compounds</span>. <span class="NLM_patent">WO 2019/167000 A1</span>, Sep 6, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+N.+Johnson&author=I.+M.+Buck&author=G.+Chessari&author=J.+E.+H.+Day&author=H.+Fujiwara&author=C.+C.+F.+Hamlett&author=S.+D.+Hiscock&author=R.+S.+Holevy&author=S.+Howard&author=J.+w.+Liebeschuetz&author=N.+J.+Palmer&author=J.+D.+St+Denis&author=D.+G.+Twigg&author=A.+J.+Woodhead&title=Pharmaceutical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26atitle%3DPharmaceutical%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Boys, M. L.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Cook, A.</span>; <span class="NLM_string-name">Elsayed, M. S. A.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Hinklin, R. J.</span>; <span class="NLM_string-name">Mcnulty, O. T.</span>; <span class="NLM_string-name">Mejia, M. J.</span>; <span class="NLM_string-name">Rodriguez, M. E.</span>; <span class="NLM_string-name">Wong, C. E.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatase Inhibitors</span>. <span class="NLM_patent">WO 2020/081848 A1</span>, Apr 23, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+F.+Blake&author=M.+L.+Boys&author=M.+J.+Chicarelli&author=A.+Cook&author=M.+S.+A.+Elsayed&author=J.+B.+Fell&author=J.+P.+Fischer&author=R.+J.+Hinklin&author=O.+T.+Mcnulty&author=M.+J.+Mejia&author=M.+E.+Rodriguez&author=C.+E.+Wong&title=Protein+Tyrosine+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DProtein%2520Tyrosine%2520Phosphatase%2520Inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Bao, M.</span>; <span class="NLM_string-name">Yuan, Y.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Derivative Inhibitor, Preparation Method Therefor, and Application Thereof</span>. <span class="NLM_patent">WO 2020/073945 A1</span>, Apr 16, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Liu&author=M.+Bao&author=Y.+Yuan&author=Y.+Wang&author=Y.+Zhou&title=Bicyclic+Derivative+Inhibitor%2C+Preparation+Method+Therefor%2C+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DBicyclic%2520Derivative%2520Inhibitor%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Application%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10205</span>– <span class="NLM_lpage">10219</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10205-10219&author=J.+J.+Xieauthor=X.+J.+Siauthor=S.+L.+Guauthor=M.+L.+Wangauthor=J.+Shenauthor=H.+Y.+Liauthor=J.+Shenauthor=D.+Liauthor=Y.+J.+Fangauthor=C.+Liuauthor=J.+D.+Zhu&title=Allosteric+inhibitors+of+SHP2+with+therapeutic+potential+for+cancer+treatment&doi=10.1021%2Facs.jmedchem.7b01520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment</span></div><div class="casAuthors">Xie, Jingjing; Si, Xiaojia; Gu, Shoulai; Wang, Mingliang; Shen, Jian; Li, Haoyan; Li, Dan; Fang, Yanjia; Liu, Cong; Zhu, Jidong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10205-10219</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2, a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene, is involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways.  SHP2 has been shown to contribute to the progression of a no. of cancer types including leukemia, gastric, and breast cancers.  It also regulates T-cell activation by interacting with inhibitory immune checkpoint receptors such as the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA).  Thus, SHP2 inhibitors have drawn great attention by both inhibiting tumor cell proliferation and activating T cell immune responses toward cancer cells.  In this study, the authors report the identification of an allosteric SHP2 inhibitor I that locks SHP2 in a closed conformation by binding to the interface of the N-terminal SH2, C-terminal SH2, and phosphatase domains.  Compd. I suppresses MAPK signaling pathway and YAP transcriptional activity and shows antitumor activity in vivo.  The results indicate that allosteric inhibition of SHP2 could be a feasible approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWHA25LKpH7Vg90H21EOLACvtfcHk0lgFrOYgpUimiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FM&md5=4aaabafae3250476b7bf3687d83cffd3</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01520%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BJ.%26aulast%3DSi%26aufirst%3DX.%2BJ.%26aulast%3DGu%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%2BD.%26atitle%3DAllosteric%2520inhibitors%2520of%2520SHP2%2520with%2520therapeutic%2520potential%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10205%26epage%3D10219%26doi%3D10.1021%2Facs.jmedchem.7b01520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argintaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual allosteric inhibition of SHP2 phosphatase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00980</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00980" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=647-656&author=M.+Fodorauthor=E.+Priceauthor=P.+Wangauthor=H.+Y.+Luauthor=A.+Argintaruauthor=Z.+L.+Chenauthor=M.+Glickauthor=H.+X.+Haoauthor=M.+Katoauthor=R.+Koenigauthor=J.+R.+LaRochelleauthor=G.+Liuauthor=E.+McNeillauthor=D.+Majumdarauthor=G.+A.+Nishiguchiauthor=L.+B.+Perezauthor=G.+Parisauthor=C.+M.+Quinnauthor=T.+Ramseyauthor=M.+Sendzikauthor=M.+D.+Shultzauthor=S.+L.+Williamsauthor=T.+Stamsauthor=S.+C.+Blacklowauthor=M.+G.+Ackerauthor=M.+J.+LaMarche&title=Dual+allosteric+inhibition+of+SHP2+phosphatase&doi=10.1021%2Facschembio.7b00980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dual allosteric inhibition of SHP2 phosphatase</span></div><div class="casAuthors">Fodor, Michelle; Price, Edmund; Wang, Ping; Lu, Hengyu; Argintaru, Andreea; Chen, Zhouliang; Glick, Meir; Hao, Huai-Xiang; Kato, Mitsunori; Koenig, Robert; La Rochelle, Jonathan R.; Liu, Gang; McNeill, Eric; Majumdar, Dyuti; Nishiguchi, Gisele A.; Perez, Lawrence B.; Paris, Gregory; Quinn, Christopher M.; Ramsey, Timothy; Sendzik, Martin; Shultz, Michael David; Williams, Sarah L.; Stams, Travis; Blacklow, Stephen C.; Acker, Michael G.; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival.  Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2.  SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small mol. inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2.  In this report, we describe further screening strategies that enabled the identification of a second, distinct small mol. allosteric site.  SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme.  X-ray crystallog. revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site-a cleft formed at the interface of the N-terminal SH2 and PTP domains.  Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochem. inhibition, and subsequent MAPK pathway modulation.  Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was obsd. in KYSE-520 cancer cells.  Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochem. inhibition expts. and X-ray crystallog.  Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacol. pathway inhibition in cells.  This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodol. and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdw7pTS6sOLVg90H21EOLACvtfcHk0lgFrOYgpUimiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D&md5=8e4de4c353b9fc196c81e1cb51e367df</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00980%26sid%3Dliteratum%253Aachs%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DH.%2BY.%26aulast%3DArgintaru%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DPerez%26aufirst%3DL.%2BB.%26aulast%3DParis%26aufirst%3DG.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DDual%2520allosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D647%26epage%3D656%26doi%3D10.1021%2Facschembio.7b00980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C. K.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1125-1137&author=X.+Q.+Wuauthor=G.+Xuauthor=X.+B.+Liauthor=W.+R.+Xuauthor=Q.+J.+Liauthor=W.+Liuauthor=K.+A.+Kirbyauthor=M.+L.+Lohauthor=J.+Liauthor=S.+G.+Sarafianosauthor=C.+K.+Qu&title=Small+molecule+inhibitor+that+stabilizes+the+autoinhibited+conformation+of+the+oncogenic+tyrosine+phosphatase+SHP2&doi=10.1021%2Facs.jmedchem.8b00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2</span></div><div class="casAuthors">Wu Xiaoqin; Li Xiaobo; Li Qianjin; Qu Cheng-Kui; Xu Gang; Li Xiaobo; Xu Weiren; Liu Wei; Qu Cheng-Kui; Kirby Karen A; Sarafianos Stefan G; Loh Mignon L; Li Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1125-1137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias.  These mutations cause hyperactivation of SHP2 due to the disruption of the autoinhibitory conformation.  By targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor ( E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1 H-benzo[ d]imidazol-2(3 H)-one (LY6, 1) using computer-aided drug design database screening combined with cell-based assays.  This compound inhibited SHP2 with an IC50 value of 9.8 μM, 7-fold more selective for SHP2 than the highly related SHP1.  Fluorescence titration, thermal shift, and microscale thermophoresis quantitative binding assays confirmed its direct binding to SHP2.  This compound was further verified to effectively inhibit SHP2-mediated cell signaling and proliferation.  Furthermore, mouse and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than wild-type cells.  This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further optimization studies to develop novel anti-SHP2 therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0hz4mjYe4HMSzjBFCN0BJfW6udTcc2eYcriiscZuuhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crivFClsQ%253D%253D&md5=e05fd7589519ad6928eb769225b9a607</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00513%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%2BB.%26aulast%3DXu%26aufirst%3DW.%2BR.%26aulast%3DLi%26aufirst%3DQ.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DQu%26aufirst%3DC.%2BK.%26atitle%3DSmall%2520molecule%2520inhibitor%2520that%2520stabilizes%2520the%2520autoinhibited%2520conformation%2520of%2520the%2520oncogenic%2520tyrosine%2520phosphatase%2520SHP2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1125%26epage%3D1137%26doi%3D10.1021%2Facs.jmedchem.8b00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T.</span></span> <span> </span><span class="NLM_article-title">New method for fast and accurate binding-site identification and analysis</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00483.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1111%2Fj.1747-0285.2007.00483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=17381729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=146-148&author=T.+Halgren&title=New+method+for+fast+and+accurate+binding-site+identification+and+analysis&doi=10.1111%2Fj.1747-0285.2007.00483.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">New method for fast and accurate binding-site identification and analysis</span></div><div class="casAuthors">Halgren, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-148</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset.  Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biol. effects or new class of compds.  It is also vital in lead optimization to clearly understand the degree to which known binders or docking hits satisfy or violate complementarity to the receptor.  SiteMap is a new technique for identifying potential binding sites and for predicting their druggability in lead-discovery applications and for characterizing binding sites and critically assessing prospective ligands in lead-optimization applications.  In large-scale validation tests, SiteMap correctly identifies the known binding site in > 96% of the cases, with best results (> 98%) coming for sites that bind ligands tightly.  It also accurately distinguishes between sites that bind ligands and sites that don't.  In binding-site anal., SiteMap provides a wealth of quant. and graphical information that can help guide efforts to modify ligand structure to enhance potency or improve phys. properties.  These attributes allow SiteMap to nicely complement techniques such as docking and computational lead optimization in structure-base drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr245hmZWXilrVg90H21EOLACvtfcHk0lifLxl7G9QLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D&md5=c233276ba9580393b282f255781f9ce6</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00483.x%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%26atitle%3DNew%2520method%2520for%2520fast%2520and%2520accurate%2520binding-site%2520identification%2520and%2520analysis%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D69%26spage%3D146%26epage%3D148%26doi%3D10.1111%2Fj.1747-0285.2007.00483.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span> <span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0liFgJPGTOtZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faitg, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnamon, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnchembio.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24390428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=181-187&author=A.+G.+Gilmartinauthor=T.+H.+Faitgauthor=M.+Richterauthor=A.+Groyauthor=M.+A.+Seefeldauthor=M.+G.+Darcyauthor=X.+Pengauthor=K.+Federowiczauthor=J.+S.+Yangauthor=S.+Y.+Zhangauthor=E.+Minthornauthor=J.+P.+Jaworskiauthor=M.+Schaberauthor=S.+Martensauthor=D.+E.+McNultyauthor=R.+H.+Sinnamonauthor=H.+Zhangauthor=R.+B.+Kirkpatrickauthor=N.+Nevinsauthor=G.+L.+Cuiauthor=B.+Pietrakauthor=E.+Diazauthor=A.+Jonesauthor=M.+Brandtauthor=B.+Schwartzauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Allosteric+Wip1+phosphatase+inhibition+through+flap-subdomain+interaction&doi=10.1038%2Fnchembio.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span></div><div class="casAuthors">Gilmartin, Aidan G.; Faitg, Thomas H.; Richter, Mark; Groy, Arthur; Seefeld, Mark A.; Darcy, Michael G.; Peng, Xin; Federowicz, Kelly; Yang, Jingsong; Zhang, Shu-Yun; Minthorn, Elisabeth; Jaworski, Jon-Paul; Schaber, Michael; Martens, Stan; McNulty, Dean E.; Sinnamon, Robert H.; Zhang, Hong; Kirkpatrick, Robert B.; Nevins, Neysa; Cui, Guanglei; Pietrak, Beth; Diaz, Elsie; Jones, Amber; Brandt, Martin; Schwartz, Benjamin; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-187</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although therapeutic interventions of signal-transduction cascades with targeted kinase inhibitors are a well-established strategy, drug-discovery efforts to identify targeted phosphatase inhibitors have proven challenging.  Herein we report a series of allosteric, small-mol. inhibitors of wild-type p53-induced phosphatase (Wip1), an oncogenic phosphatase common to multiple cancers.  Compd. binding to Wip1 is dependent on a 'flap' subdomain located near the Wip1 catalytic site that renders Wip1 structurally divergent from other members of the protein phosphatase 2C (PP2C) family and that thereby confers selectivity for Wip1 over other phosphatases.  Treatment of tumor cells with the inhibitor GSK2830371 increases phosphorylation of Wip1 substrates and causes growth inhibition in both hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.  Oral administration of Wip1 inhibitors in mice results in expected pharmacodynamic effects and causes inhibition of lymphoma xenograft growth.  To our knowledge, GSK2830371 is the first orally active, allosteric inhibitor of Wip1 phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jXZXKTKTL7Vg90H21EOLACvtfcHk0liFgJPGTOtZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D&md5=47524caa70df233fb152a2d683417e7d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1427%26sid%3Dliteratum%253Aachs%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DFaitg%26aufirst%3DT.%2BH.%26aulast%3DRichter%26aufirst%3DM.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFederowicz%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%26aulast%3DJaworski%26aufirst%3DJ.%2BP.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DMartens%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DNevins%26aufirst%3DN.%26aulast%3DCui%26aufirst%3DG.%2BL.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DAllosteric%2520Wip1%2520phosphatase%2520inhibition%2520through%2520flap-subdomain%2520interaction%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D181%26epage%3D187%26doi%3D10.1038%2Fnchembio.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Selective detection of allosteric phosphatase inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">6838</span>– <span class="NLM_lpage">6841</span>, <span class="refDoi"> DOI: 10.1021/ja4030484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4030484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=6838-6841&author=R.+Schneiderauthor=C.+Beumerauthor=J.+R.+Simardauthor=C.+Grutterauthor=D.+Rauh&title=Selective+detection+of+allosteric+phosphatase+inhibitors&doi=10.1021%2Fja4030484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Detection of Allosteric Phosphatase Inhibitors</span></div><div class="casAuthors">Schneider, Ralf; Beumer, Claudia; Simard, Jeffrey R.; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6838-6841</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal cellular function, such as signal transduction, is largely controlled by the reversible phosphorylation of cellular proteins catalyzed by two major classes of enzymes, kinases and phosphatases.  A misbalance in this complex and dynamic interplay leads to a variety of severe diseases, such as cancer, inflammation, or autoimmune diseases.  This makes kinases as well as phosphatases equally attractive targets for therapeutic manipulation by small mols.  While the development of kinase inhibitors has resulted in several blockbuster drugs, such as imatinib, with remarkable success in the clinic and sales of many billions of U.S. dollars per yr, not a single phosphatase inhibitor has yet been approved for clin. use.  Similar to the kinase world, substrate-competitive phosphatase inhibitors have been developed but were not suitable for further development into clin. candidates due to their charge and limited selectivity.  Research efforts, therefore, have shifted to the exploitation of allosteric sites that can regulate phosphatase activity and may enable the discovery of novel modulators of phosphatase activity with much improved pharmacol. properties.  However, assay systems, which enable the straightforward discovery of these inhibitor types, are missing.  Here, we present a novel binding assay capable of detecting ligands of an allosteric pocket of the protein tyrosine phosphatase 1B.  This assay is suitable for high-throughput screening and selectively detects ligands which bind to this unique site with a clear discrimination from substrate-competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMMpcm8RfGWrVg90H21EOLACvtfcHk0lgh4ozoMkvsSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D&md5=49a980ad7f749718803f1afe1d8d1a04</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fja4030484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4030484%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBeumer%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DSelective%2520detection%2520of%2520allosteric%2520phosphatase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D6838%26epage%3D6841%26doi%3D10.1021%2Fja4030484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahr, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. K.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of protein tyrosine phosphatase 1B</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/nsmb803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnsmb803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=15258570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=730-737&author=C.+Wiesmannauthor=K.+J.+Barrauthor=J.+Kungauthor=J.+Zhuauthor=D.+A.+Erlansonauthor=W.+Shenauthor=B.+J.+Fahrauthor=M.+Zhongauthor=L.+Taylorauthor=M.+Randalauthor=R.+S.+McDowellauthor=S.+K.+Hansen&title=Allosteric+inhibition+of+protein+tyrosine+phosphatase+1B&doi=10.1038%2Fnsmb803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Wiesmann, Christian; Barr, Kenneth J.; Kung, Jenny; Zhu, Jiang; Erlanson, Daniel A.; Shen, Wang; Fahr, Bruce J.; Zhong, Min; Taylor, Lisa; Randal, Mike; McDowell, Robert S.; Hansen, Stig K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Obesity and type II diabetes are closely linked metabolic syndromes that afflict >100 million people worldwide.  Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge.  Here we describe the discovery of an allosteric site in PTP1B.  Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located ∼20 Å from the catalytic site.  We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases.  Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells.  Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2mAdfb7Ou7Vg90H21EOLACvtfcHk0lgh4ozoMkvsSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D&md5=abf4042d5dd49fa810ced16426d2bcb5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnsmb803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb803%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DKung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DFahr%26aufirst%3DB.%2BJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DR.%2BS.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D730%26epage%3D737%26doi%3D10.1038%2Fnsmb803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzosiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdardottir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolotti, A.</span></span> <span> </span><span class="NLM_article-title">Target-based discovery of an inhibitor of the regulatory phosphatase PPP1R15B</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2018.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30057111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2018&pages=1216-1228&author=A.+Krzyzosiakauthor=A.+Sigurdardottirauthor=L.+Luhauthor=M.+Carraraauthor=I.+Dasauthor=K.+Schneiderauthor=A.+Bertolotti&title=Target-based+discovery+of+an+inhibitor+of+the+regulatory+phosphatase+PPP1R15B&doi=10.1016%2Fj.cell.2018.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B</span></div><div class="casAuthors">Krzyzosiak, Agnieszka; Sigurdardottir, Anna; Luh, Laura; Carrara, Marta; Das, Indrajit; Schneider, Kim; Bertolotti, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1228.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein phosphorylation is a prevalent and ubiquitous mechanism of regulation.  Kinases are popular drug targets, but identifying selective phosphatase inhibitors has been challenging.  Here, we used surface plasmon resonance to design a method to enable target-based discovery of selective serine/threonine phosphatase inhibitors.  The method targeted a regulatory subunit of protein phosphatase 1, PPP1R15B, a neg. regulator of proteostasis.  This yielded Raphin1, a selective inhibitor of R15B.  In cells, Raphin1 caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis.  In vitro, Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment.  Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease.  This identifies R15B as a druggable target and provides a platform for target-based discovery of inhibitors of serine/threonine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnL1IexJPGE7Vg90H21EOLACvtfcHk0lhHdoLc7kyPfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsLbL&md5=09415366927bac424f14e9cce05d9385</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DKrzyzosiak%26aufirst%3DA.%26aulast%3DSigurdardottir%26aufirst%3DA.%26aulast%3DLuh%26aufirst%3DL.%26aulast%3DCarrara%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DI.%26aulast%3DSchneider%26aufirst%3DK.%26aulast%3DBertolotti%26aufirst%3DA.%26atitle%3DTarget-based%2520discovery%2520of%2520an%2520inhibitor%2520of%2520the%2520regulatory%2520phosphatase%2520PPP1R15B%26jtitle%3DCell%26date%3D2018%26volume%3D174%26spage%3D1216%26epage%3D1228%26doi%3D10.1016%2Fj.cell.2018.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koveal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akshinthala, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kragelj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauss, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackledge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonks, N. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the disordered C terminus of PTP1B with an allosteric inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnchembio.1528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24845231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=558-566&author=N.+Krishnanauthor=D.+Kovealauthor=D.+H.+Millerauthor=B.+Xueauthor=S.+D.+Akshinthalaauthor=J.+Krageljauthor=M.+R.+Jensenauthor=C.+M.+Gaussauthor=R.+Pageauthor=M.+Blackledgeauthor=S.+K.+Muthuswamyauthor=W.+Petiauthor=N.+K.+Tonks&title=Targeting+the+disordered+C+terminus+of+PTP1B+with+an+allosteric+inhibitor&doi=10.1038%2Fnchembio.1528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the disordered C terminus of PTP1B with an allosteric inhibitor</span></div><div class="casAuthors">Krishnan, Navasona; Koveal, Dorothy; Miller, Daniel H.; Xue, Bin; Akshinthala, Sai Dipikaa; Kragelj, Jaka; Jensen, Malene Ringkjoebing; Gauss, Carla-Maria; Page, Rebecca; Blackledge, Martin; Muthuswamy, Senthil K.; Peti, Wolfgang; Tonks, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PTP1B, a validated therapeutic target for diabetes and obesity, has a crit. pos. role in HER2 signaling in breast tumorigenesis.  Efforts to develop therapeutic inhibitors of PTP1B have been frustrated by the chem. properties of the active site.  We define a new mechanism of allosteric inhibition that targets the C-terminal, noncatalytic segment of PTP1B.  We present what is to our knowledge the first ensemble structure of PTP1B contg. this intrinsically disordered segment, within which we identified a binding site for the small-mol. inhibitor MSI-1436.  We demonstrate binding to a second site close to the catalytic domain, with cooperative effects between the two sites locking PTP1B in an inactive state.  MSI-1436 antagonized HER2 signaling, inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2 mouse model of breast cancer, validating inhibition of PTP1B as a therapeutic strategy in breast cancer.  This new approach to inhibition of PTP1B emphasizes the potential of disordered segments of proteins as specific binding sites for therapeutic small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo526if7ja9XbVg90H21EOLACvtfcHk0lhHdoLc7kyPfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1ylsL8%253D&md5=10a460f3a5deafb9f7c206246d67a29b</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1528%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DN.%26aulast%3DKoveal%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BH.%26aulast%3DXue%26aufirst%3DB.%26aulast%3DAkshinthala%26aufirst%3DS.%2BD.%26aulast%3DKragelj%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DGauss%26aufirst%3DC.%2BM.%26aulast%3DPage%26aufirst%3DR.%26aulast%3DBlackledge%26aufirst%3DM.%26aulast%3DMuthuswamy%26aufirst%3DS.%2BK.%26aulast%3DPeti%26aufirst%3DW.%26aulast%3DTonks%26aufirst%3DN.%2BK.%26atitle%3DTargeting%2520the%2520disordered%2520C%2520terminus%2520of%2520PTP1B%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D558%26epage%3D566%26doi%3D10.1038%2Fnchembio.1528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottini, N.</span></span> <span> </span><span class="NLM_article-title">Targeting tyrosine phosphatases: time to end the stigma</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.tips.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28412041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=524-540&author=S.+M.+Stanfordauthor=N.+Bottini&title=Targeting+tyrosine+phosphatases%3A+time+to+end+the+stigma&doi=10.1016%2Fj.tips.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tyrosine Phosphatases: Time to End the Stigma</span></div><div class="casAuthors">Stanford, Stephanie M.; Bottini, Nunzio</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">524-540</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) are a family of enzymes essential for numerous cellular processes, and several PTPs have been validated as therapeutic targets for human diseases.  Historically, the development of drugs targeting PTPs has been highly challenging, leading to stigmatization of these enzymes as undruggable targets.  Despite these difficulties, efforts to drug PTPs have persisted, and recent years have seen an influx of new probes providing opportunities for biol. examn. of old and new PTP targets.  Here we discuss progress towards drugging PTPs with special emphasis on the development of selective probes with biol. activity.  We describe the development of new small-mol. orthosteric, allosteric, and oligomerization-inhibiting PTP inhibitors and discuss new studies targeting the receptor PTP (RPTP) subfamily with biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodaLAks9bm7LVg90H21EOLACvtfcHk0liQHZ0jdXnbOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWrtbc%253D&md5=539153cbe8845849b542a6d92bf2e7ed</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DS.%2BM.%26aulast%3DBottini%26aufirst%3DN.%26atitle%3DTargeting%2520tyrosine%2520phosphatases%253A%2520time%2520to%2520end%2520the%2520stigma%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D524%26epage%3D540%26doi%3D10.1016%2Fj.tips.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dempke, W. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uciechowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenchel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevassut, T.</span></span> <span> </span><span class="NLM_article-title">Targeting SHP-1, 2 and SHIP pathways: A novel strategy for cancer treatment?</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1159/000490106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1159%2F000490106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29925063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2018&pages=257-269&author=W.+C.+M.+Dempkeauthor=P.+Uciechowskiauthor=K.+Fenchelauthor=T.+Chevassut&title=Targeting+SHP-1%2C+2+and+SHIP+pathways%3A+A+novel+strategy+for+cancer+treatment%3F&doi=10.1159%2F000490106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?</span></div><div class="casAuthors">Dempke, Wolfram C. M.; Uciechowski, Peter; Fenchel, Klaus; Chevassut, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">257-269</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Well-balanced levels of tyrosine phosphorylation, maintained by the reversible and coordinated actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), are crit. for a wide range of cellular processes including growth, differentiation, metab., migration, and survival.  Aberrant tyrosine phosphorylation, as a result of a perturbed balance between the activities of PTKs and PTPs, is linked to the pathogenesis of numerous human diseases, including cancer, suggesting that PTPs may be innovative mol. targets for cancer treatment.  Two PTPs that have an important inhibitory role in haematopoietic cells are SHP-1 and SHP-2.  SHP-1, 2 promote cell growth and act by both upregulating pos. signaling pathways and by downregulating neg. signaling pathways.  SHIP is another inhibitory phosphatase that is specific for the inositol phospholipid phosphatidylinositol-3,4,5-trisphosphate (PIP3).  SHIP acts as a neg. regulator of immune response by hydrolyzing PIP3, and SHIP deficiency results in myeloproliferation and B-cell lymphoma in mice.  The validation of SHP-1, 2 and SHIP as oncol. targets has generated interest in the development of inhibitors as potential therapeutic agents for cancers; however, SHP-1, 2 and SHIP have proven to be an extremely difficult target for drug discovery, primarily due to the highly conserved and pos. charged nature of their PTP active site, and many PTP inhibitors lack either appro-priate selectivity or membrane permeability.  To overcome these caveats, novel techniques have been employed to synthesize new inhibitors that specifically attenuate the PTP-dependent signaling inside the cell and amongst them; some are already in clin. development which are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgI8vLcSbFQLVg90H21EOLACvtfcHk0lia3jaPt0dA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagur%252FP&md5=40b3d65498f4d5974235ef41b3fbc5a8</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1159%2F000490106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000490106%26sid%3Dliteratum%253Aachs%26aulast%3DDempke%26aufirst%3DW.%2BC.%2BM.%26aulast%3DUciechowski%26aufirst%3DP.%26aulast%3DFenchel%26aufirst%3DK.%26aulast%3DChevassut%26aufirst%3DT.%26atitle%3DTargeting%2520SHP-1%252C%25202%2520and%2520SHIP%2520pathways%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520treatment%253F%26jtitle%3DOncology%26date%3D2018%26volume%3D95%26spage%3D257%26epage%3D269%26doi%3D10.1159%2F000490106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulahannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T.</span></span> <span> </span><span class="NLM_article-title">The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a frst-in-man phase 1 clinical trial</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">S15</span>– <span class="NLM_lpage">S16</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.jtho.2019.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31864548" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=S15-S16&author=S.+I.+Ouauthor=M.+Koczywasauthor=S.+Ulahannanauthor=P.+Janneauthor=J.+Pachecoauthor=H.+Burrisauthor=C.+McCoachauthor=J.+S.+Wangauthor=M.+Gordonauthor=E.+Hauraauthor=J.+W.+Riessauthor=V.+Zhuauthor=K.+Ngauthor=S.+G.+Eckhardtauthor=A.+Capassoauthor=R.+Duaauthor=A.+Chenauthor=Z.+Wangauthor=J.+Hayesauthor=R.+Nicholsauthor=T.+Bivona&title=The+SHP2+inhibitor+RMC-4630+in+patients+with+KRAS-mutant+non-small+cell+lung+cancer%3A+preliminary+evaluation+of+a+frst-in-man+phase+1+clinical+trial&doi=10.1016%2Fj.jtho.2019.12.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DUlahannan%26aufirst%3DS.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DPacheco%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%2BS.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DRiess%26aufirst%3DJ.%2BW.%26aulast%3DZhu%26aufirst%3DV.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DCapasso%26aufirst%3DA.%26aulast%3DDua%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DR.%26aulast%3DBivona%26aufirst%3DT.%26atitle%3DThe%2520SHP2%2520inhibitor%2520RMC-4630%2520in%2520patients%2520with%2520KRAS-mutant%2520non-small%2520cell%2520lung%2520cancer%253A%2520preliminary%2520evaluation%2520of%2520a%2520frst-in-man%2520phase%25201%2520clinical%2520trial%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26spage%3DS15%26epage%3DS16%26doi%3D10.1016%2Fj.jtho.2019.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschhof, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembrough, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshetian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0022-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0022-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=968-977&author=G.+S.+Wongauthor=J.+Zhouauthor=J.+B.+Liuauthor=Z.+Wuauthor=X.+S.+Xuauthor=T.+X.+Liauthor=D.+Xuauthor=S.+E.+Schumacherauthor=J.+Puschhofauthor=J.+McFarlandauthor=C.+Zouauthor=A.+Dulakauthor=L.+Hendersonauthor=P.+Xuauthor=E.+O%E2%80%99Dayauthor=R.+Rendakauthor=W.+L.+Liaoauthor=F.+Cecchiauthor=T.+Hembroughauthor=S.+Schwartzauthor=C.+Szetoauthor=A.+K.+Rustgiauthor=K.+K.+Wongauthor=J.+A.+Diehlauthor=K.+Jensenauthor=F.+Grazianoauthor=A.+Ruzzoauthor=S.+Fereshetianauthor=P.+Mertinsauthor=S.+A.+Carrauthor=R.+Beroukhimauthor=K.+Nakamuraauthor=E.+Okiauthor=M.+Watanabeauthor=H.+Babaauthor=Y.+Imamuraauthor=D.+Catenacciauthor=A.+J.+Bass&title=Targeting+wild-type+KRAS-amplified+gastroesophageal+cancer+through+combined+MEK+and+SHP2+inhibition&doi=10.1038%2Fs41591-018-0022-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition</span></div><div class="casAuthors">Wong, Gabrielle S.; Zhou, Jin; Liu, Jie Bin; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven E.; Puschhof, Jens; McFarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit; Szeto, Christopher; Rustgi, Anil K.; Wong, Kwok-Kin; Diehl, J. Alan; Jensen, Karin; Graziano, Francesco; Ruzzo, Annamaria; Fereshetian, Shaunt; Mertins, Philipp; Carr, Steven A.; Beroukhim, Rameen; Nakamura, Kenichi; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo; Imamura, Yu; Catenacci, Daniel; Bass, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">968-977</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The role of KRAS, when activated through canonical mutations, has been well established in cancer1.  Here it explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations.  These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas2-4.  KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels.  Here it demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacol., can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings.  These data demonstrate the relevance of copy-no. amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTIe1Ygfy-ibVg90H21EOLACvtfcHk0lia3jaPt0dA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvE&md5=9b0e728428d655cebea911300b5ed91a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0022-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0022-x%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DG.%2BS.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BB.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BX.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3DPuschhof%26aufirst%3DJ.%26aulast%3DMcFarland%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DDulak%26aufirst%3DA.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DE.%26aulast%3DRendak%26aufirst%3DR.%26aulast%3DLiao%26aufirst%3DW.%2BL.%26aulast%3DCecchi%26aufirst%3DF.%26aulast%3DHembrough%26aufirst%3DT.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DSzeto%26aufirst%3DC.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DDiehl%26aufirst%3DJ.%2BA.%26aulast%3DJensen%26aufirst%3DK.%26aulast%3DGraziano%26aufirst%3DF.%26aulast%3DRuzzo%26aufirst%3DA.%26aulast%3DFereshetian%26aufirst%3DS.%26aulast%3DMertins%26aufirst%3DP.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DOki%26aufirst%3DE.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DCatenacci%26aufirst%3DD.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520wild-type%2520KRAS-amplified%2520gastroesophageal%2520cancer%2520through%2520combined%2520MEK%2520and%2520SHP2%2520inhibition%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D968%26epage%3D977%26doi%3D10.1038%2Fs41591-018-0022-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wormann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, E. A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algul, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Y.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+Gorguluauthor=Z.+Dantesauthor=S.+M.+Wormannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Z.+van+der+Laanauthor=M.+P.+Lopez-Albercaauthor=M.+Nazareauthor=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Algul&title=Mutant+KRAS-driven+cancers+depend+on+PTPN11%2FSHP2+phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0li1_YkkoxhzHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%2BY.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DGorgulu%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DWormann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%2BZ.%26aulast%3DLopez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlgul%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-driven%2520cancers%2520depend%2520on%2520PTPN11%252FSHP2%2520phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aaronson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.celrep.2018.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30605687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=65-78&author=T.+A.+Ahmedauthor=C.+Adamopoulosauthor=Z.+Karouliaauthor=X.+W.+Wuauthor=R.+Sachidanandamauthor=S.+A.+Aaronsonauthor=P.+I.+Poulikakos&title=SHP2+Drives+Adaptive+Resistance+to+ERK+Signaling+Inhibition+in+Molecularly+Defined+Subsets+of+ERK-Dependent+Tumors&doi=10.1016%2Fj.celrep.2018.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors</span></div><div class="casAuthors">Ahmed, Tamer A.; Adamopoulos, Christos; Karoulia, Zoi; Wu, Xuewei; Sachidanandam, Ravi; Aaronson, Stuart A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pharmacol. targeting of components of ERK signaling in ERK-dependent tumors is often limited by adaptive resistance, frequently mediated by feedback-activation of RTK signaling and rebound of ERK activity.  Here, we show that combinatorial pharmacol. targeting of ERK signaling and the SHP2 phosphatase prevents adaptive resistance in defined subsets of ERK-dependent tumors.  In each tumor that was sensitive to combined treatment, p(Y542)SHP2 induction was obsd. in response to ERK signaling inhibition.  The strategy was broadly effective in TNBC models and tumors with RAS mutations at G12, whereas tumors with RAS(G13D) or RAS(Q61X) mutations were resistant.  In addn., we identified a subset of BRAF(V600E) tumors that were resistant to the combined treatment, in which FGFR was found to drive feedback-induced RAS activation, independently of SHP2.  Thus, we identify mol. determinants of response to combined ERK signaling and SHP2 inhibition in ERK-dependent tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqffbcbbR68qLVg90H21EOLACvtfcHk0li1_YkkoxhzHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVegsg%253D%253D&md5=8c82efdc10ee2e0632d3ca9269bfb3d2</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DAdamopoulos%26aufirst%3DC.%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%2BW.%26aulast%3DSachidanandam%26aufirst%3DR.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DSHP2%2520Drives%2520Adaptive%2520Resistance%2520to%2520ERK%2520Signaling%2520Inhibition%2520in%2520Molecularly%2520Defined%2520Subsets%2520of%2520ERK-Dependent%2520Tumors%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D65%26epage%3D78%26doi%3D10.1016%2Fj.celrep.2018.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordjour, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbucher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1038/nm.4497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnm.4497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=29505033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=512-517&author=L.+Dardaeiauthor=H.+Q.+Wangauthor=M.+Singhauthor=P.+Fordjourauthor=K.+X.+Shawauthor=S.+Yodaauthor=G.+Kerrauthor=K.+Yuauthor=J.+S.+Liangauthor=Y.+C.+Caoauthor=Y.+Chenauthor=M.+S.+Lawrenceauthor=A.+Langenbucherauthor=J.+F.+Gainorauthor=L.+Fribouletauthor=I.+Dagogo-Jackauthor=D.+T.+Myersauthor=E.+Labrotauthor=D.+Ruddyauthor=M.+Parksauthor=D.+Leeauthor=R.+H.+DiCeccaauthor=S.+Moodyauthor=H.+X.+Haoauthor=M.+Mohseniauthor=M.+LaMarcheauthor=J.+Williamsauthor=K.+Hoffmasterauthor=G.+Caponigroauthor=A.+T.+Shawauthor=A.+N.+Hataauthor=C.+H.+Benesauthor=F.+Liauthor=J.+A.+Engelman&title=SHP2+inhibition+restores+sensitivity+in+ALK-rearranged+non-small-cell+lung+cancer+resistant+to+ALK+inhibitors&doi=10.1038%2Fnm.4497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors</span></div><div class="casAuthors">Dardaei, Leila; Wang, Hui Qin; Singh, Manrose; Fordjour, Paul; Shaw, Katherine X.; Yoda, Satoshi; Kerr, Grainne; Yu, Kristine; Liang, Jinsheng; Cao, Yichen; Chen, Yan; Lawrence, Michael S.; Langenbucher, Adam; Gainor, Justin F.; Friboulet, Luc; Dagogo-Jack, Ibiayi; Myers, David T.; Labrot, Emma; Ruddy, David; Parks, Melissa; Lee, Dana; Di Cecca, Richard H.; Moody, Susan; Hao, Huaixiang; Mohseni, Morvarid; LaMarche, Matthew; Williams, Juliet; Hoffmaster, Keith; Caponigro, Giordano; Shaw, Alice T.; Hata, Aaron N.; Benes, Cyril H.; Li, Fang; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-mol. ALK inhibitors, but drug resistance often develops.  Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approx. half harbor resistance mutations in ALK, while the other half have other mechanisms underlying resistance.  Members of the latter group often have activation of at least one of several different tyrosine kinases driving resistance.  Such tumors are not expected to respond to lorlatinib-a third-generation inhibitor targeting ALK that is able to overcome all clin. identified resistant mutations in ALK-and further therapeutic options are limited.  Herein, we deployed a shRNA screen of 1,000 genes in multiple ALK-inhibitor-resistant patient-derived cells (PDCs) to discover those that confer sensitivity to ALK inhibition.  This approach identified SHP2, a nonreceptor protein tyrosine phosphatase, as a common targetable resistance node in multiple PDCs.  SHP2 provides a parallel survival input downstream of multiple tyrosine kinases that promote resistance to ALK inhibitors.  Treatment with SHP099, the recently discovered small-mol. inhibitor of SHP2, in combination with the ALK tyrosine kinase inhibitor (TKI) ceritinib halted the growth of resistant PDCs through preventing compensatory RAS and ERK1 and ERK2 (ERK1/2) reactivation.  These findings suggest that combined ALK and SHP2 inhibition may be a promising therapeutic strategy for resistant cancers driven by several different ALK-independent mechanisms underlying resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBbW-AAzZ-grVg90H21EOLACvtfcHk0lh08I3heCjW4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu78%253D&md5=e40334532f10444b2df350345add9d0e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnm.4497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4497%26sid%3Dliteratum%253Aachs%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%2BQ.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DFordjour%26aufirst%3DP.%26aulast%3DShaw%26aufirst%3DK.%2BX.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DJ.%2BS.%26aulast%3DCao%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DLangenbucher%26aufirst%3DA.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DMyers%26aufirst%3DD.%2BT.%26aulast%3DLabrot%26aufirst%3DE.%26aulast%3DRuddy%26aufirst%3DD.%26aulast%3DParks%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DMoody%26aufirst%3DS.%26aulast%3DHao%26aufirst%3DH.%2BX.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DLaMarche%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DHoffmaster%26aufirst%3DK.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DSHP2%2520inhibition%2520restores%2520sensitivity%2520in%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520resistant%2520to%2520ALK%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D512%26epage%3D517%26doi%3D10.1038%2Fnm.4497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lh08I3heCjW4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0lh08I3heCjW4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">What is the right dose? The elusive optimal biologic dose in phase I clinical trials</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4054</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.07.4658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1200%2FJCO.2006.07.4658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=16943522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVantbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4054-4055&author=A.+A.+Adjei&title=What+is+the+right+dose%3F+The+elusive+optimal+biologic+dose+in+phase+I+clinical+trials&doi=10.1200%2FJCO.2006.07.4658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">What is the right dose? The elusive optimal biologic dose in phase I clinical trials</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4054-4055</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Carducci et al (2006) entitled "Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer" is reviewed with commentary and refs.  Carducci et al. found that total enzastaurin exposure increased with increasing concn. up to 240 mg and appeared to reach a plateau at 525 and 700 mg.  On the basis of plasma exposures, 525 mg was selected as the recommended phase II dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvHZhMTwjRg7Vg90H21EOLACvtfcHk0ljV5M2zhNuHsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVantbzJ&md5=6aea6009e4816da5a024fac4fcba9d91</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.07.4658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.07.4658%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DWhat%2520is%2520the%2520right%2520dose%253F%2520The%2520elusive%2520optimal%2520biologic%2520dose%2520in%2520phase%2520I%2520clinical%2520trials%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4054%26epage%3D4055%26doi%3D10.1200%2FJCO.2006.07.4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berraondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etxeberria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilboa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melero, I.</span></span> <span> </span><span class="NLM_article-title">An RNA toolbox for cancer immunotherapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fnrd.2018.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=30190565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KksLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=751-767&author=F.+Pastorauthor=P.+Berraondoauthor=I.+Etxeberriaauthor=J.+Frederickauthor=U.+Sahinauthor=E.+Gilboaauthor=I.+Melero&title=An+RNA+toolbox+for+cancer+immunotherapy&doi=10.1038%2Fnrd.2018.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">An RNA toolbox for cancer immunotherapy</span></div><div class="casAuthors">Pastor, Fernando; Berraondo, Pedro; Etxeberria, Inaki; Frederick, Josh; Sahin, Ugur; Gilboa, Eli; Melero, Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-767</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has revolutionized oncol. practice.  However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety.  RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different mols.  These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches.  These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results.  RNA and RNA derivs. can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function.  Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogs, interference RNAs and protein-binding RNA aptamers.  These approaches are already in early clin. development with promising safety and efficacy results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfpXP7YjK3HLVg90H21EOLACvtfcHk0ljV5M2zhNuHsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KksLvO&md5=8d6552734b7a329f0a6385519e343503</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.132%26sid%3Dliteratum%253Aachs%26aulast%3DPastor%26aufirst%3DF.%26aulast%3DBerraondo%26aufirst%3DP.%26aulast%3DEtxeberria%26aufirst%3DI.%26aulast%3DFrederick%26aufirst%3DJ.%26aulast%3DSahin%26aufirst%3DU.%26aulast%3DGilboa%26aufirst%3DE.%26aulast%3DMelero%26aufirst%3DI.%26atitle%3DAn%2520RNA%2520toolbox%2520for%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D751%26epage%3D767%26doi%3D10.1038%2Fnrd.2018.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jopling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geemen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hertog, J.</span></span> <span> </span><span class="NLM_article-title">Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2468</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.0030225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1371%2Fjournal.pgen.0030225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=2468-2476&author=C.+Joplingauthor=D.+van+Geemenauthor=J.+den+Hertog&title=Shp2+knockdown+and+Noonan%2FLEOPARD+mutant+Shp2-induced+gastrulation+defects&doi=10.1371%2Fjournal.pgen.0030225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects</span></div><div class="casAuthors">Jopling, Chris; van Geemen, Daphne; den Hertog, Jeroen</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2468-2476</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Shp2 is a cytoplasmic protein tyrosine phosphatase that is essential for normal development.  Activating and inactivating mutations have been identified in humans to cause the related Noonan and LEOPARD syndromes, resp.  The cell biol. cause of these syndromes remains to be detd.  The authors have used the zebrafish to assess the role of Shp2 in early development.  Here, the authors report that morpholino-mediated knockdown of Shp2 in zebrafish resulted in defects during gastrulation.  Cell tracing expts. demonstrated that Shp2 knockdown induced defects in convergence and extension cell movements.  In situ hybridization using a panel of markers indicated that cell fate was not affected by Shp2 knock down.  The Shp2 knockdown-induced defects were rescued by active Fyn and Yes and by active RhoA.  The authors generated mutants of Shp2 with mutations that were identified in human patients with Noonan or LEOPARD Syndrome and established that Noonan Shp2 was activated and LEOPARD Shp2 lacked catalytic protein tyrosine phosphatase activity.  Expression of Noonan or LEOPARD mutant Shp2 in zebrafish embryos induced convergence and extension cell movement defects without affecting cell fate.  Moreover, these embryos displayed craniofacial and cardiac defects, reminiscent of human symptoms.  Noonan and LEOPARD mutant Shp2s were not additive nor synergistic, consistent with the mutant Shp2s having activating and inactivating roles in the same signaling pathway.  The authors' results demonstrate that Shp2 is required for normal convergence and extension cell movements during gastrulation and that Src family kinases and RhoA were downstream of Shp2.  Expression of Noonan or LEOPARD Shp2 phenocopied the craniofacial and cardiac defects of human patients.  The finding that defective Shp2 signaling induced cell movement defects as early as gastrulation may have implications for the monitoring and diagnosis of Noonan and LEOPARD syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusv3uhpPLi7Vg90H21EOLACvtfcHk0ljV5M2zhNuHsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslajuw%253D%253D&md5=a64d91c3fe9b12589971d6bdabc1399c</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.0030225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.0030225%26sid%3Dliteratum%253Aachs%26aulast%3DJopling%26aufirst%3DC.%26aulast%3Dvan%2BGeemen%26aufirst%3DD.%26aulast%3Dden%2BHertog%26aufirst%3DJ.%26atitle%3DShp2%2520knockdown%2520and%2520Noonan%252FLEOPARD%2520mutant%2520Shp2-induced%2520gastrulation%2520defects%26jtitle%3DPLoS%2520Genet.%26date%3D2007%26volume%3D3%26spage%3D2468%26epage%3D2476%26doi%3D10.1371%2Fjournal.pgen.0030225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. S.</span></span> <span> </span><span class="NLM_article-title">Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro</span>. <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.oooo.2013.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.oooo.2013.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=24439919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A280%3ADC%252BC2czmvFertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=234-242&author=H.+J.+Xieauthor=S.+Y.+Huangauthor=W.+G.+Liauthor=H.+B.+Zhaoauthor=T.+Q.+Zhangauthor=D.+S.+Zhang&title=Upregulation+of+Src+homology+phosphotyrosyl+phosphatase+2+%28Shp2%29+expression+in+oral+cancer+and+knockdown+of+Shp2+expression+inhibit+tumor+cell+viability+and+invasion+in+vitro&doi=10.1016%2Fj.oooo.2013.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro</span></div><div class="casAuthors">Xie Hongjun; Huang Shengyun; Li Wengang; Zhao Hongbo; Zhang Tianqi; Zhang Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oral surgery, oral medicine, oral pathology and oral radiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">234-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study investigated the clinical significance of Shp2 protein expression in oral squamous cell carcinoma (OSCC) and elucidated its biologic significance in OSCC cells.  STUDY DESIGN:  A total of 88 OSCC cases were used to assess Shp2 expression, out of which 70 were for immunohistochemistry and 18 paired tumors vs normal tissues were for Western blot of Shp2 expression.  OSCC cells were used to assess the effects of Shp2 knockdown for cell viability, apoptosis, invasion, and protein expressions.  RESULTS:  Expression of Shp2 protein was significantly upregulated in OSCC tissues compared with the normal tissues, and Shp2 overexpression was associated with advanced tumor clinical stages and lymph node metastasis ex vivo.  Knockdown of Shp2 expression in vitro inhibited OSCC cell viability and invasion but induced apoptosis by regulating expression of the apoptosis-related proteins.  CONCLUSIONS:  The data indicated that Shp2 may play an important role in OSCC progression.  Further studies will investigate whether a target of Shp2 expression could be a novel therapeutic strategy for clinical control of OSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoyRSzjCk5vMK3uFsUIZtkfW6udTcc2eZIZjQ6fvzMGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmvFertQ%253D%253D&md5=02f04e0fc7b5196b50ccb309146de287</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.oooo.2013.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oooo.2013.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DW.%2BG.%26aulast%3DZhao%26aufirst%3DH.%2BB.%26aulast%3DZhang%26aufirst%3DT.%2BQ.%26aulast%3DZhang%26aufirst%3DD.%2BS.%26atitle%3DUpregulation%2520of%2520Src%2520homology%2520phosphotyrosyl%2520phosphatase%25202%2520%2528Shp2%2529%2520expression%2520in%2520oral%2520cancer%2520and%2520knockdown%2520of%2520Shp2%2520expression%2520inhibit%2520tumor%2520cell%2520viability%2520and%2520invasion%2520in%2520vitro%26jtitle%3DOral%2520Surg.%2520Oral%2520Med.%2520Oral%2520Pathol.%2520Oral%2520Radiol.%26date%3D2014%26volume%3D117%26spage%3D234%26epage%3D242%26doi%3D10.1016%2Fj.oooo.2013.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R. F.</span></span> <span> </span><span class="NLM_article-title">Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">395</span>, <span class="refDoi"> DOI: 10.3390/ijms18020395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.3390%2Fijms18020395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=395&author=X.+Sunauthor=J.+Zhangauthor=Z.+Y.+Wangauthor=W.+Jiauthor=R.+Tianauthor=F.+Zhangauthor=R.+F.+Niu&title=Shp2+plays+a+critical+role+in+IL-6-induced+EMT+in+breast+cancer+cells&doi=10.3390%2Fijms18020395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells</span></div><div class="casAuthors">Sun, Xuan; Zhang, Jie; Wang, Zhiyong; Ji, Wei; Tian, Ran; Zhang, Fei; Niu, Ruifang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395/1-395/16</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Accumulative evidence demonstrates that the protein tyrosine phosphatase Shp2 functions as a powerful tumor promoter in many types of cancers.  Abnormal expression of Shp2 has been implicated in many human malignancies.  Overexpression of Shp2 in cancer tissues is correlated with cancer metastasis, resistance to targeted therapy, and poor prognosis.  The well-known function of Shp2 is its pos. role in regulating cellular signaling initiated by growth factors and cytokines, including interleukin-6 (IL-6).  Several recent studies have shown that Shp2 is required for epithelial-mesenchymal transition (EMT), triggered by growth factors.  However, whether Shp2 is involved in IL-6-signaling-promoted breast cancer EMT and progression, remains undefined.  In this study, we showed that exogenous and endogenous IL-6 can enhance breast cancer invasion and migration, through the promotion of EMT.  IL-6 also induces the activation of Erk1/2 and the phosphorylation of Shp2.  Knockdown of Shp2 attenuated the IL-6-induced downregulation of E-cadherin, as well as IL-6-promoted cell migration and invasion.  Moreover, by using Shp2 phosphatase mutants, phosphor-tyrosine mimicking, and deficiency mutants, we provided evidence that the phosphatase activity of Shp2 and its tyrosine phosphorylation, are necessary for the IL-6-induced downregulation of E-cadherin and the phosphorylation of Erk1/2.  Our findings uncover an important function that links Shp2 to IL-6-promoted breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozWl0u0pgApLVg90H21EOLACvtfcHk0lhV7kTSPNAzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSgsLg%253D&md5=4b6ae20d32ee9a910efa433686b27a3b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms18020395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020395%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DJi%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DR.%2BF.%26atitle%3DShp2%2520plays%2520a%2520critical%2520role%2520in%2520IL-6-induced%2520EMT%2520in%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D395%26doi%3D10.3390%2Fijms18020395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lhV7kTSPNAzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0lhV7kTSPNAzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macartney, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G. P.</span></span> <span> </span><span class="NLM_article-title">Targeting endogenous proteins for degradation through the affinity-directed protein missile system</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">170066</span>, <span class="refDoi"> DOI: 10.1098/rsob.170066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1098%2Frsob.170066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=28490657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVaktLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=170066&author=L.+J.+Fulcherauthor=L.+D.+Hutchinsonauthor=T.+J.+Macartneyauthor=C.+Turnbullauthor=G.+P.+Sapkota&title=Targeting+endogenous+proteins+for+degradation+through+the+affinity-directed+protein+missile+system&doi=10.1098%2Frsob.170066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting endogenous proteins for degradation through the affinity-directed protein missile system</span></div><div class="casAuthors">Fulcher, Luke J.; Hutchinson, Luke D.; Macartney, Thomas J.; Turnbull, Craig; Sapkota, Gopal P.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">170066/1-170066/11</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics.  CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes.  Similarly, RNAinterference approaches necessitate prolonged treatments, can lead to incomplete knockdowns and are often assocd. with off-target effects.  Targeted proteolysis can overcome these limitations.  In this report,we describe an affinity-directed protein missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degrdn.  By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degrdn. of endogenous SHP2 and ASC in human cell lines.  We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biol.  This study demonstrates for the first time that small polypeptide binders that selectively recognize endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1fku-pJ3ORLVg90H21EOLACvtfcHk0liTNNijTkHEVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVaktLzM&md5=3fcb8b661243ff13f9d8f6e2cca29125</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1098%2Frsob.170066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.170066%26sid%3Dliteratum%253Aachs%26aulast%3DFulcher%26aufirst%3DL.%2BJ.%26aulast%3DHutchinson%26aufirst%3DL.%2BD.%26aulast%3DMacartney%26aufirst%3DT.%2BJ.%26aulast%3DTurnbull%26aufirst%3DC.%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26atitle%3DTargeting%2520endogenous%2520proteins%2520for%2520degradation%2520through%2520the%2520affinity-directed%2520protein%2520missile%2520system%26jtitle%3DOpen%2520Biol.%26date%3D2017%26volume%3D7%26spage%3D170066%26doi%3D10.1098%2Frsob.170066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+D.+Shenauthor=W.+X.+Chenauthor=J.+L.+Zhuauthor=G.+F.+Wuauthor=R.+P.+Shenauthor=M.+Y.+Xiauthor=H.+P.+Sun&title=Therapeutic+potential+of+targeting+SHP2+in+human+developmental+disorders+and+cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0liTNNijTkHEVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BD.%26aulast%3DChen%26aufirst%3DW.%2BX.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DG.%2BF.%26aulast%3DShen%26aufirst%3DR.%2BP.%26aulast%3DXi%26aufirst%3DM.%2BY.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520SHP2%2520in%2520human%2520developmental%2520disorders%2520and%2520cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PS5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PS5','PDB','3PS5'); return false;">PDB: 3PS5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP','PDB','2SHP'); return false;">PDB: 2SHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GRZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GRZ','PDB','4GRZ'); return false;">PDB: 4GRZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T19" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T19','PDB','5T19'); return false;">PDB: 5T19</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EB1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EB1','PDB','3EB1'); return false;">PDB: 3EB1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMV','PDB','6BMV'); return false;">PDB: 6BMV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B7O','PDB','3B7O'); return false;">PDB: 3B7O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4QSY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4QSY','PDB','4QSY'); return false;">PDB: 4QSY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHR','PDB','5EHR'); return false;">PDB: 5EHR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZM3','PDB','3ZM3'); return false;">PDB: 3ZM3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O5X','PDB','3O5X'); return false;">PDB: 3O5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GS0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GS0','PDB','4GS0'); return false;">PDB: 4GS0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PVG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PVG','PDB','4PVG'); return false;">PDB: 4PVG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RDD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RDD','PDB','4RDD'); return false;">PDB: 4RDD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP','PDB','5EHP'); return false;">PDB: 5EHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDC','PDB','6MDC'); return false;">PDB: 6MDC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BMR','PDB','6BMR'); return false;">PDB: 6BMR</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00249&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00249%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00249" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac2eaedad24c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
